[
  {
    "drug": "SC1982",
    "pathogen": "malignant melanoma",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "SC1982 showed an S100B-dependent death response in melanoma cell assays, indicating potential as a repurposed agent targeting S100B in melanoma.",
    "pmid": "22493700",
    "title": "Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.",
    "year": "2012",
    "doi": "10.1371/journal.pone.0034538",
    "mechanism": "covalent binding to Cys84 on S100B to inhibit its interaction with p53, thereby restoring p53 tumor suppressor activity"
  },
  {
    "drug": "methylene blue",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant|anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Methylene blue combined with laser light effectively inactivates key staphylococcal virulence factors and kills MRSA in vitro.",
    "pmid": "22927795",
    "title": "Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agent.",
    "year": "2012",
    "doi": "10.1371/journal.pbio.1001379",
    "mechanism": "generation of reactive oxygen species upon light activation leading to oxidation and inactivation of bacterial virulence factors and bacteria."
  },
  {
    "drug": "isoniazid",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Efflux pump inhibitors such as thioridazine, chlorpromazine, and verapamil can reduce the MIC of isoniazid and inhibit efflux activity, potentially preventing resistance development.",
    "pmid": "23936064",
    "title": "Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae.",
    "year": "2013",
    "doi": "10.1371/journal.pone.0069646",
    "mechanism": "Inhibition of bacterial efflux pumps to increase intracellular antibiotic concentration and prevent resistance emergence."
  },
  {
    "drug": "simvastatin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 15.65,
    "fici": null,
    "key_result": "Simvastatin exhibited antimicrobial activity against S. aureus, inhibiting biofilm formation and reducing viability of mature biofilms.",
    "pmid": "25033456",
    "title": "Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi.",
    "year": "2014",
    "doi": "10.1371/journal.pntd.0002977",
    "mechanism": "Proposed mechanism involves disruption of biofilm formation and bacterial viability, possibly through interference with bacterial cell processes."
  },
  {
    "drug": "Ticlopidine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.063,
    "key_result": "Ticlopidine strongly potentiated the activity of \u03b2-lactam antibiotics against MRSA, restoring sensitivity in resistant strains.",
    "pmid": "25268459",
    "title": "Covalent small molecule inhibitors of Ca(2+)-bound S100B.",
    "year": "2014",
    "doi": "10.1021/bi5005552",
    "mechanism": "Ticlopidine inhibits TarO, an enzyme involved in WTA biosynthesis, leading to mislocalization of PBP4, impairing peptidoglycan cross-linking, and sensitizing MRSA to \u03b2-lactam antibiotics."
  },
  {
    "drug": "Clopidogrel",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.125,
    "key_result": "Clopidogrel synergized with cefuroxime to enhance activity against MRSA.",
    "pmid": "25268459",
    "title": "Covalent small molecule inhibitors of Ca(2+)-bound S100B.",
    "year": "2014",
    "doi": "10.1021/bi5005552",
    "mechanism": "Ticlopidine inhibits TarO, an enzyme involved in WTA biosynthesis, leading to mislocalization of PBP4, impairing peptidoglycan cross-linking, and sensitizing MRSA to \u03b2-lactam antibiotics."
  },
  {
    "drug": "Prasugrel",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Prasugrel showed synergy with cefuroxime against MRSA.",
    "pmid": "25268459",
    "title": "Covalent small molecule inhibitors of Ca(2+)-bound S100B.",
    "year": "2014",
    "doi": "10.1021/bi5005552",
    "mechanism": "Ticlopidine inhibits TarO, an enzyme involved in WTA biosynthesis, leading to mislocalization of PBP4, impairing peptidoglycan cross-linking, and sensitizing MRSA to \u03b2-lactam antibiotics."
  },
  {
    "drug": "ebselen",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "Ebselen exhibited potent antimicrobial activity against MRSA with MIC90 of 0.25 mg/L, exceeding that of vancomycin and linezolid.",
    "pmid": "25515946",
    "title": "Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?",
    "year": "2015",
    "doi": "10.1007/s10096-014-2296-3",
    "mechanism": "Inhibition of bacterial translation process without affecting mitochondrial biogenesis"
  },
  {
    "drug": "ebselen",
    "pathogen": "Enterococcus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Ebselen inhibited Enterococcus with MIC90 of 0.5 mg/L, showing strong activity against VRE.",
    "pmid": "25515946",
    "title": "Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?",
    "year": "2015",
    "doi": "10.1007/s10096-014-2296-3",
    "mechanism": "Inhibition of bacterial translation process without affecting mitochondrial biogenesis"
  },
  {
    "drug": "ebselen",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen showed synergistic activity with conventional antibiotics against MRSA.",
    "pmid": "25515946",
    "title": "Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?",
    "year": "2015",
    "doi": "10.1007/s10096-014-2296-3",
    "mechanism": "Inhibition of bacterial translation process without affecting mitochondrial biogenesis"
  },
  {
    "drug": "ebselen",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen demonstrated synergy with antibiotics in reducing bacterial load.",
    "pmid": "25515946",
    "title": "Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?",
    "year": "2015",
    "doi": "10.1007/s10096-014-2296-3",
    "mechanism": "Inhibition of bacterial translation process without affecting mitochondrial biogenesis"
  },
  {
    "drug": "niclosamide",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": 0.125,
    "fici": null,
    "key_result": "Niclosamide exhibited strong in vitro and in vivo activity against MRSA with MIC of 0.125 \u03bcg/ml and was bacteriostatic.",
    "pmid": "25521459",
    "title": "Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.",
    "year": "2015",
    "doi": "10.1038/jid.2014.529",
    "mechanism": "Oxyclozanide may exert its antibacterial effect through bacterial membrane permeabilization, leading to cell death."
  },
  {
    "drug": "oxyclozanide",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Oxyclozanide showed activity against MRSA with MIC of 0.5 \u03bcg/ml and was bactericidal, permeabilizing bacterial membranes.",
    "pmid": "25521459",
    "title": "Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.",
    "year": "2015",
    "doi": "10.1038/jid.2014.529",
    "mechanism": "Oxyclozanide may exert its antibacterial effect through bacterial membrane permeabilization, leading to cell death."
  },
  {
    "drug": "niclosamide",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "Niclosamide was effective against Enterococcus faecium with MIC of 0.25 \u03bcg/ml.",
    "pmid": "25521459",
    "title": "Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.",
    "year": "2015",
    "doi": "10.1038/jid.2014.529",
    "mechanism": "Oxyclozanide may exert its antibacterial effect through bacterial membrane permeabilization, leading to cell death."
  },
  {
    "drug": "oxyclozanide",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "Oxyclozanide was effective against Enterococcus faecium with MIC of 2 \u03bcg/ml.",
    "pmid": "25521459",
    "title": "Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.",
    "year": "2015",
    "doi": "10.1038/jid.2014.529",
    "mechanism": "Oxyclozanide may exert its antibacterial effect through bacterial membrane permeabilization, leading to cell death."
  },
  {
    "drug": "ebselen",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.125,
    "fici": null,
    "key_result": "Ebselen showed potent bactericidal activity against multidrug-resistant S. aureus, including MRSA and VRSA, with MICs ranging from 0.125 to 0.5 \u03bcg/ml.",
    "pmid": "25897961",
    "title": "Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0124595",
    "mechanism": "Inhibition of bacterial protein synthesis, with secondary effects on DNA, RNA, and lipid synthesis, and suppression of toxin production."
  },
  {
    "drug": "ebselen",
    "pathogen": "S. aureus",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen significantly suppressed toxin production (PVL and \u03b1-hemolysin) in MRSA USA300.",
    "pmid": "25897961",
    "title": "Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0124595",
    "mechanism": "Inhibition of bacterial protein synthesis, with secondary effects on DNA, RNA, and lipid synthesis, and suppression of toxin production."
  },
  {
    "drug": "ebselen",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "Ebselen significantly reduced established biofilms of S. aureus and S. epidermidis, decreasing biofilm mass by approximately 60% at 2 \u03bcg/ml.",
    "pmid": "25897961",
    "title": "Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0124595",
    "mechanism": "Inhibition of bacterial protein synthesis, with secondary effects on DNA, RNA, and lipid synthesis, and suppression of toxin production."
  },
  {
    "drug": "ebselen",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Topical ebselen (1% and 2%) significantly reduced bacterial load in a mouse model of MRSA skin infection.",
    "pmid": "25897961",
    "title": "Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0124595",
    "mechanism": "Inhibition of bacterial protein synthesis, with secondary effects on DNA, RNA, and lipid synthesis, and suppression of toxin production."
  },
  {
    "drug": "ebselen",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen acted synergistically with topical antimicrobials such as mupirocin, fusidic acid, retapamulin, and daptomycin against S. aureus.",
    "pmid": "25897961",
    "title": "Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0124595",
    "mechanism": "Inhibition of bacterial protein synthesis, with secondary effects on DNA, RNA, and lipid synthesis, and suppression of toxin production."
  },
  {
    "drug": "complex 4",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Complex 4 exhibited bactericidal activity against MSSA and MRSA strains.",
    "pmid": "26020797",
    "title": "Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0128098",
    "mechanism": "Inhibition of thioredoxin reductase (TrxR), DNA damage, caspase activation, and cell cycle disturbance in cancer cells; bactericidal activity likely through disruption of bacterial redox systems."
  },
  {
    "drug": "complex 5",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Complex 5 showed bactericidal activity against MSSA and MRSA strains.",
    "pmid": "26020797",
    "title": "Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0128098",
    "mechanism": "Inhibition of thioredoxin reductase (TrxR), DNA damage, caspase activation, and cell cycle disturbance in cancer cells; bactericidal activity likely through disruption of bacterial redox systems."
  },
  {
    "drug": "complex 6",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Complex 6 demonstrated bactericidal activity against MSSA and MRSA strains.",
    "pmid": "26020797",
    "title": "Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0128098",
    "mechanism": "Inhibition of thioredoxin reductase (TrxR), DNA damage, caspase activation, and cell cycle disturbance in cancer cells; bactericidal activity likely through disruption of bacterial redox systems."
  },
  {
    "drug": "monensin",
    "pathogen": "human ovarian cancer cells",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Monensin inhibits proliferation, migration, induces apoptosis, and suppresses multiple cancer-related pathways in ovarian cancer cells.",
    "pmid": "26111644",
    "title": "Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections.",
    "year": "2015",
    "doi": "10.1038/srep11596",
    "mechanism": "Monensin inhibits EGFR expression and downstream signaling pathways including Elk1/SRF, AP1, NF\u03baB, and STAT, leading to reduced proliferation and increased apoptosis in ovarian cancer cells."
  },
  {
    "drug": "monensin",
    "pathogen": "human ovarian cancer cells",
    "activity_type": "adjuvant|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.3,
    "key_result": "Monensin synergizes with EGFR inhibitors and oxaliplatin to enhance anti-proliferative effects and induce apoptosis.",
    "pmid": "26111644",
    "title": "Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections.",
    "year": "2015",
    "doi": "10.1038/srep11596",
    "mechanism": "Monensin inhibits EGFR expression and downstream signaling pathways including Elk1/SRF, AP1, NF\u03baB, and STAT, leading to reduced proliferation and increased apoptosis in ovarian cancer cells."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "Ciclopirox inhibits growth of multidrug-resistant Acinetobacter baumannii at 5-15 \u00b5g/ml.",
    "pmid": "26222252",
    "title": "Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0133877",
    "mechanism": "Ciclopirox affects galactose metabolism and lipopolysaccharide (LPS) biosynthesis pathways, likely through iron chelation and interference with UDP-galactose/UDP-glucose utilization."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "Ciclopirox inhibits growth of multidrug-resistant Escherichia coli at 5-15 \u00b5g/ml.",
    "pmid": "26222252",
    "title": "Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0133877",
    "mechanism": "Ciclopirox affects galactose metabolism and lipopolysaccharide (LPS) biosynthesis pathways, likely through iron chelation and interference with UDP-galactose/UDP-glucose utilization."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "Ciclopirox inhibits growth of multidrug-resistant Klebsiella pneumoniae at 5-15 \u00b5g/ml.",
    "pmid": "26222252",
    "title": "Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0133877",
    "mechanism": "Ciclopirox affects galactose metabolism and lipopolysaccharide (LPS) biosynthesis pathways, likely through iron chelation and interference with UDP-galactose/UDP-glucose utilization."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ciclopirox reduces growth of Pseudomonas aeruginosa clinical isolates, requiring higher concentrations for complete inhibition.",
    "pmid": "26222252",
    "title": "Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0133877",
    "mechanism": "Ciclopirox affects galactose metabolism and lipopolysaccharide (LPS) biosynthesis pathways, likely through iron chelation and interference with UDP-galactose/UDP-glucose utilization."
  },
  {
    "drug": "polymyxin B",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "Polymyxin B alone was effective against susceptible strains but ineffective against resistant strains.",
    "pmid": "26284040",
    "title": "Repurposing celecoxib as a topical antimicrobial agent.",
    "year": "2015",
    "doi": "10.3389/fmicb.2015.00750",
    "mechanism": "The combination enhances bacterial killing and inhibits resistance development, possibly through synergistic interactions that improve efficacy of polymyxin B against resistant strains."
  },
  {
    "drug": "closantel",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 16,
    "fici": null,
    "key_result": "Closantel alone was inactive against most isolates but showed synergistic activity when combined with polymyxin B against resistant strains.",
    "pmid": "26284040",
    "title": "Repurposing celecoxib as a topical antimicrobial agent.",
    "year": "2015",
    "doi": "10.3389/fmicb.2015.00750",
    "mechanism": "The combination enhances bacterial killing and inhibits resistance development, possibly through synergistic interactions that improve efficacy of polymyxin B against resistant strains."
  },
  {
    "drug": "polymyxin B + closantel",
    "pathogen": "A. baumannii",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The combination successfully inhibited development of resistance and achieved synergistic killing against resistant isolates.",
    "pmid": "26284040",
    "title": "Repurposing celecoxib as a topical antimicrobial agent.",
    "year": "2015",
    "doi": "10.3389/fmicb.2015.00750",
    "mechanism": "The combination enhances bacterial killing and inhibits resistance development, possibly through synergistic interactions that improve efficacy of polymyxin B against resistant strains."
  },
  {
    "drug": "celecoxib",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Celecoxib exhibits broad-spectrum antimicrobial activity against Gram-positive pathogens including MRSA.",
    "pmid": "26528965",
    "title": "Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones.",
    "year": "2015",
    "doi": "10.3390/molecules201119647",
    "mechanism": "Inhibition of RNA, DNA, and protein synthesis, and inhibition of bacterial efflux pumps."
  },
  {
    "drug": "celecoxib",
    "pathogen": "Acinetobacter spp.",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Celecoxib is active against Acinetobacter when outer membrane permeability is artificially increased.",
    "pmid": "26528965",
    "title": "Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones.",
    "year": "2015",
    "doi": "10.3390/molecules201119647",
    "mechanism": "Inhibition of RNA, DNA, and protein synthesis, and inhibition of bacterial efflux pumps."
  },
  {
    "drug": "celecoxib",
    "pathogen": "Pseudomonas spp.",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Celecoxib is active against Pseudomonas when outer membrane permeability is artificially increased.",
    "pmid": "26528965",
    "title": "Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones.",
    "year": "2015",
    "doi": "10.3390/molecules201119647",
    "mechanism": "Inhibition of RNA, DNA, and protein synthesis, and inhibition of bacterial efflux pumps."
  },
  {
    "drug": "celecoxib",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Celecoxib inhibits multidrug efflux pumps in S. aureus, increasing bacterial sensitivity to antibiotics.",
    "pmid": "26528965",
    "title": "Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones.",
    "year": "2015",
    "doi": "10.3390/molecules201119647",
    "mechanism": "Inhibition of RNA, DNA, and protein synthesis, and inhibition of bacterial efflux pumps."
  },
  {
    "drug": "celecoxib",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Celecoxib exhibits synergy with conventional antimicrobials against S. aureus.",
    "pmid": "26528965",
    "title": "Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones.",
    "year": "2015",
    "doi": "10.3390/molecules201119647",
    "mechanism": "Inhibition of RNA, DNA, and protein synthesis, and inhibition of bacterial efflux pumps."
  },
  {
    "drug": "celecoxib",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Topical celecoxib reduces bacterial load in MRSA skin infection models.",
    "pmid": "26528965",
    "title": "Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones.",
    "year": "2015",
    "doi": "10.3390/molecules201119647",
    "mechanism": "Inhibition of RNA, DNA, and protein synthesis, and inhibition of bacterial efflux pumps."
  },
  {
    "drug": "thioridazine",
    "pathogen": "Mycobacterium avium complex (MAC)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine effectively kills MAC in vitro with high intracellular concentrations and prevents resistance at high bacterial burdens.",
    "pmid": "26553420",
    "title": "Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent.",
    "year": "2015",
    "doi": "10.1038/srep16407",
    "mechanism": "Inhibition of the electron transport chain and efflux pump inhibition, leading to bacterial killing."
  },
  {
    "drug": "thioridazine",
    "pathogen": "Mycobacterium avium complex (MAC)",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine inhibits efflux pumps, potentially enhancing antimicrobial activity against MAC.",
    "pmid": "26553420",
    "title": "Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent.",
    "year": "2015",
    "doi": "10.1038/srep16407",
    "mechanism": "Inhibition of the electron transport chain and efflux pump inhibition, leading to bacterial killing."
  },
  {
    "drug": "thioridazine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine shows antimicrobial activity against MRSA in vitro, with efficacy affected by protein binding.",
    "pmid": "26553420",
    "title": "Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent.",
    "year": "2015",
    "doi": "10.1038/srep16407",
    "mechanism": "Inhibition of the electron transport chain and efflux pump inhibition, leading to bacterial killing."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "Auranofin-loaded PLGA nanoparticles showed strong bactericidal activity, practically sterilizing multiresistant pneumococcal strains at 0.25 \u03bcM.",
    "pmid": "27216055",
    "title": "Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.",
    "year": "2016",
    "doi": "10.1128/AAC.02985-15",
    "mechanism": "likely involves sustained release of auranofin from PLGA nanoparticles, enhancing stability and delivery to bacterial cells, leading to bactericidal activity."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. pneumoniae",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "Auranofin-NPs decreased bacterial populations in biofilms by about 4 logs more than free auranofin.",
    "pmid": "27216055",
    "title": "Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.",
    "year": "2016",
    "doi": "10.1128/AAC.02985-15",
    "mechanism": "likely involves sustained release of auranofin from PLGA nanoparticles, enhancing stability and delivery to bacterial cells, leading to bactericidal activity."
  },
  {
    "drug": "auranofin",
    "pathogen": "Streptococcus pyogenes",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "Auranofin-loaded NPs killed S. pyogenes strains more effectively than free auranofin, with a decrease of 1-2 logs.",
    "pmid": "27216055",
    "title": "Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.",
    "year": "2016",
    "doi": "10.1128/AAC.02985-15",
    "mechanism": "likely involves sustained release of auranofin from PLGA nanoparticles, enhancing stability and delivery to bacterial cells, leading to bactericidal activity."
  },
  {
    "drug": "auranofin",
    "pathogen": "Streptococcus pyogenes",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "Auranofin-NPs at 0.25 \u03bcM killed about 4 logs of biofilm-grown S. pyogenes cells.",
    "pmid": "27216055",
    "title": "Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.",
    "year": "2016",
    "doi": "10.1128/AAC.02985-15",
    "mechanism": "likely involves sustained release of auranofin from PLGA nanoparticles, enhancing stability and delivery to bacterial cells, leading to bactericidal activity."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "In zebrafish embryos, treatment with auranofin-NPs at 0.5 \u03bcM resulted in 100% survival against pneumococcal infection, outperforming free auranofin.",
    "pmid": "27216055",
    "title": "Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.",
    "year": "2016",
    "doi": "10.1128/AAC.02985-15",
    "mechanism": "likely involves sustained release of auranofin from PLGA nanoparticles, enhancing stability and delivery to bacterial cells, leading to bactericidal activity."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Auranofin-NPs provided about 15% greater protection than free auranofin in zebrafish embryo infection model.",
    "pmid": "27216055",
    "title": "Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.",
    "year": "2016",
    "doi": "10.1128/AAC.02985-15",
    "mechanism": "likely involves sustained release of auranofin from PLGA nanoparticles, enhancing stability and delivery to bacterial cells, leading to bactericidal activity."
  },
  {
    "drug": "fluoxetine",
    "pathogen": "Proteus mirabilis",
    "activity_type": "efflux_inhibitor|anti_biofilm",
    "evidence_type": "in_vitro|computational",
    "mic_ug_ml": 256,
    "fici": null,
    "key_result": "Fluoxetine inhibits efflux and significantly reduces crystalline biofilm formation in P. mirabilis.",
    "pmid": "28085074",
    "title": "The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.",
    "year": "2017",
    "doi": "10.3390/molecules22010114",
    "mechanism": "Inhibition of the Bcr/CflA efflux pump, disrupting biofilm-associated crystal formation and bacterial motility."
  },
  {
    "drug": "thioridazine",
    "pathogen": "Proteus mirabilis",
    "activity_type": "efflux_inhibitor|anti_biofilm",
    "evidence_type": "in_vitro|computational",
    "mic_ug_ml": 800,
    "fici": null,
    "key_result": "Thioridazine inhibits efflux, reduces crystalline biofilm formation, and extends catheter blockage time in P. mirabilis.",
    "pmid": "28085074",
    "title": "The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.",
    "year": "2017",
    "doi": "10.3390/molecules22010114",
    "mechanism": "Inhibition of the Bcr/CflA efflux pump, disrupting biofilm-associated crystal formation and bacterial motility."
  },
  {
    "drug": "thioridazine",
    "pathogen": "E. coli",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine inhibits biofilm formation in E. coli.",
    "pmid": "28085074",
    "title": "The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.",
    "year": "2017",
    "doi": "10.3390/molecules22010114",
    "mechanism": "Inhibition of the Bcr/CflA efflux pump, disrupting biofilm-associated crystal formation and bacterial motility."
  },
  {
    "drug": "thioridazine",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine inhibits biofilm formation in P. aeruginosa.",
    "pmid": "28085074",
    "title": "The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.",
    "year": "2017",
    "doi": "10.3390/molecules22010114",
    "mechanism": "Inhibition of the Bcr/CflA efflux pump, disrupting biofilm-associated crystal formation and bacterial motility."
  },
  {
    "drug": "amitriptyline",
    "pathogen": "all studied species",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 100,
    "fici": null,
    "key_result": "Amitriptyline showed the highest direct antibacterial activity with MICs ranging 100-800 mg/L against all studied species.",
    "pmid": "28606995",
    "title": "Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections.",
    "year": "2017",
    "doi": "10.15252/emmm.201707661",
    "mechanism": "efflux pump substrate activity leading to decreased intracellular drug concentration, which can be reversed by efflux pump inhibitors."
  },
  {
    "drug": "alendronate",
    "pathogen": "some clinical strains of P. aeruginosa and S. maltophilia",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 200,
    "fici": null,
    "key_result": "Alendronate was active against clinical strains of P. aeruginosa and S. maltophilia, with MICs \u2264200 mg/L in most strains.",
    "pmid": "28606995",
    "title": "Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections.",
    "year": "2017",
    "doi": "10.15252/emmm.201707661",
    "mechanism": "efflux pump substrate activity leading to decreased intracellular drug concentration, which can be reversed by efflux pump inhibitors."
  },
  {
    "drug": "carboplatin",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Carboplatin was active only against clinical strains of P. aeruginosa.",
    "pmid": "28606995",
    "title": "Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections.",
    "year": "2017",
    "doi": "10.15252/emmm.201707661",
    "mechanism": "efflux pump substrate activity leading to decreased intracellular drug concentration, which can be reversed by efflux pump inhibitors."
  },
  {
    "drug": "ticlopidine",
    "pathogen": "all studied species",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 25,
    "fici": null,
    "key_result": "Ticlopidine's MIC decreased significantly in the presence of efflux pump inhibitor, indicating efflux pump substrate activity.",
    "pmid": "28606995",
    "title": "Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections.",
    "year": "2017",
    "doi": "10.15252/emmm.201707661",
    "mechanism": "efflux pump substrate activity leading to decreased intracellular drug concentration, which can be reversed by efflux pump inhibitors."
  },
  {
    "drug": "nicergoline",
    "pathogen": "E. coli, K. pneumoniae, A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 50,
    "fici": null,
    "key_result": "Nicergoline MICs decreased from >800 mg/L to 50-200 mg/L with efflux pump inhibitor, indicating efflux pump substrate activity.",
    "pmid": "28606995",
    "title": "Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections.",
    "year": "2017",
    "doi": "10.15252/emmm.201707661",
    "mechanism": "efflux pump substrate activity leading to decreased intracellular drug concentration, which can be reversed by efflux pump inhibitors."
  },
  {
    "drug": "thiomandelic acid 3",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.07,
    "key_result": "Thiomandelic acid 3 significantly lowered the MIC of meropenem against IMP-producing Klebsiella pneumoniae with strong synergy (FIC \u22640.07).",
    "pmid": "28820574",
    "title": "Thiol-Containing Metallo-\u03b2-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem.",
    "year": "2017",
    "doi": "10.1021/acsinfecdis.7b00094",
    "mechanism": "zinc chelation and inhibition of metallo-\u03b2-lactamases by thiol groups"
  },
  {
    "drug": "2-mercapto-3-phenylpropionic acid 4",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.13,
    "key_result": "Compound 4 significantly potentiated meropenem activity against IMP-producing Klebsiella pneumoniae with strong synergy (FIC \u22640.13).",
    "pmid": "28820574",
    "title": "Thiol-Containing Metallo-\u03b2-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem.",
    "year": "2017",
    "doi": "10.1021/acsinfecdis.7b00094",
    "mechanism": "zinc chelation and inhibition of metallo-\u03b2-lactamases by thiol groups"
  },
  {
    "drug": "captopril 1",
    "pathogen": "various MBL-producing strains",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Captopril showed moderate to weak synergy at 64 \u03bcg/mL with some MBL-producing strains.",
    "pmid": "28820574",
    "title": "Thiol-Containing Metallo-\u03b2-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem.",
    "year": "2017",
    "doi": "10.1021/acsinfecdis.7b00094",
    "mechanism": "zinc chelation and inhibition of metallo-\u03b2-lactamases by thiol groups"
  },
  {
    "drug": "thiosalicylic acid 2",
    "pathogen": "various MBL-producing strains",
    "activity_type": "none",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thiosalicylic acid 2 displayed no appreciable synergy with meropenem.",
    "pmid": "28820574",
    "title": "Thiol-Containing Metallo-\u03b2-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem.",
    "year": "2017",
    "doi": "10.1021/acsinfecdis.7b00094",
    "mechanism": "zinc chelation and inhibition of metallo-\u03b2-lactamases by thiol groups"
  },
  {
    "drug": "Glatiramer Acetate",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 31,
    "fici": null,
    "key_result": "Glatiramer acetate effectively kills P. aeruginosa within minutes, showing higher activity than LL-37.",
    "pmid": "28873428",
    "title": "Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.",
    "year": "2017",
    "doi": "10.1371/journal.pone.0183457",
    "mechanism": "Glatiramer acetate disrupts bacterial membranes through its cationic and amphiphilic properties, leading to rapid bacterial cell death."
  },
  {
    "drug": "Glatiramer Acetate",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 500,
    "fici": null,
    "key_result": "Glatiramer acetate inhibits E. coli growth with a MIC of 500 \u00b5g/ml, demonstrating bactericidal activity.",
    "pmid": "28873428",
    "title": "Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.",
    "year": "2017",
    "doi": "10.1371/journal.pone.0183457",
    "mechanism": "Glatiramer acetate disrupts bacterial membranes through its cationic and amphiphilic properties, leading to rapid bacterial cell death."
  },
  {
    "drug": "Glatiramer Acetate",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Glatiramer acetate demonstrated bactericidal effects on clinical MDR isolates of A. baumannii.",
    "pmid": "28873428",
    "title": "Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.",
    "year": "2017",
    "doi": "10.1371/journal.pone.0183457",
    "mechanism": "Glatiramer acetate disrupts bacterial membranes through its cationic and amphiphilic properties, leading to rapid bacterial cell death."
  },
  {
    "drug": "Glatiramer Acetate",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 500,
    "fici": null,
    "key_result": "Glatiramer acetate is less effective against S. aureus, with limited bactericidal activity observed.",
    "pmid": "28873428",
    "title": "Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.",
    "year": "2017",
    "doi": "10.1371/journal.pone.0183457",
    "mechanism": "Glatiramer acetate disrupts bacterial membranes through its cationic and amphiphilic properties, leading to rapid bacterial cell death."
  },
  {
    "drug": "Meloxicam",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_biofilm|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Meloxicam significantly inhibits P. aeruginosa biofilm formation and enhances the efficacy of various antibiotics at sub-MIC levels.",
    "pmid": "28939900",
    "title": "Fluoxetine and thioridazine inhibit efflux and attenuate crystalline biofilm formation by Proteus mirabilis.",
    "year": "2017",
    "doi": "10.1038/s41598-017-12445-w",
    "mechanism": "Inhibition of biofilm formation, motility, extracellular matrix production, and quorum sensing gene expression, possibly through interference with QS signaling pathways."
  },
  {
    "drug": "silver (Ag+)",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 42,
    "fici": null,
    "key_result": "Silver inhibits E. coli growth with MIC of 42 \u03bcM, which is significantly reduced to 4.2 \u03bcM in the presence of ebselen.",
    "pmid": "28948099",
    "title": "Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens.",
    "year": "2017",
    "doi": "10.7717/peerj.3765",
    "mechanism": "Silver ions inhibit bacterial thioredoxin and thioredoxin reductase activities, leading to depletion of GSH, increased ROS, and disruption of essential redox systems. Ebselen acts as a competitive inhibitor of bacterial TrxR, further impairing redox balance. The combination causes rapid bacterial cell death through redox system disruption and oxidative stress."
  },
  {
    "drug": "ebselen",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen enhances the antibacterial activity of silver, reducing its MIC and exhibiting synergistic effects.",
    "pmid": "28948099",
    "title": "Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens.",
    "year": "2017",
    "doi": "10.7717/peerj.3765",
    "mechanism": "Silver ions inhibit bacterial thioredoxin and thioredoxin reductase activities, leading to depletion of GSH, increased ROS, and disruption of essential redox systems. Ebselen acts as a competitive inhibitor of bacterial TrxR, further impairing redox balance. The combination causes rapid bacterial cell death through redox system disruption and oxidative stress."
  },
  {
    "drug": "silver (Ag+)",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Silver combined with ebselen shows bactericidal activity against MDR K. pneumoniae strains.",
    "pmid": "28948099",
    "title": "Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens.",
    "year": "2017",
    "doi": "10.7717/peerj.3765",
    "mechanism": "Silver ions inhibit bacterial thioredoxin and thioredoxin reductase activities, leading to depletion of GSH, increased ROS, and disruption of essential redox systems. Ebselen acts as a competitive inhibitor of bacterial TrxR, further impairing redox balance. The combination causes rapid bacterial cell death through redox system disruption and oxidative stress."
  },
  {
    "drug": "silver (Ag+)",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Silver with ebselen is effective against drug-resistant A. baumannii strains.",
    "pmid": "28948099",
    "title": "Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens.",
    "year": "2017",
    "doi": "10.7717/peerj.3765",
    "mechanism": "Silver ions inhibit bacterial thioredoxin and thioredoxin reductase activities, leading to depletion of GSH, increased ROS, and disruption of essential redox systems. Ebselen acts as a competitive inhibitor of bacterial TrxR, further impairing redox balance. The combination causes rapid bacterial cell death through redox system disruption and oxidative stress."
  },
  {
    "drug": "silver (Ag+)",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Silver combined with ebselen exhibits bactericidal effects on MDR P. aeruginosa.",
    "pmid": "28948099",
    "title": "Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens.",
    "year": "2017",
    "doi": "10.7717/peerj.3765",
    "mechanism": "Silver ions inhibit bacterial thioredoxin and thioredoxin reductase activities, leading to depletion of GSH, increased ROS, and disruption of essential redox systems. Ebselen acts as a competitive inhibitor of bacterial TrxR, further impairing redox balance. The combination causes rapid bacterial cell death through redox system disruption and oxidative stress."
  },
  {
    "drug": "silver (Ag+)",
    "pathogen": "Enterobacter spp.",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Silver with ebselen shows synergistic bactericidal activity against MDR E. cloacae.",
    "pmid": "28948099",
    "title": "Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens.",
    "year": "2017",
    "doi": "10.7717/peerj.3765",
    "mechanism": "Silver ions inhibit bacterial thioredoxin and thioredoxin reductase activities, leading to depletion of GSH, increased ROS, and disruption of essential redox systems. Ebselen acts as a competitive inhibitor of bacterial TrxR, further impairing redox balance. The combination causes rapid bacterial cell death through redox system disruption and oxidative stress."
  },
  {
    "drug": "ebselen",
    "pathogen": "multiple GSH-positive bacteria",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen inhibits bacterial thioredoxin reductase, disrupting redox systems and enhancing silver's efficacy.",
    "pmid": "28948099",
    "title": "Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens.",
    "year": "2017",
    "doi": "10.7717/peerj.3765",
    "mechanism": "Silver ions inhibit bacterial thioredoxin and thioredoxin reductase activities, leading to depletion of GSH, increased ROS, and disruption of essential redox systems. Ebselen acts as a competitive inhibitor of bacterial TrxR, further impairing redox balance. The combination causes rapid bacterial cell death through redox system disruption and oxidative stress."
  },
  {
    "drug": "auranofin",
    "pathogen": "E. faecium (VRE)",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "Auranofin exhibits potent antimicrobial activity against VRE with an MIC of 1 \u03bcg/mL and significantly reduces VRE burden in mouse gut models.",
    "pmid": "29085751",
    "title": "Statins: antimicrobial resistance breakers or makers?",
    "year": "2017",
    "doi": "10.7717/peerj.3952",
    "mechanism": "not explicitly proposed in the paper"
  },
  {
    "drug": "verapamil",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": 512,
    "fici": null,
    "key_result": "Verapamil synergizes with anti-TB drugs such as bedaquiline and clofazimine, but this effect is not due to increased intrabacterial drug accumulation.",
    "pmid": "29340835",
    "title": "Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and healthspan in rotifers.",
    "year": "2018",
    "doi": "10.1007/s10522-018-9745-9",
    "mechanism": "Verapamil disrupts membrane energetics of M. tuberculosis, causing membrane depolarization and impairing membrane potential, which affects bacterial viability and potentiates anti-TB drugs."
  },
  {
    "drug": "verapamil",
    "pathogen": "M. tuberculosis",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 512,
    "fici": 0.25,
    "key_result": "Verapamil increases intracellular ethidium bromide accumulation, indicating efflux pump inhibition or membrane energetics disruption.",
    "pmid": "29340835",
    "title": "Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and healthspan in rotifers.",
    "year": "2018",
    "doi": "10.1007/s10522-018-9745-9",
    "mechanism": "Verapamil disrupts membrane energetics of M. tuberculosis, causing membrane depolarization and impairing membrane potential, which affects bacterial viability and potentiates anti-TB drugs."
  },
  {
    "drug": "verapamil",
    "pathogen": "M. tuberculosis",
    "activity_type": "anti_biofilm|direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 512,
    "fici": null,
    "key_result": "Verapamil exhibits bactericidal activity against nonreplicating and starved M. tuberculosis, indicating intrinsic antimycobacterial activity.",
    "pmid": "29340835",
    "title": "Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and healthspan in rotifers.",
    "year": "2018",
    "doi": "10.1007/s10522-018-9745-9",
    "mechanism": "Verapamil disrupts membrane energetics of M. tuberculosis, causing membrane depolarization and impairing membrane potential, which affects bacterial viability and potentiates anti-TB drugs."
  },
  {
    "drug": "thioridazine",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine potentiates the effect of \u03b2-lactam antibiotics against MRSA and resistance involves mutations in the cls gene affecting membrane lipid cardiolipin.",
    "pmid": "29706941",
    "title": "Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens.",
    "year": "2018",
    "doi": "10.3389/fmicb.2018.00721",
    "mechanism": "Thioridazine intercalates into bacterial membranes, depolarizes the plasma membrane, and resistance involves mutations in the cardiolipin synthase gene, suggesting membrane lipid composition influences its activity."
  },
  {
    "drug": "polymyxin B",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Polymyxin B combined with mitotane enhances bacterial killing against resistant strains and prevents resistance emergence.",
    "pmid": "29740519",
    "title": "Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis.",
    "year": "2018",
    "doi": "10.7717/peerj.4761",
    "mechanism": "Polymyxin B permeabilizes the outer membrane of Gram-negative bacteria, facilitating mitotane entry into bacterial cells where it exerts antimicrobial effects, potentially affecting cell division."
  },
  {
    "drug": "polymyxin B",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combination therapy improves bacterial killing and inhibits regrowth in resistant P. aeruginosa strains.",
    "pmid": "29740519",
    "title": "Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis.",
    "year": "2018",
    "doi": "10.7717/peerj.4761",
    "mechanism": "Polymyxin B permeabilizes the outer membrane of Gram-negative bacteria, facilitating mitotane entry into bacterial cells where it exerts antimicrobial effects, potentially affecting cell division."
  },
  {
    "drug": "polymyxin B",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Synergistic effect observed with mitotane against NDM-producing resistant K. pneumoniae.",
    "pmid": "29740519",
    "title": "Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis.",
    "year": "2018",
    "doi": "10.7717/peerj.4761",
    "mechanism": "Polymyxin B permeabilizes the outer membrane of Gram-negative bacteria, facilitating mitotane entry into bacterial cells where it exerts antimicrobial effects, potentially affecting cell division."
  },
  {
    "drug": "mitotane",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mitotane enhances polymyxin B activity, likely by permeabilizing bacterial outer membrane allowing entry.",
    "pmid": "29740519",
    "title": "Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis.",
    "year": "2018",
    "doi": "10.7717/peerj.4761",
    "mechanism": "Polymyxin B permeabilizes the outer membrane of Gram-negative bacteria, facilitating mitotane entry into bacterial cells where it exerts antimicrobial effects, potentially affecting cell division."
  },
  {
    "drug": "mitotane",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Synergistic killing with polymyxin B suggests mitotane acts as an adjuvant to improve efficacy.",
    "pmid": "29740519",
    "title": "Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis.",
    "year": "2018",
    "doi": "10.7717/peerj.4761",
    "mechanism": "Polymyxin B permeabilizes the outer membrane of Gram-negative bacteria, facilitating mitotane entry into bacterial cells where it exerts antimicrobial effects, potentially affecting cell division."
  },
  {
    "drug": "mitotane",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combination prevents regrowth and resistance in resistant K. pneumoniae strains.",
    "pmid": "29740519",
    "title": "Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis.",
    "year": "2018",
    "doi": "10.7717/peerj.4761",
    "mechanism": "Polymyxin B permeabilizes the outer membrane of Gram-negative bacteria, facilitating mitotane entry into bacterial cells where it exerts antimicrobial effects, potentially affecting cell division."
  },
  {
    "drug": "flubendazole",
    "pathogen": "Cryptococcus deuterogattii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.039,
    "fici": null,
    "key_result": "Flubendazole was very active against all pathogenic Cryptococcus species, including fluconazole-resistant isolates.",
    "pmid": "29844350",
    "title": "Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.",
    "year": "2018",
    "doi": "10.1038/s41598-018-26674-0",
    "mechanism": "calcium channel blockade and potential disruption of fungal cellular processes"
  },
  {
    "drug": "nifedipine",
    "pathogen": "Cryptococcus deuterogattii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nifedipine inhibited Cryptococcus and was also effective against Candida, Saccharomyces, and Aspergillus.",
    "pmid": "29844350",
    "title": "Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.",
    "year": "2018",
    "doi": "10.1038/s41598-018-26674-0",
    "mechanism": "calcium channel blockade and potential disruption of fungal cellular processes"
  },
  {
    "drug": "nisoldipine",
    "pathogen": "Cryptococcus deuterogattii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nisoldipine inhibited Cryptococcus and was effective against Candida, Saccharomyces, and Aspergillus.",
    "pmid": "29844350",
    "title": "Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.",
    "year": "2018",
    "doi": "10.1038/s41598-018-26674-0",
    "mechanism": "calcium channel blockade and potential disruption of fungal cellular processes"
  },
  {
    "drug": "felodipine",
    "pathogen": "Cryptococcus deuterogattii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Felodipine inhibited Cryptococcus species.",
    "pmid": "29844350",
    "title": "Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.",
    "year": "2018",
    "doi": "10.1038/s41598-018-26674-0",
    "mechanism": "calcium channel blockade and potential disruption of fungal cellular processes"
  },
  {
    "drug": "UVI5008",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "UVI5008 inhibits growth of MSSA with an MIC of 8 \u03bcM and MRSA with an MIC of 25 \u03bcM.",
    "pmid": "29899092",
    "title": "Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.",
    "year": "2018",
    "doi": "10.1128/JVI.00954-18",
    "mechanism": "interferes with bacterial DNA gyrase, disrupting DNA replication and structural integrity."
  },
  {
    "drug": "UVI5008",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 25,
    "fici": null,
    "key_result": "UVI5008 degrades preformed biofilms of S. aureus by over 20% at 25 \u03bcM.",
    "pmid": "29899092",
    "title": "Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.",
    "year": "2018",
    "doi": "10.1128/JVI.00954-18",
    "mechanism": "interferes with bacterial DNA gyrase, disrupting DNA replication and structural integrity."
  },
  {
    "drug": "Demeclocycline",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial|light_activated",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Demeclocycline combined with blue light effectively eradicates E. coli, including tetracycline-resistant strains, with >6 log reduction.",
    "pmid": "30013953",
    "title": "Evaluating New Compounds to Treat Burkholderia pseudomallei Infections.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00210",
    "mechanism": "Photoactivation of tetracyclines with UVA or blue light produces reactive oxygen species (ROS) that kill bacteria, and tetracyclines can accumulate in bacterial ribosomes where they can be photoactivated to produce antimicrobial effects."
  },
  {
    "drug": "Demeclocycline",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial|light_activated",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Demeclocycline plus blue light kills MRSA bacteria with >6 log reduction at 10 \u03bcM concentration.",
    "pmid": "30013953",
    "title": "Evaluating New Compounds to Treat Burkholderia pseudomallei Infections.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00210",
    "mechanism": "Photoactivation of tetracyclines with UVA or blue light produces reactive oxygen species (ROS) that kill bacteria, and tetracyclines can accumulate in bacterial ribosomes where they can be photoactivated to produce antimicrobial effects."
  },
  {
    "drug": "Doxycycline",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial|light_activated",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Doxycycline combined with UVA light enhances bacterial killing, including tetracycline-resistant strains.",
    "pmid": "30013953",
    "title": "Evaluating New Compounds to Treat Burkholderia pseudomallei Infections.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00210",
    "mechanism": "Photoactivation of tetracyclines with UVA or blue light produces reactive oxygen species (ROS) that kill bacteria, and tetracyclines can accumulate in bacterial ribosomes where they can be photoactivated to produce antimicrobial effects."
  },
  {
    "drug": "Tetracycline",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial|light_activated",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tetracycline plus UVA light shows limited bacterial killing (~3-4 logs).",
    "pmid": "30013953",
    "title": "Evaluating New Compounds to Treat Burkholderia pseudomallei Infections.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00210",
    "mechanism": "Photoactivation of tetracyclines with UVA or blue light produces reactive oxygen species (ROS) that kill bacteria, and tetracyclines can accumulate in bacterial ribosomes where they can be photoactivated to produce antimicrobial effects."
  },
  {
    "drug": "phenothiazine",
    "pathogen": "Mycobacterium smegmatis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 6.25,
    "fici": null,
    "key_result": "The functionalized phenothiazine demonstrated an MIC value comparable to the parent phenothiazine against M. smegmatis.",
    "pmid": "30085063",
    "title": "Strategies to combat antimicrobial resistance: anti-plasmid and plasmid curing.",
    "year": "2018",
    "doi": "10.1093/femsre/fuy031",
    "mechanism": "not explicitly proposed in the paper"
  },
  {
    "drug": "niclosamide",
    "pathogen": "A. baumannii",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide in combination with colistin showed synergistic activity against colistin-resistant A. baumannii strains, reducing bacterial counts significantly.",
    "pmid": "30089175",
    "title": "Molecular mechanisms of thioridazine resistance in Staphylococcus aureus.",
    "year": "2018",
    "doi": "10.1371/journal.pone.0201767",
    "mechanism": "Potential disruption of bacterial membrane charge and enhancement of colistin activity through synergistic interaction."
  },
  {
    "drug": "niclosamide",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide combined with colistin demonstrated synergistic activity against colistin-resistant K. pneumoniae strains, especially when colistin was added for a second time at 4 hours.",
    "pmid": "30089175",
    "title": "Molecular mechanisms of thioridazine resistance in Staphylococcus aureus.",
    "year": "2018",
    "doi": "10.1371/journal.pone.0201767",
    "mechanism": "Potential disruption of bacterial membrane charge and enhancement of colistin activity through synergistic interaction."
  },
  {
    "drug": "ascorbic acid",
    "pathogen": "Enterobacteriaceae",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ascorbic acid has been shown to impact plasmid stability and may contribute to plasmid curing in bacteria.",
    "pmid": "30250466",
    "title": "Treating Influenza Infection, From Now and Into the Future.",
    "year": "2018",
    "doi": "10.3389/fimmu.2018.01946",
    "mechanism": "The proposed mechanisms include interference with plasmid replication, stability, conjugation, and maintenance, often through chemical or drug interactions that destabilize plasmid DNA or inhibit transfer systems."
  },
  {
    "drug": "chlorpromazine",
    "pathogen": "Enterobacteriaceae",
    "activity_type": "anti_plasmid",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Chlorpromazine, a psychotropic drug, has demonstrated potential to interfere with plasmid maintenance and reduce ARG prevalence.",
    "pmid": "30250466",
    "title": "Treating Influenza Infection, From Now and Into the Future.",
    "year": "2018",
    "doi": "10.3389/fimmu.2018.01946",
    "mechanism": "The proposed mechanisms include interference with plasmid replication, stability, conjugation, and maintenance, often through chemical or drug interactions that destabilize plasmid DNA or inhibit transfer systems."
  },
  {
    "drug": "aminocoumarins",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Aminocoumarins, including novobiocin, can inhibit plasmid replication, aiding in plasmid curing efforts.",
    "pmid": "30250466",
    "title": "Treating Influenza Infection, From Now and Into the Future.",
    "year": "2018",
    "doi": "10.3389/fimmu.2018.01946",
    "mechanism": "The proposed mechanisms include interference with plasmid replication, stability, conjugation, and maintenance, often through chemical or drug interactions that destabilize plasmid DNA or inhibit transfer systems."
  },
  {
    "drug": "quinolones",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Quinolones have been used to target plasmid stability and conjugation, contributing to plasmid curing strategies.",
    "pmid": "30250466",
    "title": "Treating Influenza Infection, From Now and Into the Future.",
    "year": "2018",
    "doi": "10.3389/fimmu.2018.01946",
    "mechanism": "The proposed mechanisms include interference with plasmid replication, stability, conjugation, and maintenance, often through chemical or drug interactions that destabilize plasmid DNA or inhibit transfer systems."
  },
  {
    "drug": "rifampicin",
    "pathogen": "various bacteria",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Rifampicin has been explored as part of combination therapies to facilitate plasmid loss and combat AMR.",
    "pmid": "30250466",
    "title": "Treating Influenza Infection, From Now and Into the Future.",
    "year": "2018",
    "doi": "10.3389/fimmu.2018.01946",
    "mechanism": "The proposed mechanisms include interference with plasmid replication, stability, conjugation, and maintenance, often through chemical or drug interactions that destabilize plasmid DNA or inhibit transfer systems."
  },
  {
    "drug": "diltiazem",
    "pathogen": "influenza A(H1N1)pdm09",
    "activity_type": "host_targeted_inhibitor|synergy",
    "evidence_type": "in_vitro|in_vivo|ex_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Diltiazem, a calcium channel blocker, demonstrated significant antiviral activity against influenza A(H1N1)pdm09 in vitro, in vivo, and ex vivo, and enhanced the efficacy of oseltamivir when used in combination.",
    "pmid": "30459446",
    "title": "GBF1 and Arf1 interact with Miro and regulate mitochondrial positioning within cells.",
    "year": "2018",
    "doi": "10.1038/s41598-018-35190-0",
    "mechanism": "modulation of host antiviral response and cholesterol metabolism"
  },
  {
    "drug": "itraconazole",
    "pathogen": "breast cancer cells",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Itraconazole combined with 5-fluorouracil decreased cell viability and proliferation in breast cancer cell lines, showing potential as a repurposed adjuvant therapy.",
    "pmid": "30479094",
    "title": "Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.",
    "year": "2019",
    "doi": "10.3802/jgo.2019.30.e10",
    "mechanism": "The proposed mechanism involves the drugs interfering with cellular processes such as drug efflux inhibition (verapamil) and disruption of fungal-like pathways or cellular metabolism (itraconazole), thereby enhancing the efficacy of 5-fluorouracil against breast cancer cells."
  },
  {
    "drug": "verapamil",
    "pathogen": "breast cancer cells",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Verapamil combined with 5-fluorouracil reduced cell viability and proliferation, indicating potential to enhance breast cancer treatment.",
    "pmid": "30479094",
    "title": "Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.",
    "year": "2019",
    "doi": "10.3802/jgo.2019.30.e10",
    "mechanism": "The proposed mechanism involves the drugs interfering with cellular processes such as drug efflux inhibition (verapamil) and disruption of fungal-like pathways or cellular metabolism (itraconazole), thereby enhancing the efficacy of 5-fluorouracil against breast cancer cells."
  },
  {
    "drug": "trans-cinnamaldehyde",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "trans-cinnamaldehyde significantly inhibits quorum sensing and reduces virulence factor production in P. aeruginosa without bactericidal effects.",
    "pmid": "30558247",
    "title": "Study of New Therapeutic Strategies to Combat Breast Cancer Using Drug Combinations.",
    "year": "2018",
    "doi": "10.3390/biom8040175",
    "mechanism": "interference with quorum sensing regulatory systems, downregulation of virulence gene expression"
  },
  {
    "drug": "salicylic acid",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "salicylic acid significantly inhibits quorum sensing and reduces virulence factor production in P. aeruginosa without bactericidal effects.",
    "pmid": "30558247",
    "title": "Study of New Therapeutic Strategies to Combat Breast Cancer Using Drug Combinations.",
    "year": "2018",
    "doi": "10.3390/biom8040175",
    "mechanism": "interference with quorum sensing regulatory systems, downregulation of virulence gene expression"
  },
  {
    "drug": "YM155",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 50,
    "fici": null,
    "key_result": "YM155 exhibits weak antibacterial activity against MRSA with an MIC of 50 \u03bcg/ml.",
    "pmid": "30633761",
    "title": "Sugar and iron: Toward understanding the antibacterial effect of ciclopirox in Escherichia coli.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0210547",
    "mechanism": "The antibacterial mechanism of c5 involves the generation of reactive oxygen species (ROS), likely during respiratory electron transfer, leading to bacterial cell damage."
  },
  {
    "drug": "c5",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 3.13,
    "fici": null,
    "key_result": "Chemical modification of YM155 to produce c5 significantly enhances antibacterial activity against MRSA with an MIC of 3.13 \u03bcg/ml.",
    "pmid": "30633761",
    "title": "Sugar and iron: Toward understanding the antibacterial effect of ciclopirox in Escherichia coli.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0210547",
    "mechanism": "The antibacterial mechanism of c5 involves the generation of reactive oxygen species (ROS), likely during respiratory electron transfer, leading to bacterial cell damage."
  },
  {
    "drug": "c5",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The activity of c5 involves generation of reactive oxygen species (ROS), linked to respiratory electron transfer.",
    "pmid": "30633761",
    "title": "Sugar and iron: Toward understanding the antibacterial effect of ciclopirox in Escherichia coli.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0210547",
    "mechanism": "The antibacterial mechanism of c5 involves the generation of reactive oxygen species (ROS), likely during respiratory electron transfer, leading to bacterial cell damage."
  },
  {
    "drug": "c5",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The antibacterial activity of c5 is compromised by antioxidants and anaerobic conditions, indicating ROS involvement.",
    "pmid": "30633761",
    "title": "Sugar and iron: Toward understanding the antibacterial effect of ciclopirox in Escherichia coli.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0210547",
    "mechanism": "The antibacterial mechanism of c5 involves the generation of reactive oxygen species (ROS), likely during respiratory electron transfer, leading to bacterial cell damage."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin released from polyurethane coatings effectively inhibited MRSA growth for 8 to 26 days and completely prevented MRSA biofilm formation in vitro.",
    "pmid": "30658640",
    "title": "Combined antibacterial effect of essential oils from three most commonly used Ethiopian traditional medicinal plants on multidrug resistant bacteria.",
    "year": "2019",
    "doi": "10.1186/s12906-019-2429-4",
    "mechanism": "Inhibition of bacterial thioredoxin reductase disrupting redox balance, leading to bacterial cell death."
  },
  {
    "drug": "polymyxin B",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "Polymyxin B alone has limited effect on polymyxin-resistant P. aeruginosa but disrupts outer membrane integrity.",
    "pmid": "30662875",
    "title": "Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant Acinetobacter baumannii.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00438",
    "mechanism": "Disruption of bacterial cell envelope biogenesis and inhibition of lipid A modifications that confer polymyxin resistance, leading to increased membrane permeability and bacterial death."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tamoxifen alone has minimal impact on bacterial metabolism but affects lipid metabolites.",
    "pmid": "30662875",
    "title": "Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant Acinetobacter baumannii.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00438",
    "mechanism": "Disruption of bacterial cell envelope biogenesis and inhibition of lipid A modifications that confer polymyxin resistance, leading to increased membrane permeability and bacterial death."
  },
  {
    "drug": "Polymyxin B + Tamoxifen",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The combination exhibits a synergistic bactericidal effect by disrupting cell envelope biogenesis and inhibiting lipid A modifications conferring resistance.",
    "pmid": "30662875",
    "title": "Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant Acinetobacter baumannii.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00438",
    "mechanism": "Disruption of bacterial cell envelope biogenesis and inhibition of lipid A modifications that confer polymyxin resistance, leading to increased membrane permeability and bacterial death."
  },
  {
    "drug": "5-fluorouracil",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "5-fluorouracil resensitized A. baumannii to azithromycin and colistin in combination therapy.",
    "pmid": "30665342",
    "title": "Investigating the virulence genes and antibiotic susceptibility patterns of Vibrio cholerae O1 in environmental and clinical isolates in Accra, Ghana.",
    "year": "2019",
    "doi": "10.1186/s12879-019-3714-z",
    "mechanism": "The non-antimicrobial drugs act as adjuvants, resensitizing multidrug resistant A. baumannii to existing antibiotics, likely by modulating bacterial resistance mechanisms or enhancing antibiotic uptake."
  },
  {
    "drug": "fluspirilene",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Fluspirilene enhanced colistin activity against MDR A. baumannii, reducing its IC50 by 30-fold.",
    "pmid": "30665342",
    "title": "Investigating the virulence genes and antibiotic susceptibility patterns of Vibrio cholerae O1 in environmental and clinical isolates in Accra, Ghana.",
    "year": "2019",
    "doi": "10.1186/s12879-019-3714-z",
    "mechanism": "The non-antimicrobial drugs act as adjuvants, resensitizing multidrug resistant A. baumannii to existing antibiotics, likely by modulating bacterial resistance mechanisms or enhancing antibiotic uptake."
  },
  {
    "drug": "Bay 11-7082",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Bay 11-7082 increased colistin efficacy, decreasing its IC50 by 4-fold.",
    "pmid": "30665342",
    "title": "Investigating the virulence genes and antibiotic susceptibility patterns of Vibrio cholerae O1 in environmental and clinical isolates in Accra, Ghana.",
    "year": "2019",
    "doi": "10.1186/s12879-019-3714-z",
    "mechanism": "The non-antimicrobial drugs act as adjuvants, resensitizing multidrug resistant A. baumannii to existing antibiotics, likely by modulating bacterial resistance mechanisms or enhancing antibiotic uptake."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "Ciclopirox inhibits growth of E. coli clinical isolates regardless of antibiotic resistance status.",
    "pmid": "30675370",
    "title": "Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention.",
    "year": "2019",
    "doi": "10.1038/s41522-018-0075-0",
    "mechanism": "Ciclopirox alters lipopolysaccharide structure, stimulates enterobactin production, and interferes with iron transport pathways, affecting bacterial growth and motility."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "Ciclopirox equally blocks growth of A. baumannii clinical isolates, unaffected by resistance mechanisms.",
    "pmid": "30675370",
    "title": "Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention.",
    "year": "2019",
    "doi": "10.1038/s41522-018-0075-0",
    "mechanism": "Ciclopirox alters lipopolysaccharide structure, stimulates enterobactin production, and interferes with iron transport pathways, affecting bacterial growth and motility."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "Ciclopirox inhibits K. pneumoniae growth regardless of resistance profile.",
    "pmid": "30675370",
    "title": "Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention.",
    "year": "2019",
    "doi": "10.1038/s41522-018-0075-0",
    "mechanism": "Ciclopirox alters lipopolysaccharide structure, stimulates enterobactin production, and interferes with iron transport pathways, affecting bacterial growth and motility."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Disruption of genes involved in enterobactin transport and synthesis lowers MIC, indicating interference with iron acquisition pathways.",
    "pmid": "30675370",
    "title": "Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention.",
    "year": "2019",
    "doi": "10.1038/s41522-018-0075-0",
    "mechanism": "Ciclopirox alters lipopolysaccharide structure, stimulates enterobactin production, and interferes with iron transport pathways, affecting bacterial growth and motility."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ciclopirox induces enterobactin production and affects bacterial swarming behavior.",
    "pmid": "30675370",
    "title": "Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention.",
    "year": "2019",
    "doi": "10.1038/s41522-018-0075-0",
    "mechanism": "Ciclopirox alters lipopolysaccharide structure, stimulates enterobactin production, and interferes with iron transport pathways, affecting bacterial growth and motility."
  },
  {
    "drug": "Cyclosporine-A",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cyclosporine-A inhibits biofilm formation and interacts with PpiB, reducing drug tolerance in M.tb.",
    "pmid": "30745898",
    "title": "Drug Repurposing for the Treatment of Bacterial and Fungal Infections.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.00041",
    "mechanism": "Inhibition of PpiB, a peptidyl-prolyl isomerase involved in biofilm formation and drug tolerance, by binding of repurposed drugs such as cyclosporine-A and acarbose, and disruption of biofilm matrix by gallium nanoparticles."
  },
  {
    "drug": "Acarbose",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Acarbose interacts with PpiB and inhibits biofilm formation in M.tb, potentially enhancing drug efficacy.",
    "pmid": "30745898",
    "title": "Drug Repurposing for the Treatment of Bacterial and Fungal Infections.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.00041",
    "mechanism": "Inhibition of PpiB, a peptidyl-prolyl isomerase involved in biofilm formation and drug tolerance, by binding of repurposed drugs such as cyclosporine-A and acarbose, and disruption of biofilm matrix by gallium nanoparticles."
  },
  {
    "drug": "Gallium nanoparticle (GaNP)",
    "pathogen": "M. tuberculosis",
    "activity_type": "bactericidal|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Gallium nanoparticles exhibit bactericidal activity and disrupt M.tb biofilm formation.",
    "pmid": "30745898",
    "title": "Drug Repurposing for the Treatment of Bacterial and Fungal Infections.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.00041",
    "mechanism": "Inhibition of PpiB, a peptidyl-prolyl isomerase involved in biofilm formation and drug tolerance, by binding of repurposed drugs such as cyclosporine-A and acarbose, and disruption of biofilm matrix by gallium nanoparticles."
  },
  {
    "drug": "Florfenicol",
    "pathogen": "Mycobacterium bovis BCG",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Resistant mutants to florfenicol suggest new pathways that could be exploited in drug repurposing for TB.",
    "pmid": "30761132",
    "title": "Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.",
    "year": "2019",
    "doi": "10.3389/fimmu.2019.00060",
    "mechanism": "Targeting of novel bacterial pathways as indicated by resistant mutant analysis, suggesting these drugs may inhibit mycobacterial growth through mechanisms distinct from their original indications."
  },
  {
    "drug": "Vanoxerine",
    "pathogen": "Mycobacterium bovis BCG",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Resistant mutants to vanoxerine highlight potential new targets for anti-mycobacterial drug development.",
    "pmid": "30761132",
    "title": "Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.",
    "year": "2019",
    "doi": "10.3389/fimmu.2019.00060",
    "mechanism": "Targeting of novel bacterial pathways as indicated by resistant mutant analysis, suggesting these drugs may inhibit mycobacterial growth through mechanisms distinct from their original indications."
  },
  {
    "drug": "pentamidine",
    "pathogen": "Mycobacterium bovis BCG",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mutant analysis of pentamidine resistance indicates possible new pathways for TB drug targeting.",
    "pmid": "30761132",
    "title": "Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.",
    "year": "2019",
    "doi": "10.3389/fimmu.2019.00060",
    "mechanism": "Targeting of novel bacterial pathways as indicated by resistant mutant analysis, suggesting these drugs may inhibit mycobacterial growth through mechanisms distinct from their original indications."
  },
  {
    "drug": "essential oils from B. cuspidata and T. schimperi",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.39,
    "fici": null,
    "key_result": "The combined essential oils of B. cuspidata and T. schimperi showed a 39 mm inhibition zone and MIC of 0.39 \u03bcl/ml against MRSA.",
    "pmid": "30852658",
    "title": "Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors.",
    "year": "2019",
    "doi": "10.1007/s00253-019-09618-0",
    "mechanism": "The essential oils likely exert antimicrobial effects through disruption of bacterial cell membranes, leakage of cell contents, and inhibition of protein synthesis and DNA replication."
  },
  {
    "drug": "essential oils from B. cuspidata and T. schimperi",
    "pathogen": "MDR E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.39,
    "fici": null,
    "key_result": "The combined oils exhibited inhibition zones of 28-35 mm, MIC of 0.39-6.25 \u03bcl/ml, and MBC of 0.78-12.5 \u03bcl/ml against MDR E. coli.",
    "pmid": "30852658",
    "title": "Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors.",
    "year": "2019",
    "doi": "10.1007/s00253-019-09618-0",
    "mechanism": "The essential oils likely exert antimicrobial effects through disruption of bacterial cell membranes, leakage of cell contents, and inhibition of protein synthesis and DNA replication."
  },
  {
    "drug": "essential oils from B. cuspidata and B. ogadensis",
    "pathogen": "MDR K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.78,
    "fici": null,
    "key_result": "The combination had MIC values ranging from 0.78-6.25 \u03bcl/ml against K. pneumoniae.",
    "pmid": "30852658",
    "title": "Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors.",
    "year": "2019",
    "doi": "10.1007/s00253-019-09618-0",
    "mechanism": "The essential oils likely exert antimicrobial effects through disruption of bacterial cell membranes, leakage of cell contents, and inhibition of protein synthesis and DNA replication."
  },
  {
    "drug": "essential oils from B. cuspidata and B. ogadensis",
    "pathogen": "MDR E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.78,
    "fici": null,
    "key_result": "The combination showed MIC values from 0.78-6.25 \u03bcl/ml against E. coli.",
    "pmid": "30852658",
    "title": "Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors.",
    "year": "2019",
    "doi": "10.1007/s00253-019-09618-0",
    "mechanism": "The essential oils likely exert antimicrobial effects through disruption of bacterial cell membranes, leakage of cell contents, and inhibition of protein synthesis and DNA replication."
  },
  {
    "drug": "essential oils from B. cuspidata and B. ogadensis",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1.56,
    "fici": null,
    "key_result": "The combination had MIC of 1.56 \u03bcl/ml against MRSA.",
    "pmid": "30852658",
    "title": "Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors.",
    "year": "2019",
    "doi": "10.1007/s00253-019-09618-0",
    "mechanism": "The essential oils likely exert antimicrobial effects through disruption of bacterial cell membranes, leakage of cell contents, and inhibition of protein synthesis and DNA replication."
  },
  {
    "drug": "5-fluorouracil (5-FU)",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 20,
    "fici": null,
    "key_result": "5-FU exhibits growth inhibitory activity against P. aeruginosa and can select for resistant mutants with mutations in the upp gene.",
    "pmid": "30858845",
    "title": "Redirecting an Anticancer to an Antibacterial Hit Against Methicillin-Resistant Staphylococcus aureus.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.00350",
    "mechanism": "5-FU inhibits bacterial growth by targeting pyrimidine metabolism, with resistance arising from mutations in the upp gene; 5-FC requires conversion to 5-FU via cytosine deaminase for activity, but poor conversion limits its efficacy."
  },
  {
    "drug": "5-fluorocytosine (5-FC)",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "5-FC does not significantly inhibit bacterial growth but reduces pyoverdine production; however, it can select for resistant mutants that are insensitive to both 5-FC and 5-FU.",
    "pmid": "30858845",
    "title": "Redirecting an Anticancer to an Antibacterial Hit Against Methicillin-Resistant Staphylococcus aureus.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.00350",
    "mechanism": "5-FU inhibits bacterial growth by targeting pyrimidine metabolism, with resistance arising from mutations in the upp gene; 5-FC requires conversion to 5-FU via cytosine deaminase for activity, but poor conversion limits its efficacy."
  },
  {
    "drug": "niclosamide",
    "pathogen": "Mycobacterium tuberculosis Beijing strain",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "Niclosamide inhibits growth of M. tuberculosis Beijing strain in liquid culture at concentrations as low as 5 \u03bcM.",
    "pmid": "30861059",
    "title": "Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0213713",
    "mechanism": "Inhibition of host cell signaling pathways such as NF-\u03baB, leading to suppression of HIV pro-virus transcription and direct inhibition of mycobacterial growth."
  },
  {
    "drug": "niclosamide",
    "pathogen": "Mycobacterium bovis BCG",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "Niclosamide limits growth of M. bovis BCG in liquid culture dose-dependently.",
    "pmid": "30861059",
    "title": "Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0213713",
    "mechanism": "Inhibition of host cell signaling pathways such as NF-\u03baB, leading to suppression of HIV pro-virus transcription and direct inhibition of mycobacterial growth."
  },
  {
    "drug": "niclosamide",
    "pathogen": "HIV-1",
    "activity_type": "direct_antiviral",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1.25,
    "fici": null,
    "key_result": "Niclosamide inhibits HIV replication in human macrophages and T cells by affecting post-integration pro-virus transcription.",
    "pmid": "30861059",
    "title": "Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0213713",
    "mechanism": "Inhibition of host cell signaling pathways such as NF-\u03baB, leading to suppression of HIV pro-virus transcription and direct inhibition of mycobacterial growth."
  },
  {
    "drug": "niclosamide",
    "pathogen": "HIV-1",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1.25,
    "fici": null,
    "key_result": "Niclosamide reduces HIV p24 expression in infected cells without toxicity, indicating suppression of viral transcription.",
    "pmid": "30861059",
    "title": "Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0213713",
    "mechanism": "Inhibition of host cell signaling pathways such as NF-\u03baB, leading to suppression of HIV pro-virus transcription and direct inhibition of mycobacterial growth."
  },
  {
    "drug": "Lifirafenib",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Lifirafenib predicted to inhibit multiple enzymes in the phenazine biosynthesis pathway, potentially reducing virulence of P. aeruginosa.",
    "pmid": "30915278",
    "title": "Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in Pseudomonas aeruginosa.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00049",
    "mechanism": "Inhibition of enzymes involved in phenazine biosynthesis, disrupting pyocyanin production and bacterial virulence."
  },
  {
    "drug": "statins (class)",
    "pathogen": "ovarian cancer",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Statins have shown to inhibit ovarian cancer cell proliferation and improve overall survival in patients.",
    "pmid": "31028540",
    "title": "The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.",
    "year": "2019",
    "doi": "10.1007/s00432-019-02920-4",
    "mechanism": "Repositioned drugs may exert antitumor effects through various mechanisms such as inhibition of cell proliferation, induction of apoptosis, suppression of metastasis, and modulation of tumor microenvironment, often via pathways like the mevalonate pathway or immune modulation."
  },
  {
    "drug": "Bisphosphonates",
    "pathogen": "ovarian cancer",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Bisphosphonates inhibit proliferation of ovarian cancer cell lines and delay tumor formation in mouse models.",
    "pmid": "31028540",
    "title": "The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.",
    "year": "2019",
    "doi": "10.1007/s00432-019-02920-4",
    "mechanism": "Repositioned drugs may exert antitumor effects through various mechanisms such as inhibition of cell proliferation, induction of apoptosis, suppression of metastasis, and modulation of tumor microenvironment, often via pathways like the mevalonate pathway or immune modulation."
  },
  {
    "drug": "metformin",
    "pathogen": "ovarian cancer",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Metformin use is associated with improved progression-free survival and overall survival in ovarian cancer patients.",
    "pmid": "31028540",
    "title": "The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.",
    "year": "2019",
    "doi": "10.1007/s00432-019-02920-4",
    "mechanism": "Repositioned drugs may exert antitumor effects through various mechanisms such as inhibition of cell proliferation, induction of apoptosis, suppression of metastasis, and modulation of tumor microenvironment, often via pathways like the mevalonate pathway or immune modulation."
  },
  {
    "drug": "Non-steroidal anti-inflammatory drugs",
    "pathogen": "ovarian cancer",
    "activity_type": "potential_therapy",
    "evidence_type": "not_specified",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "NSAIDs are mentioned as drugs with potential for repositioning but specific evidence for ovarian cancer is not detailed.",
    "pmid": "31028540",
    "title": "The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.",
    "year": "2019",
    "doi": "10.1007/s00432-019-02920-4",
    "mechanism": "Repositioned drugs may exert antitumor effects through various mechanisms such as inhibition of cell proliferation, induction of apoptosis, suppression of metastasis, and modulation of tumor microenvironment, often via pathways like the mevalonate pathway or immune modulation."
  },
  {
    "drug": "ivermectin",
    "pathogen": "ovarian cancer",
    "activity_type": "potential_therapy",
    "evidence_type": "not_specified",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ivermectin is listed as a candidate for drug repositioning in ovarian cancer, but specific activity evidence is not provided.",
    "pmid": "31028540",
    "title": "The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.",
    "year": "2019",
    "doi": "10.1007/s00432-019-02920-4",
    "mechanism": "Repositioned drugs may exert antitumor effects through various mechanisms such as inhibition of cell proliferation, induction of apoptosis, suppression of metastasis, and modulation of tumor microenvironment, often via pathways like the mevalonate pathway or immune modulation."
  },
  {
    "drug": "Itraconazole",
    "pathogen": "ovarian cancer",
    "activity_type": "potential_therapy",
    "evidence_type": "not_specified",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Itraconazole is mentioned as a candidate for drug repositioning, with no detailed activity evidence provided.",
    "pmid": "31028540",
    "title": "The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.",
    "year": "2019",
    "doi": "10.1007/s00432-019-02920-4",
    "mechanism": "Repositioned drugs may exert antitumor effects through various mechanisms such as inhibition of cell proliferation, induction of apoptosis, suppression of metastasis, and modulation of tumor microenvironment, often via pathways like the mevalonate pathway or immune modulation."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ciclopirox demonstrated antibacterial activity against carbapenem and colistin-resistant K. pneumoniae in vitro.",
    "pmid": "31080089",
    "title": "Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing).",
    "year": "2019",
    "doi": "10.1016/j.tube.2019.04.008",
    "mechanism": "The proposed mechanisms involve disruption of bacterial metabolic pathways, iron metabolism interference, and targeting of bacterial DNA or membrane integrity, independent of traditional antibiotic targets."
  },
  {
    "drug": "gallium nitrate",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Gallium showed potential as an adjuvant to disrupt iron metabolism in resistant K. pneumoniae in vitro.",
    "pmid": "31080089",
    "title": "Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing).",
    "year": "2019",
    "doi": "10.1016/j.tube.2019.04.008",
    "mechanism": "The proposed mechanisms involve disruption of bacterial metabolic pathways, iron metabolism interference, and targeting of bacterial DNA or membrane integrity, independent of traditional antibiotic targets."
  },
  {
    "drug": "zidovudine",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Zidovudine exhibited antibacterial activity against MDR A. baumannii in vitro.",
    "pmid": "31080089",
    "title": "Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing).",
    "year": "2019",
    "doi": "10.1016/j.tube.2019.04.008",
    "mechanism": "The proposed mechanisms involve disruption of bacterial metabolic pathways, iron metabolism interference, and targeting of bacterial DNA or membrane integrity, independent of traditional antibiotic targets."
  },
  {
    "drug": "gentamicin",
    "pathogen": "drug-resistant bacteria",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Synergistic antibacterial effects observed between highly membrane-active AMPs like protegrin 1 and gentamicin, suggesting increased bioavailability.",
    "pmid": "31114762",
    "title": "Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00128",
    "mechanism": "The proposed mechanism of antimicrobial synergy involves increased bioavailability of antibiotics due to membrane disruption by AMPs, modulation of bacterial membrane interaction dynamics, and combined membrane destabilization effects."
  },
  {
    "drug": "rifampicin",
    "pathogen": "drug-resistant bacteria",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Synergy mainly occurs between membrane-active AMPs and antibiotics with intracellular targets, indicating enhanced bacterial membrane interaction.",
    "pmid": "31114762",
    "title": "Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00128",
    "mechanism": "The proposed mechanism of antimicrobial synergy involves increased bioavailability of antibiotics due to membrane disruption by AMPs, modulation of bacterial membrane interaction dynamics, and combined membrane destabilization effects."
  },
  {
    "drug": "silver nanoparticles",
    "pathogen": "drug-resistant bacteria",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combined use with other antimicrobials can reduce effective concentrations and improve efficacy against resistant strains.",
    "pmid": "31114762",
    "title": "Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00128",
    "mechanism": "The proposed mechanism of antimicrobial synergy involves increased bioavailability of antibiotics due to membrane disruption by AMPs, modulation of bacterial membrane interaction dynamics, and combined membrane destabilization effects."
  },
  {
    "drug": "salinomycin",
    "pathogen": "small cell lung cancer (SCLC)",
    "activity_type": "adjuvant|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "Salinomycin exerted dose-dependent cytotoxicity against SCLC lines, with variable activity on tumorospheres.",
    "pmid": "31281836",
    "title": "Antitumor Effect of Albendazole on Cutaneous Squamous Cell Carcinoma (SCC) Cells.",
    "year": "2019",
    "doi": "10.1155/2019/3689517",
    "mechanism": "Inhibition of Wnt/\u03b2-catenin signaling and mitochondrial uncoupling, targeting cancer stemness and resistance pathways."
  },
  {
    "drug": "niclosamide",
    "pathogen": "small cell lung cancer (SCLC)",
    "activity_type": "adjuvant|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "Niclosamide showed high activity against some SCLC tumorospheres, indicating potential to target CSC-like properties.",
    "pmid": "31281836",
    "title": "Antitumor Effect of Albendazole on Cutaneous Squamous Cell Carcinoma (SCC) Cells.",
    "year": "2019",
    "doi": "10.1155/2019/3689517",
    "mechanism": "Inhibition of Wnt/\u03b2-catenin signaling and mitochondrial uncoupling, targeting cancer stemness and resistance pathways."
  },
  {
    "drug": "azithromycin",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.03,
    "key_result": "Peptidomimetic H-(Lys-\u03b2NPhe)8-NH2 synergized with azithromycin, inducing susceptibility in MDR E. coli at sub-micromolar concentrations.",
    "pmid": "31334131",
    "title": "Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00236",
    "mechanism": "Peptidomimetics increase outer membrane permeability and potentiate the activity of antibiotics like azithromycin and rifampicin against Gram-negative pathogens."
  },
  {
    "drug": "rifampicin",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.03,
    "key_result": "Peptidomimetic H-(Lys-\u03b2NPhe)8-NH2 synergized with rifampicin, inducing susceptibility in MDR E. coli at sub-micromolar concentrations.",
    "pmid": "31334131",
    "title": "Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00236",
    "mechanism": "Peptidomimetics increase outer membrane permeability and potentiate the activity of antibiotics like azithromycin and rifampicin against Gram-negative pathogens."
  },
  {
    "drug": "azithromycin",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.03,
    "key_result": "Synergy observed with peptidomimetic H-(Lys-\u03b2NPhe)8-NH2, potentiating azithromycin against MDR K. pneumoniae.",
    "pmid": "31334131",
    "title": "Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00236",
    "mechanism": "Peptidomimetics increase outer membrane permeability and potentiate the activity of antibiotics like azithromycin and rifampicin against Gram-negative pathogens."
  },
  {
    "drug": "rifampicin",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.03,
    "key_result": "Synergy observed with peptidomimetic H-(Lys-\u03b2NPhe)8-NH2, potentiating rifampicin against MDR K. pneumoniae.",
    "pmid": "31334131",
    "title": "Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00236",
    "mechanism": "Peptidomimetics increase outer membrane permeability and potentiate the activity of antibiotics like azithromycin and rifampicin against Gram-negative pathogens."
  },
  {
    "drug": "azithromycin",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.03,
    "key_result": "Peptidomimetic H-(Lys-\u03b2NPhe)8-NH2 synergized with azithromycin, enhancing activity against P. aeruginosa.",
    "pmid": "31334131",
    "title": "Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00236",
    "mechanism": "Peptidomimetics increase outer membrane permeability and potentiate the activity of antibiotics like azithromycin and rifampicin against Gram-negative pathogens."
  },
  {
    "drug": "rifampicin",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.03,
    "key_result": "Peptidomimetic H-(Lys-\u03b2NPhe)8-NH2 synergized with rifampicin, enhancing activity against P. aeruginosa.",
    "pmid": "31334131",
    "title": "Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00236",
    "mechanism": "Peptidomimetics increase outer membrane permeability and potentiate the activity of antibiotics like azithromycin and rifampicin against Gram-negative pathogens."
  },
  {
    "drug": "desmethylclomipramine",
    "pathogen": "Traumatic Brain Injury",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Desmethylclomipramine showed anti-inflammatory and neuroprotective effects in vitro but failed to improve outcomes in vivo.",
    "pmid": "31439817",
    "title": "An in situ high-throughput screen identifies inhibitors of intracellular Burkholderia pseudomallei with therapeutic efficacy.",
    "year": "2019",
    "doi": "10.1073/pnas.1906388116",
    "mechanism": "Modulation of post-TBI transcriptomics, upregulation of Nrf2 target genes, anti-inflammatory and antioxidant effects."
  },
  {
    "drug": "ionomycin",
    "pathogen": "Traumatic Brain Injury",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ionomycin reduced neuroinflammation and nitrite levels in vitro but lacked in vivo efficacy.",
    "pmid": "31439817",
    "title": "An in situ high-throughput screen identifies inhibitors of intracellular Burkholderia pseudomallei with therapeutic efficacy.",
    "year": "2019",
    "doi": "10.1073/pnas.1906388116",
    "mechanism": "Modulation of post-TBI transcriptomics, upregulation of Nrf2 target genes, anti-inflammatory and antioxidant effects."
  },
  {
    "drug": "sirolimus",
    "pathogen": "Traumatic Brain Injury",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sirolimus improved neuronal viability and reduced neurotoxicity markers in vitro but was not tested in vivo for efficacy.",
    "pmid": "31439817",
    "title": "An in situ high-throughput screen identifies inhibitors of intracellular Burkholderia pseudomallei with therapeutic efficacy.",
    "year": "2019",
    "doi": "10.1073/pnas.1906388116",
    "mechanism": "Modulation of post-TBI transcriptomics, upregulation of Nrf2 target genes, anti-inflammatory and antioxidant effects."
  },
  {
    "drug": "trimipramine",
    "pathogen": "Traumatic Brain Injury",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Trimipramine reduced neuroinflammation and nitrite production in vitro but did not demonstrate in vivo benefits.",
    "pmid": "31439817",
    "title": "An in situ high-throughput screen identifies inhibitors of intracellular Burkholderia pseudomallei with therapeutic efficacy.",
    "year": "2019",
    "doi": "10.1073/pnas.1906388116",
    "mechanism": "Modulation of post-TBI transcriptomics, upregulation of Nrf2 target genes, anti-inflammatory and antioxidant effects."
  },
  {
    "drug": "cloxacillin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.1,
    "key_result": "Combination of cloxacillin with thioridazine and miconazole significantly reduced MIC values and showed synergistic activity against S. aureus, including MRSA strains.",
    "pmid": "31446534",
    "title": "Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.",
    "year": "2020",
    "doi": "10.1007/s10637-019-00847-8",
    "mechanism": "The combination therapy enhances antibacterial activity by inhibiting efflux pumps (thioridazine), inducing autolysis (miconazole), and disrupting cell wall synthesis (cloxacillin)."
  },
  {
    "drug": "thioridazine",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor|adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.14,
    "key_result": "Thioridazine acts as an efflux pump inhibitor, enhancing the antibacterial activity of cloxacillin against MRSA.",
    "pmid": "31446534",
    "title": "Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.",
    "year": "2020",
    "doi": "10.1007/s10637-019-00847-8",
    "mechanism": "The combination therapy enhances antibacterial activity by inhibiting efflux pumps (thioridazine), inducing autolysis (miconazole), and disrupting cell wall synthesis (cloxacillin)."
  },
  {
    "drug": "miconazole",
    "pathogen": "S. aureus",
    "activity_type": "autolysis_inducer|adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.14,
    "key_result": "Miconazole induces autolysis, synergizing with cloxacillin to inhibit MRSA growth.",
    "pmid": "31446534",
    "title": "Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.",
    "year": "2020",
    "doi": "10.1007/s10637-019-00847-8",
    "mechanism": "The combination therapy enhances antibacterial activity by inhibiting efflux pumps (thioridazine), inducing autolysis (miconazole), and disrupting cell wall synthesis (cloxacillin)."
  },
  {
    "drug": "burkfloxacin",
    "pathogen": "Burkholderia pseudomallei",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Burkfloxacin potently inhibits growth of intracellular Burkholderia pseudomallei.",
    "pmid": "31671916",
    "title": "In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned.",
    "year": "2019",
    "doi": "10.3390/ijms20215395",
    "mechanism": "5-FC is converted inside bacteria to 5-fluorouracil and subsequently to FUMP, which inhibits T6SS-5 assembly or secretion, impairing cell\u2013cell spread; burkfloxacin inhibits bacterial DNA gyrase, blocking bacterial replication."
  },
  {
    "drug": "flucytosine",
    "pathogen": "Burkholderia pseudomallei",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Flucytosine inhibits intracellular cell\u2013cell spread of Burkholderia pseudomallei by targeting T6SS-5-mediated membrane fusion.",
    "pmid": "31671916",
    "title": "In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned.",
    "year": "2019",
    "doi": "10.3390/ijms20215395",
    "mechanism": "5-FC is converted inside bacteria to 5-fluorouracil and subsequently to FUMP, which inhibits T6SS-5 assembly or secretion, impairing cell\u2013cell spread; burkfloxacin inhibits bacterial DNA gyrase, blocking bacterial replication."
  },
  {
    "drug": "ciprofloxacin",
    "pathogen": "Burkholderia pseudomallei",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ciprofloxacin shows similar in vitro activity to burkfloxacin against gram-negative bacteria.",
    "pmid": "31671916",
    "title": "In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned.",
    "year": "2019",
    "doi": "10.3390/ijms20215395",
    "mechanism": "5-FC is converted inside bacteria to 5-fluorouracil and subsequently to FUMP, which inhibits T6SS-5 assembly or secretion, impairing cell\u2013cell spread; burkfloxacin inhibits bacterial DNA gyrase, blocking bacterial replication."
  },
  {
    "drug": "ceftazidime",
    "pathogen": "Burkholderia pseudomallei",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ceftazidime was less effective than BFX or 5-FC in murine models for treating melioidosis.",
    "pmid": "31671916",
    "title": "In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned.",
    "year": "2019",
    "doi": "10.3390/ijms20215395",
    "mechanism": "5-FC is converted inside bacteria to 5-fluorouracil and subsequently to FUMP, which inhibits T6SS-5 assembly or secretion, impairing cell\u2013cell spread; burkfloxacin inhibits bacterial DNA gyrase, blocking bacterial replication."
  },
  {
    "drug": "P2",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "P2 exhibited high activity with MIC <2 \u03bcg/mL, killed 99% of persistent S. aureus, and disrupted biofilm formation.",
    "pmid": "31861228",
    "title": "The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors.",
    "year": "2019",
    "doi": "10.3390/antibiotics8040270",
    "mechanism": "Antimicrobial peptides disrupt bacterial membranes, bind to DNA, inhibit biofilm formation, and downregulate virulence genes; some inhibit key two-component systems like vanRS."
  },
  {
    "drug": "P5",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial|anti_biofilm|anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "P5 significantly inhibited S. aureus biofilm, disrupted cell membranes, and downregulated virulence genes.",
    "pmid": "31861228",
    "title": "The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors.",
    "year": "2019",
    "doi": "10.3390/antibiotics8040270",
    "mechanism": "Antimicrobial peptides disrupt bacterial membranes, bind to DNA, inhibit biofilm formation, and downregulate virulence genes; some inhibit key two-component systems like vanRS."
  },
  {
    "drug": "P9",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial|anti_biofilm|anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "P9 showed potent activity against S. aureus, inhibiting biofilm and virulence gene expression.",
    "pmid": "31861228",
    "title": "The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors.",
    "year": "2019",
    "doi": "10.3390/antibiotics8040270",
    "mechanism": "Antimicrobial peptides disrupt bacterial membranes, bind to DNA, inhibit biofilm formation, and downregulate virulence genes; some inhibit key two-component systems like vanRS."
  },
  {
    "drug": "vancomycin",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": 1.0,
    "key_result": "Peptides demonstrated synergistic interactions with vancomycin against VRE.",
    "pmid": "31861228",
    "title": "The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors.",
    "year": "2019",
    "doi": "10.3390/antibiotics8040270",
    "mechanism": "Antimicrobial peptides disrupt bacterial membranes, bind to DNA, inhibit biofilm formation, and downregulate virulence genes; some inhibit key two-component systems like vanRS."
  },
  {
    "drug": "azidothymidine (AZT)",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "AZT reduced plasmid transmission in E. coli by 83.3% at 0.25 \u03bcg/ml.",
    "pmid": "31880892",
    "title": "Inhibition of Drug Resistance of Staphylococcus aureus by Efflux Pump Inhibitor and Autolysis Inducer to Strengthen the Antibacterial Activity of \u03b2-lactam Drugs.",
    "year": "2019",
    "doi": "10.33073/pjm-2019-047",
    "mechanism": "Proposed mechanism involves inhibition of plasmid transfer, possibly through interference with conjugation processes, as suggested by the activity of HIV nucleoside analogues on plasmid transmission."
  },
  {
    "drug": "abacavir",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Abacavir reduced plasmid transmission in E. coli in the screening assay.",
    "pmid": "31880892",
    "title": "Inhibition of Drug Resistance of Staphylococcus aureus by Efflux Pump Inhibitor and Autolysis Inducer to Strengthen the Antibacterial Activity of \u03b2-lactam Drugs.",
    "year": "2019",
    "doi": "10.33073/pjm-2019-047",
    "mechanism": "Proposed mechanism involves inhibition of plasmid transfer, possibly through interference with conjugation processes, as suggested by the activity of HIV nucleoside analogues on plasmid transmission."
  },
  {
    "drug": "azidothymidine (AZT)",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "AZT reduced plasmid transmission in K. pneumoniae by approximately 80.8%.",
    "pmid": "31880892",
    "title": "Inhibition of Drug Resistance of Staphylococcus aureus by Efflux Pump Inhibitor and Autolysis Inducer to Strengthen the Antibacterial Activity of \u03b2-lactam Drugs.",
    "year": "2019",
    "doi": "10.33073/pjm-2019-047",
    "mechanism": "Proposed mechanism involves inhibition of plasmid transfer, possibly through interference with conjugation processes, as suggested by the activity of HIV nucleoside analogues on plasmid transmission."
  },
  {
    "drug": "abacavir",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Abacavir also reduced plasmid transmission in K. pneumoniae.",
    "pmid": "31880892",
    "title": "Inhibition of Drug Resistance of Staphylococcus aureus by Efflux Pump Inhibitor and Autolysis Inducer to Strengthen the Antibacterial Activity of \u03b2-lactam Drugs.",
    "year": "2019",
    "doi": "10.33073/pjm-2019-047",
    "mechanism": "Proposed mechanism involves inhibition of plasmid transfer, possibly through interference with conjugation processes, as suggested by the activity of HIV nucleoside analogues on plasmid transmission."
  },
  {
    "drug": "auranofin",
    "pathogen": "Clostridium difficile",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 4.07,
    "fici": null,
    "key_result": "Auranofin showed bactericidal activity at concentrations as low as 4.07 \u00b5g/mL, effectively reducing bacterial cell density and spore viability in vitro.",
    "pmid": "32098822",
    "title": "HIV Drugs Inhibit Transfer of Plasmids Carrying Extended-Spectrum \u03b2-Lactamase and Carbapenemase Genes.",
    "year": "2020",
    "doi": "10.1128/mBio.03355-19",
    "mechanism": "Auranofin inhibits thioredoxin reductase and sequesters inorganic selenium, disrupting selenium-dependent enzymes essential for C. difficile growth and sporulation."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial|synergy|anti_biofilm",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": 0.125,
    "fici": 0.375,
    "key_result": "Auranofin exhibits potent antimicrobial activity against S. aureus and shows synergistic effects with linezolid and fosfomycin both in vitro and in vivo.",
    "pmid": "32131427",
    "title": "Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance.",
    "year": "2020",
    "doi": "10.3390/antibiotics9030107",
    "mechanism": "Auranofin inhibits thioredoxin reductase (TrxR), disrupting bacterial redox homeostasis and biofilm formation, thereby enhancing the efficacy of conventional antibiotics."
  },
  {
    "drug": "auranofin",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial|synergy|anti_biofilm",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": 1,
    "fici": 0.375,
    "key_result": "Auranofin demonstrates antimicrobial activity against E. faecalis and synergizes with chloramphenicol in vitro and in vivo.",
    "pmid": "32131427",
    "title": "Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance.",
    "year": "2020",
    "doi": "10.3390/antibiotics9030107",
    "mechanism": "Auranofin inhibits thioredoxin reductase (TrxR), disrupting bacterial redox homeostasis and biofilm formation, thereby enhancing the efficacy of conventional antibiotics."
  },
  {
    "drug": "Fosfomycin",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": 0.375,
    "key_result": "Fosfomycin shows synergistic activity with auranofin against S. aureus.",
    "pmid": "32131427",
    "title": "Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance.",
    "year": "2020",
    "doi": "10.3390/antibiotics9030107",
    "mechanism": "Auranofin inhibits thioredoxin reductase (TrxR), disrupting bacterial redox homeostasis and biofilm formation, thereby enhancing the efficacy of conventional antibiotics."
  },
  {
    "drug": "Linezolid",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": 0.375,
    "key_result": "Linezolid exhibits synergistic effects with auranofin against S. aureus.",
    "pmid": "32131427",
    "title": "Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance.",
    "year": "2020",
    "doi": "10.3390/antibiotics9030107",
    "mechanism": "Auranofin inhibits thioredoxin reductase (TrxR), disrupting bacterial redox homeostasis and biofilm formation, thereby enhancing the efficacy of conventional antibiotics."
  },
  {
    "drug": "Chloramphenicol",
    "pathogen": "E. faecalis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": 0.375,
    "key_result": "Chloramphenicol shows synergistic antimicrobial activity with auranofin against E. faecalis.",
    "pmid": "32131427",
    "title": "Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance.",
    "year": "2020",
    "doi": "10.3390/antibiotics9030107",
    "mechanism": "Auranofin inhibits thioredoxin reductase (TrxR), disrupting bacterial redox homeostasis and biofilm formation, thereby enhancing the efficacy of conventional antibiotics."
  },
  {
    "drug": "Prednisone",
    "pathogen": "DMD",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Glucocorticoids like prednisone improve and stabilize skeletal muscle strength and prolong ambulation in DMD patients.",
    "pmid": "32221472",
    "title": "Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae.",
    "year": "2020",
    "doi": "10.1038/s41598-020-62696-3",
    "mechanism": "Repurposed drugs target inflammation, oxidative stress, fibrosis, and gene splicing pathways involved in DMD pathogenesis."
  },
  {
    "drug": "Deflazacort",
    "pathogen": "DMD",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Deflazacort, a glucocorticoid, is used as standard therapy to delay disease progression in DMD.",
    "pmid": "32221472",
    "title": "Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae.",
    "year": "2020",
    "doi": "10.1038/s41598-020-62696-3",
    "mechanism": "Repurposed drugs target inflammation, oxidative stress, fibrosis, and gene splicing pathways involved in DMD pathogenesis."
  },
  {
    "drug": "Eteplirsen",
    "pathogen": "DMD",
    "activity_type": "antisense therapy",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Eteplirsen facilitates exon 51 skipping, applicable to a subset of DMD patients.",
    "pmid": "32221472",
    "title": "Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae.",
    "year": "2020",
    "doi": "10.1038/s41598-020-62696-3",
    "mechanism": "Repurposed drugs target inflammation, oxidative stress, fibrosis, and gene splicing pathways involved in DMD pathogenesis."
  },
  {
    "drug": "simvastatin",
    "pathogen": "DMD",
    "activity_type": "efflux_inhibitor|anti_inflammatory|anti_fibrotic",
    "evidence_type": "preclinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Simvastatin reduces muscle damage, inflammation, oxidative stress, and fibrosis in mdx mouse models of DMD.",
    "pmid": "32221472",
    "title": "Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae.",
    "year": "2020",
    "doi": "10.1038/s41598-020-62696-3",
    "mechanism": "Repurposed drugs target inflammation, oxidative stress, fibrosis, and gene splicing pathways involved in DMD pathogenesis."
  },
  {
    "drug": "N-acetylcysteine",
    "pathogen": "DMD",
    "activity_type": "antioxidant|adjuvant",
    "evidence_type": "preclinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "N-acetylcysteine alleviates skeletal muscle dysfunction and histopathology in mdx mice.",
    "pmid": "32221472",
    "title": "Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae.",
    "year": "2020",
    "doi": "10.1038/s41598-020-62696-3",
    "mechanism": "Repurposed drugs target inflammation, oxidative stress, fibrosis, and gene splicing pathways involved in DMD pathogenesis."
  },
  {
    "drug": "Safinamide",
    "pathogen": "DMD",
    "activity_type": "efflux_inhibitor|antioxidant",
    "evidence_type": "preclinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Safinamide, a MAO-B inhibitor, targets oxidative stress pathways implicated in DMD pathology.",
    "pmid": "32221472",
    "title": "Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae.",
    "year": "2020",
    "doi": "10.1038/s41598-020-62696-3",
    "mechanism": "Repurposed drugs target inflammation, oxidative stress, fibrosis, and gene splicing pathways involved in DMD pathogenesis."
  },
  {
    "drug": "auranofin",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.007,
    "fici": null,
    "key_result": "Auranofin inhibited growth of N. gonorrhoeae clinical isolates at MICs as low as 0.007 \u00b5g/mL and exhibited rapid bactericidal activity.",
    "pmid": "32377889",
    "title": "In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.",
    "year": "2020",
    "doi": "10.1007/s40268-020-00306-3",
    "mechanism": "Proposed mechanisms include direct antibacterial activity, intracellular bacterial clearance, and anti-inflammatory effects, possibly through inhibition of bacterial enzymes and modulation of host immune responses."
  },
  {
    "drug": "sodium aurothiomalate",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "Sodium aurothiomalate inhibited N. gonorrhoeae at MICs around 0.25 \u00b5g/mL, showing antibacterial activity.",
    "pmid": "32377889",
    "title": "In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.",
    "year": "2020",
    "doi": "10.1007/s40268-020-00306-3",
    "mechanism": "Proposed mechanisms include direct antibacterial activity, intracellular bacterial clearance, and anti-inflammatory effects, possibly through inhibition of bacterial enzymes and modulation of host immune responses."
  },
  {
    "drug": "aurothioglucose",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Aurothioglucose inhibited N. gonorrhoeae at MICs around 0.5 \u00b5g/mL.",
    "pmid": "32377889",
    "title": "In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.",
    "year": "2020",
    "doi": "10.1007/s40268-020-00306-3",
    "mechanism": "Proposed mechanisms include direct antibacterial activity, intracellular bacterial clearance, and anti-inflammatory effects, possibly through inhibition of bacterial enzymes and modulation of host immune responses."
  },
  {
    "drug": "auranofin",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 1.2,
    "key_result": "Auranofin showed an additive effect when combined with azithromycin, ceftriaxone, cefixime, or tetracycline.",
    "pmid": "32377889",
    "title": "In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.",
    "year": "2020",
    "doi": "10.1007/s40268-020-00306-3",
    "mechanism": "Proposed mechanisms include direct antibacterial activity, intracellular bacterial clearance, and anti-inflammatory effects, possibly through inhibition of bacterial enzymes and modulation of host immune responses."
  },
  {
    "drug": "auranofin",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin reduced intracellular N. gonorrhoeae burden by over 99%, outperforming ceftriaxone.",
    "pmid": "32377889",
    "title": "In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.",
    "year": "2020",
    "doi": "10.1007/s40268-020-00306-3",
    "mechanism": "Proposed mechanisms include direct antibacterial activity, intracellular bacterial clearance, and anti-inflammatory effects, possibly through inhibition of bacterial enzymes and modulation of host immune responses."
  },
  {
    "drug": "auranofin",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin demonstrated prolonged post-antibiotic effect (>10 hours) and did not generate resistant mutants.",
    "pmid": "32377889",
    "title": "In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.",
    "year": "2020",
    "doi": "10.1007/s40268-020-00306-3",
    "mechanism": "Proposed mechanisms include direct antibacterial activity, intracellular bacterial clearance, and anti-inflammatory effects, possibly through inhibition of bacterial enzymes and modulation of host immune responses."
  },
  {
    "drug": "metformin",
    "pathogen": "M. tuberculosis",
    "activity_type": "host_modulation|adjuvant",
    "evidence_type": "in_vitro|retrospective",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Metformin enhances immune response and phagosome-lysosome fusion, potentially improving TB treatment outcomes.",
    "pmid": "32411100",
    "title": "Metformin as Host-Directed Therapy for TB Treatment: Scoping Review.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.00435",
    "mechanism": "Metformin modulates host immune responses, promotes phagosome-lysosome fusion, and may inhibit bacterial respiration via targeting bacterial NDH-I complex, thereby enhancing host defense against Mtb."
  },
  {
    "drug": "metformin",
    "pathogen": "M. tuberculosis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "computational|in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In silico studies suggest bacterial NDH-I as a potential target, but direct antibacterial activity of metformin is not conclusively demonstrated.",
    "pmid": "32411100",
    "title": "Metformin as Host-Directed Therapy for TB Treatment: Scoping Review.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.00435",
    "mechanism": "Metformin modulates host immune responses, promotes phagosome-lysosome fusion, and may inhibit bacterial respiration via targeting bacterial NDH-I complex, thereby enhancing host defense against Mtb."
  },
  {
    "drug": "metformin",
    "pathogen": "M. tuberculosis",
    "activity_type": "efflux_inhibitor|adjuvant",
    "evidence_type": "in_vivo|retrospective",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Retrospective studies indicate reduced mortality and improved treatment outcomes when used as adjunct therapy.",
    "pmid": "32411100",
    "title": "Metformin as Host-Directed Therapy for TB Treatment: Scoping Review.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.00435",
    "mechanism": "Metformin modulates host immune responses, promotes phagosome-lysosome fusion, and may inhibit bacterial respiration via targeting bacterial NDH-I complex, thereby enhancing host defense against Mtb."
  },
  {
    "drug": "chlorpromazine",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Chlorpromazine binds to AcrB and inhibits its efflux activity by interfering with substrate binding.",
    "pmid": "32428379",
    "title": "Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.",
    "year": "2020",
    "doi": "10.1111/febs.15369",
    "mechanism": "Binding at the hydrophobic trap within AcrB's distal pocket, interfering with substrate binding and efflux function."
  },
  {
    "drug": "Amitriptyline",
    "pathogen": "Salmonella enterica serovar Typhimurium",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Amitriptyline binds to AcrB and inhibits its efflux activity, reverting mutants to wild-type acrB sequence.",
    "pmid": "32428379",
    "title": "Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.",
    "year": "2020",
    "doi": "10.1111/febs.15369",
    "mechanism": "Binding at the hydrophobic trap within AcrB's distal pocket, interfering with substrate binding and efflux function."
  },
  {
    "drug": "idarubicin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Idarubicin kills MRSA by disrupting lipid bilayers and inhibiting DNA topoisomerase II, showing potential as an antimicrobial agent.",
    "pmid": "32443498",
    "title": "A Selective Serotonin Reuptake Inhibitor, a Proton Pump Inhibitor, and Two Calcium Channel Blockers Inhibit Candida albicans Biofilms.",
    "year": "2020",
    "doi": "10.3390/microorganisms8050756",
    "mechanism": "Idarubicin disrupts bacterial lipid bilayers and inhibits DNA topoisomerase II, leading to bacterial cell death."
  },
  {
    "drug": "idarubicin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.25,
    "key_result": "Idarubicin exhibits synergistic effects with fosfomycin against MRSA.",
    "pmid": "32443498",
    "title": "A Selective Serotonin Reuptake Inhibitor, a Proton Pump Inhibitor, and Two Calcium Channel Blockers Inhibit Candida albicans Biofilms.",
    "year": "2020",
    "doi": "10.3390/microorganisms8050756",
    "mechanism": "Idarubicin disrupts bacterial lipid bilayers and inhibits DNA topoisomerase II, leading to bacterial cell death."
  },
  {
    "drug": "fosfomycin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Fosfomycin enhances the antimicrobial efficacy of idarubicin against MRSA.",
    "pmid": "32443498",
    "title": "A Selective Serotonin Reuptake Inhibitor, a Proton Pump Inhibitor, and Two Calcium Channel Blockers Inhibit Candida albicans Biofilms.",
    "year": "2020",
    "doi": "10.3390/microorganisms8050756",
    "mechanism": "Idarubicin disrupts bacterial lipid bilayers and inhibits DNA topoisomerase II, leading to bacterial cell death."
  },
  {
    "drug": "idarubicin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Idarubicin shows low probability of resistance development and good postantibiotic effects.",
    "pmid": "32443498",
    "title": "A Selective Serotonin Reuptake Inhibitor, a Proton Pump Inhibitor, and Two Calcium Channel Blockers Inhibit Candida albicans Biofilms.",
    "year": "2020",
    "doi": "10.3390/microorganisms8050756",
    "mechanism": "Idarubicin disrupts bacterial lipid bilayers and inhibits DNA topoisomerase II, leading to bacterial cell death."
  },
  {
    "drug": "idarubicin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Idarubicin effectively inhibits and eradicates MRSA biofilms.",
    "pmid": "32443498",
    "title": "A Selective Serotonin Reuptake Inhibitor, a Proton Pump Inhibitor, and Two Calcium Channel Blockers Inhibit Candida albicans Biofilms.",
    "year": "2020",
    "doi": "10.3390/microorganisms8050756",
    "mechanism": "Idarubicin disrupts bacterial lipid bilayers and inhibits DNA topoisomerase II, leading to bacterial cell death."
  },
  {
    "drug": "Ellipticine Hydrochloride",
    "pathogen": "Escherichia coli (ExPEC, colistin-resistant, mcr-1 positive)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ellipticine hydrochloride binds to E. coli topoisomerase IV and exhibits antibacterial activity against colistin-resistant ExPEC strains.",
    "pmid": "32487753",
    "title": "Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.",
    "year": "2020",
    "doi": "10.1128/mBio.00465-20",
    "mechanism": "Ellipticine hydrochloride inhibits bacterial topoisomerase IV, disrupting DNA replication and cell division."
  },
  {
    "drug": "Ellipticine Hydrochloride",
    "pathogen": "Escherichia coli (ExPEC, colistin-resistant, mcr-1 positive)",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "EH shows synergistic effects with colistin in most tested strains, enhancing antibacterial efficacy.",
    "pmid": "32487753",
    "title": "Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.",
    "year": "2020",
    "doi": "10.1128/mBio.00465-20",
    "mechanism": "Ellipticine hydrochloride inhibits bacterial topoisomerase IV, disrupting DNA replication and cell division."
  },
  {
    "drug": "Ellipticine Hydrochloride",
    "pathogen": "Escherichia coli (ExPEC, colistin-resistant, mcr-1 positive)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In infected mice, EH treatment reduced bacterial load and inflammation, indicating therapeutic potential.",
    "pmid": "32487753",
    "title": "Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.",
    "year": "2020",
    "doi": "10.1128/mBio.00465-20",
    "mechanism": "Ellipticine hydrochloride inhibits bacterial topoisomerase IV, disrupting DNA replication and cell division."
  },
  {
    "drug": "ebselen",
    "pathogen": "HIV-1",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen inhibits HIV-1 capsid assembly and interferes with integration by binding to LEDGF/p75, suggesting antiviral potential.",
    "pmid": "32571820",
    "title": "Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.",
    "year": "2020",
    "doi": "10.1128/AAC.00559-20",
    "mechanism": "Ebselen covalently binds to cysteine residues in viral proteases and other proteins, forming selenosulfide bonds that inhibit enzymatic activity, and also exerts anti-inflammatory effects."
  },
  {
    "drug": "ebselen",
    "pathogen": "HCV",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen inhibits HCV NS3 helicase activity and viral replication.",
    "pmid": "32571820",
    "title": "Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.",
    "year": "2020",
    "doi": "10.1128/AAC.00559-20",
    "mechanism": "Ebselen covalently binds to cysteine residues in viral proteases and other proteins, forming selenosulfide bonds that inhibit enzymatic activity, and also exerts anti-inflammatory effects."
  },
  {
    "drug": "rifampicin",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Polymer combination reduced rifampicin MIC by 2048-fold against A. baumannii, restoring activity.",
    "pmid": "32810364",
    "title": "Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma.",
    "year": "2020",
    "doi": "10.1002/2211-5463.12960",
    "mechanism": "The polymer binds nonspecifically to cytosolic enzymes or genes responsible for antibiotic resistance, disrupts bacterial defense mechanisms, and increases intracellular ROS, thereby reversing resistance phenotypes and potentiating antibiotic activity."
  },
  {
    "drug": "auranofin",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Polymer combination reduced auranofin MIC by 128-fold against A. baumannii, enhancing its activity.",
    "pmid": "32810364",
    "title": "Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma.",
    "year": "2020",
    "doi": "10.1002/2211-5463.12960",
    "mechanism": "The polymer binds nonspecifically to cytosolic enzymes or genes responsible for antibiotic resistance, disrupts bacterial defense mechanisms, and increases intracellular ROS, thereby reversing resistance phenotypes and potentiating antibiotic activity."
  },
  {
    "drug": "colistimethate sodium",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Polymer significantly lowered colistin MIC from 15.6\u201331.3 \u00b5g/mL to 0.49 \u00b5g/mL in MCR-1 positive E. coli.",
    "pmid": "32810364",
    "title": "Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma.",
    "year": "2020",
    "doi": "10.1002/2211-5463.12960",
    "mechanism": "The polymer binds nonspecifically to cytosolic enzymes or genes responsible for antibiotic resistance, disrupts bacterial defense mechanisms, and increases intracellular ROS, thereby reversing resistance phenotypes and potentiating antibiotic activity."
  },
  {
    "drug": "penicillic acid",
    "pathogen": "human pancreatic cancer cells",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Penicillic acid preferentially induces apoptosis in nutrient-deprived pancreatic cancer cells by targeting redox systems and depleting GSH.",
    "pmid": "32930523",
    "title": "Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19.",
    "year": "2020",
    "doi": "10.1002/prp2.653",
    "mechanism": "PCA and PPA covalently bind to GSH, depleting cellular GSH levels, which leads to increased ROS and apoptosis in nutrient-deprived pancreatic cancer cells. Auranofin inhibits redox systems, contributing to oxidative stress."
  },
  {
    "drug": "papyracillic acid",
    "pathogen": "human pancreatic cancer cells",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Papyracillic acid shows selective cytotoxicity under nutrient-deprived conditions by binding to GSH and increasing ROS levels in pancreatic cancer cells.",
    "pmid": "32930523",
    "title": "Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19.",
    "year": "2020",
    "doi": "10.1002/prp2.653",
    "mechanism": "PCA and PPA covalently bind to GSH, depleting cellular GSH levels, which leads to increased ROS and apoptosis in nutrient-deprived pancreatic cancer cells. Auranofin inhibits redox systems, contributing to oxidative stress."
  },
  {
    "drug": "auranofin",
    "pathogen": "human pancreatic cancer cells",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin inhibits pancreatic cancer cell growth under nutrient-deprived conditions by disrupting redox balance, similar to PCA and PPA.",
    "pmid": "32930523",
    "title": "Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19.",
    "year": "2020",
    "doi": "10.1002/prp2.653",
    "mechanism": "PCA and PPA covalently bind to GSH, depleting cellular GSH levels, which leads to increased ROS and apoptosis in nutrient-deprived pancreatic cancer cells. Auranofin inhibits redox systems, contributing to oxidative stress."
  },
  {
    "drug": "daptomycin",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Systemic daptomycin treatment can select for resistant E. faecium in the gut, but co-administration with cholestyramine reduces fecal shedding of resistant strains by up to 80-fold.",
    "pmid": "32934086",
    "title": "Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections.",
    "year": "2020",
    "doi": "10.1128/mBio.02068-20",
    "mechanism": "Cholestyramine binds daptomycin in the gastrointestinal tract, preventing it from reaching and exerting selective pressure on gut bacteria, thus inhibiting the evolution of resistance."
  },
  {
    "drug": "cholestyramine",
    "pathogen": "E. faecium",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cholestyramine binds daptomycin in the gut, inactivating it locally without affecting plasma concentrations, thereby preventing resistance emergence in gut colonizing E. faecium.",
    "pmid": "32934086",
    "title": "Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections.",
    "year": "2020",
    "doi": "10.1128/mBio.02068-20",
    "mechanism": "Cholestyramine binds daptomycin in the gastrointestinal tract, preventing it from reaching and exerting selective pressure on gut bacteria, thus inhibiting the evolution of resistance."
  },
  {
    "drug": "curcumin",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 50,
    "fici": null,
    "key_result": "Curcumin exhibited potent antibacterial activity with MIC of 50 \u03bcg/ml against P. aeruginosa and enhanced the effect of ciprofloxacin.",
    "pmid": "32952938",
    "title": "Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.",
    "year": "2020",
    "doi": "10.1016/j.csbj.2020.08.008",
    "mechanism": "Curcumin causes protein and nucleic acid leakage from bacterial cell membranes, disrupting membrane integrity."
  },
  {
    "drug": "curcumin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 100,
    "fici": null,
    "key_result": "Curcumin showed antibacterial activity with MIC of 100 \u03bcg/ml against S. aureus and increased ciprofloxacin efficacy.",
    "pmid": "32952938",
    "title": "Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.",
    "year": "2020",
    "doi": "10.1016/j.csbj.2020.08.008",
    "mechanism": "Curcumin causes protein and nucleic acid leakage from bacterial cell membranes, disrupting membrane integrity."
  },
  {
    "drug": "ellagic acid",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 100,
    "fici": null,
    "key_result": "Ellagic acid had MIC of 100 \u03bcg/ml against S. aureus.",
    "pmid": "32952938",
    "title": "Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.",
    "year": "2020",
    "doi": "10.1016/j.csbj.2020.08.008",
    "mechanism": "Curcumin causes protein and nucleic acid leakage from bacterial cell membranes, disrupting membrane integrity."
  },
  {
    "drug": "curcumin + ciprofloxacin",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combination reduced MIC of ciprofloxacin from 0.5 \u03bcg/ml to 0.0625 \u03bcg/ml, indicating synergistic effect.",
    "pmid": "32952938",
    "title": "Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.",
    "year": "2020",
    "doi": "10.1016/j.csbj.2020.08.008",
    "mechanism": "Curcumin causes protein and nucleic acid leakage from bacterial cell membranes, disrupting membrane integrity."
  },
  {
    "drug": "curcumin + ciprofloxacin",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combination reduced MIC of ciprofloxacin from 0.25 \u03bcg/ml to 0.0625 \u03bcg/ml, showing enhanced antibacterial activity.",
    "pmid": "32952938",
    "title": "Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.",
    "year": "2020",
    "doi": "10.1016/j.csbj.2020.08.008",
    "mechanism": "Curcumin causes protein and nucleic acid leakage from bacterial cell membranes, disrupting membrane integrity."
  },
  {
    "drug": "Tetrandrine",
    "pathogen": "MERS-CoV",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.33,
    "fici": null,
    "key_result": "Tetrandrine showed efficacy against MERS-CoV in vitro with an IC50 of 0.055 \u03bcmol/L.",
    "pmid": "32975381",
    "title": "Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion.",
    "year": "2020",
    "doi": "10.1111/jcmm.15920",
    "mechanism": "Antagonism of host cell TPC2 channels, inhibiting virus egress and replication, along with calcium channel blockade and anti-inflammatory effects."
  },
  {
    "drug": "Tetrandrine",
    "pathogen": "HCoV-OC43",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.33,
    "fici": null,
    "key_result": "Tetrandrine inhibited HCoV-OC43 infection in vitro with an IC50 of 0.33 \u03bcmol/L.",
    "pmid": "32975381",
    "title": "Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion.",
    "year": "2020",
    "doi": "10.1111/jcmm.15920",
    "mechanism": "Antagonism of host cell TPC2 channels, inhibiting virus egress and replication, along with calcium channel blockade and anti-inflammatory effects."
  },
  {
    "drug": "ebselen",
    "pathogen": "UPEC BC1",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen exhibits potent bactericidal activity against MDR UPEC BC1 by disrupting redox homeostasis.",
    "pmid": "32978257",
    "title": "Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.",
    "year": "2020",
    "doi": "10.1074/jbc.RA120.013893",
    "mechanism": "Disruption of bacterial redox homeostasis through consumption of intracellular GSH and inhibition of thioredoxin reductase activity, leading to increased reactive oxygen species and bacterial cell death."
  },
  {
    "drug": "silver ion",
    "pathogen": "UPEC BC1",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Silver ion shows strong bactericidal activity against MDR UPEC BC1, especially in combination with ebselen.",
    "pmid": "32978257",
    "title": "Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.",
    "year": "2020",
    "doi": "10.1074/jbc.RA120.013893",
    "mechanism": "Disruption of bacterial redox homeostasis through consumption of intracellular GSH and inhibition of thioredoxin reductase activity, leading to increased reactive oxygen species and bacterial cell death."
  },
  {
    "drug": "ebselen and silver ion",
    "pathogen": "UPEC BC1",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combination of ebselen and silver ion exerts synergistic bactericidal activity against MDR UPEC BC1.",
    "pmid": "32978257",
    "title": "Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.",
    "year": "2020",
    "doi": "10.1074/jbc.RA120.013893",
    "mechanism": "Disruption of bacterial redox homeostasis through consumption of intracellular GSH and inhibition of thioredoxin reductase activity, leading to increased reactive oxygen species and bacterial cell death."
  },
  {
    "drug": "ebselen and silver ion",
    "pathogen": "UPEC BC1",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Treatment with ebselen and silver ion significantly reduces bacterial loads in a mouse model of cystitis.",
    "pmid": "32978257",
    "title": "Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.",
    "year": "2020",
    "doi": "10.1074/jbc.RA120.013893",
    "mechanism": "Disruption of bacterial redox homeostasis through consumption of intracellular GSH and inhibition of thioredoxin reductase activity, leading to increased reactive oxygen species and bacterial cell death."
  },
  {
    "drug": "auranofin",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial|synergy|adjuvant",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin synergizes with antibiotics to kill carbapenem- and colistin-resistant bacteria and rescues infected mice.",
    "pmid": "32995131",
    "title": "A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics.",
    "year": "2020",
    "doi": "10.1002/advs.202001374",
    "mechanism": "Auranofin irreversibly inhibits metallo-\u03b2-lactamases and MCR enzymes by displacing Zn(II) cofactors with Au(I), disrupting enzyme activity."
  },
  {
    "drug": "polymyxin B + prochlorperazine",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.15,
    "key_result": "The combination showed synergistic antibacterial activity against P. aeruginosa, including polymyxin-resistant strains, by disrupting bacterial cell membranes.",
    "pmid": "33031791",
    "title": "Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.",
    "year": "2020",
    "doi": "10.1016/j.cbi.2020.109282",
    "mechanism": "Disruption of bacterial membrane integrity and biosynthesis of cell envelope components, leading to enhanced bacterial cell damage and death."
  },
  {
    "drug": "polymyxin B + prochlorperazine",
    "pathogen": "A. baumannii",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": "<0.5",
    "key_result": "The combination demonstrated synergistic activity against MDR A. baumannii, causing greater bacterial cell damage.",
    "pmid": "33031791",
    "title": "Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.",
    "year": "2020",
    "doi": "10.1016/j.cbi.2020.109282",
    "mechanism": "Disruption of bacterial membrane integrity and biosynthesis of cell envelope components, leading to enhanced bacterial cell damage and death."
  },
  {
    "drug": "polymyxin B + chlorpromazine",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": "<0.5",
    "key_result": "Synergistic effects observed with enhanced bacterial membrane disruption.",
    "pmid": "33031791",
    "title": "Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.",
    "year": "2020",
    "doi": "10.1016/j.cbi.2020.109282",
    "mechanism": "Disruption of bacterial membrane integrity and biosynthesis of cell envelope components, leading to enhanced bacterial cell damage and death."
  },
  {
    "drug": "polymyxin B + thiethylperazine",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": "<0.5",
    "key_result": "Synergistic antibacterial activity was demonstrated, including against resistant strains.",
    "pmid": "33031791",
    "title": "Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.",
    "year": "2020",
    "doi": "10.1016/j.cbi.2020.109282",
    "mechanism": "Disruption of bacterial membrane integrity and biosynthesis of cell envelope components, leading to enhanced bacterial cell damage and death."
  },
  {
    "drug": "PQ401",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 4,
    "fici": null,
    "key_result": "PQ401 kills antibiotic-resistant and tolerant S. aureus by disrupting bacterial membranes.",
    "pmid": "33067430",
    "title": "Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using auranofin.",
    "year": "2020",
    "doi": "10.1038/s41467-020-18939-y",
    "mechanism": "Membrane disruption through lipid bilayer permeabilization, with the neutral form of PQ401 penetrating and embedding into bacterial membranes more effectively than the cationic form."
  },
  {
    "drug": "PQ401",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "PQ401 shows synergism with gentamicin.",
    "pmid": "33067430",
    "title": "Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using auranofin.",
    "year": "2020",
    "doi": "10.1038/s41467-020-18939-y",
    "mechanism": "Membrane disruption through lipid bilayer permeabilization, with the neutral form of PQ401 penetrating and embedding into bacterial membranes more effectively than the cationic form."
  },
  {
    "drug": "Thioridazine photoproducts",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Photoproducts of irradiated thioridazine show enhanced antimicrobial activity against S. aureus, including MRSA, with MIC values four to sixteen times lower than unirradiated TZ.",
    "pmid": "33093568",
    "title": "Anti-staphylococcal activity and mode of action of thioridazine photoproducts.",
    "year": "2020",
    "doi": "10.1038/s41598-020-74752-z",
    "mechanism": "Photoproducts of TZ, such as mesoridazine and sulforidazine, may inhibit penicillin-binding proteins PBP3 and PBP2a, disrupting cell wall biosynthesis in S. aureus and MRSA strains."
  },
  {
    "drug": "Thioridazine photoproducts",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Photoproducts do not significantly inhibit efflux pumps, as they do not reduce ciprofloxacin MICs in efflux-overexpressing strains.",
    "pmid": "33093568",
    "title": "Anti-staphylococcal activity and mode of action of thioridazine photoproducts.",
    "year": "2020",
    "doi": "10.1038/s41598-020-74752-z",
    "mechanism": "Photoproducts of TZ, such as mesoridazine and sulforidazine, may inhibit penicillin-binding proteins PBP3 and PBP2a, disrupting cell wall biosynthesis in S. aureus and MRSA strains."
  },
  {
    "drug": "Demeclocycline hydrochloride (DMCT)",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "DMCT shows antibacterial activity and synergizes with SAAP-148 against P. aeruginosa.",
    "pmid": "33204411",
    "title": "Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19.",
    "year": "2020",
    "doi": "10.12688/f1000research.26359.1",
    "mechanism": "Synergistic antibacterial effect through combined action of tetracycline antibiotic and antimicrobial peptide, likely involving disruption of bacterial membranes and inhibition of protein synthesis."
  },
  {
    "drug": "SAAP-148",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant|synergy",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "SAAP-148 synergizes with DMCT to enhance antibacterial effects against P. aeruginosa, including MDR strains.",
    "pmid": "33204411",
    "title": "Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19.",
    "year": "2020",
    "doi": "10.12688/f1000research.26359.1",
    "mechanism": "Synergistic antibacterial effect through combined action of tetracycline antibiotic and antimicrobial peptide, likely involving disruption of bacterial membranes and inhibition of protein synthesis."
  },
  {
    "drug": "disulfiram",
    "pathogen": "Entamoeba histolytica",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Disulfiram combined with zinc forms a zinc-ditiocarb complex (ZnDTC) that is highly effective against E. histolytica at low nanomolar concentrations, significantly below the serum levels achieved with standard doses.",
    "pmid": "33345466",
    "title": "Drug repurposing: Antimicrobial and antibiofilm effects of penfluridol against Enterococcus faecalis.",
    "year": "2021",
    "doi": "10.1002/mbo3.1148",
    "mechanism": "formation of metal complexes (ZnDTC) that inhibit the ubiquitin-proteasome pathway in the parasite"
  },
  {
    "drug": "auranofin",
    "pathogen": "Clostridioides difficile",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin demonstrated in vivo efficacy in hamster models, with survival rates comparable to vancomycin and significant reduction in bacterial load.",
    "pmid": "33348292",
    "title": "Interferon-inducer antivirals: Potential candidates to combat COVID-19.",
    "year": "2021",
    "doi": "10.1016/j.intimp.2020.107245",
    "mechanism": "Inhibition of toxin and spore production in C. difficile, possibly through targeting bacterial virulence factors and biofilm formation."
  },
  {
    "drug": "auranofin",
    "pathogen": "Clostridioides difficile",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin showed potential to prevent CDI recurrence, indicating activity against spores and biofilm formation.",
    "pmid": "33348292",
    "title": "Interferon-inducer antivirals: Potential candidates to combat COVID-19.",
    "year": "2021",
    "doi": "10.1016/j.intimp.2020.107245",
    "mechanism": "Inhibition of toxin and spore production in C. difficile, possibly through targeting bacterial virulence factors and biofilm formation."
  },
  {
    "drug": "ciprofloxacin",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combinations of ciprofloxacin with chlorpromazine, propranolol, or diclofenac showed synergism in most XDR/PDR A. baumannii isolates.",
    "pmid": "33362739",
    "title": "High-Throughput Identification of Antibacterials Against Pseudomonas aeruginosa.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.591426",
    "mechanism": "Proposed mechanisms include disruption of bacterial cell processes and efflux pump inhibition by non-antimicrobial agents, restoring antibiotic susceptibility."
  },
  {
    "drug": "levofloxacin",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Levofloxacin combined with chlorpromazine, propranolol, or diclofenac demonstrated synergistic effects against resistant A. baumannii strains.",
    "pmid": "33362739",
    "title": "High-Throughput Identification of Antibacterials Against Pseudomonas aeruginosa.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.591426",
    "mechanism": "Proposed mechanisms include disruption of bacterial cell processes and efflux pump inhibition by non-antimicrobial agents, restoring antibiotic susceptibility."
  },
  {
    "drug": "chlorpromazine",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 200,
    "fici": null,
    "key_result": "Chlorpromazine at 200 \u03bcg/ml significantly restored susceptibility of XDR A. baumannii to fluoroquinolones.",
    "pmid": "33362739",
    "title": "High-Throughput Identification of Antibacterials Against Pseudomonas aeruginosa.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.591426",
    "mechanism": "Proposed mechanisms include disruption of bacterial cell processes and efflux pump inhibition by non-antimicrobial agents, restoring antibiotic susceptibility."
  },
  {
    "drug": "propranolol",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Propranolol at 0.5 mg/ml enhanced the activity of fluoroquinolones against resistant A. baumannii isolates.",
    "pmid": "33362739",
    "title": "High-Throughput Identification of Antibacterials Against Pseudomonas aeruginosa.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.591426",
    "mechanism": "Proposed mechanisms include disruption of bacterial cell processes and efflux pump inhibition by non-antimicrobial agents, restoring antibiotic susceptibility."
  },
  {
    "drug": "diclofenac",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 4,
    "fici": null,
    "key_result": "Diclofenac at 4 mg/ml showed synergism with fluoroquinolones in resistant A. baumannii strains.",
    "pmid": "33362739",
    "title": "High-Throughput Identification of Antibacterials Against Pseudomonas aeruginosa.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.591426",
    "mechanism": "Proposed mechanisms include disruption of bacterial cell processes and efflux pump inhibition by non-antimicrobial agents, restoring antibiotic susceptibility."
  },
  {
    "drug": "carvedilol",
    "pathogen": "HSV-1",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Carvedilol rescues \u03b2-arrestin 2 expression, which is degraded during viral infection, thereby potentially enhancing antiviral immune responses.",
    "pmid": "33385878",
    "title": "The plausible mechanisms of tramadol for treatment of COVID-19.",
    "year": "2021",
    "doi": "10.1016/j.mehy.2020.110468",
    "mechanism": "Carvedilol inhibits virus-induced degradation of \u03b2-arrestin 2, maintaining its levels to promote cGAS-STING pathway activation and enhance type I interferon responses."
  },
  {
    "drug": "carvedilol",
    "pathogen": "VSV",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Carvedilol prevents degradation of \u03b2-arrestin 2 during VSV infection, supporting its potential as an antiviral agent.",
    "pmid": "33385878",
    "title": "The plausible mechanisms of tramadol for treatment of COVID-19.",
    "year": "2021",
    "doi": "10.1016/j.mehy.2020.110468",
    "mechanism": "Carvedilol inhibits virus-induced degradation of \u03b2-arrestin 2, maintaining its levels to promote cGAS-STING pathway activation and enhance type I interferon responses."
  },
  {
    "drug": "tramadol",
    "pathogen": "P. aeruginosa",
    "activity_type": "bactericidal",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tramadol exhibits bactericidal activity against Pseudomonas aeruginosa, which may help prevent secondary bacterial infections in COVID-19 patients.",
    "pmid": "33471513",
    "title": "Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality.",
    "year": "2021",
    "doi": "10.1021/acsinfecdis.0c00721",
    "mechanism": "anti-inflammatory, immune-enhancing, hypocoagulable, antioxidant, cardioprotective, analgesic, antitussive, bactericidal, antidepressant effects"
  },
  {
    "drug": "p-coumaric acid 3,3'-dimethyl allyl ester (compound 13)",
    "pathogen": "Fusarium spp.",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 62,
    "fici": null,
    "key_result": "Compound 13 showed antifungal activity comparable to terbinafine and amphotericin B against clinical Fusarium strains.",
    "pmid": "33513915",
    "title": "Prenylated Trans-Cinnamic Esters and Ethers against Clinical Fusarium spp.: Repositioning of Natural Compounds in Antimicrobial Discovery.",
    "year": "2021",
    "doi": "10.3390/molecules26030658",
    "mechanism": "The study suggests that prenylated cinnamic esters and ethers may exert antifungal activity potentially through membrane disruption or interference with fungal cell processes, although the exact mechanism remains to be elucidated."
  },
  {
    "drug": "CC-11050",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "CC-11050 was safe and well tolerated, and may enhance lung function recovery in tuberculosis patients.",
    "pmid": "33740465",
    "title": "Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.",
    "year": "2021",
    "doi": "10.1016/S2213-2600(20)30448-3",
    "mechanism": "Host-directed therapies modulate immune response, reduce inflammation, induce autophagy, and improve drug penetration to enhance treatment outcomes in tuberculosis."
  },
  {
    "drug": "everolimus",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Everolimus was safe and may improve lung function recovery in tuberculosis patients.",
    "pmid": "33740465",
    "title": "Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.",
    "year": "2021",
    "doi": "10.1016/S2213-2600(20)30448-3",
    "mechanism": "Host-directed therapies modulate immune response, reduce inflammation, induce autophagy, and improve drug penetration to enhance treatment outcomes in tuberculosis."
  },
  {
    "drug": "auranofin",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin was associated with serious adverse events including life-threatening thrombocytopenia and intra-abdominal sepsis, limiting its safety profile.",
    "pmid": "33740465",
    "title": "Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.",
    "year": "2021",
    "doi": "10.1016/S2213-2600(20)30448-3",
    "mechanism": "Host-directed therapies modulate immune response, reduce inflammation, induce autophagy, and improve drug penetration to enhance treatment outcomes in tuberculosis."
  },
  {
    "drug": "ergocalciferol",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ergocalciferol did not show significant effects on sputum culture conversion or lung function, and was associated with paradoxical reactions.",
    "pmid": "33740465",
    "title": "Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.",
    "year": "2021",
    "doi": "10.1016/S2213-2600(20)30448-3",
    "mechanism": "Host-directed therapies modulate immune response, reduce inflammation, induce autophagy, and improve drug penetration to enhance treatment outcomes in tuberculosis."
  },
  {
    "drug": "vancomycin",
    "pathogen": "Gram-positive bacteria",
    "activity_type": "direct_antibacterial",
    "evidence_type": "literature review",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Vancomycin remains effective against Gram-positive bacteria but resistance mechanisms are known.",
    "pmid": "33754035",
    "title": "Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.",
    "year": "2021",
    "doi": "10.7150/thno.56205",
    "mechanism": "Repurposing non-antibiotic drugs as adjuvants to inhibit resistance mechanisms, enhance antibiotic activity, or restore efficacy of existing antibiotics."
  },
  {
    "drug": "rifampicin",
    "pathogen": "various bacteria including Mycobacteria",
    "activity_type": "direct_antibacterial",
    "evidence_type": "literature review",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Resistance to rifampicin can be mediated by mutations and enzymatic modification.",
    "pmid": "33754035",
    "title": "Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.",
    "year": "2021",
    "doi": "10.7150/thno.56205",
    "mechanism": "Repurposing non-antibiotic drugs as adjuvants to inhibit resistance mechanisms, enhance antibiotic activity, or restore efficacy of existing antibiotics."
  },
  {
    "drug": "penicillin",
    "pathogen": "Gram-positive bacteria",
    "activity_type": "direct_antibacterial",
    "evidence_type": "literature review",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Penicillin resistance is primarily due to beta-lactamase production.",
    "pmid": "33754035",
    "title": "Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.",
    "year": "2021",
    "doi": "10.7150/thno.56205",
    "mechanism": "Repurposing non-antibiotic drugs as adjuvants to inhibit resistance mechanisms, enhance antibiotic activity, or restore efficacy of existing antibiotics."
  },
  {
    "drug": "streptomycin",
    "pathogen": "various bacteria",
    "activity_type": "direct_antibacterial",
    "evidence_type": "literature review",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Aminoglycoside-modifying enzymes confer resistance to streptomycin.",
    "pmid": "33754035",
    "title": "Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.",
    "year": "2021",
    "doi": "10.7150/thno.56205",
    "mechanism": "Repurposing non-antibiotic drugs as adjuvants to inhibit resistance mechanisms, enhance antibiotic activity, or restore efficacy of existing antibiotics."
  },
  {
    "drug": "tigecycline",
    "pathogen": "various bacteria including Tet(X) producers",
    "activity_type": "direct_antibacterial",
    "evidence_type": "literature review",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tet(X) enzymes hydroxylate tigecycline, leading to resistance.",
    "pmid": "33754035",
    "title": "Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.",
    "year": "2021",
    "doi": "10.7150/thno.56205",
    "mechanism": "Repurposing non-antibiotic drugs as adjuvants to inhibit resistance mechanisms, enhance antibiotic activity, or restore efficacy of existing antibiotics."
  },
  {
    "drug": "colistin",
    "pathogen": "Gram-negative bacteria including MCR-producing strains",
    "activity_type": "direct_antibacterial",
    "evidence_type": "literature review",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "mcr gene confers colistin resistance by modifying lipid A.",
    "pmid": "33754035",
    "title": "Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.",
    "year": "2021",
    "doi": "10.7150/thno.56205",
    "mechanism": "Repurposing non-antibiotic drugs as adjuvants to inhibit resistance mechanisms, enhance antibiotic activity, or restore efficacy of existing antibiotics."
  },
  {
    "drug": "disulfiram",
    "pathogen": "H. pylori",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "Disulfiram suppresses the growth of H. pylori strains at 1 \u00b5g/mL, regardless of their resistance to current antibiotics.",
    "pmid": "33777846",
    "title": "Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent.",
    "year": "2021",
    "doi": "10.3389/fcimb.2021.633194",
    "mechanism": "Disulfiram exerts a bactericidal effect on H. pylori and decreases virulence protein expression, possibly through interference with bacterial growth and virulence factor production."
  },
  {
    "drug": "disulfiram",
    "pathogen": "H. pylori",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Disulfiram reduces the expression levels of virulence proteins urease, VacA, and CagA in H. pylori.",
    "pmid": "33777846",
    "title": "Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent.",
    "year": "2021",
    "doi": "10.3389/fcimb.2021.633194",
    "mechanism": "Disulfiram exerts a bactericidal effect on H. pylori and decreases virulence protein expression, possibly through interference with bacterial growth and virulence factor production."
  },
  {
    "drug": "silver",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Silver ions exert bactericidal effects by binding to DNA, proteins, and membranes, causing morphological changes and impairing bacterial functions.",
    "pmid": "33782498",
    "title": "In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.",
    "year": "2021",
    "doi": "10.1038/s41598-021-86595-3",
    "mechanism": "Silver ions bind to bacterial DNA, proteins, and membranes, causing DNA modification, protein inhibition via sulfhydryl group binding, and structural damage, leading to bacterial cell death."
  },
  {
    "drug": "silver",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Silver targets bacterial DNA and proteins, leading to DNA condensation, structural changes, and increased permeability, contributing to its antibacterial activity.",
    "pmid": "33782498",
    "title": "In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.",
    "year": "2021",
    "doi": "10.1038/s41598-021-86595-3",
    "mechanism": "Silver ions bind to bacterial DNA, proteins, and membranes, causing DNA modification, protein inhibition via sulfhydryl group binding, and structural damage, leading to bacterial cell death."
  },
  {
    "drug": "Bithionol",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Bithionol exhibits significant antimicrobial and antibiofilm effects against E. faecalis in vitro and reduces bacterial load in mouse peritonitis models.",
    "pmid": "33810067",
    "title": "Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli.",
    "year": "2021",
    "doi": "10.3390/antibiotics10030336",
    "mechanism": "disruption of bacterial cell membrane lipid bilayers"
  },
  {
    "drug": "Bithionol",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Bithionol shows activity against vancomycin-resistant E. faecium in vitro and in vivo, disrupting bacterial membranes.",
    "pmid": "33810067",
    "title": "Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli.",
    "year": "2021",
    "doi": "10.3390/antibiotics10030336",
    "mechanism": "disruption of bacterial cell membrane lipid bilayers"
  },
  {
    "drug": "Clofazimine",
    "pathogen": "M. tuberculosis",
    "activity_type": "direct_antibacterial|adjuvant",
    "evidence_type": "clinical|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Clofazimine shows efficacy against MDR-TB and enhances TCM responses while reducing TEM populations.",
    "pmid": "33886255",
    "title": "Strategies to Combat Multi-Drug Resistance in Tuberculosis.",
    "year": "2021",
    "doi": "10.1021/acs.accounts.0c00878",
    "mechanism": "Clofazimine releases reactive oxygen species and modulates potassium channels; statins inhibit cholesterol synthesis, enhance autophagy, and modulate cytokine responses."
  },
  {
    "drug": "statins (class)",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant|immunomodulatory",
    "evidence_type": "in_vivo|clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Statins reduce bacterial burden, modulate immune responses, and synergize with first-line anti-TB drugs, potentially shortening therapy duration.",
    "pmid": "33886255",
    "title": "Strategies to Combat Multi-Drug Resistance in Tuberculosis.",
    "year": "2021",
    "doi": "10.1021/acs.accounts.0c00878",
    "mechanism": "Clofazimine releases reactive oxygen species and modulates potassium channels; statins inhibit cholesterol synthesis, enhance autophagy, and modulate cytokine responses."
  },
  {
    "drug": "perhexiline",
    "pathogen": "Schistosoma mansoni",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Perhexiline showed a defined anti-schistosomal phenotype on juvenile worms in vitro.",
    "pmid": "33922083",
    "title": "Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling.",
    "year": "2021",
    "doi": "10.3390/ijms22094371",
    "mechanism": "not explicitly proposed in the paper"
  },
  {
    "drug": "astemizole",
    "pathogen": "Schistosoma mansoni",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Astemizole demonstrated activity against juvenile worms in vitro.",
    "pmid": "33922083",
    "title": "Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling.",
    "year": "2021",
    "doi": "10.3390/ijms22094371",
    "mechanism": "not explicitly proposed in the paper"
  },
  {
    "drug": "methylene blue",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Methylene blue combined with biogenic gold nanoparticles significantly enhances bacterial photoinactivation under LED light, achieving up to 99.98% kill.",
    "pmid": "33927718",
    "title": "Repurposing Immunomodulatory Drugs to Combat Tuberculosis.",
    "year": "2021",
    "doi": "10.3389/fimmu.2021.645485",
    "mechanism": "enhancement of photodynamic activity through prevention of methylene blue photobleaching and improved cellular penetration facilitated by biogenic gold nanoparticles"
  },
  {
    "drug": "methylene blue",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The combination of methylene blue with biogenic gold nanoparticles significantly improves photodynamic killing of E. coli, reaching up to 99.99% kill after prolonged irradiation.",
    "pmid": "33927718",
    "title": "Repurposing Immunomodulatory Drugs to Combat Tuberculosis.",
    "year": "2021",
    "doi": "10.3389/fimmu.2021.645485",
    "mechanism": "enhancement of photodynamic activity through prevention of methylene blue photobleaching and improved cellular penetration facilitated by biogenic gold nanoparticles"
  },
  {
    "drug": "atorvastatin",
    "pathogen": "HCoV-229E",
    "activity_type": "adjuvant",
    "evidence_type": "experimental",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cholesterol-altering agents can reduce infection of cholesterol-dependent coronaviruses in vitro.",
    "pmid": "34012274",
    "title": "Antibacterial Effects of Disulfiram in Helicobacter pylori.",
    "year": "2021",
    "doi": "10.2147/IDR.S299177",
    "mechanism": "Disruption of cholesterol-rich membrane microdomains (lipid rafts and caveolae) to inhibit virus entry into host cells."
  },
  {
    "drug": "atorvastatin",
    "pathogen": "HCoV-OC43",
    "activity_type": "adjuvant",
    "evidence_type": "experimental",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Disruption of membrane microdomains may impair virus entry.",
    "pmid": "34012274",
    "title": "Antibacterial Effects of Disulfiram in Helicobacter pylori.",
    "year": "2021",
    "doi": "10.2147/IDR.S299177",
    "mechanism": "Disruption of cholesterol-rich membrane microdomains (lipid rafts and caveolae) to inhibit virus entry into host cells."
  },
  {
    "drug": "atorvastatin",
    "pathogen": "MERS-CoV",
    "activity_type": "adjuvant",
    "evidence_type": "theoretical/experimental",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Potential to inhibit virus entry by perturbing cholesterol-rich membrane domains.",
    "pmid": "34012274",
    "title": "Antibacterial Effects of Disulfiram in Helicobacter pylori.",
    "year": "2021",
    "doi": "10.2147/IDR.S299177",
    "mechanism": "Disruption of cholesterol-rich membrane microdomains (lipid rafts and caveolae) to inhibit virus entry into host cells."
  },
  {
    "drug": "N-desmethyltamoxifen",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 16,
    "fici": null,
    "key_result": "Exhibited bactericidal activity with MIC90 of 16 mg/L against A. baumannii.",
    "pmid": "34025592",
    "title": "Drug Repurposing: In vitro and in vivo Antimicrobial and Antibiofilm Effects of Bithionol Against Enterococcus faecalis and Enterococcus faecium.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.579806",
    "mechanism": "Tamoxifen metabolites increase bacterial membrane permeability without affecting outer membrane protein profiles, leading to bacterial cell wall disruption."
  },
  {
    "drug": "4-hydroxytamoxifen",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 16,
    "fici": null,
    "key_result": "Exhibited bactericidal activity with MIC90 of 16 mg/L against E. coli.",
    "pmid": "34025592",
    "title": "Drug Repurposing: In vitro and in vivo Antimicrobial and Antibiofilm Effects of Bithionol Against Enterococcus faecalis and Enterococcus faecium.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.579806",
    "mechanism": "Tamoxifen metabolites increase bacterial membrane permeability without affecting outer membrane protein profiles, leading to bacterial cell wall disruption."
  },
  {
    "drug": "Endoxifen",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 16,
    "fici": null,
    "key_result": "Exhibited bactericidal activity with MIC90 of 16 mg/L against E. coli.",
    "pmid": "34025592",
    "title": "Drug Repurposing: In vitro and in vivo Antimicrobial and Antibiofilm Effects of Bithionol Against Enterococcus faecalis and Enterococcus faecium.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.579806",
    "mechanism": "Tamoxifen metabolites increase bacterial membrane permeability without affecting outer membrane protein profiles, leading to bacterial cell wall disruption."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant|immune_modulation",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Reduced bacterial load and increased survival in immunosuppressed mice infected with A. baumannii.",
    "pmid": "34025592",
    "title": "Drug Repurposing: In vitro and in vivo Antimicrobial and Antibiofilm Effects of Bithionol Against Enterococcus faecalis and Enterococcus faecium.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.579806",
    "mechanism": "Tamoxifen metabolites increase bacterial membrane permeability without affecting outer membrane protein profiles, leading to bacterial cell wall disruption."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "E. coli",
    "activity_type": "adjuvant|immune_modulation",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Reduced bacterial load and increased survival in immunosuppressed mice infected with E. coli.",
    "pmid": "34025592",
    "title": "Drug Repurposing: In vitro and in vivo Antimicrobial and Antibiofilm Effects of Bithionol Against Enterococcus faecalis and Enterococcus faecium.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.579806",
    "mechanism": "Tamoxifen metabolites increase bacterial membrane permeability without affecting outer membrane protein profiles, leading to bacterial cell wall disruption."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant|immune_modulation",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Did not significantly reduce bacterial load or improve survival in P. aeruginosa infection models.",
    "pmid": "34025592",
    "title": "Drug Repurposing: In vitro and in vivo Antimicrobial and Antibiofilm Effects of Bithionol Against Enterococcus faecalis and Enterococcus faecium.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.579806",
    "mechanism": "Tamoxifen metabolites increase bacterial membrane permeability without affecting outer membrane protein profiles, leading to bacterial cell wall disruption."
  },
  {
    "drug": "Dantrolene",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant|anti_virulence",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Dantrolene reduces necrotic death of infected macrophages by attenuating RyR activity, promoting autophagy, and potentially serving as a host-directed therapy for TB.",
    "pmid": "34073235",
    "title": "Potential Tamoxifen Repurposing to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli.",
    "year": "2021",
    "doi": "10.3390/ph14060507",
    "mechanism": "Modulation of host ion channels affecting calcium signaling, autophagy, apoptosis, and efflux pump activity, as well as direct interference with bacterial efflux mechanisms."
  },
  {
    "drug": "Resveratrol",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant|anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Resveratrol enhances elimination of Mtb in macrophages by upregulating sirtuin 1 and modulating inflammatory responses.",
    "pmid": "34073235",
    "title": "Potential Tamoxifen Repurposing to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli.",
    "year": "2021",
    "doi": "10.3390/ph14060507",
    "mechanism": "Modulation of host ion channels affecting calcium signaling, autophagy, apoptosis, and efflux pump activity, as well as direct interference with bacterial efflux mechanisms."
  },
  {
    "drug": "verapamil",
    "pathogen": "M. tuberculosis",
    "activity_type": "direct_antibacterial|synergy|adjuvant",
    "evidence_type": "in_vitro|in_vivo|clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Verapamil exhibits bactericidal activity against Mtb, enhances autophagy, inhibits efflux pumps, and shows synergy with standard TB drugs, reducing bacterial load in models.",
    "pmid": "34073235",
    "title": "Potential Tamoxifen Repurposing to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli.",
    "year": "2021",
    "doi": "10.3390/ph14060507",
    "mechanism": "Modulation of host ion channels affecting calcium signaling, autophagy, apoptosis, and efflux pump activity, as well as direct interference with bacterial efflux mechanisms."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tamoxifen reduced bacterial load and increased survival in murine models of A. baumannii infection.",
    "pmid": "34153377",
    "title": "Coronaviruses, cholesterol and statins: Involvement and application for Covid-19.",
    "year": "2021",
    "doi": "10.1016/j.biochi.2021.06.005",
    "mechanism": "Tamoxifen downregulates MCP-1 and IL-18, impairing immune cell migration from bone marrow to blood, and enhances immune cell bacterial killing activity."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tamoxifen decreased bacterial burden and modulated immune response in P. aeruginosa infected mice.",
    "pmid": "34153377",
    "title": "Coronaviruses, cholesterol and statins: Involvement and application for Covid-19.",
    "year": "2021",
    "doi": "10.1016/j.biochi.2021.06.005",
    "mechanism": "Tamoxifen downregulates MCP-1 and IL-18, impairing immune cell migration from bone marrow to blood, and enhances immune cell bacterial killing activity."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tamoxifen treatment led to reduced bacterial counts and improved survival in E. coli infection models.",
    "pmid": "34153377",
    "title": "Coronaviruses, cholesterol and statins: Involvement and application for Covid-19.",
    "year": "2021",
    "doi": "10.1016/j.biochi.2021.06.005",
    "mechanism": "Tamoxifen downregulates MCP-1 and IL-18, impairing immune cell migration from bone marrow to blood, and enhances immune cell bacterial killing activity."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "A. baumannii",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tamoxifen increased bacterial killing by macrophages and neutrophils in vitro.",
    "pmid": "34153377",
    "title": "Coronaviruses, cholesterol and statins: Involvement and application for Covid-19.",
    "year": "2021",
    "doi": "10.1016/j.biochi.2021.06.005",
    "mechanism": "Tamoxifen downregulates MCP-1 and IL-18, impairing immune cell migration from bone marrow to blood, and enhances immune cell bacterial killing activity."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "P. aeruginosa",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tamoxifen enhanced bacterial killing activity of immune cells against P. aeruginosa in vitro.",
    "pmid": "34153377",
    "title": "Coronaviruses, cholesterol and statins: Involvement and application for Covid-19.",
    "year": "2021",
    "doi": "10.1016/j.biochi.2021.06.005",
    "mechanism": "Tamoxifen downregulates MCP-1 and IL-18, impairing immune cell migration from bone marrow to blood, and enhances immune cell bacterial killing activity."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tamoxifen improved macrophage and neutrophil bacterial killing of E. coli in vitro.",
    "pmid": "34153377",
    "title": "Coronaviruses, cholesterol and statins: Involvement and application for Covid-19.",
    "year": "2021",
    "doi": "10.1016/j.biochi.2021.06.005",
    "mechanism": "Tamoxifen downregulates MCP-1 and IL-18, impairing immune cell migration from bone marrow to blood, and enhances immune cell bacterial killing activity."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin rapidly eradicated MRSA in infected pressure ulcers in diabetic mice within four days, showing superior bacterial reduction compared to mupirocin and clindamycin.",
    "pmid": "34321273",
    "title": "Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.",
    "year": "2021",
    "doi": "10.1136/jitc-2020-001587",
    "mechanism": "Auranofin exerts antimicrobial activity through direct bacterial killing and modulates inflammation by decreasing pro-inflammatory cytokines and MMPs, while promoting wound healing biomarkers."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "anti_inflammatory",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin treatment decreased expression of pro-inflammatory cytokines IL-1\u03b2 and IL-17, and MMPs, while increasing biomarkers associated with wound healing such as IGF and VEGF.",
    "pmid": "34321273",
    "title": "Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.",
    "year": "2021",
    "doi": "10.1136/jitc-2020-001587",
    "mechanism": "Auranofin exerts antimicrobial activity through direct bacterial killing and modulates inflammation by decreasing pro-inflammatory cytokines and MMPs, while promoting wound healing biomarkers."
  },
  {
    "drug": "mupirocin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mupirocin reduced MRSA burden by 2.15-log10 in pressure ulcers but was less effective than auranofin.",
    "pmid": "34321273",
    "title": "Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.",
    "year": "2021",
    "doi": "10.1136/jitc-2020-001587",
    "mechanism": "Auranofin exerts antimicrobial activity through direct bacterial killing and modulates inflammation by decreasing pro-inflammatory cytokines and MMPs, while promoting wound healing biomarkers."
  },
  {
    "drug": "clindamycin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Clindamycin reduced MRSA burden by 0.73-log10 in pressure ulcers, less effective than auranofin.",
    "pmid": "34321273",
    "title": "Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.",
    "year": "2021",
    "doi": "10.1136/jitc-2020-001587",
    "mechanism": "Auranofin exerts antimicrobial activity through direct bacterial killing and modulates inflammation by decreasing pro-inflammatory cytokines and MMPs, while promoting wound healing biomarkers."
  },
  {
    "drug": "disulfiram",
    "pathogen": "bacteria (via LPS-induced sepsis model)",
    "activity_type": "adjuvant|anti_inflammatory",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Disulfiram effectively reduces inflammation and improves survival in LPS-induced sepsis mouse models by inhibiting pyroptosis.",
    "pmid": "34364941",
    "title": "Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease.",
    "year": "2021",
    "doi": "10.1016/j.ijbiomac.2021.07.184",
    "mechanism": "Inhibition of gasdermin D (GSDMD)-mediated pore formation, suppressing pyroptosis and inflammatory cytokine release."
  },
  {
    "drug": "auranofin",
    "pathogen": "Enterobacterales",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin potentiated the activity of aztreonam-avibactam against MBL-producing Enterobacterales and restored activity against ATM-AVI resistant mutants.",
    "pmid": "34442776",
    "title": "Repurposing of the Fasciolicide Triclabendazole to Treat Infections Caused by Staphylococcus spp. and Vancomycin-Resistant Enterococci.",
    "year": "2021",
    "doi": "10.3390/microorganisms9081697",
    "mechanism": "displacement of Zn(II) cofactors from MBL active sites, inhibiting carbapenemase activity"
  },
  {
    "drug": "Penfluridol",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 4,
    "fici": null,
    "key_result": "Penfluridol exhibits strong bactericidal activity against S. aureus with MIC of 4-8 \u03bcg/ml.",
    "pmid": "34451920",
    "title": "In Vitro and In Vivo Activity of AS101 against Carbapenem-Resistant Acinetobacter baumannii.",
    "year": "2021",
    "doi": "10.3390/ph14080823",
    "mechanism": "Penfluridol induces bacterial membrane permeability, causes ATP release, and disrupts membrane integrity, leading to bacterial cell death."
  },
  {
    "drug": "Penfluridol",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "Penfluridol significantly inhibits biofilm formation and eradicates preformed biofilms in a dose-dependent manner.",
    "pmid": "34451920",
    "title": "In Vitro and In Vivo Activity of AS101 against Carbapenem-Resistant Acinetobacter baumannii.",
    "year": "2021",
    "doi": "10.3390/ph14080823",
    "mechanism": "Penfluridol induces bacterial membrane permeability, causes ATP release, and disrupts membrane integrity, leading to bacterial cell death."
  },
  {
    "drug": "Penfluridol",
    "pathogen": "S. aureus",
    "activity_type": "anti_persister",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Penfluridol effectively kills MRSA persister cells in vitro and demonstrates efficacy in mouse infection models.",
    "pmid": "34451920",
    "title": "In Vitro and In Vivo Activity of AS101 against Carbapenem-Resistant Acinetobacter baumannii.",
    "year": "2021",
    "doi": "10.3390/ph14080823",
    "mechanism": "Penfluridol induces bacterial membrane permeability, causes ATP release, and disrupts membrane integrity, leading to bacterial cell death."
  },
  {
    "drug": "ebselen",
    "pathogen": "Clostridioides difficile",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "Ebselen inhibits most C. difficile strains with MICs of 2 to 8 \u03bcg/ml in BHI medium, except for ribotype 078 which is resistant.",
    "pmid": "34489917",
    "title": "Antimicrobial, Antibiofilm, and Anti-persister Activities of Penfluridol Against Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.727692",
    "mechanism": "Ebselen kills C. difficile by disrupting redox homeostasis, altering NAD+/NADH ratios, depleting nonprotein thiols, and affecting cysteine metabolism, leading to oxidative stress and metabolic imbalance."
  },
  {
    "drug": "ebselen",
    "pathogen": "Clostridioides difficile",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen disrupts intracellular redox homeostasis by altering NAD+/NADH ratio and depleting nonprotein thiols, contributing to bacterial killing.",
    "pmid": "34489917",
    "title": "Antimicrobial, Antibiofilm, and Anti-persister Activities of Penfluridol Against Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.727692",
    "mechanism": "Ebselen kills C. difficile by disrupting redox homeostasis, altering NAD+/NADH ratios, depleting nonprotein thiols, and affecting cysteine metabolism, leading to oxidative stress and metabolic imbalance."
  },
  {
    "drug": "ebselen",
    "pathogen": "Clostridioides difficile",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The study suggests potential anti-biofilm activity through redox disruption, but specific biofilm assays were not detailed.",
    "pmid": "34489917",
    "title": "Antimicrobial, Antibiofilm, and Anti-persister Activities of Penfluridol Against Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.727692",
    "mechanism": "Ebselen kills C. difficile by disrupting redox homeostasis, altering NAD+/NADH ratios, depleting nonprotein thiols, and affecting cysteine metabolism, leading to oxidative stress and metabolic imbalance."
  },
  {
    "drug": "ZnCexFe2\u2212xO4; X = 0.06",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 6.25,
    "fici": null,
    "key_result": "ZnCexFe2\u2212xO4; X = 0.06 significantly inhibited P. aeruginosa growth with a MIC of 6.250 \u00b5g/mL.",
    "pmid": "34561552",
    "title": "Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases.",
    "year": "2021",
    "doi": "10.1038/s41401-021-00770-w",
    "mechanism": "The nanoparticles induce morphological bacterial cell lysis, decrease viable microbial counts, and inhibit biofilm growth, likely through oxidative stress and membrane disruption."
  },
  {
    "drug": "ZnCexFe2\u2212xO4; X = 0.06",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.39,
    "fici": null,
    "key_result": "ZnCexFe2\u2212xO4; X = 0.06 exhibited potent activity against S. aureus with a MIC of 0.390 \u00b5g/mL.",
    "pmid": "34561552",
    "title": "Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases.",
    "year": "2021",
    "doi": "10.1038/s41401-021-00770-w",
    "mechanism": "The nanoparticles induce morphological bacterial cell lysis, decrease viable microbial counts, and inhibit biofilm growth, likely through oxidative stress and membrane disruption."
  },
  {
    "drug": "ebselen",
    "pathogen": "various bacteria and fungi",
    "activity_type": "adjuvant|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen combined with ZnCexFe2\u2212xO4 nanoparticles enhanced antimicrobial and antibiofilm effects.",
    "pmid": "34561552",
    "title": "Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases.",
    "year": "2021",
    "doi": "10.1038/s41401-021-00770-w",
    "mechanism": "The nanoparticles induce morphological bacterial cell lysis, decrease viable microbial counts, and inhibit biofilm growth, likely through oxidative stress and membrane disruption."
  },
  {
    "drug": "polymyxin B",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Localized and sustained release of PMB from the hydrogel effectively treated P. aeruginosa infection in vivo, reducing mortality from 93% to 13%.",
    "pmid": "34564137",
    "title": "Metabolites from Marine-Derived Fungi as Potential Antimicrobial Adjuvants.",
    "year": "2021",
    "doi": "10.3390/md19090475",
    "mechanism": "Polymyxin B interacts electrostatically with bacterial outer membranes and disrupts membrane integrity; in the hydrogel, PMB is released in a sustained manner for localized antimicrobial activity."
  },
  {
    "drug": "Fusidic acid",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Incorporation of fusidic acid into the hydrogel enhanced antimicrobial activity against S. aureus.",
    "pmid": "34564137",
    "title": "Metabolites from Marine-Derived Fungi as Potential Antimicrobial Adjuvants.",
    "year": "2021",
    "doi": "10.3390/md19090475",
    "mechanism": "Polymyxin B interacts electrostatically with bacterial outer membranes and disrupts membrane integrity; in the hydrogel, PMB is released in a sustained manner for localized antimicrobial activity."
  },
  {
    "drug": "Fusidic acid",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The hydrogel demonstrated enhanced antimicrobial effect against A. baumannii when fusidic acid was incorporated.",
    "pmid": "34564137",
    "title": "Metabolites from Marine-Derived Fungi as Potential Antimicrobial Adjuvants.",
    "year": "2021",
    "doi": "10.3390/md19090475",
    "mechanism": "Polymyxin B interacts electrostatically with bacterial outer membranes and disrupts membrane integrity; in the hydrogel, PMB is released in a sustained manner for localized antimicrobial activity."
  },
  {
    "drug": "phytochemicals",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Phytochemicals exhibit quorum quenching activity that can attenuate virulence factors and biofilm formation in P. aeruginosa.",
    "pmid": "34576334",
    "title": "Influence of Ce3+ Substitution on Antimicrobial and Antibiofilm Properties of ZnCexFe2-xO4 Nanoparticles (X = 0.0, 0.02, 0.04, 0.06, and 0.08) Conjugated with Ebselen and Its Role Subsidised with \u03b3-Radiation in Mitigating Human TNBC and Colorectal Adenocarcinoma Proliferation In Vitro.",
    "year": "2021",
    "doi": "10.3390/ijms221810171",
    "mechanism": "quorum sensing inhibition (quorum quenching) disrupting bacterial communication and virulence regulation"
  },
  {
    "drug": "Acacia macrostachya extract",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The extract demonstrated significant efflux pump inhibition and biofilm formation reduction in S. aureus.",
    "pmid": "34589063",
    "title": "Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.688772",
    "mechanism": "The plant extracts contain phytochemicals such as flavonoids, tannins, and phytosterols that may inhibit bacterial efflux pumps and biofilm formation, thereby counteracting resistance mechanisms."
  },
  {
    "drug": "Acacia macrostachya extract",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The extract showed notable efflux pump inhibition and biofilm inhibition in E. coli.",
    "pmid": "34589063",
    "title": "Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.688772",
    "mechanism": "The plant extracts contain phytochemicals such as flavonoids, tannins, and phytosterols that may inhibit bacterial efflux pumps and biofilm formation, thereby counteracting resistance mechanisms."
  },
  {
    "drug": "Acacia macrostachya extract",
    "pathogen": "P. aeruginosa",
    "activity_type": "efflux_inhibitor|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The extract exhibited efflux pump inhibition and antibiofilm activity against P. aeruginosa.",
    "pmid": "34589063",
    "title": "Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.688772",
    "mechanism": "The plant extracts contain phytochemicals such as flavonoids, tannins, and phytosterols that may inhibit bacterial efflux pumps and biofilm formation, thereby counteracting resistance mechanisms."
  },
  {
    "drug": "Stigmasterol",
    "pathogen": "not specified",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Stigmasterol was identified as a phytosterol component, potentially interacting with bacterial resistance mechanisms.",
    "pmid": "34589063",
    "title": "Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.688772",
    "mechanism": "The plant extracts contain phytochemicals such as flavonoids, tannins, and phytosterols that may inhibit bacterial efflux pumps and biofilm formation, thereby counteracting resistance mechanisms."
  },
  {
    "drug": "Tamoxifen metabolites mixture (DTAM, HTAM, ENDX)",
    "pathogen": "MRSE",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "The mixture of tamoxifen metabolites exhibited bactericidal activity against MRSE strains at 4\u00d7 MIC with MIC90 of 2 mg/liter.",
    "pmid": "34668743",
    "title": "Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00403-21",
    "mechanism": "The proposed mechanism involves increased bacterial membrane permeability, leading to disruption of cell integrity."
  },
  {
    "drug": "Tamoxifen metabolites mixture (DTAM, HTAM, ENDX)",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "The mixture showed bactericidal activity against vancomycin-resistant E. faecalis strains at 2\u00d7 MIC with MIC90 of 2 mg/liter.",
    "pmid": "34668743",
    "title": "Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00403-21",
    "mechanism": "The proposed mechanism involves increased bacterial membrane permeability, leading to disruption of cell integrity."
  },
  {
    "drug": "Tamoxifen metabolites mixture (DTAM, HTAM, ENDX)",
    "pathogen": "MRSE",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The metabolites increased membrane permeability and potentially disrupt biofilms, contributing to antibacterial activity.",
    "pmid": "34668743",
    "title": "Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00403-21",
    "mechanism": "The proposed mechanism involves increased bacterial membrane permeability, leading to disruption of cell integrity."
  },
  {
    "drug": "Tamoxifen metabolites mixture (DTAM, HTAM, ENDX)",
    "pathogen": "E. faecalis",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The metabolites increased membrane permeability of E. faecalis strains.",
    "pmid": "34668743",
    "title": "Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00403-21",
    "mechanism": "The proposed mechanism involves increased bacterial membrane permeability, leading to disruption of cell integrity."
  },
  {
    "drug": "Candesartan Cilexetil",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "Candesartan cilexetil exhibits strong antimicrobial activity against S. aureus with MICs of 8-16 \u03bcg/ml.",
    "pmid": "34696514",
    "title": "Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.",
    "year": "2021",
    "doi": "10.3390/v13102084",
    "mechanism": "Disruption of membrane permeability and damage to cell structure."
  },
  {
    "drug": "Candesartan Cilexetil",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": "<0.5",
    "key_result": "It shows a synergistic antibacterial effect when combined with gentamicin and tobramycin.",
    "pmid": "34696514",
    "title": "Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.",
    "year": "2021",
    "doi": "10.3390/v13102084",
    "mechanism": "Disruption of membrane permeability and damage to cell structure."
  },
  {
    "drug": "Candesartan Cilexetil",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 16,
    "fici": null,
    "key_result": "Effective concentrations to inhibit MRSA biofilm formation were 16-64 \u03bcg/ml.",
    "pmid": "34696514",
    "title": "Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.",
    "year": "2021",
    "doi": "10.3390/v13102084",
    "mechanism": "Disruption of membrane permeability and damage to cell structure."
  },
  {
    "drug": "Candesartan Cilexetil",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Disrupted membrane permeability and damaged cell structure, indicating membrane-targeting activity.",
    "pmid": "34696514",
    "title": "Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.",
    "year": "2021",
    "doi": "10.3390/v13102084",
    "mechanism": "Disruption of membrane permeability and damage to cell structure."
  },
  {
    "drug": "Candesartan Cilexetil",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Enhanced antibacterial effects when combined with conventional antibiotics.",
    "pmid": "34696514",
    "title": "Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.",
    "year": "2021",
    "doi": "10.3390/v13102084",
    "mechanism": "Disruption of membrane permeability and damage to cell structure."
  },
  {
    "drug": "Candesartan Cilexetil",
    "pathogen": "S. aureus",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 4,
    "fici": null,
    "key_result": "Killed intractable persisters at 4-8\u00d7 MIC.",
    "pmid": "34696514",
    "title": "Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.",
    "year": "2021",
    "doi": "10.3390/v13102084",
    "mechanism": "Disruption of membrane permeability and damage to cell structure."
  },
  {
    "drug": "AS101",
    "pathogen": "CRAB",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "AS101 exhibited bactericidal activity against CRAB with MICs ranging from 0.5 to 32 \u03bcg/mL and was effective in reducing bacterial load in vitro.",
    "pmid": "34720766",
    "title": "Antibacterial, Antibiofilm, and Efflux Pump Inhibitory Properties of the Crude Extract and Fractions from Acacia macrostachya Stem Bark.",
    "year": "2021",
    "doi": "10.1155/2021/5381993",
    "mechanism": "AS101 induces accumulation of reactive oxygen species (ROS) and disrupts bacterial cell membrane integrity, leading to cell death."
  },
  {
    "drug": "AS101",
    "pathogen": "CRAB",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The antibacterial mechanism involves ROS accumulation and disruption of the bacterial cell membrane.",
    "pmid": "34720766",
    "title": "Antibacterial, Antibiofilm, and Efflux Pump Inhibitory Properties of the Crude Extract and Fractions from Acacia macrostachya Stem Bark.",
    "year": "2021",
    "doi": "10.1155/2021/5381993",
    "mechanism": "AS101 induces accumulation of reactive oxygen species (ROS) and disrupts bacterial cell membrane integrity, leading to cell death."
  },
  {
    "drug": "AS101",
    "pathogen": "CRAB",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Not explicitly tested for biofilm activity in this study.",
    "pmid": "34720766",
    "title": "Antibacterial, Antibiofilm, and Efflux Pump Inhibitory Properties of the Crude Extract and Fractions from Acacia macrostachya Stem Bark.",
    "year": "2021",
    "doi": "10.1155/2021/5381993",
    "mechanism": "AS101 induces accumulation of reactive oxygen species (ROS) and disrupts bacterial cell membrane integrity, leading to cell death."
  },
  {
    "drug": "AS101",
    "pathogen": "CRAB",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Not reported.",
    "pmid": "34720766",
    "title": "Antibacterial, Antibiofilm, and Efflux Pump Inhibitory Properties of the Crude Extract and Fractions from Acacia macrostachya Stem Bark.",
    "year": "2021",
    "doi": "10.1155/2021/5381993",
    "mechanism": "AS101 induces accumulation of reactive oxygen species (ROS) and disrupts bacterial cell membrane integrity, leading to cell death."
  },
  {
    "drug": "AS101",
    "pathogen": "CRAB",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo, high-dose AS101 improved survival rates in a mouse sepsis model and significantly decreased bacterial loads in organs.",
    "pmid": "34720766",
    "title": "Antibacterial, Antibiofilm, and Efflux Pump Inhibitory Properties of the Crude Extract and Fractions from Acacia macrostachya Stem Bark.",
    "year": "2021",
    "doi": "10.1155/2021/5381993",
    "mechanism": "AS101 induces accumulation of reactive oxygen species (ROS) and disrupts bacterial cell membrane integrity, leading to cell death."
  },
  {
    "drug": "Eltrombopag",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1.4,
    "fici": null,
    "key_result": "Eltrombopag showed potent activity against S. aureus, including MDR strains, with MIC50 values around 1.4 mg/L.",
    "pmid": "34824393",
    "title": "Reversion of antibiotic resistance in multidrug-resistant pathogens using non-antibiotic pharmaceutical benzydamine.",
    "year": "2021",
    "doi": "10.1038/s42003-021-02854-z",
    "mechanism": "Eltrombopag likely exerts a bacteriostatic effect by affecting bacterial stress response pathways and autolysin activity, involving mutations in regulatory genes such as ydeL and walR, and impairing enzymes like LytE and YokF."
  },
  {
    "drug": "Eltrombopag",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Eltrombopag reduced bacterial loads in infected mice, demonstrating in vivo efficacy.",
    "pmid": "34824393",
    "title": "Reversion of antibiotic resistance in multidrug-resistant pathogens using non-antibiotic pharmaceutical benzydamine.",
    "year": "2021",
    "doi": "10.1038/s42003-021-02854-z",
    "mechanism": "Eltrombopag likely exerts a bacteriostatic effect by affecting bacterial stress response pathways and autolysin activity, involving mutations in regulatory genes such as ydeL and walR, and impairing enzymes like LytE and YokF."
  },
  {
    "drug": "Eltrombopag",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The study suggests potential for combination therapy, though specific synergy data is not detailed.",
    "pmid": "34824393",
    "title": "Reversion of antibiotic resistance in multidrug-resistant pathogens using non-antibiotic pharmaceutical benzydamine.",
    "year": "2021",
    "doi": "10.1038/s42003-021-02854-z",
    "mechanism": "Eltrombopag likely exerts a bacteriostatic effect by affecting bacterial stress response pathways and autolysin activity, involving mutations in regulatory genes such as ydeL and walR, and impairing enzymes like LytE and YokF."
  },
  {
    "drug": "ethoxzolamide",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.125,
    "fici": null,
    "key_result": "Ethoxzolamide exhibited an MIC50 of 0.125 \u03bcg/mL against N. gonorrhoeae, 16-fold more potent than acetazolamide.",
    "pmid": "34827309",
    "title": "Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections.",
    "year": "2021",
    "doi": "10.3390/antibiotics10111372",
    "mechanism": "Inhibition of bacterial carbonic anhydrase enzyme, with increased permeability of ethoxzolamide contributing to its higher potency."
  },
  {
    "drug": "acetazolamide",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Both acetazolamide and ethoxzolamide demonstrated bacteriostatic activity and post-antibiotic effects against N. gonorrhoeae.",
    "pmid": "34827309",
    "title": "Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections.",
    "year": "2021",
    "doi": "10.3390/antibiotics10111372",
    "mechanism": "Inhibition of bacterial carbonic anhydrase enzyme, with increased permeability of ethoxzolamide contributing to its higher potency."
  },
  {
    "drug": "apramycin",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo mouse studies showed apramycin reduced bacterial load against carbapenem-resistant A. baumannii.",
    "pmid": "34848761",
    "title": "Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence.",
    "year": "2021",
    "doi": "10.1038/s41598-021-02353-5",
    "mechanism": "not explicitly proposed in the paper; generally, aminoglycosides inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit."
  },
  {
    "drug": "benzydamine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.188,
    "key_result": "Benzydamine significantly potentiated doxycycline activity against MRSA, reducing its MIC from 16 to 1 \u03bcg/mL.",
    "pmid": "34884459",
    "title": "Effects of Itxasol\u00a9 Components on Gene Expression in Bacteria Related to Infections of the Urinary Tract and to the Inflammation Process.",
    "year": "2021",
    "doi": "10.3390/ijms222312655",
    "mechanism": "Benzydamine dissipates bacterial membrane potential (\u0394\u03a8), upregulates transmembrane proton gradient (\u0394pH), promotes antibiotic uptake, and triggers oxidative stress via ROS production, thereby reversing resistance and enhancing antibiotic efficacy."
  },
  {
    "drug": "benzydamine",
    "pathogen": "E. faecium (VRE)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.375,
    "key_result": "Benzydamine enhanced doxycycline efficacy against VRE, lowering MIC values by 4-fold.",
    "pmid": "34884459",
    "title": "Effects of Itxasol\u00a9 Components on Gene Expression in Bacteria Related to Infections of the Urinary Tract and to the Inflammation Process.",
    "year": "2021",
    "doi": "10.3390/ijms222312655",
    "mechanism": "Benzydamine dissipates bacterial membrane potential (\u0394\u03a8), upregulates transmembrane proton gradient (\u0394pH), promotes antibiotic uptake, and triggers oxidative stress via ROS production, thereby reversing resistance and enhancing antibiotic efficacy."
  },
  {
    "drug": "benzydamine",
    "pathogen": "E. coli G6",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.375,
    "key_result": "Benzydamine potentiated doxycycline activity against blaNDM-5-positive E. coli, decreasing MICs significantly.",
    "pmid": "34884459",
    "title": "Effects of Itxasol\u00a9 Components on Gene Expression in Bacteria Related to Infections of the Urinary Tract and to the Inflammation Process.",
    "year": "2021",
    "doi": "10.3390/ijms222312655",
    "mechanism": "Benzydamine dissipates bacterial membrane potential (\u0394\u03a8), upregulates transmembrane proton gradient (\u0394pH), promotes antibiotic uptake, and triggers oxidative stress via ROS production, thereby reversing resistance and enhancing antibiotic efficacy."
  },
  {
    "drug": "benzydamine",
    "pathogen": "K. pneumoniae D120",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.375,
    "key_result": "Benzydamine restored doxycycline activity against mcr-1-carrying K. pneumoniae, reducing MICs.",
    "pmid": "34884459",
    "title": "Effects of Itxasol\u00a9 Components on Gene Expression in Bacteria Related to Infections of the Urinary Tract and to the Inflammation Process.",
    "year": "2021",
    "doi": "10.3390/ijms222312655",
    "mechanism": "Benzydamine dissipates bacterial membrane potential (\u0394\u03a8), upregulates transmembrane proton gradient (\u0394pH), promotes antibiotic uptake, and triggers oxidative stress via ROS production, thereby reversing resistance and enhancing antibiotic efficacy."
  },
  {
    "drug": "benzydamine",
    "pathogen": "A. baumannii C222",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Benzydamine enhanced doxycycline activity against tet(X)-positive A. baumannii, lowering MICs.",
    "pmid": "34884459",
    "title": "Effects of Itxasol\u00a9 Components on Gene Expression in Bacteria Related to Infections of the Urinary Tract and to the Inflammation Process.",
    "year": "2021",
    "doi": "10.3390/ijms222312655",
    "mechanism": "Benzydamine dissipates bacterial membrane potential (\u0394\u03a8), upregulates transmembrane proton gradient (\u0394pH), promotes antibiotic uptake, and triggers oxidative stress via ROS production, thereby reversing resistance and enhancing antibiotic efficacy."
  },
  {
    "drug": "\u03b2-Arbutin",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "\u03b2-Arbutin exhibits antimicrobial activity against E. coli and impairs biofilm formation.",
    "pmid": "34905109",
    "title": "Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?",
    "year": "2021",
    "doi": "10.1007/s00284-021-02693-5",
    "mechanism": "The components of Itxasol\u00a9 act through antimicrobial effects, biofilm disruption, anti-inflammatory modulation, and antioxidant activity, collectively reducing bacterial virulence and resistance mechanisms."
  },
  {
    "drug": "\u03b2-Arbutin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "\u03b2-Arbutin inhibits S. aureus growth and biofilm development.",
    "pmid": "34905109",
    "title": "Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?",
    "year": "2021",
    "doi": "10.1007/s00284-021-02693-5",
    "mechanism": "The components of Itxasol\u00a9 act through antimicrobial effects, biofilm disruption, anti-inflammatory modulation, and antioxidant activity, collectively reducing bacterial virulence and resistance mechanisms."
  },
  {
    "drug": "N-acetyl cysteine",
    "pathogen": "P. aeruginosa",
    "activity_type": "efflux_inhibitor|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "NAC disrupts P. aeruginosa biofilms and may inhibit efflux mechanisms.",
    "pmid": "34905109",
    "title": "Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?",
    "year": "2021",
    "doi": "10.1007/s00284-021-02693-5",
    "mechanism": "The components of Itxasol\u00a9 act through antimicrobial effects, biofilm disruption, anti-inflammatory modulation, and antioxidant activity, collectively reducing bacterial virulence and resistance mechanisms."
  },
  {
    "drug": "MS-40S",
    "pathogen": "Burkholderia cenocepacia",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MS-40S is bactericidal against B. cenocepacia, killing stationary-phase cells and persisters without resistance development.",
    "pmid": "34908453",
    "title": "Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00951-21",
    "mechanism": "likely involves disruption of thiol-redox homeostasis via inhibition of thioredoxin reductase, similar to auranofin."
  },
  {
    "drug": "MS-40",
    "pathogen": "Burkholderia cenocepacia",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MS-40 is bactericidal against B. cenocepacia, killing stationary-phase cells and persisters without resistance development.",
    "pmid": "34908453",
    "title": "Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00951-21",
    "mechanism": "likely involves disruption of thiol-redox homeostasis via inhibition of thioredoxin reductase, similar to auranofin."
  },
  {
    "drug": "MS-40S",
    "pathogen": "Burkholderia mallei",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MS-40S shows activity against B. mallei with low MICs.",
    "pmid": "34908453",
    "title": "Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00951-21",
    "mechanism": "likely involves disruption of thiol-redox homeostasis via inhibition of thioredoxin reductase, similar to auranofin."
  },
  {
    "drug": "MS-40S",
    "pathogen": "Burkholderia pseudomallei",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MS-40S shows activity against B. pseudomallei with low MICs.",
    "pmid": "34908453",
    "title": "Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00951-21",
    "mechanism": "likely involves disruption of thiol-redox homeostasis via inhibition of thioredoxin reductase, similar to auranofin."
  },
  {
    "drug": "MS-40S",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MS-40S exhibits bactericidal activity with MICs 1-16 \u03bcg/mL.",
    "pmid": "34908453",
    "title": "Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00951-21",
    "mechanism": "likely involves disruption of thiol-redox homeostasis via inhibition of thioredoxin reductase, similar to auranofin."
  },
  {
    "drug": "MS-40S",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MS-40S is bactericidal against S. aureus, including MRSA.",
    "pmid": "34908453",
    "title": "Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00951-21",
    "mechanism": "likely involves disruption of thiol-redox homeostasis via inhibition of thioredoxin reductase, similar to auranofin."
  },
  {
    "drug": "HDC1",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 48.23,
    "fici": null,
    "key_result": "HDC1 exhibits bactericidal activity against multidrug-resistant A. baumannii with an IC50 of 48.23 \u00b5M.",
    "pmid": "34943654",
    "title": "New Auranofin Analogs with Antibacterial Properties against Burkholderia Clinical Isolates.",
    "year": "2021",
    "doi": "10.3390/antibiotics10121443",
    "mechanism": "not explicitly proposed in the paper"
  },
  {
    "drug": "HDC1",
    "pathogen": "A. baumannii",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "HDC1 impairs growth of 43 clinical A. baumannii isolates, including carbapenem-resistant strains.",
    "pmid": "34943654",
    "title": "New Auranofin Analogs with Antibacterial Properties against Burkholderia Clinical Isolates.",
    "year": "2021",
    "doi": "10.3390/antibiotics10121443",
    "mechanism": "not explicitly proposed in the paper"
  },
  {
    "drug": "Eltrombopag",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Eltrombopag exhibits antimicrobial activity against MRSA and its biofilms by interfering with proton motive force.",
    "pmid": "35011432",
    "title": "A Double-Edged Sword: Thioxanthenes Act on Both the Mind and the Microbiome.",
    "year": "2021",
    "doi": "10.3390/molecules27010196",
    "mechanism": "interference with proton motive force in S. aureus"
  },
  {
    "drug": "Eltrombopag",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo models confirmed the efficacy of eltrombopag in treating MRSA infections.",
    "pmid": "35011432",
    "title": "A Double-Edged Sword: Thioxanthenes Act on Both the Mind and the Microbiome.",
    "year": "2021",
    "doi": "10.3390/molecules27010196",
    "mechanism": "interference with proton motive force in S. aureus"
  },
  {
    "drug": "Unithiol",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Unithiol acts as a competitive inhibitor of metallo-\u03b2-lactamases NDM-1, inhibiting meropenem hydrolysis with a KI of 16.7 \u00b5M.",
    "pmid": "35011508",
    "title": "Development of Phenothiazine Hybrids with Potential Medicinal Interest: A Review.",
    "year": "2022",
    "doi": "10.3390/molecules27010276",
    "mechanism": "Unithiol binds to the active site of metallo-\u03b2-lactamases by coordinating with zinc ions via its thiol group, occupying the same position as the catalytic hydroxide, thus inhibiting enzyme activity."
  },
  {
    "drug": "Unithiol",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Unithiol inhibits natural VIM-2 metallo-\u03b2-lactamases, increasing zones of inhibition in disk diffusion assays and protecting antibiotics from hydrolysis.",
    "pmid": "35011508",
    "title": "Development of Phenothiazine Hybrids with Potential Medicinal Interest: A Review.",
    "year": "2022",
    "doi": "10.3390/molecules27010276",
    "mechanism": "Unithiol binds to the active site of metallo-\u03b2-lactamases by coordinating with zinc ions via its thiol group, occupying the same position as the catalytic hydroxide, thus inhibiting enzyme activity."
  },
  {
    "drug": "raloxifene",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor|synergy|anti_biofilm",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Raloxifene inhibits NorA efflux pump, synergizes with ciprofloxacin, and enhances biofilm eradication in S. aureus.",
    "pmid": "35018330",
    "title": "Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030.",
    "year": "2021",
    "doi": "10.1099/acmi.0.000288",
    "mechanism": "The drugs bind to and block the NorA efflux pump, inhibiting the extrusion of antibiotics and dyes, thereby increasing bacterial susceptibility and biofilm eradication."
  },
  {
    "drug": "ezetimibe",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor|synergy|anti_biofilm",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Ezetimibe acts as a NorA efflux pump inhibitor, potentiates fluoroquinolones, and reduces biofilm formation.",
    "pmid": "35018330",
    "title": "Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030.",
    "year": "2021",
    "doi": "10.1099/acmi.0.000288",
    "mechanism": "The drugs bind to and block the NorA efflux pump, inhibiting the extrusion of antibiotics and dyes, thereby increasing bacterial susceptibility and biofilm eradication."
  },
  {
    "drug": "propafenone",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Propafenone inhibits NorA, enhances ciprofloxacin activity, and shows synergy in vitro.",
    "pmid": "35018330",
    "title": "Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030.",
    "year": "2021",
    "doi": "10.1099/acmi.0.000288",
    "mechanism": "The drugs bind to and block the NorA efflux pump, inhibiting the extrusion of antibiotics and dyes, thereby increasing bacterial susceptibility and biofilm eradication."
  },
  {
    "drug": "nefazodone",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Nefazodone inhibits NorA, synergizes with fluoroquinolones, and improves bacterial eradication.",
    "pmid": "35018330",
    "title": "Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030.",
    "year": "2021",
    "doi": "10.1099/acmi.0.000288",
    "mechanism": "The drugs bind to and block the NorA efflux pump, inhibiting the extrusion of antibiotics and dyes, thereby increasing bacterial susceptibility and biofilm eradication."
  },
  {
    "drug": "chlorprothixene",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Chlorprothixene inhibits NorA, enhances antibiotic susceptibility, and shows synergistic effects.",
    "pmid": "35018330",
    "title": "Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030.",
    "year": "2021",
    "doi": "10.1099/acmi.0.000288",
    "mechanism": "The drugs bind to and block the NorA efflux pump, inhibiting the extrusion of antibiotics and dyes, thereby increasing bacterial susceptibility and biofilm eradication."
  },
  {
    "drug": "pyrvinium",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor|synergy|anti_biofilm",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": 0.39,
    "fici": 0.5,
    "key_result": "Pyrvinium inhibits NorA, potentiates ciprofloxacin, reduces biofilms, and significantly decreases bacterial burden in a murine model.",
    "pmid": "35018330",
    "title": "Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030.",
    "year": "2021",
    "doi": "10.1099/acmi.0.000288",
    "mechanism": "The drugs bind to and block the NorA efflux pump, inhibiting the extrusion of antibiotics and dyes, thereby increasing bacterial susceptibility and biofilm eradication."
  },
  {
    "drug": "risedronate",
    "pathogen": "NDM-1 producing bacteria",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Risedronate binds stably to NDM-1, forming hydrogen bonds and electrostatic interactions, and decreases catalytic efficiency of NDM-1 in vitro.",
    "pmid": "35039683",
    "title": "Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability.",
    "year": "2022",
    "doi": "10.1038/s41565-021-01048-2",
    "mechanism": "Inhibition of NDM-1 enzymatic activity through stable binding at the active site, involving hydrogen bonds and electrostatic interactions with catalytic residues and zinc ions."
  },
  {
    "drug": "methotrexate",
    "pathogen": "NDM-1 producing bacteria",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Methotrexate binds to NDM-1 with high affinity, forming multiple hydrogen bonds and electrostatic interactions, reducing enzyme activity in vitro.",
    "pmid": "35039683",
    "title": "Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability.",
    "year": "2022",
    "doi": "10.1038/s41565-021-01048-2",
    "mechanism": "Inhibition of NDM-1 enzymatic activity through stable binding at the active site, involving hydrogen bonds and electrostatic interactions with catalytic residues and zinc ions."
  },
  {
    "drug": "clopenthixol",
    "pathogen": "Gram-positive bacteria",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Clopenthixol exhibits moderate to powerful antibacterial activity against both Gram-positive and Gram-negative bacteria.",
    "pmid": "35140693",
    "title": "Repurposing Eltrombopag as an Antimicrobial Agent Against Methicillin-Resistant Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.790686",
    "mechanism": "The proposed mechanism involves the inhibition of microbial growth, potentially through interference with bacterial cell processes, although specific mechanisms are not detailed in the paper."
  },
  {
    "drug": "Ciclopirox (CPX)",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "CPX was more active against \u03b2-lactamase-producing MDR E. coli strains and effectively killed AZT-resistant strains.",
    "pmid": "35141168",
    "title": "Antimicrobial Activity of a Repurposed Harmine-Derived Compound on Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.",
    "year": "2021",
    "doi": "10.3389/fcimb.2021.789672",
    "mechanism": "CPX chelates polyvalent metal cations such as iron, inhibiting metal-dependent enzymes, disrupting membrane permeability, DNA repair, and cell division, leading to antibacterial effects."
  },
  {
    "drug": "Zidovudine (AZT)",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "AZT displayed no selectivity for resistant strains and resistance developed rapidly within 2 days.",
    "pmid": "35141168",
    "title": "Antimicrobial Activity of a Repurposed Harmine-Derived Compound on Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.",
    "year": "2021",
    "doi": "10.3389/fcimb.2021.789672",
    "mechanism": "CPX chelates polyvalent metal cations such as iron, inhibiting metal-dependent enzymes, disrupting membrane permeability, DNA repair, and cell division, leading to antibacterial effects."
  },
  {
    "drug": "Ciclopirox (CPX)",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Resistance to CPX was not observed after 25 days of continuous exposure, indicating low propensity for resistance development.",
    "pmid": "35141168",
    "title": "Antimicrobial Activity of a Repurposed Harmine-Derived Compound on Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.",
    "year": "2021",
    "doi": "10.3389/fcimb.2021.789672",
    "mechanism": "CPX chelates polyvalent metal cations such as iron, inhibiting metal-dependent enzymes, disrupting membrane permeability, DNA repair, and cell division, leading to antibacterial effects."
  },
  {
    "drug": "Bismuth nitrate",
    "pathogen": "Escherichia coli B3-1",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.125,
    "key_result": "Bismuth nitrate synergistically enhances tigecycline activity against tet(X4)-positive bacteria by inhibiting Tet(X4) enzymatic activity.",
    "pmid": "35163756",
    "title": "Drug Repurposing of the Unithiol: Inhibition of Metallo-\u03b2-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections.",
    "year": "2022",
    "doi": "10.3390/ijms23031834",
    "mechanism": "Bismuth drugs competitively bind to the active center of Tet(X4) enzyme, inhibiting its enzymatic activity and preventing tigecycline degradation."
  },
  {
    "drug": "Bismuth nitrate",
    "pathogen": "Escherichia coli B3-1",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.125,
    "key_result": "Bismuth nitrate significantly reduces the MIC of tigecycline and prevents resistance development in tet(X4)-positive bacteria.",
    "pmid": "35163756",
    "title": "Drug Repurposing of the Unithiol: Inhibition of Metallo-\u03b2-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections.",
    "year": "2022",
    "doi": "10.3390/ijms23031834",
    "mechanism": "Bismuth drugs competitively bind to the active center of Tet(X4) enzyme, inhibiting its enzymatic activity and preventing tigecycline degradation."
  },
  {
    "drug": "Bismuth nitrate",
    "pathogen": "Acinetobacter baumannii C222",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.188,
    "key_result": "Bismuth nitrate synergizes with tigecycline to restore activity against tet(X4)-positive A. baumannii.",
    "pmid": "35163756",
    "title": "Drug Repurposing of the Unithiol: Inhibition of Metallo-\u03b2-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections.",
    "year": "2022",
    "doi": "10.3390/ijms23031834",
    "mechanism": "Bismuth drugs competitively bind to the active center of Tet(X4) enzyme, inhibiting its enzymatic activity and preventing tigecycline degradation."
  },
  {
    "drug": "Bismuth nitrate",
    "pathogen": "Escherichia coli B3-1",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Bismuth nitrate inhibits Tet(X4) enzymatic activity by binding to its active site, restoring tigecycline efficacy.",
    "pmid": "35163756",
    "title": "Drug Repurposing of the Unithiol: Inhibition of Metallo-\u03b2-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections.",
    "year": "2022",
    "doi": "10.3390/ijms23031834",
    "mechanism": "Bismuth drugs competitively bind to the active center of Tet(X4) enzyme, inhibiting its enzymatic activity and preventing tigecycline degradation."
  },
  {
    "drug": "phenothiazine hybrid with 1,2,4-triazolo[4,3-a]pyridine",
    "pathogen": "cancer cells",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "A phenothiazine-triazolopyridine hybrid induced apoptosis and showed cytotoxic effects against multiple human breast cancer cell lines, with selective activity and potential to disrupt cell cycle via tubulin binding.",
    "pmid": "35203788",
    "title": "Drug Repurposing Targeting Pseudomonas aeruginosa MvfR Using Docking, Virtual Screening, Molecular Dynamics, and Free-Energy Calculations.",
    "year": "2022",
    "doi": "10.3390/antibiotics11020185",
    "mechanism": "binding to tubulin and disrupting microtubule dynamics, inducing apoptosis, and inhibiting cell migration and proliferation"
  },
  {
    "drug": "phenothiazine derivative with tubulin polymerization inhibitory effect",
    "pathogen": "cancer cells",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "A phenothiazine-based hybrid inhibited gastric cancer cell proliferation, migration, and tubulin polymerization, with in vivo tumor growth inhibition demonstrated in mice.",
    "pmid": "35203788",
    "title": "Drug Repurposing Targeting Pseudomonas aeruginosa MvfR Using Docking, Virtual Screening, Molecular Dynamics, and Free-Energy Calculations.",
    "year": "2022",
    "doi": "10.3390/antibiotics11020185",
    "mechanism": "binding to tubulin and disrupting microtubule dynamics, inducing apoptosis, and inhibiting cell migration and proliferation"
  },
  {
    "drug": "phenothiazine hybrid with 1,2,3-triazole",
    "pathogen": "cancer cells",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Methylene-bridged phenothiazine-triazole hybrids showed potent antiproliferative activity against various cancer cell lines, with activity influenced by substituents on the phenyl ring.",
    "pmid": "35203788",
    "title": "Drug Repurposing Targeting Pseudomonas aeruginosa MvfR Using Docking, Virtual Screening, Molecular Dynamics, and Free-Energy Calculations.",
    "year": "2022",
    "doi": "10.3390/antibiotics11020185",
    "mechanism": "binding to tubulin and disrupting microtubule dynamics, inducing apoptosis, and inhibiting cell migration and proliferation"
  },
  {
    "drug": "disulfiram",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Disulfiram and its S-octyl derivative sensitize S. aureus to fosfomycin by decreasing intracellular bacillithiol levels.",
    "pmid": "35286809",
    "title": "The Pandemic Response Box\u2500Accelerating Drug Discovery Efforts after Disease Outbreaks.",
    "year": "2022",
    "doi": "10.1021/acsinfecdis.1c00527",
    "mechanism": "Disulfiram analogs decrease intracellular bacillithiol levels in S. aureus through a thiol-disulfide exchange reaction, impairing fosB-mediated fosfomycin resistance and sensitizing bacteria to fosfomycin."
  },
  {
    "drug": "S-octyl disulfide",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "S-octyl disulfide enhances fosfomycin activity against S. aureus by depleting bacillithiol.",
    "pmid": "35286809",
    "title": "The Pandemic Response Box\u2500Accelerating Drug Discovery Efforts after Disease Outbreaks.",
    "year": "2022",
    "doi": "10.1021/acsinfecdis.1c00527",
    "mechanism": "Disulfiram analogs decrease intracellular bacillithiol levels in S. aureus through a thiol-disulfide exchange reaction, impairing fosB-mediated fosfomycin resistance and sensitizing bacteria to fosfomycin."
  },
  {
    "drug": "N,N-Dimethyl dithiocarbamate",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "N,N-Dimethyl dithiocarbamate exhibits antimicrobial activity against MRSA.",
    "pmid": "35286809",
    "title": "The Pandemic Response Box\u2500Accelerating Drug Discovery Efforts after Disease Outbreaks.",
    "year": "2022",
    "doi": "10.1021/acsinfecdis.1c00527",
    "mechanism": "Disulfiram analogs decrease intracellular bacillithiol levels in S. aureus through a thiol-disulfide exchange reaction, impairing fosB-mediated fosfomycin resistance and sensitizing bacteria to fosfomycin."
  },
  {
    "drug": "N,N-Diethyl dithiocarbamate",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "N,N-Diethyl dithiocarbamate shows antimicrobial activity against MRSA.",
    "pmid": "35286809",
    "title": "The Pandemic Response Box\u2500Accelerating Drug Discovery Efforts after Disease Outbreaks.",
    "year": "2022",
    "doi": "10.1021/acsinfecdis.1c00527",
    "mechanism": "Disulfiram analogs decrease intracellular bacillithiol levels in S. aureus through a thiol-disulfide exchange reaction, impairing fosB-mediated fosfomycin resistance and sensitizing bacteria to fosfomycin."
  },
  {
    "drug": "auranofin",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": 0.125,
    "fici": null,
    "key_result": "Auranofin significantly reduced N. gonorrhoeae colonization in a female mouse model of genital infection.",
    "pmid": "35299994",
    "title": "Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.",
    "year": "2022",
    "doi": "10.2147/JEP.S346006",
    "mechanism": "unknown; proposed to involve inhibition of bacterial thioredoxin reductase and disruption of redox homeostasis"
  },
  {
    "drug": "polymyxin B",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Polymyxin B shows activity against A. baumannii, with increased efficacy when combined with cannabidiol.",
    "pmid": "35326755",
    "title": "In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria.",
    "year": "2022",
    "doi": "10.3390/antibiotics11030291",
    "mechanism": "Disorganization of bacterial envelope formation, perturbation of membrane lipids, and disruption of DNA and RNA biosynthetic pathways."
  },
  {
    "drug": "cannabidiol",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.25,
    "key_result": "Cannabidiol exhibits synergistic antibacterial activity with polymyxin B against A. baumannii, including resistant strains.",
    "pmid": "35326755",
    "title": "In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria.",
    "year": "2022",
    "doi": "10.3390/antibiotics11030291",
    "mechanism": "Disorganization of bacterial envelope formation, perturbation of membrane lipids, and disruption of DNA and RNA biosynthetic pathways."
  },
  {
    "drug": "Glatiramer Acetate",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant|synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Glatiramer acetate synergizes with tobramycin, reducing its MICs and enhancing antibacterial activity against P. aeruginosa strains.",
    "pmid": "35446884",
    "title": "Auranofin exerts antibacterial activity against Neisseria gonorrhoeae in a female mouse model of genital tract infection.",
    "year": "2022",
    "doi": "10.1371/journal.pone.0266764",
    "mechanism": "Glatiramer acetate disrupts outer membranes, depolarizes cytoplasmic membranes, and permeabilizes P. aeruginosa, facilitating increased uptake and efficacy of tobramycin."
  },
  {
    "drug": "niclosamide",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.125,
    "fici": null,
    "key_result": "Niclosamide exhibits potent in vitro antibacterial activity against S. aureus, including resistant strains, with MICs ranging from 0.125 to 0.5 \u03bcg/ml.",
    "pmid": "35456620",
    "title": "Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against Acinetobacter baumannii: A Metabolomic Study.",
    "year": "2022",
    "doi": "10.3390/pharmaceutics14040786",
    "mechanism": "Targeting the proton motive force, effectively stopping cell growth and inhibiting biofilm maturation."
  },
  {
    "drug": "niclosamide",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide inhibits S. aureus biofilm maturation and exhibits anti-biofilm activity.",
    "pmid": "35456620",
    "title": "Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against Acinetobacter baumannii: A Metabolomic Study.",
    "year": "2022",
    "doi": "10.3390/pharmaceutics14040786",
    "mechanism": "Targeting the proton motive force, effectively stopping cell growth and inhibiting biofilm maturation."
  },
  {
    "drug": "niclosamide",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Previous studies suggest niclosamide can work synergistically with other antibiotics against S. aureus.",
    "pmid": "35456620",
    "title": "Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against Acinetobacter baumannii: A Metabolomic Study.",
    "year": "2022",
    "doi": "10.3390/pharmaceutics14040786",
    "mechanism": "Targeting the proton motive force, effectively stopping cell growth and inhibiting biofilm maturation."
  },
  {
    "drug": "polymyxin B",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Polymyxin B shows efficacy against MDR K. pneumoniae and enhances permeability for combination therapy.",
    "pmid": "35498219",
    "title": "Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical Candida albicans and non-albicans isolates.",
    "year": "2022",
    "doi": "10.1016/j.jsps.2022.01.011",
    "mechanism": "Polymyxin B disrupts the outer membrane of K. pneumoniae, facilitating entry of caspofungin, which then interferes with cell wall synthesis and other metabolic pathways, leading to bacterial death."
  },
  {
    "drug": "Caspofungin",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Caspofungin, an antifungal, exhibits synergistic activity when combined with polymyxin B against K. pneumoniae.",
    "pmid": "35498219",
    "title": "Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical Candida albicans and non-albicans isolates.",
    "year": "2022",
    "doi": "10.1016/j.jsps.2022.01.011",
    "mechanism": "Polymyxin B disrupts the outer membrane of K. pneumoniae, facilitating entry of caspofungin, which then interferes with cell wall synthesis and other metabolic pathways, leading to bacterial death."
  },
  {
    "drug": "polymyxin B",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.03,
    "key_result": "Combination with caspofungin results in synergistic antibacterial activity, including against resistant strains.",
    "pmid": "35498219",
    "title": "Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical Candida albicans and non-albicans isolates.",
    "year": "2022",
    "doi": "10.1016/j.jsps.2022.01.011",
    "mechanism": "Polymyxin B disrupts the outer membrane of K. pneumoniae, facilitating entry of caspofungin, which then interferes with cell wall synthesis and other metabolic pathways, leading to bacterial death."
  },
  {
    "drug": "niclosamide",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide exhibited in vitro antibacterial activity against S. aureus, including MRSA strains.",
    "pmid": "35522900",
    "title": "Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.",
    "year": "2022",
    "doi": "10.1002/ctm2.790",
    "mechanism": "unknown, but likely involves disruption of bacterial biofilm formation or bacterial viability due to sustained release of NIC from the catheter surface"
  },
  {
    "drug": "niclosamide",
    "pathogen": "Staphylococcus epidermidis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide showed antibacterial activity against S. epidermidis in vitro.",
    "pmid": "35522900",
    "title": "Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.",
    "year": "2022",
    "doi": "10.1002/ctm2.790",
    "mechanism": "unknown, but likely involves disruption of bacterial biofilm formation or bacterial viability due to sustained release of NIC from the catheter surface"
  },
  {
    "drug": "niclosamide",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "NIC-loaded catheters prevented S. aureus colonization and reduced bacterial load in a mouse biomaterial-associated infection model.",
    "pmid": "35522900",
    "title": "Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.",
    "year": "2022",
    "doi": "10.1002/ctm2.790",
    "mechanism": "unknown, but likely involves disruption of bacterial biofilm formation or bacterial viability due to sustained release of NIC from the catheter surface"
  },
  {
    "drug": "cephalothin",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Chlorpromazine increased E. coli susceptibility to cephalothin by fourfold.",
    "pmid": "35558127",
    "title": "Antifungal Activity of Sodium New Houttuyfonate Against Aspergillus fumigatus in vitro and in vivo.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.856272",
    "mechanism": "activation of efflux pump mechanisms and alterations in bacterial cell wall permeability."
  },
  {
    "drug": "ceftriaxone",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Chlorpromazine increased E. coli susceptibility to ceftriaxone by fourfold.",
    "pmid": "35558127",
    "title": "Antifungal Activity of Sodium New Houttuyfonate Against Aspergillus fumigatus in vitro and in vivo.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.856272",
    "mechanism": "activation of efflux pump mechanisms and alterations in bacterial cell wall permeability."
  },
  {
    "drug": "ampicillin",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine increased E. coli susceptibility to ampicillin by fourfold.",
    "pmid": "35558127",
    "title": "Antifungal Activity of Sodium New Houttuyfonate Against Aspergillus fumigatus in vitro and in vivo.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.856272",
    "mechanism": "activation of efflux pump mechanisms and alterations in bacterial cell wall permeability."
  },
  {
    "drug": "oxacillin",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Chlorpromazine increased S. aureus susceptibility to oxacillin by eightfold.",
    "pmid": "35558127",
    "title": "Antifungal Activity of Sodium New Houttuyfonate Against Aspergillus fumigatus in vitro and in vivo.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.856272",
    "mechanism": "activation of efflux pump mechanisms and alterations in bacterial cell wall permeability."
  },
  {
    "drug": "ciprofloxacin",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine increased P. aeruginosa susceptibility to ciprofloxacin by eightfold.",
    "pmid": "35558127",
    "title": "Antifungal Activity of Sodium New Houttuyfonate Against Aspergillus fumigatus in vitro and in vivo.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.856272",
    "mechanism": "activation of efflux pump mechanisms and alterations in bacterial cell wall permeability."
  },
  {
    "drug": "Tetracycline",
    "pathogen": "Salmonella enterica ser. Typhimurium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nano-encapsulated tetracycline combined with silica nanoparticles improved antibacterial efficacy against MDR Salmonella Typhimurium.",
    "pmid": "35616371",
    "title": "Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation.",
    "year": "2022",
    "doi": "10.1128/spectrum.02781-21",
    "mechanism": "Nanoparticle delivery enhances drug stability, controls release, targets bacteria, and inhibits resistance mechanisms such as efflux pumps and beta-lactamase enzymes."
  },
  {
    "drug": "chlorpromazine",
    "pathogen": "Salmonella enterica ser. Typhimurium",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Chlorpromazine loaded in silica nanoparticles inhibited efflux pump activity, reducing intracellular pathogen load by 83.02%.",
    "pmid": "35616371",
    "title": "Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation.",
    "year": "2022",
    "doi": "10.1128/spectrum.02781-21",
    "mechanism": "Nanoparticle delivery enhances drug stability, controls release, targets bacteria, and inhibits resistance mechanisms such as efflux pumps and beta-lactamase enzymes."
  },
  {
    "drug": "Tetracycline",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nano-encapsulated tetracycline showed enhanced activity against MDR S. aureus when delivered via chitosan nanoparticles.",
    "pmid": "35616371",
    "title": "Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation.",
    "year": "2022",
    "doi": "10.1128/spectrum.02781-21",
    "mechanism": "Nanoparticle delivery enhances drug stability, controls release, targets bacteria, and inhibits resistance mechanisms such as efflux pumps and beta-lactamase enzymes."
  },
  {
    "drug": "Methylene Blue",
    "pathogen": "A. baumannii",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MB-aPDT with methylene blue effectively reduced viable counts of XDR A. baumannii in vitro.",
    "pmid": "35625295",
    "title": "Niclosamide as a Repurposing Drug against Corynebacterium striatum Multidrug-Resistant Infections.",
    "year": "2022",
    "doi": "10.3390/antibiotics11050651",
    "mechanism": "photodynamic activation of methylene blue generates reactive oxygen species that damage bacterial cells."
  },
  {
    "drug": "Methylene Blue",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MB-aPDT significantly decreased viable counts of XDR P. aeruginosa in vitro.",
    "pmid": "35625295",
    "title": "Niclosamide as a Repurposing Drug against Corynebacterium striatum Multidrug-Resistant Infections.",
    "year": "2022",
    "doi": "10.3390/antibiotics11050651",
    "mechanism": "photodynamic activation of methylene blue generates reactive oxygen species that damage bacterial cells."
  },
  {
    "drug": "Methylene Blue",
    "pathogen": "K. pneumoniae",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MB-aPDT with methylene blue achieved substantial bacterial reduction in MDR K. pneumoniae in vitro.",
    "pmid": "35625295",
    "title": "Niclosamide as a Repurposing Drug against Corynebacterium striatum Multidrug-Resistant Infections.",
    "year": "2022",
    "doi": "10.3390/antibiotics11050651",
    "mechanism": "photodynamic activation of methylene blue generates reactive oxygen species that damage bacterial cells."
  },
  {
    "drug": "acetazolamide",
    "pathogen": "E. faecium",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Acetazolamide exhibits anti-VRE activity likely through inhibition of bacterial carbonic anhydrases.",
    "pmid": "35674439",
    "title": "Crizotinib Shows Antibacterial Activity against Gram-Positive Bacteria by Reducing ATP Production and Targeting the CTP Synthase PyrG.",
    "year": "2022",
    "doi": "10.1128/spectrum.00884-22",
    "mechanism": "Inhibition of bacterial carbonic anhydrase isoforms Ef\u03b1-CA and Ef\u03b3-CA, disrupting bacterial pH homeostasis and growth."
  },
  {
    "drug": "acetazolamide",
    "pathogen": "E. faecalis",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Acetazolamide shows activity against VRE strains, suggesting potential as a repurposed antimicrobial.",
    "pmid": "35674439",
    "title": "Crizotinib Shows Antibacterial Activity against Gram-Positive Bacteria by Reducing ATP Production and Targeting the CTP Synthase PyrG.",
    "year": "2022",
    "doi": "10.1128/spectrum.00884-22",
    "mechanism": "Inhibition of bacterial carbonic anhydrase isoforms Ef\u03b1-CA and Ef\u03b3-CA, disrupting bacterial pH homeostasis and growth."
  },
  {
    "drug": "Sodium new houttuyfonate",
    "pathogen": "Aspergillus fumigatus",
    "activity_type": "direct_antibacterial|anti_biofilm|anti_virulence",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "SNH exhibits significant fungicidal activity against A. fumigatus, inhibits growth, sporulation, germination, pigment formation, and biofilm development.",
    "pmid": "35727066",
    "title": "Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.",
    "year": "2022",
    "doi": "10.1128/spectrum.00813-22",
    "mechanism": "Interferes with ergosterol synthesis by disrupting the steroid synthesis pathway, leading to cell membrane stress and impaired fungal growth."
  },
  {
    "drug": "Sodium new houttuyfonate",
    "pathogen": "Aspergillus fumigatus",
    "activity_type": "efflux_inhibitor|adjuvant",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "SNH interferes with ergosterol synthesis by disrupting the steroid synthesis pathway, leading to cell membrane stress.",
    "pmid": "35727066",
    "title": "Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.",
    "year": "2022",
    "doi": "10.1128/spectrum.00813-22",
    "mechanism": "Interferes with ergosterol synthesis by disrupting the steroid synthesis pathway, leading to cell membrane stress and impaired fungal growth."
  },
  {
    "drug": "Au(III) bis(dithiolene) complexes",
    "pathogen": "bacteria",
    "activity_type": "antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Most complexes with the N counter-ion showed notable antibacterial activity, especially against Gram-positive bacteria, including MDR strains.",
    "pmid": "35740222",
    "title": "Non-Antibiotic Drug Repositioning as an Alternative Antimicrobial Approach.",
    "year": "2022",
    "doi": "10.3390/antibiotics11060816",
    "mechanism": "likely inhibition of thioredoxin reductase (TrxR), disrupting cellular redox balance, with negligible DNA interaction"
  },
  {
    "drug": "Au(III) bis(dithiolene) complexes",
    "pathogen": "fungi",
    "activity_type": "anti_fungal",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Most complexes with the N counter-ion demonstrated activity against Candida spp., including MDR strains.",
    "pmid": "35740222",
    "title": "Non-Antibiotic Drug Repositioning as an Alternative Antimicrobial Approach.",
    "year": "2022",
    "doi": "10.3390/antibiotics11060816",
    "mechanism": "likely inhibition of thioredoxin reductase (TrxR), disrupting cellular redox balance, with negligible DNA interaction"
  },
  {
    "drug": "auranofin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Auranofin exhibits antimicrobial activity against S. aureus by inhibiting thioredoxin reductase and inducing ROS accumulation.",
    "pmid": "35774400",
    "title": "Synergistic Microbicidal Effect of AUR and PEITC Against Staphylococcus aureus Skin Infection.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.927289",
    "mechanism": "AUR inhibits thioredoxin reductase leading to ROS accumulation and bacterial cell disruption; PEITC induces oxidative stress and ROS generation, synergistically enhancing bacterial killing."
  },
  {
    "drug": "Phenethyl isothiocyanate",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "PEITC effectively inhibits Gram-positive bacteria and induces oxidative stress via ROS generation.",
    "pmid": "35774400",
    "title": "Synergistic Microbicidal Effect of AUR and PEITC Against Staphylococcus aureus Skin Infection.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.927289",
    "mechanism": "AUR inhibits thioredoxin reductase leading to ROS accumulation and bacterial cell disruption; PEITC induces oxidative stress and ROS generation, synergistically enhancing bacterial killing."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "AUR combined with PEITC shows a synergistic antimicrobial effect against S. aureus, including MRSA.",
    "pmid": "35774400",
    "title": "Synergistic Microbicidal Effect of AUR and PEITC Against Staphylococcus aureus Skin Infection.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.927289",
    "mechanism": "AUR inhibits thioredoxin reductase leading to ROS accumulation and bacterial cell disruption; PEITC induces oxidative stress and ROS generation, synergistically enhancing bacterial killing."
  },
  {
    "drug": "Phenethyl isothiocyanate",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "PEITC enhances the antimicrobial activity of AUR and prevents resistance development.",
    "pmid": "35774400",
    "title": "Synergistic Microbicidal Effect of AUR and PEITC Against Staphylococcus aureus Skin Infection.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.927289",
    "mechanism": "AUR inhibits thioredoxin reductase leading to ROS accumulation and bacterial cell disruption; PEITC induces oxidative stress and ROS generation, synergistically enhancing bacterial killing."
  },
  {
    "drug": "auranofin",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "AUR in combination with PEITC effectively clears S. aureus infections in mice and restores susceptibility.",
    "pmid": "35774400",
    "title": "Synergistic Microbicidal Effect of AUR and PEITC Against Staphylococcus aureus Skin Infection.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.927289",
    "mechanism": "AUR inhibits thioredoxin reductase leading to ROS accumulation and bacterial cell disruption; PEITC induces oxidative stress and ROS generation, synergistically enhancing bacterial killing."
  },
  {
    "drug": "N-2-succinyl ornithine",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "N-2-succinyl ornithine showed strong binding affinity to PvdA with a binding energy of -12.8 kcal/mol, suggesting potential as a substrate analog inhibitor.",
    "pmid": "35846758",
    "title": "Methylene Blue-Mediated Antimicrobial\u00a0\u200bPhotodynamic Therapy Against Clinical Isolates of Extensively Drug Resistant\u00a0\u200bGram-Negative Bacteria Causing Nosocomial Infections in Thailand,\u00a0An In Vitro\u00a0Study.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.929242",
    "mechanism": "inhibition of PvdA enzyme involved in pyoverdine biosynthesis, disrupting iron sequestration in P. aeruginosa"
  },
  {
    "drug": "cilazapril",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cilazapril demonstrated significant binding to PvdA with a binding energy of -9.1 kcal/mol, indicating potential as a repurposed inhibitor.",
    "pmid": "35846758",
    "title": "Methylene Blue-Mediated Antimicrobial\u00a0\u200bPhotodynamic Therapy Against Clinical Isolates of Extensively Drug Resistant\u00a0\u200bGram-Negative Bacteria Causing Nosocomial Infections in Thailand,\u00a0An In Vitro\u00a0Study.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.929242",
    "mechanism": "inhibition of PvdA enzyme involved in pyoverdine biosynthesis, disrupting iron sequestration in P. aeruginosa"
  },
  {
    "drug": "ebselen",
    "pathogen": "Yersinia pseudotuberculosis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.94,
    "key_result": "Ebselen synergistically enhances the antibacterial activity of silver nitrate against Y. pseudotuberculosis in vitro.",
    "pmid": "35854044",
    "title": "A Niclosamide-releasing hot-melt extruded catheter prevents Staphylococcus aureus experimental biomaterial-associated infection.",
    "year": "2022",
    "doi": "10.1038/s41598-022-16107-4",
    "mechanism": "Disruption of thiol-dependent redox systems leading to intracellular oxidative stress, depletion of glutathione, and inhibition of thioredoxin reductase activity."
  },
  {
    "drug": "Silver nitrate",
    "pathogen": "Yersinia pseudotuberculosis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "Silver nitrate inhibits Y. pseudotuberculosis growth with MIC90 of 8 \u03bcM.",
    "pmid": "35854044",
    "title": "A Niclosamide-releasing hot-melt extruded catheter prevents Staphylococcus aureus experimental biomaterial-associated infection.",
    "year": "2022",
    "doi": "10.1038/s41598-022-16107-4",
    "mechanism": "Disruption of thiol-dependent redox systems leading to intracellular oxidative stress, depletion of glutathione, and inhibition of thioredoxin reductase activity."
  },
  {
    "drug": "carbamazepine",
    "pathogen": "Acinetobacter",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Carbamazepine at environmentally relevant concentrations promotes conjugative plasmid transfer, increasing antibiotic resistance dissemination.",
    "pmid": "35934727",
    "title": "Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline-a review.",
    "year": "2022",
    "doi": "10.1186/s43046-022-00137-0",
    "mechanism": "Non-antibiotic pharmaceuticals induce over-generation of reactive oxygen species (ROS), which enhances conjugative plasmid transfer among bacteria."
  },
  {
    "drug": "ibuprofen",
    "pathogen": "Legionella",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Ibuprofen enhances conjugative transfer of resistance plasmids in bacterial communities.",
    "pmid": "35934727",
    "title": "Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline-a review.",
    "year": "2022",
    "doi": "10.1186/s43046-022-00137-0",
    "mechanism": "Non-antibiotic pharmaceuticals induce over-generation of reactive oxygen species (ROS), which enhances conjugative plasmid transfer among bacteria."
  },
  {
    "drug": "naproxen",
    "pathogen": "Acinetobacter",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Naproxen facilitates horizontal gene transfer, potentially spreading multidrug resistance.",
    "pmid": "35934727",
    "title": "Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline-a review.",
    "year": "2022",
    "doi": "10.1186/s43046-022-00137-0",
    "mechanism": "Non-antibiotic pharmaceuticals induce over-generation of reactive oxygen species (ROS), which enhances conjugative plasmid transfer among bacteria."
  },
  {
    "drug": "propranolol",
    "pathogen": "Legionella",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Propranolol exposure increases conjugation rates, promoting resistance gene dissemination.",
    "pmid": "35934727",
    "title": "Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline-a review.",
    "year": "2022",
    "doi": "10.1186/s43046-022-00137-0",
    "mechanism": "Non-antibiotic pharmaceuticals induce over-generation of reactive oxygen species (ROS), which enhances conjugative plasmid transfer among bacteria."
  },
  {
    "drug": "ciclopirox",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 128,
    "fici": null,
    "key_result": "Ciclopirox showed the most effective activity against planktonic cells and mature biofilms, significantly reducing biofilm biomass and viability.",
    "pmid": "35958130",
    "title": "The Assessment on Synergistic Activity of Ebselen and Silver Ion Against Yersinia pseudotuberculosis.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.963901",
    "mechanism": "The proposed mechanisms include direct antibacterial activity, biofilm dispersal, and modulation of virulence gene expression, with some drugs acting as efflux inhibitors or antivirulence agents."
  },
  {
    "drug": "ribavirin",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ribavirin demonstrated a specific antibiofilm effect, significantly decreasing biofilm biomass without killing bacteria.",
    "pmid": "35958130",
    "title": "The Assessment on Synergistic Activity of Ebselen and Silver Ion Against Yersinia pseudotuberculosis.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.963901",
    "mechanism": "The proposed mechanisms include direct antibacterial activity, biofilm dispersal, and modulation of virulence gene expression, with some drugs acting as efflux inhibitors or antivirulence agents."
  },
  {
    "drug": "5-fluorouracil",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 128,
    "fici": null,
    "key_result": "5-Fluorouracil showed limited antibacterial activity and tended to stimulate biofilm biomass.",
    "pmid": "35958130",
    "title": "The Assessment on Synergistic Activity of Ebselen and Silver Ion Against Yersinia pseudotuberculosis.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.963901",
    "mechanism": "The proposed mechanisms include direct antibacterial activity, biofilm dispersal, and modulation of virulence gene expression, with some drugs acting as efflux inhibitors or antivirulence agents."
  },
  {
    "drug": "actinomycin D",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial|anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 133,
    "fici": null,
    "key_result": "Actinomycin D exhibited strain-dependent bactericidal activity and downregulated virulence gene expression.",
    "pmid": "35958130",
    "title": "The Assessment on Synergistic Activity of Ebselen and Silver Ion Against Yersinia pseudotuberculosis.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.963901",
    "mechanism": "The proposed mechanisms include direct antibacterial activity, biofilm dispersal, and modulation of virulence gene expression, with some drugs acting as efflux inhibitors or antivirulence agents."
  },
  {
    "drug": "Chloroquine",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Plant extracts from Syzygium aromaticum, Zingiber officinale, and Curcuma longa enhanced chloroquine susceptibility in P. aeruginosa by increasing zones of inhibition.",
    "pmid": "36110398",
    "title": "Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach.",
    "year": "2022",
    "doi": "10.2147/DDDT.S366423",
    "mechanism": "Plant phytochemicals, such as flavonoids, alkaloids, and phenols, likely inhibit bacterial efflux pumps, thereby increasing intracellular chloroquine concentration and susceptibility."
  },
  {
    "drug": "verapamil",
    "pathogen": "P. aeruginosa",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Verapamil, a known efflux pump inhibitor, was used as a standard to demonstrate increased chloroquine sensitivity.",
    "pmid": "36110398",
    "title": "Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach.",
    "year": "2022",
    "doi": "10.2147/DDDT.S366423",
    "mechanism": "Plant phytochemicals, such as flavonoids, alkaloids, and phenols, likely inhibit bacterial efflux pumps, thereby increasing intracellular chloroquine concentration and susceptibility."
  },
  {
    "drug": "auranofin",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Auranofin displayed consistent bactericidal activity with MIC90 of 0.5 mg/L against multidrug-resistant N. gonorrhoeae, including ceftriaxone-resistant strains.",
    "pmid": "36112342",
    "title": "Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?",
    "year": "2022",
    "doi": "10.1007/s40265-022-01757-5",
    "mechanism": "Proposed mechanisms include inhibition of bacterial enzymes or pathways related to metal ion homeostasis (auranofin), disruption of bacterial membrane or metabolic processes (cannabidivarin), and inhibition of prostaglandin synthesis affecting bacterial growth (tolfenamic acid)."
  },
  {
    "drug": "Cannabidivarin",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "Cannabidivarin showed antimicrobial activity with MIC90 of 8 mg/L and demonstrated rapid bactericidal activity.",
    "pmid": "36112342",
    "title": "Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?",
    "year": "2022",
    "doi": "10.1007/s40265-022-01757-5",
    "mechanism": "Proposed mechanisms include inhibition of bacterial enzymes or pathways related to metal ion homeostasis (auranofin), disruption of bacterial membrane or metabolic processes (cannabidivarin), and inhibition of prostaglandin synthesis affecting bacterial growth (tolfenamic acid)."
  },
  {
    "drug": "Tolfenamic acid",
    "pathogen": "N. gonorrhoeae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "Tolfenamic acid exhibited antimicrobial activity with MIC90 of 8 mg/L and was bactericidal in time-kill assays.",
    "pmid": "36112342",
    "title": "Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?",
    "year": "2022",
    "doi": "10.1007/s40265-022-01757-5",
    "mechanism": "Proposed mechanisms include inhibition of bacterial enzymes or pathways related to metal ion homeostasis (auranofin), disruption of bacterial membrane or metabolic processes (cannabidivarin), and inhibition of prostaglandin synthesis affecting bacterial growth (tolfenamic acid)."
  },
  {
    "drug": "dexamethasone",
    "pathogen": "COVID-19",
    "activity_type": "anti_virulence",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Dexamethasone is a high-ranking candidate for disrupting cytokine storm in COVID-19 based on model predictions.",
    "pmid": "36216820",
    "title": "Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.",
    "year": "2022",
    "doi": "10.1038/s41540-022-00250-9",
    "mechanism": "Modulation of immune signaling pathways involved in cytokine production and inflammatory response, targeting multiple immune mediators to restore immune homeostasis."
  },
  {
    "drug": "rapamycin",
    "pathogen": "COVID-19",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Rapamycin shows potential as an immune modulator targeting multiple network nodes involved in cytokine storm.",
    "pmid": "36216820",
    "title": "Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.",
    "year": "2022",
    "doi": "10.1038/s41540-022-00250-9",
    "mechanism": "Modulation of immune signaling pathways involved in cytokine production and inflammatory response, targeting multiple immune mediators to restore immune homeostasis."
  },
  {
    "drug": "ciprofloxacin",
    "pathogen": "COVID-19",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ciprofloxacin, an antimicrobial, is predicted to contribute to disrupting immune dysregulation in COVID-19.",
    "pmid": "36216820",
    "title": "Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.",
    "year": "2022",
    "doi": "10.1038/s41540-022-00250-9",
    "mechanism": "Modulation of immune signaling pathways involved in cytokine production and inflammatory response, targeting multiple immune mediators to restore immune homeostasis."
  },
  {
    "drug": "levofloxacin",
    "pathogen": "COVID-19",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Levofloxacin may enhance immune modulation when combined with other agents in COVID-19 cytokine storm mitigation.",
    "pmid": "36216820",
    "title": "Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.",
    "year": "2022",
    "doi": "10.1038/s41540-022-00250-9",
    "mechanism": "Modulation of immune signaling pathways involved in cytokine production and inflammatory response, targeting multiple immune mediators to restore immune homeostasis."
  },
  {
    "drug": "simvastatin",
    "pathogen": "COVID-19",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Simvastatin is predicted to help modulate immune response and reduce cytokine storm severity.",
    "pmid": "36216820",
    "title": "Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.",
    "year": "2022",
    "doi": "10.1038/s41540-022-00250-9",
    "mechanism": "Modulation of immune signaling pathways involved in cytokine production and inflammatory response, targeting multiple immune mediators to restore immune homeostasis."
  },
  {
    "drug": "medroxyprogesterone acetate",
    "pathogen": "COVID-19",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Medroxyprogesterone acetate may contribute to immune regulation in COVID-19 cytokine storm control.",
    "pmid": "36216820",
    "title": "Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.",
    "year": "2022",
    "doi": "10.1038/s41540-022-00250-9",
    "mechanism": "Modulation of immune signaling pathways involved in cytokine production and inflammatory response, targeting multiple immune mediators to restore immune homeostasis."
  },
  {
    "drug": "metformin",
    "pathogen": "colorectal cancer",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Metformin shows oncological benefits in early-stage colorectal cancer, especially in diabetic patients, and enhances tumor radiosensitivity.",
    "pmid": "36285247",
    "title": "Study of chloroquine susceptibility potential of plants using pseudomonas aeruginosa as in vitro model.",
    "year": "2022",
    "doi": "10.1007/s13205-022-03382-1",
    "mechanism": "Metformin inhibits mitochondrial ETC and activates AMPK, reducing insulin levels and tumor cell proliferation; mebendazole binds tubulin and inhibits tyrosine kinases; atorvastatin inhibits HMG-CoA reductase, inducing autophagy; propranolol blocks beta-adrenergic receptors, affecting tumor signaling pathways."
  },
  {
    "drug": "metformin",
    "pathogen": "prostate cancer",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Metformin improves response to radiotherapy and reduces biochemical relapse in prostate cancer models.",
    "pmid": "36285247",
    "title": "Study of chloroquine susceptibility potential of plants using pseudomonas aeruginosa as in vitro model.",
    "year": "2022",
    "doi": "10.1007/s13205-022-03382-1",
    "mechanism": "Metformin inhibits mitochondrial ETC and activates AMPK, reducing insulin levels and tumor cell proliferation; mebendazole binds tubulin and inhibits tyrosine kinases; atorvastatin inhibits HMG-CoA reductase, inducing autophagy; propranolol blocks beta-adrenergic receptors, affecting tumor signaling pathways."
  },
  {
    "drug": "mebendazole",
    "pathogen": "brain and colon cancers",
    "activity_type": "direct_antibacterial",
    "evidence_type": "preclinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mebendazole exhibits antiproliferative activity and inhibits signaling pathways like VEGFR2, TNIK, and BRAF, with ongoing clinical trials for various cancers.",
    "pmid": "36285247",
    "title": "Study of chloroquine susceptibility potential of plants using pseudomonas aeruginosa as in vitro model.",
    "year": "2022",
    "doi": "10.1007/s13205-022-03382-1",
    "mechanism": "Metformin inhibits mitochondrial ETC and activates AMPK, reducing insulin levels and tumor cell proliferation; mebendazole binds tubulin and inhibits tyrosine kinases; atorvastatin inhibits HMG-CoA reductase, inducing autophagy; propranolol blocks beta-adrenergic receptors, affecting tumor signaling pathways."
  },
  {
    "drug": "atorvastatin",
    "pathogen": "head and neck cancer",
    "activity_type": "adjuvant|anti_biofilm",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Atorvastatin provides clinical benefits in head and neck cancer, with potential radioprotective effects.",
    "pmid": "36285247",
    "title": "Study of chloroquine susceptibility potential of plants using pseudomonas aeruginosa as in vitro model.",
    "year": "2022",
    "doi": "10.1007/s13205-022-03382-1",
    "mechanism": "Metformin inhibits mitochondrial ETC and activates AMPK, reducing insulin levels and tumor cell proliferation; mebendazole binds tubulin and inhibits tyrosine kinases; atorvastatin inhibits HMG-CoA reductase, inducing autophagy; propranolol blocks beta-adrenergic receptors, affecting tumor signaling pathways."
  },
  {
    "drug": "propranolol",
    "pathogen": "melanoma",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Propranolol is associated with increased outcomes in melanoma, breast cancer, and sarcoma.",
    "pmid": "36285247",
    "title": "Study of chloroquine susceptibility potential of plants using pseudomonas aeruginosa as in vitro model.",
    "year": "2022",
    "doi": "10.1007/s13205-022-03382-1",
    "mechanism": "Metformin inhibits mitochondrial ETC and activates AMPK, reducing insulin levels and tumor cell proliferation; mebendazole binds tubulin and inhibits tyrosine kinases; atorvastatin inhibits HMG-CoA reductase, inducing autophagy; propranolol blocks beta-adrenergic receptors, affecting tumor signaling pathways."
  },
  {
    "drug": "3-aminopyrazine-2-carboxamide derivatives",
    "pathogen": "M. tuberculosis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Compounds showed high antimycobacterial activity with MICs from 1.95 to 31.25 \u00b5g/mL, including activity against MDR strains.",
    "pmid": "36297331",
    "title": "A Review of the Biological Activity of Amidrazone Derivatives.",
    "year": "2022",
    "doi": "10.3390/ph15101219",
    "mechanism": "Inhibition of mycobacterial prolyl-tRNA synthetase, mimicking ATP-competitive binding of human ProRS inhibitors."
  },
  {
    "drug": "polymyxins",
    "pathogen": "MDR Gram-negative pathogens",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Polymyxins are last-resort antibiotics against MDR Gram-negative bacteria but are increasingly encountering resistance.",
    "pmid": "36350125",
    "title": "Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid against Multidrug-Resistant Neisseria gonorrhoeae.",
    "year": "2022",
    "doi": "10.1128/spectrum.03952-22",
    "mechanism": "combination of polymyxins with non-antibiotics enhances bacterial membrane disruption, efflux pump inhibition, and resistance suppression"
  },
  {
    "drug": "non-antibiotics (adjuvants)",
    "pathogen": "MDR Gram-negative pathogens",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Non-antibiotics can potentiate polymyxin activity and help overcome resistance mechanisms in MDR Gram-negative bacteria.",
    "pmid": "36350125",
    "title": "Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid against Multidrug-Resistant Neisseria gonorrhoeae.",
    "year": "2022",
    "doi": "10.1128/spectrum.03952-22",
    "mechanism": "combination of polymyxins with non-antibiotics enhances bacterial membrane disruption, efflux pump inhibition, and resistance suppression"
  },
  {
    "drug": "rifabutin",
    "pathogen": "E. faecium",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.19,
    "key_result": "Rifabutin demonstrated the most potent synergy with vancomycin against VREfm, with a FIC index of 0.19.",
    "pmid": "36358911",
    "title": "Adenosine-Mimicking Derivatives of 3-Aminopyrazine-2-Carboxamide: Towards Inhibitors of Prolyl-tRNA Synthetase with Antimycobacterial Activity.",
    "year": "2022",
    "doi": "10.3390/biom12111561",
    "mechanism": "The proposed mechanisms involve inhibition of RNA and protein biosynthesis pathways, which may block the expression of vancomycin resistance in VREfm."
  },
  {
    "drug": "linezolid",
    "pathogen": "E. faecium",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Linezolid showed a modest synergistic effect with vancomycin against VREfm.",
    "pmid": "36358911",
    "title": "Adenosine-Mimicking Derivatives of 3-Aminopyrazine-2-Carboxamide: Towards Inhibitors of Prolyl-tRNA Synthetase with Antimycobacterial Activity.",
    "year": "2022",
    "doi": "10.3390/biom12111561",
    "mechanism": "The proposed mechanisms involve inhibition of RNA and protein biosynthesis pathways, which may block the expression of vancomycin resistance in VREfm."
  },
  {
    "drug": "mupirocin",
    "pathogen": "E. faecium",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mupirocin demonstrated modest synergy with vancomycin, possibly due to induction of stringent response.",
    "pmid": "36358911",
    "title": "Adenosine-Mimicking Derivatives of 3-Aminopyrazine-2-Carboxamide: Towards Inhibitors of Prolyl-tRNA Synthetase with Antimycobacterial Activity.",
    "year": "2022",
    "doi": "10.3390/biom12111561",
    "mechanism": "The proposed mechanisms involve inhibition of RNA and protein biosynthesis pathways, which may block the expression of vancomycin resistance in VREfm."
  },
  {
    "drug": "retapamulin",
    "pathogen": "E. faecium",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Retapamulin, a pleuromutilin, demonstrated synergy with vancomycin.",
    "pmid": "36358911",
    "title": "Adenosine-Mimicking Derivatives of 3-Aminopyrazine-2-Carboxamide: Towards Inhibitors of Prolyl-tRNA Synthetase with Antimycobacterial Activity.",
    "year": "2022",
    "doi": "10.3390/biom12111561",
    "mechanism": "The proposed mechanisms involve inhibition of RNA and protein biosynthesis pathways, which may block the expression of vancomycin resistance in VREfm."
  },
  {
    "drug": "valnemulin",
    "pathogen": "E. faecium",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Valnemulin, a veterinary pleuromutilin, demonstrated synergy with vancomycin.",
    "pmid": "36358911",
    "title": "Adenosine-Mimicking Derivatives of 3-Aminopyrazine-2-Carboxamide: Towards Inhibitors of Prolyl-tRNA Synthetase with Antimycobacterial Activity.",
    "year": "2022",
    "doi": "10.3390/biom12111561",
    "mechanism": "The proposed mechanisms involve inhibition of RNA and protein biosynthesis pathways, which may block the expression of vancomycin resistance in VREfm."
  },
  {
    "drug": "gemcitabine",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Gemcitabine showed activity against VREfm but did not demonstrate synergy with vancomycin.",
    "pmid": "36358911",
    "title": "Adenosine-Mimicking Derivatives of 3-Aminopyrazine-2-Carboxamide: Towards Inhibitors of Prolyl-tRNA Synthetase with Antimycobacterial Activity.",
    "year": "2022",
    "doi": "10.3390/biom12111561",
    "mechanism": "The proposed mechanisms involve inhibition of RNA and protein biosynthesis pathways, which may block the expression of vancomycin resistance in VREfm."
  },
  {
    "drug": "tavaborole",
    "pathogen": "E. coli",
    "activity_type": "adjuvant|synergy",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Tavaborole exhibits synergistic activity with aminoglycosides against E. coli and reduces resistance development.",
    "pmid": "36430555",
    "title": "Tobramycin Nanoantibiotics and Their Advantages: A Minireview.",
    "year": "2022",
    "doi": "10.3390/ijms232214080",
    "mechanism": "Tavaborole inhibits leucyl-tRNA synthetase, leading to mistranslation and interference with protein synthesis, which enhances the efficacy of aminoglycosides and slows resistance development."
  },
  {
    "drug": "tavaborole",
    "pathogen": "E. coli",
    "activity_type": "adjuvant|synergy",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "In mouse peritonitis models, tavaborole enhanced aminoglycoside bactericidal activity and slowed resistance.",
    "pmid": "36430555",
    "title": "Tobramycin Nanoantibiotics and Their Advantages: A Minireview.",
    "year": "2022",
    "doi": "10.3390/ijms232214080",
    "mechanism": "Tavaborole inhibits leucyl-tRNA synthetase, leading to mistranslation and interference with protein synthesis, which enhances the efficacy of aminoglycosides and slows resistance development."
  },
  {
    "drug": "SBC3",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "SBC3 combined with Ebselen exhibits synergistic antibacterial activity against E. coli, including MDR strains.",
    "pmid": "36432288",
    "title": "Antimicrobial Activity of Graphene-Based Nanocomposites: Synthesis, Characterization, and Their Applications for Human Welfare.",
    "year": "2022",
    "doi": "10.3390/nano12224002",
    "mechanism": "The synergistic antibacterial effect is based on direct inhibition of E. coli thioredoxin reductase and rapid depletion of glutathione, leading to increased reactive oxygen species and bacterial cell death."
  },
  {
    "drug": "ebselen",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen enhances the antibacterial effect of SBC3 against E. coli through synergistic interaction.",
    "pmid": "36432288",
    "title": "Antimicrobial Activity of Graphene-Based Nanocomposites: Synthesis, Characterization, and Their Applications for Human Welfare.",
    "year": "2022",
    "doi": "10.3390/nano12224002",
    "mechanism": "The synergistic antibacterial effect is based on direct inhibition of E. coli thioredoxin reductase and rapid depletion of glutathione, leading to increased reactive oxygen species and bacterial cell death."
  },
  {
    "drug": "rifampicin",
    "pathogen": "Methicillin resistant Staphylococcus aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Co-localization of rifampicin with benzothiazole in nanoscopic micelles significantly reduced MRSA bacterial growth by 99.88%.",
    "pmid": "36432719",
    "title": "Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis.",
    "year": "2022",
    "doi": "10.3390/pharmaceutics14112528",
    "mechanism": "co-localization of drugs within nanoscopic micelles enhances their delivery and efficacy against MDR bacteria, possibly through synergistic antibacterial activity."
  },
  {
    "drug": "benzothiazole",
    "pathogen": "Methicillin resistant Staphylococcus aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Benzothiazole, when co-localized with rifampicin in micelles, contributed to the sterilization effect against MRSA.",
    "pmid": "36432719",
    "title": "Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis.",
    "year": "2022",
    "doi": "10.3390/pharmaceutics14112528",
    "mechanism": "co-localization of drugs within nanoscopic micelles enhances their delivery and efficacy against MDR bacteria, possibly through synergistic antibacterial activity."
  },
  {
    "drug": "oxyclozanide",
    "pathogen": "Xanthomonas oryzae PV. oryzae (Xoo)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.78,
    "fici": null,
    "key_result": "Oxyclozanide exhibits potent antibacterial activity against Xoo with an MIC of 0.78 \u03bcg/ml.",
    "pmid": "36443539",
    "title": "Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01492-w",
    "mechanism": "Disruption of bacterial cell envelope and inhibition of bacterial growth."
  },
  {
    "drug": "niclosamide",
    "pathogen": "Xanthomonas oryzae PV. oryzae (Xoo)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 3.12,
    "fici": null,
    "key_result": "Niclosamide shows antibacterial activity against Xoo with an MIC of 3.12 \u03bcg/ml.",
    "pmid": "36443539",
    "title": "Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01492-w",
    "mechanism": "Disruption of bacterial cell envelope and inhibition of bacterial growth."
  },
  {
    "drug": "streptomycin",
    "pathogen": "Xanthomonas oryzae PV. oryzae (Xoo)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1.56,
    "fici": null,
    "key_result": "Streptomycin demonstrates strong activity against Xoo with MIC values between 1.56 and 3.12 \u03bcg/ml.",
    "pmid": "36443539",
    "title": "Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01492-w",
    "mechanism": "Disruption of bacterial cell envelope and inhibition of bacterial growth."
  },
  {
    "drug": "salicylanilides (general)",
    "pathogen": "Xanthomonas oryzae PV. oryzae (Xoo)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.78,
    "fici": null,
    "key_result": "Salicylanilides, including oxyclozanide, exhibit potent antibacterial activity with MICs as low as 0.78 \u03bcg/ml.",
    "pmid": "36443539",
    "title": "Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01492-w",
    "mechanism": "Disruption of bacterial cell envelope and inhibition of bacterial growth."
  },
  {
    "drug": "ceritinib",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ceritinib exhibits bactericidal activity against S. aureus by disrupting cell membrane integrity and inducing reactive oxygen species production.",
    "pmid": "36454354",
    "title": "Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01488-6",
    "mechanism": "Disruption of bacterial cell membrane integrity and induction of reactive oxygen species production."
  },
  {
    "drug": "ceritinib",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ceritinib inhibits biofilm formation and eradicates mature biofilms of S. aureus.",
    "pmid": "36454354",
    "title": "Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01488-6",
    "mechanism": "Disruption of bacterial cell membrane integrity and induction of reactive oxygen species production."
  },
  {
    "drug": "ceritinib",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mechanistic studies suggest ceritinib disrupts cell membrane integrity, contributing to its antimicrobial effect.",
    "pmid": "36454354",
    "title": "Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01488-6",
    "mechanism": "Disruption of bacterial cell membrane integrity and induction of reactive oxygen species production."
  },
  {
    "drug": "ceritinib",
    "pathogen": "S. aureus",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ceritinib reduces infection severity in a mouse subcutaneous abscess model with negligible systemic toxicity.",
    "pmid": "36454354",
    "title": "Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01488-6",
    "mechanism": "Disruption of bacterial cell membrane integrity and induction of reactive oxygen species production."
  },
  {
    "drug": "ascorbic acid",
    "pathogen": "S. aureus",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sub-inhibitory concentrations of ascorbic acid significantly reduced S. aureus virulence factors including biofilm formation, hemolysin, protease production, and resistance to oxidative stress.",
    "pmid": "36499402",
    "title": "Design, Synthesis and Antimicrobial Properties of New Tetracyclic Quinobenzothiazine Derivatives.",
    "year": "2022",
    "doi": "10.3390/ijms232315078",
    "mechanism": "The drugs reduce the expression of virulence genes and inhibit virulence factor production, thereby attenuating S. aureus pathogenicity without directly killing the bacteria."
  },
  {
    "drug": "dexamethasone",
    "pathogen": "S. aureus",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Dexamethasone at sub-MIC levels decreased production of S. aureus virulence factors such as biofilm, hemolysin, proteases, and oxidative stress resistance.",
    "pmid": "36499402",
    "title": "Design, Synthesis and Antimicrobial Properties of New Tetracyclic Quinobenzothiazine Derivatives.",
    "year": "2022",
    "doi": "10.3390/ijms232315078",
    "mechanism": "The drugs reduce the expression of virulence genes and inhibit virulence factor production, thereby attenuating S. aureus pathogenicity without directly killing the bacteria."
  },
  {
    "drug": "sodium bicarbonate",
    "pathogen": "S. aureus",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sodium bicarbonate at sub-MIC concentrations reduced S. aureus virulence factors including biofilm, hemolysin, protease activity, and oxidative stress resistance.",
    "pmid": "36499402",
    "title": "Design, Synthesis and Antimicrobial Properties of New Tetracyclic Quinobenzothiazine Derivatives.",
    "year": "2022",
    "doi": "10.3390/ijms232315078",
    "mechanism": "The drugs reduce the expression of virulence genes and inhibit virulence factor production, thereby attenuating S. aureus pathogenicity without directly killing the bacteria."
  },
  {
    "drug": "Tobramycin",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nanoantibiotics formulations of tobramycin show potential to enhance activity against MDR Pseudomonas aeruginosa.",
    "pmid": "36533811",
    "title": "Identification of potential pathways and biomarkers linked to progression in ALS.",
    "year": "2023",
    "doi": "10.1002/acn3.51697",
    "mechanism": "Encapsulation of tobramycin in nanosized delivery systems enhances bacterial uptake, improves stability, and may reduce toxicity, thereby overcoming some mechanisms of antimicrobial resistance."
  },
  {
    "drug": "Tobramycin",
    "pathogen": "Gram-negative bacteria",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nanocarrier systems improve delivery and efficacy of tobramycin against Gram-negative bacteria.",
    "pmid": "36533811",
    "title": "Identification of potential pathways and biomarkers linked to progression in ALS.",
    "year": "2023",
    "doi": "10.1002/acn3.51697",
    "mechanism": "Encapsulation of tobramycin in nanosized delivery systems enhances bacterial uptake, improves stability, and may reduce toxicity, thereby overcoming some mechanisms of antimicrobial resistance."
  },
  {
    "drug": "Florfenicol",
    "pathogen": "Avian pathogenic Escherichia coli (APEC)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.1,
    "fici": null,
    "key_result": "PEG-6000 coated ZnO-NPs enhanced the efficacy of Florfenicol, restoring sensitivity in resistant APEC strains with a 60% high sensitivity rate.",
    "pmid": "36588729",
    "title": "The synergistic activity of SBC3 in combination with Ebselen against Escherichia coli infection.",
    "year": "2022",
    "doi": "10.3389/fphar.2022.1080281",
    "mechanism": "ZnO-NPs coated with PEG-6000 likely enhance antibiotic activity by disrupting bacterial cell membranes and increasing drug uptake, thereby overcoming resistance mechanisms."
  },
  {
    "drug": "Streptomycin",
    "pathogen": "Avian pathogenic Escherichia coli (APEC)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.1,
    "fici": null,
    "key_result": "PEG-6000 coated ZnO-NPs improved Streptomycin activity, achieving 50% high sensitivity in resistant APEC strains.",
    "pmid": "36588729",
    "title": "The synergistic activity of SBC3 in combination with Ebselen against Escherichia coli infection.",
    "year": "2022",
    "doi": "10.3389/fphar.2022.1080281",
    "mechanism": "ZnO-NPs coated with PEG-6000 likely enhance antibiotic activity by disrupting bacterial cell membranes and increasing drug uptake, thereby overcoming resistance mechanisms."
  },
  {
    "drug": "DSM186",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.055,
    "fici": null,
    "key_result": "DSM186 exhibits submicromolar activity against A. baumannii strains, including resistant isolates, with MIC \u22641 \u00b5g/mL.",
    "pmid": "36597079",
    "title": "In vitro assessment of PEG-6000 coated-ZnO nanoparticles: modulating action to the resisted antibiotic activity against APEC.",
    "year": "2023",
    "doi": "10.1186/s12917-022-03562-4",
    "mechanism": "Inhibition of bacterial dihydroorotate dehydrogenase (DHODH), disrupting pyrimidine biosynthesis essential for bacterial survival."
  },
  {
    "drug": "DSM186",
    "pathogen": "A. baumannii",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Efflux inhibitors like PA\u03b2N enhance DSM186 activity, indicating efflux contributes to reduced efficacy.",
    "pmid": "36597079",
    "title": "In vitro assessment of PEG-6000 coated-ZnO nanoparticles: modulating action to the resisted antibiotic activity against APEC.",
    "year": "2023",
    "doi": "10.1186/s12917-022-03562-4",
    "mechanism": "Inhibition of bacterial dihydroorotate dehydrogenase (DHODH), disrupting pyrimidine biosynthesis essential for bacterial survival."
  },
  {
    "drug": "DSM186",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo, DSM186 analog DSM161 conferred protection in mouse infection models, supporting its potential as a therapeutic agent.",
    "pmid": "36597079",
    "title": "In vitro assessment of PEG-6000 coated-ZnO nanoparticles: modulating action to the resisted antibiotic activity against APEC.",
    "year": "2023",
    "doi": "10.1186/s12917-022-03562-4",
    "mechanism": "Inhibition of bacterial dihydroorotate dehydrogenase (DHODH), disrupting pyrimidine biosynthesis essential for bacterial survival."
  },
  {
    "drug": "9-benzyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Demonstrated high activity against S. aureus, comparable to oxacillin.",
    "pmid": "36671340",
    "title": "Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases.",
    "year": "2023",
    "doi": "10.3390/antibiotics12010137",
    "mechanism": "The compounds inhibit bacterial respiration and exhibit bacteriostatic and bactericidal effects, likely through interaction with bacterial cell components affecting respiration."
  },
  {
    "drug": "9-benzyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Effective against E. faecalis, comparable to tetracycline.",
    "pmid": "36671340",
    "title": "Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases.",
    "year": "2023",
    "doi": "10.3390/antibiotics12010137",
    "mechanism": "The compounds inhibit bacterial respiration and exhibit bacteriostatic and bactericidal effects, likely through interaction with bacterial cell components affecting respiration."
  },
  {
    "drug": "9-propoxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
    "pathogen": "Mycobacterium smegmatis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Exhibited activity comparable to rifampicin against M. smegmatis.",
    "pmid": "36671340",
    "title": "Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases.",
    "year": "2023",
    "doi": "10.3390/antibiotics12010137",
    "mechanism": "The compounds inhibit bacterial respiration and exhibit bacteriostatic and bactericidal effects, likely through interaction with bacterial cell components affecting respiration."
  },
  {
    "drug": "9-allyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
    "pathogen": "M. marinum",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Showed activity similar to rifampicin against M. marinum.",
    "pmid": "36671340",
    "title": "Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases.",
    "year": "2023",
    "doi": "10.3390/antibiotics12010137",
    "mechanism": "The compounds inhibit bacterial respiration and exhibit bacteriostatic and bactericidal effects, likely through interaction with bacterial cell components affecting respiration."
  },
  {
    "drug": "9-benzyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
    "pathogen": "S. aureus",
    "activity_type": "bacteriostatic|bactericidal",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Displayed both bacteriostatic and bactericidal activity.",
    "pmid": "36671340",
    "title": "Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases.",
    "year": "2023",
    "doi": "10.3390/antibiotics12010137",
    "mechanism": "The compounds inhibit bacterial respiration and exhibit bacteriostatic and bactericidal effects, likely through interaction with bacterial cell components affecting respiration."
  },
  {
    "drug": "Cefoperazone Sulbactam",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cefoperazone sulbactam shows variable susceptibility with some isolates being 100% susceptible and others resistant, and it demonstrates clinical efficacy in treating AB infections in observational studies.",
    "pmid": "36834854",
    "title": "Antibacterial Activity of Nanostructured Zinc Oxide Tetrapods.",
    "year": "2023",
    "doi": "10.3390/ijms24043444",
    "mechanism": "Sulbactam inhibits beta-lactamase enzymes produced by AB and has intrinsic activity against the pathogen, while cefoperazone provides broad-spectrum beta-lactam activity."
  },
  {
    "drug": "Cefoperazone Sulbactam",
    "pathogen": "A. baumannii",
    "activity_type": "synergy",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "When used in combination with other antibiotics such as colistin, tigecycline, or carbapenems, CS shows improved clinical and microbiological cure rates, especially with colistin.",
    "pmid": "36834854",
    "title": "Antibacterial Activity of Nanostructured Zinc Oxide Tetrapods.",
    "year": "2023",
    "doi": "10.3390/ijms24043444",
    "mechanism": "Sulbactam inhibits beta-lactamase enzymes produced by AB and has intrinsic activity against the pathogen, while cefoperazone provides broad-spectrum beta-lactam activity."
  },
  {
    "drug": "Zinc Oxide Tetrapods",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "ZnO tetrapods showed dose- and time-dependent bactericidal activity against S. aureus, including MRSA, with significant reduction in bacterial counts after 24 hours.",
    "pmid": "36835564",
    "title": "Pharmacological Efficacy of Repurposing Drugs in the Treatment of Prostate Cancer.",
    "year": "2023",
    "doi": "10.3390/ijms24044154",
    "mechanism": "Surface contact leading to bacterial cell damage, possibly involving reactive oxygen species or zinc ion release, with physical nanostructured surfaces providing active interfaces for bacterial killing."
  },
  {
    "drug": "Zinc Oxide Tetrapods",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "ZnO tetrapods achieved complete eradication of K. pneumoniae at low concentrations after 24 hours, including multidrug-resistant strains.",
    "pmid": "36835564",
    "title": "Pharmacological Efficacy of Repurposing Drugs in the Treatment of Prostate Cancer.",
    "year": "2023",
    "doi": "10.3390/ijms24044154",
    "mechanism": "Surface contact leading to bacterial cell damage, possibly involving reactive oxygen species or zinc ion release, with physical nanostructured surfaces providing active interfaces for bacterial killing."
  },
  {
    "drug": "Pillar[5]arene",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Pillar[5]arene binds to long-chain homoserine lactones, suppressing toxin production and biofilm formation in P. aeruginosa.",
    "pmid": "36868316",
    "title": "Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.",
    "year": "2023",
    "doi": "10.1016/j.antiviral.2023.105575",
    "mechanism": "Pillar[5]arene sequesters homoserine lactones and lipopolysaccharides, neutralizing virulence signaling and disrupting outer membrane barrier functions, thereby suppressing toxin production and biofilm formation."
  },
  {
    "drug": "Pillar[5]arene",
    "pathogen": "A. baumannii",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Pillar[5]arene inhibits biofilm formation and suppresses virulence factors in MDR A. baumannii.",
    "pmid": "36868316",
    "title": "Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.",
    "year": "2023",
    "doi": "10.1016/j.antiviral.2023.105575",
    "mechanism": "Pillar[5]arene sequesters homoserine lactones and lipopolysaccharides, neutralizing virulence signaling and disrupting outer membrane barrier functions, thereby suppressing toxin production and biofilm formation."
  },
  {
    "drug": "Pillar[5]arene",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Pillar[5]arene increases the penetration and efficacy of standard antibiotics when used in combination.",
    "pmid": "36868316",
    "title": "Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.",
    "year": "2023",
    "doi": "10.1016/j.antiviral.2023.105575",
    "mechanism": "Pillar[5]arene sequesters homoserine lactones and lipopolysaccharides, neutralizing virulence signaling and disrupting outer membrane barrier functions, thereby suppressing toxin production and biofilm formation."
  },
  {
    "drug": "spiro-acridine derivatives",
    "pathogen": "Aspergillus fumigatus",
    "activity_type": "anti_biofilm|anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Compound 5 exhibited potent inhibitory activity against fungal chitinases with an IC50 of 0.6 ng/\u00b5L, indicating potential antifungal activity.",
    "pmid": "36951188",
    "title": "Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade.",
    "year": "2023",
    "doi": "10.1080/22221751.2023.2195020",
    "mechanism": "Inhibition of fungal chitinases by binding to the active site, particularly interacting with the DXDXE motif, disrupting cell wall remodeling and fungal growth."
  },
  {
    "drug": "spiro-acridine derivatives",
    "pathogen": "Trichoderma harzianum",
    "activity_type": "anti_biofilm|anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Compounds showed strong binding interactions with T. harzianum chitinases in silico, suggesting potential antifungal activity.",
    "pmid": "36951188",
    "title": "Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade.",
    "year": "2023",
    "doi": "10.1080/22221751.2023.2195020",
    "mechanism": "Inhibition of fungal chitinases by binding to the active site, particularly interacting with the DXDXE motif, disrupting cell wall remodeling and fungal growth."
  },
  {
    "drug": "9-Aminoacridine",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": 0.375,
    "key_result": "9-Aminoacridine synergistically enhances the antimicrobial effect of rifampin against multidrug-resistant K. pneumoniae in vitro.",
    "pmid": "36978084",
    "title": "Gram-negative bacteria resist antimicrobial agents by a DzrR-mediated envelope stress response.",
    "year": "2023",
    "doi": "10.1186/s12915-023-01565-7",
    "mechanism": "9-Aminoacridine interacts with bacterial DNA, intercalates into the DNA structure, and disrupts the proton motive force, impairing bacterial energy processes and enhancing antibiotic efficacy."
  },
  {
    "drug": "9-Aminoacridine",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "9-Aminoacridine exhibits antimicrobial activity against K. pneumoniae with MICs ranging from 8 to 16 \u03bcg/mL.",
    "pmid": "36978084",
    "title": "Gram-negative bacteria resist antimicrobial agents by a DzrR-mediated envelope stress response.",
    "year": "2023",
    "doi": "10.1186/s12915-023-01565-7",
    "mechanism": "9-Aminoacridine interacts with bacterial DNA, intercalates into the DNA structure, and disrupts the proton motive force, impairing bacterial energy processes and enhancing antibiotic efficacy."
  },
  {
    "drug": "9-Aminoacridine",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "When combined with rifampin, 9-Aminoacridine reduces resistance development and enhances in vivo antimicrobial efficacy.",
    "pmid": "36978084",
    "title": "Gram-negative bacteria resist antimicrobial agents by a DzrR-mediated envelope stress response.",
    "year": "2023",
    "doi": "10.1186/s12915-023-01565-7",
    "mechanism": "9-Aminoacridine interacts with bacterial DNA, intercalates into the DNA structure, and disrupts the proton motive force, impairing bacterial energy processes and enhancing antibiotic efficacy."
  },
  {
    "drug": "9-Aminoacridine",
    "pathogen": "K. pneumoniae",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "mechanistic",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mechanistic studies suggest 9-Aminoacridine interacts with bacterial DNA and disrupts proton motive force, contributing to its antimicrobial activity.",
    "pmid": "36978084",
    "title": "Gram-negative bacteria resist antimicrobial agents by a DzrR-mediated envelope stress response.",
    "year": "2023",
    "doi": "10.1186/s12915-023-01565-7",
    "mechanism": "9-Aminoacridine interacts with bacterial DNA, intercalates into the DNA structure, and disrupts the proton motive force, impairing bacterial energy processes and enhancing antibiotic efficacy."
  },
  {
    "drug": "zeamines",
    "pathogen": "Dickeya oryzae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 450,
    "fici": null,
    "key_result": "DzrR regulates resistance to zeamines by inducing the expression of the RND efflux pump desAB.",
    "pmid": "36978449",
    "title": "Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature.",
    "year": "2023",
    "doi": "10.3390/antibiotics12030582",
    "mechanism": "DzrR, a response regulator, induces expression of RND efflux pumps (DesABC and others) in response to envelope-targeting antimicrobial agents, independent of phosphorylation."
  },
  {
    "drug": "chlorhexidine",
    "pathogen": "Burkholderia cenocepacia",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 900,
    "fici": null,
    "key_result": "DzrR homolog in B. cenocepacia activates efflux pump expression in response to chlorhexidine, contributing to resistance.",
    "pmid": "36978449",
    "title": "Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature.",
    "year": "2023",
    "doi": "10.3390/antibiotics12030582",
    "mechanism": "DzrR, a response regulator, induces expression of RND efflux pumps (DesABC and others) in response to envelope-targeting antimicrobial agents, independent of phosphorylation."
  },
  {
    "drug": "chlorpromazine",
    "pathogen": "not specified",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Structural divergence suggests potential modulation of bacterial response, but specific activity not detailed.",
    "pmid": "36978449",
    "title": "Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature.",
    "year": "2023",
    "doi": "10.3390/antibiotics12030582",
    "mechanism": "DzrR, a response regulator, induces expression of RND efflux pumps (DesABC and others) in response to envelope-targeting antimicrobial agents, independent of phosphorylation."
  },
  {
    "drug": "H7",
    "pathogen": "CRAB",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "H7 shows potent antibacterial activity against MDR Gram-negative bacteria by inhibiting thioredoxin reductase, leading to oxidative stress.",
    "pmid": "37036368",
    "title": "Repurposing 9-Aminoacridine as an Adjuvant Enhances the Antimicrobial Effects of Rifampin against Multidrug-Resistant Klebsiella pneumoniae.",
    "year": "2023",
    "doi": "10.1128/spectrum.04474-22",
    "mechanism": "Inhibition of bacterial thioredoxin reductase (TrxR), leading to increased reactive oxygen species (ROS), oxidative stress, and disruption of redox balance and cellular functions."
  },
  {
    "drug": "H8",
    "pathogen": "CRAB",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "H8 exhibits stronger antibacterial effects than auranofin against MDR bacteria via TrxR inhibition.",
    "pmid": "37036368",
    "title": "Repurposing 9-Aminoacridine as an Adjuvant Enhances the Antimicrobial Effects of Rifampin against Multidrug-Resistant Klebsiella pneumoniae.",
    "year": "2023",
    "doi": "10.1128/spectrum.04474-22",
    "mechanism": "Inhibition of bacterial thioredoxin reductase (TrxR), leading to increased reactive oxygen species (ROS), oxidative stress, and disruption of redox balance and cellular functions."
  },
  {
    "drug": "H7",
    "pathogen": "CRAB",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo, H7 promotes wound healing and prolongs survival in CRAB-induced peritonitis models.",
    "pmid": "37036368",
    "title": "Repurposing 9-Aminoacridine as an Adjuvant Enhances the Antimicrobial Effects of Rifampin against Multidrug-Resistant Klebsiella pneumoniae.",
    "year": "2023",
    "doi": "10.1128/spectrum.04474-22",
    "mechanism": "Inhibition of bacterial thioredoxin reductase (TrxR), leading to increased reactive oxygen species (ROS), oxidative stress, and disruption of redox balance and cellular functions."
  },
  {
    "drug": "H8",
    "pathogen": "CRAB",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "H8 demonstrates superior antibacterial activity in vivo compared to auranofin.",
    "pmid": "37036368",
    "title": "Repurposing 9-Aminoacridine as an Adjuvant Enhances the Antimicrobial Effects of Rifampin against Multidrug-Resistant Klebsiella pneumoniae.",
    "year": "2023",
    "doi": "10.1128/spectrum.04474-22",
    "mechanism": "Inhibition of bacterial thioredoxin reductase (TrxR), leading to increased reactive oxygen species (ROS), oxidative stress, and disruption of redox balance and cellular functions."
  },
  {
    "drug": "atorvastatin",
    "pathogen": "prostate cancer",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Atorvastatin reduces serum PSA levels and tumor proliferation in prostate cancer patients.",
    "pmid": "37059703",
    "title": "Repurposing host-guest chemistry to sequester virulence and eradicate biofilms in multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii.",
    "year": "2023",
    "doi": "10.1038/s41467-023-37749-6",
    "mechanism": "Repurposed drugs modulate lipid metabolism, inhibit cell proliferation, induce apoptosis, and interfere with signaling pathways such as PI3K/Akt/mTOR in prostate cancer."
  },
  {
    "drug": "fluvastatin",
    "pathogen": "prostate cancer",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Fluvastatin administration induces apoptosis and is detected in prostate tissue, enhancing prostate cancer treatment.",
    "pmid": "37059703",
    "title": "Repurposing host-guest chemistry to sequester virulence and eradicate biofilms in multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii.",
    "year": "2023",
    "doi": "10.1038/s41467-023-37749-6",
    "mechanism": "Repurposed drugs modulate lipid metabolism, inhibit cell proliferation, induce apoptosis, and interfere with signaling pathways such as PI3K/Akt/mTOR in prostate cancer."
  },
  {
    "drug": "simvastatin",
    "pathogen": "prostate cancer",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Simvastatin resensitizes resistant prostate cancer cells and reduces PSA levels.",
    "pmid": "37059703",
    "title": "Repurposing host-guest chemistry to sequester virulence and eradicate biofilms in multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii.",
    "year": "2023",
    "doi": "10.1038/s41467-023-37749-6",
    "mechanism": "Repurposed drugs modulate lipid metabolism, inhibit cell proliferation, induce apoptosis, and interfere with signaling pathways such as PI3K/Akt/mTOR in prostate cancer."
  },
  {
    "drug": "fenofibrate",
    "pathogen": "prostate cancer",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Fenofibrate induces apoptosis and reduces androgen receptor expression in prostate cancer cells.",
    "pmid": "37059703",
    "title": "Repurposing host-guest chemistry to sequester virulence and eradicate biofilms in multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii.",
    "year": "2023",
    "doi": "10.1038/s41467-023-37749-6",
    "mechanism": "Repurposed drugs modulate lipid metabolism, inhibit cell proliferation, induce apoptosis, and interfere with signaling pathways such as PI3K/Akt/mTOR in prostate cancer."
  },
  {
    "drug": "metformin",
    "pathogen": "prostate cancer",
    "activity_type": "adjuvant",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Metformin promotes apoptosis and inhibits growth in prostate cancer, reducing incidence and mortality.",
    "pmid": "37059703",
    "title": "Repurposing host-guest chemistry to sequester virulence and eradicate biofilms in multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii.",
    "year": "2023",
    "doi": "10.1038/s41467-023-37749-6",
    "mechanism": "Repurposed drugs modulate lipid metabolism, inhibit cell proliferation, induce apoptosis, and interfere with signaling pathways such as PI3K/Akt/mTOR in prostate cancer."
  },
  {
    "drug": "Gliotoxin",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Gliotoxin significantly enhances vancomycin activity against S. aureus in vitro.",
    "pmid": "37147323",
    "title": "Scaffold repositioning of spiro-acridine derivatives as fungi chitinase inhibitor by target fishing and in vitro studies.",
    "year": "2023",
    "doi": "10.1038/s41598-023-33279-9",
    "mechanism": "Zinc chelation and disruption of metalloenzyme activity, interference with bacterial metal ion homeostasis, and potential inhibition of resistance enzymes such as metallo-\u03b2-lactamases."
  },
  {
    "drug": "Holomycin",
    "pathogen": "not specified",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Reduced holomycin can inhibit metallo-\u03b2-lactamases, suggesting potential to inhibit zinc-dependent resistance enzymes.",
    "pmid": "37147323",
    "title": "Scaffold repositioning of spiro-acridine derivatives as fungi chitinase inhibitor by target fishing and in vitro studies.",
    "year": "2023",
    "doi": "10.1038/s41598-023-33279-9",
    "mechanism": "Zinc chelation and disruption of metalloenzyme activity, interference with bacterial metal ion homeostasis, and potential inhibition of resistance enzymes such as metallo-\u03b2-lactamases."
  },
  {
    "drug": "PBT2",
    "pathogen": "multiple bacteria including VRE and others",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "PBT2-Zn destabilizes bacterial resistance pathways, re-sensitizing VRE to vancomycin and enhancing sensitivity to other antibiotics.",
    "pmid": "37147323",
    "title": "Scaffold repositioning of spiro-acridine derivatives as fungi chitinase inhibitor by target fishing and in vitro studies.",
    "year": "2023",
    "doi": "10.1038/s41598-023-33279-9",
    "mechanism": "Zinc chelation and disruption of metalloenzyme activity, interference with bacterial metal ion homeostasis, and potential inhibition of resistance enzymes such as metallo-\u03b2-lactamases."
  },
  {
    "drug": "auranofin",
    "pathogen": "M. tuberculosis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin inhibits bacterial thioredoxin reductase, disrupting redox balance and causing bacterial cell death.",
    "pmid": "37147323",
    "title": "Scaffold repositioning of spiro-acridine derivatives as fungi chitinase inhibitor by target fishing and in vitro studies.",
    "year": "2023",
    "doi": "10.1038/s41598-023-33279-9",
    "mechanism": "Zinc chelation and disruption of metalloenzyme activity, interference with bacterial metal ion homeostasis, and potential inhibition of resistance enzymes such as metallo-\u03b2-lactamases."
  },
  {
    "drug": "ticagrelor",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ticagrelor shows potential as an adjuvant to enhance antimicrobial activity against MRSA.",
    "pmid": "37178319",
    "title": "Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections.",
    "year": "2023",
    "doi": "10.1111/1751-7915.14268",
    "mechanism": "The proposed mechanisms involve repurposing these drugs as adjuvants that can enhance the activity of existing antibiotics or directly inhibit resistant bacterial targets, possibly through interference with bacterial metabolism, efflux pumps, or cell wall synthesis."
  },
  {
    "drug": "mitomycin C",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mitomycin C demonstrates synergistic effects with antibiotics against resistant bacteria.",
    "pmid": "37178319",
    "title": "Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections.",
    "year": "2023",
    "doi": "10.1111/1751-7915.14268",
    "mechanism": "The proposed mechanisms involve repurposing these drugs as adjuvants that can enhance the activity of existing antibiotics or directly inhibit resistant bacterial targets, possibly through interference with bacterial metabolism, efflux pumps, or cell wall synthesis."
  },
  {
    "drug": "auranofin",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin exhibits activity as an adjuvant to combat MDR A. baumannii.",
    "pmid": "37178319",
    "title": "Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections.",
    "year": "2023",
    "doi": "10.1111/1751-7915.14268",
    "mechanism": "The proposed mechanisms involve repurposing these drugs as adjuvants that can enhance the activity of existing antibiotics or directly inhibit resistant bacterial targets, possibly through interference with bacterial metabolism, efflux pumps, or cell wall synthesis."
  },
  {
    "drug": "pentamidine",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Pentamidine shows potential in combination therapies against resistant strains.",
    "pmid": "37178319",
    "title": "Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections.",
    "year": "2023",
    "doi": "10.1111/1751-7915.14268",
    "mechanism": "The proposed mechanisms involve repurposing these drugs as adjuvants that can enhance the activity of existing antibiotics or directly inhibit resistant bacterial targets, possibly through interference with bacterial metabolism, efflux pumps, or cell wall synthesis."
  },
  {
    "drug": "zidovudine",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Zidovudine may serve as an adjuvant to enhance antimicrobial efficacy.",
    "pmid": "37178319",
    "title": "Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections.",
    "year": "2023",
    "doi": "10.1111/1751-7915.14268",
    "mechanism": "The proposed mechanisms involve repurposing these drugs as adjuvants that can enhance the activity of existing antibiotics or directly inhibit resistant bacterial targets, possibly through interference with bacterial metabolism, efflux pumps, or cell wall synthesis."
  },
  {
    "drug": "ebselen",
    "pathogen": "Escherichia coli (ESBL-producing)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen inhibits diguanylate cyclases, reducing c-di-GMP levels and significantly decreasing the MIC of ceftriaxone against ESBL-E. coli.",
    "pmid": "37191826",
    "title": "Evaluation of off-label rapamycin use to promote healthspan in 333 adults.",
    "year": "2023",
    "doi": "10.1007/s11357-023-00818-1",
    "mechanism": "Inhibition of diguanylate cyclases, leading to decreased c-di-GMP synthesis, which modulates bacterial self-saving responses and resistance mechanisms."
  },
  {
    "drug": "ebselen",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "Ebselen demonstrated potent bactericidal activity against S. aureus, including methicillin- and vancomycin-resistant strains, with MICs as low as 0.0625-1 \u03bcg/mL.",
    "pmid": "37240241",
    "title": "Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.",
    "year": "2023",
    "doi": "10.3390/ijms24108896",
    "mechanism": "Inhibition of bacterial thioredoxin reductase, covalent modification of cysteine residues, disruption of protein, nucleic acid, and lipid synthesis, and attenuation of biofilm formation and quorum sensing."
  },
  {
    "drug": "ebselen",
    "pathogen": "Staphylococcus epidermidis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.125,
    "fici": null,
    "key_result": "Ebselen reduced biofilm formation and exhibited activity against S. epidermidis with MICs typically between 0.125-0.5 \u03bcg/mL.",
    "pmid": "37240241",
    "title": "Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.",
    "year": "2023",
    "doi": "10.3390/ijms24108896",
    "mechanism": "Inhibition of bacterial thioredoxin reductase, covalent modification of cysteine residues, disruption of protein, nucleic acid, and lipid synthesis, and attenuation of biofilm formation and quorum sensing."
  },
  {
    "drug": "ebselen",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.25,
    "fici": null,
    "key_result": "Ebselen inhibited vancomycin-resistant E. faecium with MICs ranging from 0.25-4 \u03bcg/mL and was effective in eradicating mature biofilms.",
    "pmid": "37240241",
    "title": "Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.",
    "year": "2023",
    "doi": "10.3390/ijms24108896",
    "mechanism": "Inhibition of bacterial thioredoxin reductase, covalent modification of cysteine residues, disruption of protein, nucleic acid, and lipid synthesis, and attenuation of biofilm formation and quorum sensing."
  },
  {
    "drug": "ebselen",
    "pathogen": "Various Gram-positive bacteria (Streptococcus spp., Enterococcus spp.)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.0625,
    "fici": null,
    "key_result": "Demonstrated broad activity with MICs generally between 0.0625-1 \u03bcg/mL, outperforming some traditional antibiotics.",
    "pmid": "37240241",
    "title": "Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.",
    "year": "2023",
    "doi": "10.3390/ijms24108896",
    "mechanism": "Inhibition of bacterial thioredoxin reductase, covalent modification of cysteine residues, disruption of protein, nucleic acid, and lipid synthesis, and attenuation of biofilm formation and quorum sensing."
  },
  {
    "drug": "ebselen",
    "pathogen": "Neisseria mucosa",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Used to treat mature biofilms by degrading extracellular polymeric substances and inhibiting quorum sensing.",
    "pmid": "37240241",
    "title": "Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.",
    "year": "2023",
    "doi": "10.3390/ijms24108896",
    "mechanism": "Inhibition of bacterial thioredoxin reductase, covalent modification of cysteine residues, disruption of protein, nucleic acid, and lipid synthesis, and attenuation of biofilm formation and quorum sensing."
  },
  {
    "drug": "Ceftazidime\u2013Avibactam",
    "pathogen": "Enterobacterales",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ceftazidime\u2013avibactam shows activity against XDR Enterobacterales producing \u03b2-lactamases, with promising clinical use in pediatric infections.",
    "pmid": "37306577",
    "title": "Repurposing High-Throughput Screening Identifies Unconventional Drugs with Antibacterial and Antibiofilm Activities against Pseudomonas aeruginosa under Experimental Conditions Relevant to Cystic Fibrosis.",
    "year": "2023",
    "doi": "10.1128/spectrum.00352-23",
    "mechanism": "Inhibition of Ambler class A, C, and D \u03b2-lactamases by avibactam, protecting ceftazidime from degradation and restoring activity against resistant Gram-negative bacteria."
  },
  {
    "drug": "Ceftazidime\u2013Avibactam",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ceftazidime\u2013avibactam demonstrates activity against MDR P. aeruginosa, with limited pediatric data but promising case reports.",
    "pmid": "37306577",
    "title": "Repurposing High-Throughput Screening Identifies Unconventional Drugs with Antibacterial and Antibiofilm Activities against Pseudomonas aeruginosa under Experimental Conditions Relevant to Cystic Fibrosis.",
    "year": "2023",
    "doi": "10.1128/spectrum.00352-23",
    "mechanism": "Inhibition of Ambler class A, C, and D \u03b2-lactamases by avibactam, protecting ceftazidime from degradation and restoring activity against resistant Gram-negative bacteria."
  },
  {
    "drug": "thioridazine",
    "pathogen": "A. baumannii",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine significantly inhibits biofilm formation in A. baumannii at micromolar concentrations.",
    "pmid": "37341603",
    "title": "Type IV Pilus-Mediated Inhibition of Acinetobacter baumannii Biofilm Formation by Phenothiazine Compounds.",
    "year": "2023",
    "doi": "10.1128/spectrum.01023-23",
    "mechanism": "Inhibition of type IV pilus biogenesis, disrupting biofilm formation and twitching motility."
  },
  {
    "drug": "Trifluoperazine",
    "pathogen": "A. baumannii",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Trifluoperazine reduces biofilm formation in A. baumannii, with dose-dependent effects observed.",
    "pmid": "37341603",
    "title": "Type IV Pilus-Mediated Inhibition of Acinetobacter baumannii Biofilm Formation by Phenothiazine Compounds.",
    "year": "2023",
    "doi": "10.1128/spectrum.01023-23",
    "mechanism": "Inhibition of type IV pilus biogenesis, disrupting biofilm formation and twitching motility."
  },
  {
    "drug": "thioridazine",
    "pathogen": "Acinetobacter nosocomialis",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine shows variable inhibition of biofilm formation in A. nosocomialis.",
    "pmid": "37341603",
    "title": "Type IV Pilus-Mediated Inhibition of Acinetobacter baumannii Biofilm Formation by Phenothiazine Compounds.",
    "year": "2023",
    "doi": "10.1128/spectrum.01023-23",
    "mechanism": "Inhibition of type IV pilus biogenesis, disrupting biofilm formation and twitching motility."
  },
  {
    "drug": "Compound 1771",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Compound 1771 inhibits LTA synthesis and shows antibacterial activity against S. aureus.",
    "pmid": "37370391",
    "title": "Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.",
    "year": "2023",
    "doi": "10.3390/antibiotics12061072",
    "mechanism": "Inhibition of lipoteichoic acid biosynthesis and FtsZ polymerization, disrupting cell wall integrity and bacterial cytokinesis."
  },
  {
    "drug": "Compound 4",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Structural reconfiguration of compound 1771 resulted in compound 4 with improved activity and \u03b2-lactam synergy.",
    "pmid": "37370391",
    "title": "Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.",
    "year": "2023",
    "doi": "10.3390/antibiotics12061072",
    "mechanism": "Inhibition of lipoteichoic acid biosynthesis and FtsZ polymerization, disrupting cell wall integrity and bacterial cytokinesis."
  },
  {
    "drug": "HSGN-94",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "HSGN-94 interacts with PgcA, downregulates PgsA, and shows activity against S. aureus with low resistance development.",
    "pmid": "37370391",
    "title": "Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.",
    "year": "2023",
    "doi": "10.3390/antibiotics12061072",
    "mechanism": "Inhibition of lipoteichoic acid biosynthesis and FtsZ polymerization, disrupting cell wall integrity and bacterial cytokinesis."
  },
  {
    "drug": "PC190723",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "PC190723 targets FtsZ, exhibits bactericidal activity against MRSA, and shows efficacy in murine models.",
    "pmid": "37370391",
    "title": "Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.",
    "year": "2023",
    "doi": "10.3390/antibiotics12061072",
    "mechanism": "Inhibition of lipoteichoic acid biosynthesis and FtsZ polymerization, disrupting cell wall integrity and bacterial cytokinesis."
  },
  {
    "drug": "TXY436",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Prodrug of PC190723 with improved pharmacokinetics, undergoing clinical trials.",
    "pmid": "37370391",
    "title": "Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.",
    "year": "2023",
    "doi": "10.3390/antibiotics12061072",
    "mechanism": "Inhibition of lipoteichoic acid biosynthesis and FtsZ polymerization, disrupting cell wall integrity and bacterial cytokinesis."
  },
  {
    "drug": "TXY541",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Prodrug of PC190723 with enhanced physiochemical properties.",
    "pmid": "37370391",
    "title": "Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.",
    "year": "2023",
    "doi": "10.3390/antibiotics12061072",
    "mechanism": "Inhibition of lipoteichoic acid biosynthesis and FtsZ polymerization, disrupting cell wall integrity and bacterial cytokinesis."
  },
  {
    "drug": "TXA709",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "A prodrug targeting FtsZ, currently in phase I clinical trials for MRSA.",
    "pmid": "37370391",
    "title": "Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.",
    "year": "2023",
    "doi": "10.3390/antibiotics12061072",
    "mechanism": "Inhibition of lipoteichoic acid biosynthesis and FtsZ polymerization, disrupting cell wall integrity and bacterial cytokinesis."
  },
  {
    "drug": "rapamycin",
    "pathogen": "TSC2 mutant cells",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Rapamycin normalized mitochondrial membrane potential and reduced proliferation in TSC2 mutant cells by inhibiting mTOR signaling.",
    "pmid": "37386581",
    "title": "Repurposing Amphotericin B: anti-microbial, molecular docking and molecular dynamics simulation studies suggest inhibition potential of Amphotericin B against MRSA.",
    "year": "2023",
    "doi": "10.1186/s13065-023-00980-9",
    "mechanism": "Inhibition of mTOR signaling by rapamycin and TrxR activity by auranofin reduces Prdx5 levels, induces ER stress, and promotes cell death in TSC2 mutant cells."
  },
  {
    "drug": "auranofin",
    "pathogen": "TSC2 mutant cells",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin reduced TrxR activity and decreased Prdx5 levels, contributing to ER stress and cell death in TSC2 mutant cells.",
    "pmid": "37386581",
    "title": "Repurposing Amphotericin B: anti-microbial, molecular docking and molecular dynamics simulation studies suggest inhibition potential of Amphotericin B against MRSA.",
    "year": "2023",
    "doi": "10.1186/s13065-023-00980-9",
    "mechanism": "Inhibition of mTOR signaling by rapamycin and TrxR activity by auranofin reduces Prdx5 levels, induces ER stress, and promotes cell death in TSC2 mutant cells."
  },
  {
    "drug": "combination of rapamycin and auranofin",
    "pathogen": "TSC2 mutant cells",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combined treatment synergistically decreased Prdx5 levels, inhibited TrxR and mTOR, and induced ER stress leading to cell death.",
    "pmid": "37386581",
    "title": "Repurposing Amphotericin B: anti-microbial, molecular docking and molecular dynamics simulation studies suggest inhibition potential of Amphotericin B against MRSA.",
    "year": "2023",
    "doi": "10.1186/s13065-023-00980-9",
    "mechanism": "Inhibition of mTOR signaling by rapamycin and TrxR activity by auranofin reduces Prdx5 levels, induces ER stress, and promotes cell death in TSC2 mutant cells."
  },
  {
    "drug": "ebselen",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen exhibits rapid, dose-dependent bactericidal activity and damages bacterial cell membranes.",
    "pmid": "37428033",
    "title": "Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus In Vitro and In Vivo.",
    "year": "2023",
    "doi": "10.1128/spectrum.05031-22",
    "mechanism": "The drugs primarily target bacterial cell membranes, increasing permeability, leading to leakage, cytoplasm loss, and cell lysis."
  },
  {
    "drug": "carmofur",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Carmofur effectively prevents biofilm formation and damages cell membranes, increasing membrane permeability.",
    "pmid": "37428033",
    "title": "Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus In Vitro and In Vivo.",
    "year": "2023",
    "doi": "10.1128/spectrum.05031-22",
    "mechanism": "The drugs primarily target bacterial cell membranes, increasing permeability, leading to leakage, cytoplasm loss, and cell lysis."
  },
  {
    "drug": "5-fluorouracil",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "5-Fluorouracil prevents biofilm formation and damages bacterial membranes.",
    "pmid": "37428033",
    "title": "Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus In Vitro and In Vivo.",
    "year": "2023",
    "doi": "10.1128/spectrum.05031-22",
    "mechanism": "The drugs primarily target bacterial cell membranes, increasing permeability, leading to leakage, cytoplasm loss, and cell lysis."
  },
  {
    "drug": "tirapazamine",
    "pathogen": "P. aeruginosa",
    "activity_type": "dispersing_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tirapazamine actively disperses preformed biofilms and damages cell membranes.",
    "pmid": "37428033",
    "title": "Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus In Vitro and In Vivo.",
    "year": "2023",
    "doi": "10.1128/spectrum.05031-22",
    "mechanism": "The drugs primarily target bacterial cell membranes, increasing permeability, leading to leakage, cytoplasm loss, and cell lysis."
  },
  {
    "drug": "tavaborole",
    "pathogen": "P. aeruginosa",
    "activity_type": "dispersing_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tavaborole disperses preformed biofilms and shows activity against other CF pathogens like B. cepacia and A. baumannii.",
    "pmid": "37428033",
    "title": "Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus In Vitro and In Vivo.",
    "year": "2023",
    "doi": "10.1128/spectrum.05031-22",
    "mechanism": "The drugs primarily target bacterial cell membranes, increasing permeability, leading to leakage, cytoplasm loss, and cell lysis."
  },
  {
    "drug": "Nifedipine",
    "pathogen": "Trichinella spiralis",
    "activity_type": "anthelmintic|efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nifedipine showed dose-dependent in vitro activity against T. spiralis muscle larvae and adult worms, with low LC50 values indicating potent anthelmintic effects.",
    "pmid": "37443747",
    "title": "Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms.",
    "year": "2023",
    "doi": "10.3390/cells12131713",
    "mechanism": "Nifedipine may inhibit T. spiralis \u03b2-tubulin polymerization, disrupting parasite microtubule formation; C. coronarium extract's mechanism is not explicitly detailed but shows morphological damage to the parasite tegument."
  },
  {
    "drug": "Chrysanthemum coronarium extract",
    "pathogen": "Trichinella spiralis",
    "activity_type": "anthelmintic",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "C. coronarium extract demonstrated dose-dependent in vitro activity against T. spiralis larvae and adult worms, causing tegument destruction.",
    "pmid": "37443747",
    "title": "Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms.",
    "year": "2023",
    "doi": "10.3390/cells12131713",
    "mechanism": "Nifedipine may inhibit T. spiralis \u03b2-tubulin polymerization, disrupting parasite microtubule formation; C. coronarium extract's mechanism is not explicitly detailed but shows morphological damage to the parasite tegument."
  },
  {
    "drug": "fluconazole",
    "pathogen": "Cryptococcus neoformans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Fluconazole is widely used for cryptococcosis but has contributed to increased resistance and relapse cases.",
    "pmid": "37446795",
    "title": "The Impact of Copper Ions on the Activity of Antibiotic Drugs.",
    "year": "2023",
    "doi": "10.3390/molecules28135133",
    "mechanism": "Existing antifungal drugs target ergosterol synthesis or function, but resistance mechanisms include mutations in ergosterol biosynthesis genes (amphotericin B resistance) and overexpression of efflux pumps (azole resistance). Flucytosine resistance mechanisms are not fully understood."
  },
  {
    "drug": "amphotericin B",
    "pathogen": "Cryptococcus neoformans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Amphotericin B is effective but limited by nephrotoxicity; lipid formulations reduce toxicity but are costly.",
    "pmid": "37446795",
    "title": "The Impact of Copper Ions on the Activity of Antibiotic Drugs.",
    "year": "2023",
    "doi": "10.3390/molecules28135133",
    "mechanism": "Existing antifungal drugs target ergosterol synthesis or function, but resistance mechanisms include mutations in ergosterol biosynthesis genes (amphotericin B resistance) and overexpression of efflux pumps (azole resistance). Flucytosine resistance mechanisms are not fully understood."
  },
  {
    "drug": "flucytosine",
    "pathogen": "Cryptococcus neoformans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Flucytosine is effective in combination therapy but has issues with toxicity and resistance development.",
    "pmid": "37446795",
    "title": "The Impact of Copper Ions on the Activity of Antibiotic Drugs.",
    "year": "2023",
    "doi": "10.3390/molecules28135133",
    "mechanism": "Existing antifungal drugs target ergosterol synthesis or function, but resistance mechanisms include mutations in ergosterol biosynthesis genes (amphotericin B resistance) and overexpression of efflux pumps (azole resistance). Flucytosine resistance mechanisms are not fully understood."
  },
  {
    "drug": "curcumin",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Curcumin exhibited bactericidal activity against P. aeruginosa with molecular docking confirming interaction with quorum-sensing proteins.",
    "pmid": "37458598",
    "title": "Therapeutic Switching of Rafoxanide: a New Approach To Fighting Drug-Resistant Bacteria and Fungi.",
    "year": "2023",
    "doi": "10.1128/spectrum.02679-22",
    "mechanism": "Curcumin inhibits bacterial growth and virulence by targeting quorum sensing proteins such as SecA-SecY, LsrR, PqsR, and AgrA, disrupting bacterial communication and biofilm formation."
  },
  {
    "drug": "curcumin",
    "pathogen": "Bacillus subtilis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Curcumin showed antibacterial activity against B. subtilis, with molecular docking indicating interaction with QS regulator proteins.",
    "pmid": "37458598",
    "title": "Therapeutic Switching of Rafoxanide: a New Approach To Fighting Drug-Resistant Bacteria and Fungi.",
    "year": "2023",
    "doi": "10.1128/spectrum.02679-22",
    "mechanism": "Curcumin inhibits bacterial growth and virulence by targeting quorum sensing proteins such as SecA-SecY, LsrR, PqsR, and AgrA, disrupting bacterial communication and biofilm formation."
  },
  {
    "drug": "curcumin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Curcumin demonstrated activity against S. aureus, supported by molecular docking studies on QS proteins.",
    "pmid": "37458598",
    "title": "Therapeutic Switching of Rafoxanide: a New Approach To Fighting Drug-Resistant Bacteria and Fungi.",
    "year": "2023",
    "doi": "10.1128/spectrum.02679-22",
    "mechanism": "Curcumin inhibits bacterial growth and virulence by targeting quorum sensing proteins such as SecA-SecY, LsrR, PqsR, and AgrA, disrupting bacterial communication and biofilm formation."
  },
  {
    "drug": "curcumin",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Curcumin exhibited antibacterial effects against E. coli, with molecular docking confirming binding to key QS proteins.",
    "pmid": "37458598",
    "title": "Therapeutic Switching of Rafoxanide: a New Approach To Fighting Drug-Resistant Bacteria and Fungi.",
    "year": "2023",
    "doi": "10.1128/spectrum.02679-22",
    "mechanism": "Curcumin inhibits bacterial growth and virulence by targeting quorum sensing proteins such as SecA-SecY, LsrR, PqsR, and AgrA, disrupting bacterial communication and biofilm formation."
  },
  {
    "drug": "curcumin",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nano-curcumin lotion significantly reduced bacterial load and promoted wound healing in infected rat models.",
    "pmid": "37458598",
    "title": "Therapeutic Switching of Rafoxanide: a New Approach To Fighting Drug-Resistant Bacteria and Fungi.",
    "year": "2023",
    "doi": "10.1128/spectrum.02679-22",
    "mechanism": "Curcumin inhibits bacterial growth and virulence by targeting quorum sensing proteins such as SecA-SecY, LsrR, PqsR, and AgrA, disrupting bacterial communication and biofilm formation."
  },
  {
    "drug": "disulfiram",
    "pathogen": "NDM-positive E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.188,
    "key_result": "Disulfiram synergistically enhances meropenem activity against NDM-positive E. coli by inhibiting NDM enzyme activity.",
    "pmid": "37461016",
    "title": "Repurposing drugs to treat trichinellosis: in vitro analysis of the anthelmintic activity of nifedipine and Chrysanthemum coronarium extract.",
    "year": "2023",
    "doi": "10.1186/s12906-023-04076-8",
    "mechanism": "Disulfiram inhibits NDM enzyme activity by binding to its active site, and disrupts bacterial membrane integrity and metabolism, thereby restoring antibiotic efficacy."
  },
  {
    "drug": "disulfiram",
    "pathogen": "MCR-positive K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.047,
    "key_result": "Disulfiram synergistically restores colistin activity against MCR-positive pathogens, effectively eliminating resistant bacteria.",
    "pmid": "37461016",
    "title": "Repurposing drugs to treat trichinellosis: in vitro analysis of the anthelmintic activity of nifedipine and Chrysanthemum coronarium extract.",
    "year": "2023",
    "doi": "10.1186/s12906-023-04076-8",
    "mechanism": "Disulfiram inhibits NDM enzyme activity by binding to its active site, and disrupts bacterial membrane integrity and metabolism, thereby restoring antibiotic efficacy."
  },
  {
    "drug": "Diethyldithiocarbamate (DDC)",
    "pathogen": "NDM-positive E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.125,
    "key_result": "DDC enhances meropenem efficacy against NDM-positive E. coli, reversing resistance.",
    "pmid": "37461016",
    "title": "Repurposing drugs to treat trichinellosis: in vitro analysis of the anthelmintic activity of nifedipine and Chrysanthemum coronarium extract.",
    "year": "2023",
    "doi": "10.1186/s12906-023-04076-8",
    "mechanism": "Disulfiram inhibits NDM enzyme activity by binding to its active site, and disrupts bacterial membrane integrity and metabolism, thereby restoring antibiotic efficacy."
  },
  {
    "drug": "Dimethyldithiocarbamate (DMDC)",
    "pathogen": "NDM-positive E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.25,
    "key_result": "DMDC potentiates meropenem activity against NDM-positive E. coli by inhibiting NDM enzymes.",
    "pmid": "37461016",
    "title": "Repurposing drugs to treat trichinellosis: in vitro analysis of the anthelmintic activity of nifedipine and Chrysanthemum coronarium extract.",
    "year": "2023",
    "doi": "10.1186/s12906-023-04076-8",
    "mechanism": "Disulfiram inhibits NDM enzyme activity by binding to its active site, and disrupts bacterial membrane integrity and metabolism, thereby restoring antibiotic efficacy."
  },
  {
    "drug": "ciprofloxacin",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.25,
    "key_result": "Combination of ciprofloxacin with pentamidine showed synergistic inhibition of MDR P. aeruginosa strains in vitro.",
    "pmid": "37498498",
    "title": "Single-dose pharmacokinetics and lung function of nebulized niclosamide ethanolamine in sheep.",
    "year": "2023",
    "doi": "10.1007/s11095-023-03559-0",
    "mechanism": "Pentamidine inhibits RND efflux pumps (notably MexCD-OprJ and MexEF-OprN) and disrupts bacterial membrane integrity, enhancing antibiotic access and activity."
  },
  {
    "drug": "pentamidine",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant|efflux_inhibitor|anti_biofilm",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": 256,
    "fici": null,
    "key_result": "Pentamidine acts as an efflux pump inhibitor and membrane disruptor, potentiating ciprofloxacin activity.",
    "pmid": "37498498",
    "title": "Single-dose pharmacokinetics and lung function of nebulized niclosamide ethanolamine in sheep.",
    "year": "2023",
    "doi": "10.1007/s11095-023-03559-0",
    "mechanism": "Pentamidine inhibits RND efflux pumps (notably MexCD-OprJ and MexEF-OprN) and disrupts bacterial membrane integrity, enhancing antibiotic access and activity."
  },
  {
    "drug": "Oxiconazole",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Oxiconazole exhibits potent antibacterial activity against S. aureus, including MDR strains, with equipotent activity against drug-susceptible and resistant strains.",
    "pmid": "37537267",
    "title": "Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram.",
    "year": "2023",
    "doi": "10.1038/s42003-023-05173-7",
    "mechanism": "Proposed mechanism involves permeabilization of bacterial membranes and targeting conserved cytosolic components, leading to concentration-dependent bactericidal activity."
  },
  {
    "drug": "Oxiconazole",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Oxiconazole synergizes with gentamicin and daptomycin, significantly enhancing their antibacterial effects against S. aureus.",
    "pmid": "37537267",
    "title": "Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram.",
    "year": "2023",
    "doi": "10.1038/s42003-023-05173-7",
    "mechanism": "Proposed mechanism involves permeabilization of bacterial membranes and targeting conserved cytosolic components, leading to concentration-dependent bactericidal activity."
  },
  {
    "drug": "Oxiconazole",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo, oxiconazole combined with gentamicin significantly reduces bacterial load in a murine skin infection model.",
    "pmid": "37537267",
    "title": "Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram.",
    "year": "2023",
    "doi": "10.1038/s42003-023-05173-7",
    "mechanism": "Proposed mechanism involves permeabilization of bacterial membranes and targeting conserved cytosolic components, leading to concentration-dependent bactericidal activity."
  },
  {
    "drug": "Oxiconazole",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Oxiconazole significantly eradicates preformed S. aureus biofilms in vitro.",
    "pmid": "37537267",
    "title": "Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram.",
    "year": "2023",
    "doi": "10.1038/s42003-023-05173-7",
    "mechanism": "Proposed mechanism involves permeabilization of bacterial membranes and targeting conserved cytosolic components, leading to concentration-dependent bactericidal activity."
  },
  {
    "drug": "1,2,3-triazole derivatives",
    "pathogen": "S. aureus",
    "activity_type": "antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Some synthesized 1,2,3-triazole derivatives showed antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).",
    "pmid": "37574739",
    "title": "Reduced Prevalence of Dementia in Patients Prescribed Tacrolimus, Sirolimus, or Cyclosporine.",
    "year": "2023",
    "doi": "10.3233/JAD-230526",
    "mechanism": "The proposed mechanism involves the interaction of the 1,2,3-triazole moiety with bacterial targets, potentially disrupting cell wall synthesis or DNA intercalation, depending on the derivative."
  },
  {
    "drug": "1,2,3-triazole derivatives",
    "pathogen": "E. faecalis",
    "activity_type": "antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Certain derivatives exhibited activity against vancomycin-resistant enterococci (VRE).",
    "pmid": "37574739",
    "title": "Reduced Prevalence of Dementia in Patients Prescribed Tacrolimus, Sirolimus, or Cyclosporine.",
    "year": "2023",
    "doi": "10.3233/JAD-230526",
    "mechanism": "The proposed mechanism involves the interaction of the 1,2,3-triazole moiety with bacterial targets, potentially disrupting cell wall synthesis or DNA intercalation, depending on the derivative."
  },
  {
    "drug": "1,2,3-triazole derivatives",
    "pathogen": "Mycobacteria",
    "activity_type": "antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Some compounds demonstrated activity against mycobacterial strains, indicating potential as anti-tubercular agents.",
    "pmid": "37574739",
    "title": "Reduced Prevalence of Dementia in Patients Prescribed Tacrolimus, Sirolimus, or Cyclosporine.",
    "year": "2023",
    "doi": "10.3233/JAD-230526",
    "mechanism": "The proposed mechanism involves the interaction of the 1,2,3-triazole moiety with bacterial targets, potentially disrupting cell wall synthesis or DNA intercalation, depending on the derivative."
  },
  {
    "drug": "ticagrelor",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ticagrelor synergized with cationic antibiotics by modifying the surface charge of S. aureus.",
    "pmid": "37627656",
    "title": "Combination Therapy with Ciprofloxacin and Pentamidine against Multidrug-Resistant Pseudomonas aeruginosa: Assessment of In Vitro and In Vivo Efficacy and the Role of Resistance-Nodulation-Division (RND) Efflux Pumps.",
    "year": "2023",
    "doi": "10.3390/antibiotics12081236",
    "mechanism": "Modulation of bacterial surface charge and inhibition of key bacterial processes through drug combinations."
  },
  {
    "drug": "sulfamethoxazole",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sulfamethoxazole showed synergy with trimethoprim against S. aureus.",
    "pmid": "37627656",
    "title": "Combination Therapy with Ciprofloxacin and Pentamidine against Multidrug-Resistant Pseudomonas aeruginosa: Assessment of In Vitro and In Vivo Efficacy and the Role of Resistance-Nodulation-Division (RND) Efflux Pumps.",
    "year": "2023",
    "doi": "10.3390/antibiotics12081236",
    "mechanism": "Modulation of bacterial surface charge and inhibition of key bacterial processes through drug combinations."
  },
  {
    "drug": "Selamectin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 6.2,
    "fici": 0.5,
    "key_result": "Selamectin completely inhibited S. aureus growth at MIC of 6.2 \u03bcg/mL and showed synergistic effect with ampicillin against MRSA.",
    "pmid": "37646510",
    "title": "A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa.",
    "year": "2023",
    "doi": "10.1128/msphere.00190-23",
    "mechanism": "likely involves disruption of bacterial cell surface integrity and potential interaction with bacterial targets, as suggested by cell surface alterations observed via SEM."
  },
  {
    "drug": "Selamectin",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5.89,
    "fici": null,
    "key_result": "Selamectin reduced S. aureus biofilm biomass with MBEC50 at 5.89 \u03bcg/mL.",
    "pmid": "37646510",
    "title": "A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa.",
    "year": "2023",
    "doi": "10.1128/msphere.00190-23",
    "mechanism": "likely involves disruption of bacterial cell surface integrity and potential interaction with bacterial targets, as suggested by cell surface alterations observed via SEM."
  },
  {
    "drug": "Selamectin",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Synergistic effect observed between selamectin and ampicillin against MRSA.",
    "pmid": "37646510",
    "title": "A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa.",
    "year": "2023",
    "doi": "10.1128/msphere.00190-23",
    "mechanism": "likely involves disruption of bacterial cell surface integrity and potential interaction with bacterial targets, as suggested by cell surface alterations observed via SEM."
  },
  {
    "drug": "Amphotericin B",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 32,
    "fici": null,
    "key_result": "Amphotericin B shows significant antibacterial activity against MRSA in vitro with MIC of 32 \u03bcg/ml.",
    "pmid": "37660210",
    "title": "In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae.",
    "year": "2023",
    "doi": "10.1038/s41598-023-39647-9",
    "mechanism": "Hydrophobic and hydrophilic interactions with PBP 2a, affecting its conformational dynamics and potentially inhibiting cell wall synthesis."
  },
  {
    "drug": "Amphotericin B",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "mode_of_action",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Molecular docking and molecular dynamics simulations suggest Amphotericin B interacts with PBP 2a, potentially inhibiting cell wall synthesis.",
    "pmid": "37660210",
    "title": "In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae.",
    "year": "2023",
    "doi": "10.1038/s41598-023-39647-9",
    "mechanism": "Hydrophobic and hydrophilic interactions with PBP 2a, affecting its conformational dynamics and potentially inhibiting cell wall synthesis."
  },
  {
    "drug": "atorvastatin",
    "pathogen": "Mycobacterium ulcerans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 81.42,
    "fici": null,
    "key_result": "Atorvastatin exhibited antimicrobial activity against M. ulcerans with an IC50 of 81.42 \u03bcg/mL and reduced bacterial load in infected macrophages.",
    "pmid": "37686059",
    "title": "Towards Anticancer and Antibacterial Agents: Design and Synthesis of 1,2,3-Triazol-quinobenzothiazine Derivatives.",
    "year": "2023",
    "doi": "10.3390/ijms241713250",
    "mechanism": "Proposed mechanism involves statins exerting antimicrobial effects possibly through interference with bacterial cell processes, though exact mechanisms require further validation."
  },
  {
    "drug": "simvastatin",
    "pathogen": "Mycobacterium ulcerans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 54.13,
    "fici": null,
    "key_result": "Simvastatin showed antimicrobial activity with an IC50 of 54.13 \u03bcg/mL and a slight reduction in bacterial load in infected macrophages.",
    "pmid": "37686059",
    "title": "Towards Anticancer and Antibacterial Agents: Design and Synthesis of 1,2,3-Triazol-quinobenzothiazine Derivatives.",
    "year": "2023",
    "doi": "10.3390/ijms241713250",
    "mechanism": "Proposed mechanism involves statins exerting antimicrobial effects possibly through interference with bacterial cell processes, though exact mechanisms require further validation."
  },
  {
    "drug": "fluvastatin",
    "pathogen": "Mycobacterium ulcerans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 17.6,
    "fici": null,
    "key_result": "Fluvastatin had the highest antimicrobial activity among tested statins with an IC50 of 17.60 \u03bcg/mL and significantly reduced bacterial load in macrophages.",
    "pmid": "37686059",
    "title": "Towards Anticancer and Antibacterial Agents: Design and Synthesis of 1,2,3-Triazol-quinobenzothiazine Derivatives.",
    "year": "2023",
    "doi": "10.3390/ijms241713250",
    "mechanism": "Proposed mechanism involves statins exerting antimicrobial effects possibly through interference with bacterial cell processes, though exact mechanisms require further validation."
  },
  {
    "drug": "lovastatin",
    "pathogen": "Mycobacterium ulcerans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 357.2,
    "fici": null,
    "key_result": "Lovastatin showed high IC50 (357.20 \u03bcg/mL) with variable results, leading to its exclusion from further studies.",
    "pmid": "37686059",
    "title": "Towards Anticancer and Antibacterial Agents: Design and Synthesis of 1,2,3-Triazol-quinobenzothiazine Derivatives.",
    "year": "2023",
    "doi": "10.3390/ijms241713250",
    "mechanism": "Proposed mechanism involves statins exerting antimicrobial effects possibly through interference with bacterial cell processes, though exact mechanisms require further validation."
  },
  {
    "drug": "rifampicin",
    "pathogen": "Mycobacterium ulcerans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.0076,
    "fici": null,
    "key_result": "Rifampicin demonstrated potent antimicrobial activity with an IC50 of 0.0076 \u03bcg/mL.",
    "pmid": "37686059",
    "title": "Towards Anticancer and Antibacterial Agents: Design and Synthesis of 1,2,3-Triazol-quinobenzothiazine Derivatives.",
    "year": "2023",
    "doi": "10.3390/ijms241713250",
    "mechanism": "Proposed mechanism involves statins exerting antimicrobial effects possibly through interference with bacterial cell processes, though exact mechanisms require further validation."
  },
  {
    "drug": "streptomycin",
    "pathogen": "Mycobacterium ulcerans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.034,
    "fici": null,
    "key_result": "Streptomycin showed effective activity with an IC50 of 0.034 \u03bcg/mL.",
    "pmid": "37686059",
    "title": "Towards Anticancer and Antibacterial Agents: Design and Synthesis of 1,2,3-Triazol-quinobenzothiazine Derivatives.",
    "year": "2023",
    "doi": "10.3390/ijms241713250",
    "mechanism": "Proposed mechanism involves statins exerting antimicrobial effects possibly through interference with bacterial cell processes, though exact mechanisms require further validation."
  },
  {
    "drug": "C10LE",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "C10LE enhances the potency of antibiotics such as norfloxacin against E. coli, with up to 128-fold increase.",
    "pmid": "37764086",
    "title": "Repurposing Selamectin as an Antimicrobial Drug against Hospital-Acquired Staphylococcus aureus Infections.",
    "year": "2023",
    "doi": "10.3390/microorganisms11092242",
    "mechanism": "formation of complexes with antimicrobials, disruption of bacterial membrane permeability, and inhibition of efflux pump function, leading to increased drug penetration and potency."
  },
  {
    "drug": "C12LE\u20222MeI",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "C12LE methyl iodide salt shows activity against E. coli, unlike its hydrochloride counterpart.",
    "pmid": "37764086",
    "title": "Repurposing Selamectin as an Antimicrobial Drug against Hospital-Acquired Staphylococcus aureus Infections.",
    "year": "2023",
    "doi": "10.3390/microorganisms11092242",
    "mechanism": "formation of complexes with antimicrobials, disruption of bacterial membrane permeability, and inhibition of efflux pump function, leading to increased drug penetration and potency."
  },
  {
    "drug": "C10LE",
    "pathogen": "S. aureus",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "C10LE enhances the activity of antibiotics against resistant S. aureus, including strains overexpressing NorA efflux pump.",
    "pmid": "37764086",
    "title": "Repurposing Selamectin as an Antimicrobial Drug against Hospital-Acquired Staphylococcus aureus Infections.",
    "year": "2023",
    "doi": "10.3390/microorganisms11092242",
    "mechanism": "formation of complexes with antimicrobials, disruption of bacterial membrane permeability, and inhibition of efflux pump function, leading to increased drug penetration and potency."
  },
  {
    "drug": "tafenoquine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial|anti_biofilm|efflux_inhibitor",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tafenoquine exhibits antimicrobial activity against MRSA, including planktonic cells, biofilms, and persister cells, by targeting bacterial cell membranes.",
    "pmid": "37770760",
    "title": "Systematic analysis of drug combinations against Gram-positive bacteria.",
    "year": "2023",
    "doi": "10.1038/s41564-023-01486-9",
    "mechanism": "targets bacterial cell membranes, disrupting their integrity and function"
  },
  {
    "drug": "Amphotericin B",
    "pathogen": "Rhizopus oryzae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Liposomal amphotericin B is recommended as first-line therapy for mucormycosis post-COVID-19.",
    "pmid": "37773101",
    "title": "Antibacterial and anti-corona virus (229E) activity of Nigella sativa oil combined with photodynamic therapy based on methylene blue in wound infection: in vitro and in vivo study.",
    "year": "2023",
    "doi": "10.1186/s12866-023-03018-1",
    "mechanism": "The antifungal agents target fungal cell membrane integrity and inhibit ergosterol synthesis, leading to fungal cell death."
  },
  {
    "drug": "Posaconazole",
    "pathogen": "Rhizopus oryzae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Posaconazole is used as an alternative antifungal treatment for mucormycosis.",
    "pmid": "37773101",
    "title": "Antibacterial and anti-corona virus (229E) activity of Nigella sativa oil combined with photodynamic therapy based on methylene blue in wound infection: in vitro and in vivo study.",
    "year": "2023",
    "doi": "10.1186/s12866-023-03018-1",
    "mechanism": "The antifungal agents target fungal cell membrane integrity and inhibit ergosterol synthesis, leading to fungal cell death."
  },
  {
    "drug": "Isavuconazole",
    "pathogen": "Rhizopus oryzae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Isavuconazole is administered orally for mucormycosis management.",
    "pmid": "37773101",
    "title": "Antibacterial and anti-corona virus (229E) activity of Nigella sativa oil combined with photodynamic therapy based on methylene blue in wound infection: in vitro and in vivo study.",
    "year": "2023",
    "doi": "10.1186/s12866-023-03018-1",
    "mechanism": "The antifungal agents target fungal cell membrane integrity and inhibit ergosterol synthesis, leading to fungal cell death."
  },
  {
    "drug": "Nigella sativa oil",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 12.5,
    "fici": null,
    "key_result": "Nigella sativa oil inhibited S. aureus with a MIC of 12.5%",
    "pmid": "37907954",
    "title": "The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.",
    "year": "2023",
    "doi": "10.1186/s13071-023-05909-8",
    "mechanism": "Nigella sativa oil exhibits antibacterial and antiviral activity, possibly through phytochemicals with antimicrobial properties; methylene blue acts as a photosensitizer generating reactive oxygen species upon light activation, leading to microbial inactivation and tissue regeneration."
  },
  {
    "drug": "methylene blue",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Methylene blue-based photodynamic therapy (MB-PDT) effectively reduced bacterial counts and accelerated wound healing",
    "pmid": "37907954",
    "title": "The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.",
    "year": "2023",
    "doi": "10.1186/s13071-023-05909-8",
    "mechanism": "Nigella sativa oil exhibits antibacterial and antiviral activity, possibly through phytochemicals with antimicrobial properties; methylene blue acts as a photosensitizer generating reactive oxygen species upon light activation, leading to microbial inactivation and tissue regeneration."
  },
  {
    "drug": "Nigella sativa oil + methylene blue",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combined therapy (NS oil + MB-PDT) showed the most effective wound healing and bacterial reduction",
    "pmid": "37907954",
    "title": "The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.",
    "year": "2023",
    "doi": "10.1186/s13071-023-05909-8",
    "mechanism": "Nigella sativa oil exhibits antibacterial and antiviral activity, possibly through phytochemicals with antimicrobial properties; methylene blue acts as a photosensitizer generating reactive oxygen species upon light activation, leading to microbial inactivation and tissue regeneration."
  },
  {
    "drug": "Simeprevir",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "synergy",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Simeprevir significantly enhances the antibacterial activity of polymyxins against MRSA in vitro and in vivo.",
    "pmid": "37917339",
    "title": "Simeprevir restores the anti-Staphylococcus activity of polymyxins.",
    "year": "2023",
    "doi": "10.1186/s13568-023-01634-8",
    "mechanism": "Simeprevir enhances the destruction of MRSA cell membrane, disrupting membrane integrity and increasing susceptibility to polymyxins."
  },
  {
    "drug": "Polymyxin B sulfate",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Polymyxins alone have limited activity against MRSA but show synergistic effects when combined with simeprevir.",
    "pmid": "37917339",
    "title": "Simeprevir restores the anti-Staphylococcus activity of polymyxins.",
    "year": "2023",
    "doi": "10.1186/s13568-023-01634-8",
    "mechanism": "Simeprevir enhances the destruction of MRSA cell membrane, disrupting membrane integrity and increasing susceptibility to polymyxins."
  },
  {
    "drug": "Colistin (Polymyxin E)",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Colistin combined with simeprevir exhibits enhanced activity against MRSA, especially in biofilm and persister cell models.",
    "pmid": "37917339",
    "title": "Simeprevir restores the anti-Staphylococcus activity of polymyxins.",
    "year": "2023",
    "doi": "10.1186/s13568-023-01634-8",
    "mechanism": "Simeprevir enhances the destruction of MRSA cell membrane, disrupting membrane integrity and increasing susceptibility to polymyxins."
  },
  {
    "drug": "amlodipine",
    "pathogen": "Sporothrix brasiliensis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 32,
    "fici": null,
    "key_result": "Amlodipine showed inhibitory and fungicidal activity against all isolates, with MICs ranging from 32 to 256 \u00b5g/mL.",
    "pmid": "38032179",
    "title": "Antiparasitic nitazoxanide potentiates colistin against colistin-resistant Acinetobacter baumannii and Escherichia coli in vitro and in vivo.",
    "year": "2024",
    "doi": "10.1128/spectrum.02295-23",
    "mechanism": "Amlodipine likely inhibits fungal efflux pumps, enhancing antifungal activity; lufenuron targets chitin synthesis but was ineffective alone, possibly acting as an adjuvant."
  },
  {
    "drug": "Lufenuron",
    "pathogen": "Sporothrix brasiliensis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Lufenuron did not inhibit any S. brasiliensis isolates at tested concentrations.",
    "pmid": "38032179",
    "title": "Antiparasitic nitazoxanide potentiates colistin against colistin-resistant Acinetobacter baumannii and Escherichia coli in vitro and in vivo.",
    "year": "2024",
    "doi": "10.1128/spectrum.02295-23",
    "mechanism": "Amlodipine likely inhibits fungal efflux pumps, enhancing antifungal activity; lufenuron targets chitin synthesis but was ineffective alone, possibly acting as an adjuvant."
  },
  {
    "drug": "Itraconazole",
    "pathogen": "Sporothrix brasiliensis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.125,
    "fici": null,
    "key_result": "Itraconazole exhibited MIC values ranging from 0.125 to 1 \u00b5g/mL, with some isolates showing non-wild type resistance.",
    "pmid": "38032179",
    "title": "Antiparasitic nitazoxanide potentiates colistin against colistin-resistant Acinetobacter baumannii and Escherichia coli in vitro and in vivo.",
    "year": "2024",
    "doi": "10.1128/spectrum.02295-23",
    "mechanism": "Amlodipine likely inhibits fungal efflux pumps, enhancing antifungal activity; lufenuron targets chitin synthesis but was ineffective alone, possibly acting as an adjuvant."
  },
  {
    "drug": "Amlodipine + Itraconazole",
    "pathogen": "Sporothrix brasiliensis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Synergic interaction observed in 50% of isolates, with increased activity when combined.",
    "pmid": "38032179",
    "title": "Antiparasitic nitazoxanide potentiates colistin against colistin-resistant Acinetobacter baumannii and Escherichia coli in vitro and in vivo.",
    "year": "2024",
    "doi": "10.1128/spectrum.02295-23",
    "mechanism": "Amlodipine likely inhibits fungal efflux pumps, enhancing antifungal activity; lufenuron targets chitin synthesis but was ineffective alone, possibly acting as an adjuvant."
  },
  {
    "drug": "Lufenuron + Itraconazole",
    "pathogen": "Sporothrix brasiliensis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Beneficial interaction in 40% of isolates, though lufenuron alone was ineffective.",
    "pmid": "38032179",
    "title": "Antiparasitic nitazoxanide potentiates colistin against colistin-resistant Acinetobacter baumannii and Escherichia coli in vitro and in vivo.",
    "year": "2024",
    "doi": "10.1128/spectrum.02295-23",
    "mechanism": "Amlodipine likely inhibits fungal efflux pumps, enhancing antifungal activity; lufenuron targets chitin synthesis but was ineffective alone, possibly acting as an adjuvant."
  },
  {
    "drug": "Nitazoxanide",
    "pathogen": "A. baumannii",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.25,
    "key_result": "Nitazoxanide combined with colistin exhibits a synergistic antibacterial effect against colistin-resistant A. baumannii.",
    "pmid": "38047647",
    "title": "Repurposing of the antimalarial agent tafenoquine to combat MRSA.",
    "year": "2023",
    "doi": "10.1128/msystems.01026-23",
    "mechanism": "Nitazoxanide enhances colistin activity possibly by efflux pump inhibition and biofilm disruption, restoring colistin susceptibility in resistant strains."
  },
  {
    "drug": "Nitazoxanide",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.25,
    "key_result": "Nitazoxanide combined with colistin exhibits a synergistic antibacterial effect against colistin-resistant E. coli.",
    "pmid": "38047647",
    "title": "Repurposing of the antimalarial agent tafenoquine to combat MRSA.",
    "year": "2023",
    "doi": "10.1128/msystems.01026-23",
    "mechanism": "Nitazoxanide enhances colistin activity possibly by efflux pump inhibition and biofilm disruption, restoring colistin susceptibility in resistant strains."
  },
  {
    "drug": "Nitazoxanide",
    "pathogen": "A. baumannii",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 128,
    "fici": null,
    "key_result": "The combination of NTZ and colistin significantly inhibits biofilm formation and eradicates established biofilms of COL-R A. baumannii.",
    "pmid": "38047647",
    "title": "Repurposing of the antimalarial agent tafenoquine to combat MRSA.",
    "year": "2023",
    "doi": "10.1128/msystems.01026-23",
    "mechanism": "Nitazoxanide enhances colistin activity possibly by efflux pump inhibition and biofilm disruption, restoring colistin susceptibility in resistant strains."
  },
  {
    "drug": "Nitazoxanide",
    "pathogen": "E. coli",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 128,
    "fici": null,
    "key_result": "The combination of NTZ and colistin significantly inhibits biofilm formation and eradicates established biofilms of COL-R E. coli.",
    "pmid": "38047647",
    "title": "Repurposing of the antimalarial agent tafenoquine to combat MRSA.",
    "year": "2023",
    "doi": "10.1128/msystems.01026-23",
    "mechanism": "Nitazoxanide enhances colistin activity possibly by efflux pump inhibition and biofilm disruption, restoring colistin susceptibility in resistant strains."
  },
  {
    "drug": "Nitazoxanide",
    "pathogen": "A. baumannii",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The combination restores colistin susceptibility, possibly by inhibiting efflux mechanisms.",
    "pmid": "38047647",
    "title": "Repurposing of the antimalarial agent tafenoquine to combat MRSA.",
    "year": "2023",
    "doi": "10.1128/msystems.01026-23",
    "mechanism": "Nitazoxanide enhances colistin activity possibly by efflux pump inhibition and biofilm disruption, restoring colistin susceptibility in resistant strains."
  },
  {
    "drug": "Nitazoxanide",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The combination restores colistin susceptibility, possibly by inhibiting efflux mechanisms.",
    "pmid": "38047647",
    "title": "Repurposing of the antimalarial agent tafenoquine to combat MRSA.",
    "year": "2023",
    "doi": "10.1128/msystems.01026-23",
    "mechanism": "Nitazoxanide enhances colistin activity possibly by efflux pump inhibition and biofilm disruption, restoring colistin susceptibility in resistant strains."
  },
  {
    "drug": "compound 3h",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 16,
    "fici": null,
    "key_result": "Compound 3h showed MIC of 16 \u00b5g/mL against S. aureus ATCC 25923.",
    "pmid": "38049492",
    "title": "In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches.",
    "year": "2023",
    "doi": "10.1038/s41598-023-48398-6",
    "mechanism": "The compound 3h damages nuclear DNA, triggers apoptosis, and inhibits cellular migration in cancer cells; antimicrobial activity likely involves disruption of bacterial and fungal cell structures or functions."
  },
  {
    "drug": "compound 3h",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 32,
    "fici": null,
    "key_result": "Compound 3h exhibited MIC of 32 \u00b5g/mL against E. faecium.",
    "pmid": "38049492",
    "title": "In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches.",
    "year": "2023",
    "doi": "10.1038/s41598-023-48398-6",
    "mechanism": "The compound 3h damages nuclear DNA, triggers apoptosis, and inhibits cellular migration in cancer cells; antimicrobial activity likely involves disruption of bacterial and fungal cell structures or functions."
  },
  {
    "drug": "compound 3h",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 32,
    "fici": null,
    "key_result": "Compound 3h showed MIC of 32 \u00b5g/mL against K. pneumoniae.",
    "pmid": "38049492",
    "title": "In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches.",
    "year": "2023",
    "doi": "10.1038/s41598-023-48398-6",
    "mechanism": "The compound 3h damages nuclear DNA, triggers apoptosis, and inhibits cellular migration in cancer cells; antimicrobial activity likely involves disruption of bacterial and fungal cell structures or functions."
  },
  {
    "drug": "compound 3h",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 32,
    "fici": null,
    "key_result": "Compound 3h demonstrated MIC of 32 \u00b5g/mL against P. aeruginosa.",
    "pmid": "38049492",
    "title": "In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches.",
    "year": "2023",
    "doi": "10.1038/s41598-023-48398-6",
    "mechanism": "The compound 3h damages nuclear DNA, triggers apoptosis, and inhibits cellular migration in cancer cells; antimicrobial activity likely involves disruption of bacterial and fungal cell structures or functions."
  },
  {
    "drug": "N,N-Diethyldithiocarbamate (DDC)",
    "pathogen": "Ureaplasma urealyticum",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "DDC exhibits both bacteriostatic and bactericidal activity against Ureaplasma urealyticum in vitro at concentrations of 2-200 \u00b5g/mL.",
    "pmid": "38136685",
    "title": "Benzothiazole-Phthalimide Hybrids as Anti-Breast Cancer and Antimicrobial Agents.",
    "year": "2023",
    "doi": "10.3390/antibiotics12121651",
    "mechanism": "not explicitly proposed in the paper"
  },
  {
    "drug": "N,N-Diethyldithiocarbamate (DDC)",
    "pathogen": "Ureaplasma parvum",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "DDC shows bacteriostatic and bactericidal effects against Ureaplasma parvum in vitro at concentrations of 2-200 \u00b5g/mL.",
    "pmid": "38136685",
    "title": "Benzothiazole-Phthalimide Hybrids as Anti-Breast Cancer and Antimicrobial Agents.",
    "year": "2023",
    "doi": "10.3390/antibiotics12121651",
    "mechanism": "not explicitly proposed in the paper"
  },
  {
    "drug": "AKBA",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 4,
    "fici": null,
    "key_result": "AKBA exhibits effective antimicrobial activity against MRSA with MIC of 4-8 \u00b5g/mL and no detectable resistance after 20 days of passage.",
    "pmid": "38143555",
    "title": "Small molecular adjuvants repurpose antibiotics towards Gram-negative bacterial infections and multispecies bacterial biofilms.",
    "year": "2023",
    "doi": "10.1039/d3sc05124b",
    "mechanism": "Proposed mechanism involves direct antimicrobial activity, biofilm disruption, and synergy with conventional antibiotics, potentially through membrane interaction or stress response modulation."
  },
  {
    "drug": "AKBA",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "AKBA shows synergistic effects with gentamycin and amikacin against S. aureus and clinical isolates.",
    "pmid": "38143555",
    "title": "Small molecular adjuvants repurpose antibiotics towards Gram-negative bacterial infections and multispecies bacterial biofilms.",
    "year": "2023",
    "doi": "10.1039/d3sc05124b",
    "mechanism": "Proposed mechanism involves direct antimicrobial activity, biofilm disruption, and synergy with conventional antibiotics, potentially through membrane interaction or stress response modulation."
  },
  {
    "drug": "AKBA",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "AKBA exhibits strong biofilm inhibitory and eradication effects at 1-4 \u00b5g/mL.",
    "pmid": "38143555",
    "title": "Small molecular adjuvants repurpose antibiotics towards Gram-negative bacterial infections and multispecies bacterial biofilms.",
    "year": "2023",
    "doi": "10.1039/d3sc05124b",
    "mechanism": "Proposed mechanism involves direct antimicrobial activity, biofilm disruption, and synergy with conventional antibiotics, potentially through membrane interaction or stress response modulation."
  },
  {
    "drug": "AKBA",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo mouse model confirms effective antimicrobial activity of AKBA with no detectable toxicity.",
    "pmid": "38143555",
    "title": "Small molecular adjuvants repurpose antibiotics towards Gram-negative bacterial infections and multispecies bacterial biofilms.",
    "year": "2023",
    "doi": "10.1039/d3sc05124b",
    "mechanism": "Proposed mechanism involves direct antimicrobial activity, biofilm disruption, and synergy with conventional antibiotics, potentially through membrane interaction or stress response modulation."
  },
  {
    "drug": "AKBA",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "anti_persister",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "AKBA effectively kills S. aureus persister cells at 1-8\u00d7MIC concentrations.",
    "pmid": "38143555",
    "title": "Small molecular adjuvants repurpose antibiotics towards Gram-negative bacterial infections and multispecies bacterial biofilms.",
    "year": "2023",
    "doi": "10.1039/d3sc05124b",
    "mechanism": "Proposed mechanism involves direct antimicrobial activity, biofilm disruption, and synergy with conventional antibiotics, potentially through membrane interaction or stress response modulation."
  },
  {
    "drug": "auranofin",
    "pathogen": "Burkholderia cenocepacia",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin inhibits thioredoxin reductase in B. cenocepacia but is inactive against GOR, and its activity may be limited by cell envelope permeability.",
    "pmid": "38169981",
    "title": "Ebselen Optimized the Therapeutic Effects of Silver Nanoparticles for Periodontal Treatment.",
    "year": "2023",
    "doi": "10.2147/IJN.S434579",
    "mechanism": "Inhibition of thioredoxin reductase leading to increased reactive oxygen species (ROS) and oxidative stress in bacteria, with the glutathione system providing protective effects."
  },
  {
    "drug": "MS-40",
    "pathogen": "Burkholderia cenocepacia",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MS-40 inhibits thioredoxin reductase and induces ROS in B. cenocepacia, leading to bactericidal activity.",
    "pmid": "38169981",
    "title": "Ebselen Optimized the Therapeutic Effects of Silver Nanoparticles for Periodontal Treatment.",
    "year": "2023",
    "doi": "10.2147/IJN.S434579",
    "mechanism": "Inhibition of thioredoxin reductase leading to increased reactive oxygen species (ROS) and oxidative stress in bacteria, with the glutathione system providing protective effects."
  },
  {
    "drug": "MS-40S",
    "pathogen": "Burkholderia cenocepacia",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MS-40S inhibits thioredoxin reductase and induces ROS in B. cenocepacia, resulting in bactericidal effects.",
    "pmid": "38169981",
    "title": "Ebselen Optimized the Therapeutic Effects of Silver Nanoparticles for Periodontal Treatment.",
    "year": "2023",
    "doi": "10.2147/IJN.S434579",
    "mechanism": "Inhibition of thioredoxin reductase leading to increased reactive oxygen species (ROS) and oxidative stress in bacteria, with the glutathione system providing protective effects."
  },
  {
    "drug": "MS-40",
    "pathogen": "Burkholderia cenocepacia",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "genetic",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Genetic disruption of glutathione biosynthesis genes increases susceptibility to MS-40, indicating involvement of ROS detoxification pathways.",
    "pmid": "38169981",
    "title": "Ebselen Optimized the Therapeutic Effects of Silver Nanoparticles for Periodontal Treatment.",
    "year": "2023",
    "doi": "10.2147/IJN.S434579",
    "mechanism": "Inhibition of thioredoxin reductase leading to increased reactive oxygen species (ROS) and oxidative stress in bacteria, with the glutathione system providing protective effects."
  },
  {
    "drug": "MS-40S",
    "pathogen": "Burkholderia cenocepacia",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "genetic",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Disruption of glutathione biosynthesis genes increases susceptibility to MS-40S, supporting ROS-mediated killing.",
    "pmid": "38169981",
    "title": "Ebselen Optimized the Therapeutic Effects of Silver Nanoparticles for Periodontal Treatment.",
    "year": "2023",
    "doi": "10.2147/IJN.S434579",
    "mechanism": "Inhibition of thioredoxin reductase leading to increased reactive oxygen species (ROS) and oxidative stress in bacteria, with the glutathione system providing protective effects."
  },
  {
    "drug": "ebselen",
    "pathogen": "Porphyromonas gingivalis",
    "activity_type": "direct_antibacterial|anti_biofilm|adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen enhances the antibacterial and antibiofilm effects of silver nanoparticles against P. gingivalis and F. nucleatum.",
    "pmid": "38252641",
    "title": "Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.",
    "year": "2024",
    "doi": "10.1371/journal.pone.0295627",
    "mechanism": "Ebselen inhibits bacterial thioredoxin reductase, disrupting ROS scavenging in bacteria, while acting as a glutathione peroxidase mimic in mammalian cells, reducing oxidative stress. AgNPs induce bacterial membrane damage and ROS production, leading to bacterial death. The combination enhances antibacterial efficacy and reduces oxidative damage in host cells."
  },
  {
    "drug": "ebselen",
    "pathogen": "Porphyromonas gingivalis",
    "activity_type": "adjuvant|anti_inflammatory",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen combined with AgNPs reduces inflammatory cytokine release and alveolar bone resorption in periodontal models.",
    "pmid": "38252641",
    "title": "Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.",
    "year": "2024",
    "doi": "10.1371/journal.pone.0295627",
    "mechanism": "Ebselen inhibits bacterial thioredoxin reductase, disrupting ROS scavenging in bacteria, while acting as a glutathione peroxidase mimic in mammalian cells, reducing oxidative stress. AgNPs induce bacterial membrane damage and ROS production, leading to bacterial death. The combination enhances antibacterial efficacy and reduces oxidative damage in host cells."
  },
  {
    "drug": "Silver nanoparticles (AgNPs)",
    "pathogen": "Porphyromonas gingivalis",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "AgNPs exhibit excellent antibacterial and antibiofilm effects against periodontal pathogens.",
    "pmid": "38252641",
    "title": "Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.",
    "year": "2024",
    "doi": "10.1371/journal.pone.0295627",
    "mechanism": "Ebselen inhibits bacterial thioredoxin reductase, disrupting ROS scavenging in bacteria, while acting as a glutathione peroxidase mimic in mammalian cells, reducing oxidative stress. AgNPs induce bacterial membrane damage and ROS production, leading to bacterial death. The combination enhances antibacterial efficacy and reduces oxidative damage in host cells."
  },
  {
    "drug": "Silver nanoparticles (AgNPs)",
    "pathogen": "Porphyromonas gingivalis",
    "activity_type": "intracellular_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 5,
    "fici": null,
    "key_result": "AgNPs can kill intracellular P. gingivalis within human gingival fibroblasts, especially when combined with ebselen.",
    "pmid": "38252641",
    "title": "Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.",
    "year": "2024",
    "doi": "10.1371/journal.pone.0295627",
    "mechanism": "Ebselen inhibits bacterial thioredoxin reductase, disrupting ROS scavenging in bacteria, while acting as a glutathione peroxidase mimic in mammalian cells, reducing oxidative stress. AgNPs induce bacterial membrane damage and ROS production, leading to bacterial death. The combination enhances antibacterial efficacy and reduces oxidative damage in host cells."
  },
  {
    "drug": "fusidic acid",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "FA MICs against standard strains were 2 \u00b5g/mL, and 98 clinical isolates had MICs \u22648 \u00b5g/mL, suggesting susceptibility at high serum levels.",
    "pmid": "38259963",
    "title": "In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota.",
    "year": "2023",
    "doi": "10.3389/fcimb.2023.1306430",
    "mechanism": "Inhibition of protein synthesis by binding to elongation factor G (EF-G), preventing peptide translocation."
  },
  {
    "drug": "fusidic acid",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 4,
    "fici": null,
    "key_result": "FA MICs against standard strains were 4 \u00b5g/mL, indicating potential activity at elevated serum concentrations.",
    "pmid": "38259963",
    "title": "In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota.",
    "year": "2023",
    "doi": "10.3389/fcimb.2023.1306430",
    "mechanism": "Inhibition of protein synthesis by binding to elongation factor G (EF-G), preventing peptide translocation."
  },
  {
    "drug": "fusidic acid",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo, FA significantly reduced bacterial burden in mice infected with enterococci, including resistant strains.",
    "pmid": "38259963",
    "title": "In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota.",
    "year": "2023",
    "doi": "10.3389/fcimb.2023.1306430",
    "mechanism": "Inhibition of protein synthesis by binding to elongation factor G (EF-G), preventing peptide translocation."
  },
  {
    "drug": "fusidic acid",
    "pathogen": "E. faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "FA treatment decreased bacterial load in infected mice, demonstrating in vivo efficacy.",
    "pmid": "38259963",
    "title": "In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota.",
    "year": "2023",
    "doi": "10.3389/fcimb.2023.1306430",
    "mechanism": "Inhibition of protein synthesis by binding to elongation factor G (EF-G), preventing peptide translocation."
  },
  {
    "drug": "fusidic acid",
    "pathogen": "E. faecalis",
    "activity_type": "resistance_development",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 128,
    "fici": null,
    "key_result": "Serial exposure to increasing FA concentrations led to resistant strains with MICs of 128 \u00b5g/mL, thicker cell walls, and slower growth.",
    "pmid": "38259963",
    "title": "In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota.",
    "year": "2023",
    "doi": "10.3389/fcimb.2023.1306430",
    "mechanism": "Inhibition of protein synthesis by binding to elongation factor G (EF-G), preventing peptide translocation."
  },
  {
    "drug": "fusidic acid",
    "pathogen": "E. faecium",
    "activity_type": "resistance_development",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 128,
    "fici": null,
    "key_result": "Resistance emerged after serial passage, with a mutation (M651I) in fusA gene, but revertant strains retained this mutation.",
    "pmid": "38259963",
    "title": "In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota.",
    "year": "2023",
    "doi": "10.3389/fcimb.2023.1306430",
    "mechanism": "Inhibition of protein synthesis by binding to elongation factor G (EF-G), preventing peptide translocation."
  },
  {
    "drug": "oxethazine",
    "pathogen": "Gram-negative bacteria",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": 0.25,
    "key_result": "Oxethazine significantly enhances the antibacterial activity of colistin against MDR Gram-negative pathogens through membrane disruption and ROS accumulation.",
    "pmid": "38275586",
    "title": "Ezetimibe Induces Paraptosis through Niemann-Pick C1-like 1 Inhibition of Mammalian-Target-of-Rapamycin Signaling in Hepatocellular Carcinoma Cells.",
    "year": "2023",
    "doi": "10.3390/genes15010004",
    "mechanism": "Oxethazine improves colistin's ability to disrupt bacterial outer and cytoplasmic membranes, increases membrane permeability, and induces reactive oxygen species accumulation, leading to bacterial cell death."
  },
  {
    "drug": "l-thyroxine",
    "pathogen": "S. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 64,
    "fici": null,
    "key_result": "l-thyroxine specifically inhibits the growth of Streptococcus pneumoniae with MIC of 64 \u03bcg/mL.",
    "pmid": "38295025",
    "title": "Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans.",
    "year": "2024",
    "doi": "10.1021/acsinfecdis.3c00371",
    "mechanism": "binding to bacterial flavodoxin, disrupting electron transfer processes essential for bacterial growth"
  },
  {
    "drug": "3,5,3\u2032,5\u2032-tetraiodo thyroacetic acid",
    "pathogen": "S. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 64,
    "fici": null,
    "key_result": "analogues with a carboxyl group show similar activity against Sp with MIC of 64 \u03bcg/mL.",
    "pmid": "38295025",
    "title": "Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans.",
    "year": "2024",
    "doi": "10.1021/acsinfecdis.3c00371",
    "mechanism": "binding to bacterial flavodoxin, disrupting electron transfer processes essential for bacterial growth"
  },
  {
    "drug": "3,3\u2032,5-triiodo thyropropionic acid",
    "pathogen": "S. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 64,
    "fici": null,
    "key_result": "analogues lacking iodine on the distal ring also show activity at MIC 64 \u03bcg/mL.",
    "pmid": "38295025",
    "title": "Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans.",
    "year": "2024",
    "doi": "10.1021/acsinfecdis.3c00371",
    "mechanism": "binding to bacterial flavodoxin, disrupting electron transfer processes essential for bacterial growth"
  },
  {
    "drug": "harmaline",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant|efflux_inhibitor",
    "evidence_type": "in_vitro|in_vivo|computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Harmaline synergistically potentiates tigecycline efficacy against tmexCD1-toprJ1-positive K. pneumoniae by inhibiting efflux pump function and disrupting membrane integrity.",
    "pmid": "38345040",
    "title": "ABDpred: Prediction of active antimicrobial compounds using supervised machine learning techniques.",
    "year": "2024",
    "doi": "10.4103/ijmr.ijmr_1832_22",
    "mechanism": "Harmaline interacts with TMexCD1-TOprJ1 active residues, dissipates the proton motive force, and disrupts cell membrane integrity, thereby inhibiting the efflux pump and restoring tigecycline activity."
  },
  {
    "drug": "miconazole",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Miconazole significantly inhibited P. aeruginosa virulence factors including biofilm formation, hemolytic activity, pyocyanin, rhamnolipids, and protease activities, and reduced expression of quorum sensing genes.",
    "pmid": "38373973",
    "title": "Understanding the nebulisation of antibiotics: the key role of lung microdialysis studies.",
    "year": "2024",
    "doi": "10.1186/s13054-024-04828-z",
    "mechanism": "Miconazole and phenothiazine inhibit quorum sensing-regulated virulence gene expression, reducing production of virulence factors such as biofilm, pyocyanin, hemolysin, rhamnolipids, and proteases, likely through interference with QS-proteins LasR, RhlR, and PqsR."
  },
  {
    "drug": "phenothiazine",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Phenothiazine showed moderate inhibition of P. aeruginosa virulence factors, including biofilm, pyocyanin, protease, rhamnolipids, and hemolytic activity, with less impact than miconazole.",
    "pmid": "38373973",
    "title": "Understanding the nebulisation of antibiotics: the key role of lung microdialysis studies.",
    "year": "2024",
    "doi": "10.1186/s13054-024-04828-z",
    "mechanism": "Miconazole and phenothiazine inhibit quorum sensing-regulated virulence gene expression, reducing production of virulence factors such as biofilm, pyocyanin, hemolysin, rhamnolipids, and proteases, likely through interference with QS-proteins LasR, RhlR, and PqsR."
  },
  {
    "drug": "miconazole",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Miconazole treatment resulted in 100% survival in mice infected with P. aeruginosa, indicating effective anti-virulence activity in vivo.",
    "pmid": "38373973",
    "title": "Understanding the nebulisation of antibiotics: the key role of lung microdialysis studies.",
    "year": "2024",
    "doi": "10.1186/s13054-024-04828-z",
    "mechanism": "Miconazole and phenothiazine inhibit quorum sensing-regulated virulence gene expression, reducing production of virulence factors such as biofilm, pyocyanin, hemolysin, rhamnolipids, and proteases, likely through interference with QS-proteins LasR, RhlR, and PqsR."
  },
  {
    "drug": "ebselen",
    "pathogen": "Aspergillus fumigatus",
    "activity_type": "direct_antibacterial|anti_biofilm|anti_virulence",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen inhibits A. fumigatus spore germination, reduces mycelial growth, disrupts biofilm formation, and damages fungal cell membranes via oxidative stress mechanisms.",
    "pmid": "38576480",
    "title": "The synergistic antibacterial activity and mechanism of colistin-oxethazaine combination against gram-negative pathogens.",
    "year": "2024",
    "doi": "10.3389/fphar.2024.1363441",
    "mechanism": "Inhibition of thioredoxin reductase (TrxR) leading to oxidative stress in fungi, cell membrane damage, and regulation of host inflammatory and oxidative stress pathways via PI3K/Akt/Nrf2 and p38 MAPK signaling."
  },
  {
    "drug": "ebselen",
    "pathogen": "host tissues",
    "activity_type": "anti_inflammatory|antioxidant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ebselen suppresses inflammatory mediators and reduces oxidative stress markers in infected mouse corneas, improving prognosis and decreasing fungal burden.",
    "pmid": "38576480",
    "title": "The synergistic antibacterial activity and mechanism of colistin-oxethazaine combination against gram-negative pathogens.",
    "year": "2024",
    "doi": "10.3389/fphar.2024.1363441",
    "mechanism": "Inhibition of thioredoxin reductase (TrxR) leading to oxidative stress in fungi, cell membrane damage, and regulation of host inflammatory and oxidative stress pathways via PI3K/Akt/Nrf2 and p38 MAPK signaling."
  },
  {
    "drug": "closantel",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.125,
    "fici": null,
    "key_result": "Closantel exhibits strong antibacterial activity against MRSA with MIC values ranging from 0.125 to 1.000 \u03bcg/mL.",
    "pmid": "38689973",
    "title": "L-Thyroxine and L-thyroxine-based antimicrobials against Streptococcus pneumoniae and other Gram-positive bacteria.",
    "year": "2024",
    "doi": "10.1016/j.heliyon.2024.e27982",
    "mechanism": "Closantel disrupts the integrity of S. aureus cell membranes, increasing membrane permeability and causing cell death."
  },
  {
    "drug": "closantel",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.0625,
    "fici": null,
    "key_result": "Closantel significantly inhibits biofilm formation at 0.0625 \u03bcg/mL and eradicates established biofilms at 2 \u03bcg/mL.",
    "pmid": "38689973",
    "title": "L-Thyroxine and L-thyroxine-based antimicrobials against Streptococcus pneumoniae and other Gram-positive bacteria.",
    "year": "2024",
    "doi": "10.1016/j.heliyon.2024.e27982",
    "mechanism": "Closantel disrupts the integrity of S. aureus cell membranes, increasing membrane permeability and causing cell death."
  },
  {
    "drug": "closantel",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "No data on synergy with other antibiotics provided.",
    "pmid": "38689973",
    "title": "L-Thyroxine and L-thyroxine-based antimicrobials against Streptococcus pneumoniae and other Gram-positive bacteria.",
    "year": "2024",
    "doi": "10.1016/j.heliyon.2024.e27982",
    "mechanism": "Closantel disrupts the integrity of S. aureus cell membranes, increasing membrane permeability and causing cell death."
  },
  {
    "drug": "meropenem/vaborbactam",
    "pathogen": "Enterobacterales",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Effective against KPC-producing Enterobacterales but not against carbapenem-resistant P. aeruginosa.",
    "pmid": "38724627",
    "title": "Miconazole and phenothiazine hinder the quorum sensing regulated virulence in Pseudomonas aeruginosa.",
    "year": "2024",
    "doi": "10.1038/s41429-024-00731-5",
    "mechanism": "Inhibition of \u03b2-lactamases (including serine carbapenemases and some class D enzymes) by \u03b2-lactamase inhibitors, restoring activity of \u03b2-lactam antibiotics against resistant bacteria."
  },
  {
    "drug": "ceftazidime/avibactam",
    "pathogen": "Enterobacterales",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Effective against KPC- and OXA-48-like carbapenemase producers; resistance linked to KPC mutations and porin loss.",
    "pmid": "38724627",
    "title": "Miconazole and phenothiazine hinder the quorum sensing regulated virulence in Pseudomonas aeruginosa.",
    "year": "2024",
    "doi": "10.1038/s41429-024-00731-5",
    "mechanism": "Inhibition of \u03b2-lactamases (including serine carbapenemases and some class D enzymes) by \u03b2-lactamase inhibitors, restoring activity of \u03b2-lactam antibiotics against resistant bacteria."
  },
  {
    "drug": "imipenem/relebactam",
    "pathogen": "Enterobacterales",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Effective against certain carbapenemase producers; resistance associated with non-inhibited carbapenemases and porin mutations.",
    "pmid": "38724627",
    "title": "Miconazole and phenothiazine hinder the quorum sensing regulated virulence in Pseudomonas aeruginosa.",
    "year": "2024",
    "doi": "10.1038/s41429-024-00731-5",
    "mechanism": "Inhibition of \u03b2-lactamases (including serine carbapenemases and some class D enzymes) by \u03b2-lactamase inhibitors, restoring activity of \u03b2-lactam antibiotics against resistant bacteria."
  },
  {
    "drug": "ceftolozane/tazobactam",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Active against P. aeruginosa with certain resistance mechanisms; compromised by ESBLs and carbapenemases.",
    "pmid": "38724627",
    "title": "Miconazole and phenothiazine hinder the quorum sensing regulated virulence in Pseudomonas aeruginosa.",
    "year": "2024",
    "doi": "10.1038/s41429-024-00731-5",
    "mechanism": "Inhibition of \u03b2-lactamases (including serine carbapenemases and some class D enzymes) by \u03b2-lactamase inhibitors, restoring activity of \u03b2-lactam antibiotics against resistant bacteria."
  },
  {
    "drug": "Ribavirin",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ribavirin exhibits antimicrobial activity against P. aeruginosa by perturbing its virulence system without inhibiting growth.",
    "pmid": "38765678",
    "title": "Synergistic antibacterial effects of closantel and its enantiomers in combination with colistin against multidrug resistant gram-negative bacteria.",
    "year": "2024",
    "doi": "10.3389/fmicb.2024.1374910",
    "mechanism": "Perturbation of microbial virulence systems without killing or inhibiting growth, disarming pathogens and potentially preventing resistance development."
  },
  {
    "drug": "MK-3207",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MK-3207 demonstrated high binding affinity to RND efflux pump proteins, suggesting potential as a repurposed inhibitor.",
    "pmid": "38796864",
    "title": "Ebselen improves fungal keratitis through exerting anti-inflammation, anti-oxidative stress, and antifungal effects.",
    "year": "2024",
    "doi": "10.1016/j.redox.2024.103206",
    "mechanism": "binding and inhibition of RND efflux pump proteins, disrupting antibiotic resistance mechanisms"
  },
  {
    "drug": "R-428",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "R-428 showed effective binding to RND proteins, indicating possible inhibitory activity against P. aeruginosa efflux mechanisms.",
    "pmid": "38796864",
    "title": "Ebselen improves fungal keratitis through exerting anti-inflammation, anti-oxidative stress, and antifungal effects.",
    "year": "2024",
    "doi": "10.1016/j.redox.2024.103206",
    "mechanism": "binding and inhibition of RND efflux pump proteins, disrupting antibiotic resistance mechanisms"
  },
  {
    "drug": "Suramin",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Suramin exhibited superior binding energies to RND efflux proteins, supporting its potential for repurposing as an antimicrobial agent.",
    "pmid": "38796864",
    "title": "Ebselen improves fungal keratitis through exerting anti-inflammation, anti-oxidative stress, and antifungal effects.",
    "year": "2024",
    "doi": "10.1016/j.redox.2024.103206",
    "mechanism": "binding and inhibition of RND efflux pump proteins, disrupting antibiotic resistance mechanisms"
  },
  {
    "drug": "Zidovudine",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Zidovudine synergized with nitrofurantoin and omadacycline against MDR K. pneumoniae in vitro.",
    "pmid": "38904380",
    "title": "Nitazoxanide synergizes polymyxin B against Escherichia coli by depleting cellular energy.",
    "year": "2024",
    "doi": "10.1128/spectrum.00191-24",
    "mechanism": "Zidovudine may incorporate into bacterial DNA as a chain terminator, disrupting DNA synthesis, and synergize with antibiotics by increasing intracellular antibiotic concentrations or targeting bacterial DNA replication."
  },
  {
    "drug": "Nitrofurantoin",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nitrofurantoin combined with zidovudine showed synergistic activity against MDR K. pneumoniae in vitro.",
    "pmid": "38904380",
    "title": "Nitazoxanide synergizes polymyxin B against Escherichia coli by depleting cellular energy.",
    "year": "2024",
    "doi": "10.1128/spectrum.00191-24",
    "mechanism": "Zidovudine may incorporate into bacterial DNA as a chain terminator, disrupting DNA synthesis, and synergize with antibiotics by increasing intracellular antibiotic concentrations or targeting bacterial DNA replication."
  },
  {
    "drug": "Omadacycline",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Omadacycline combined with zidovudine demonstrated synergy against MDR K. pneumoniae in vitro.",
    "pmid": "38904380",
    "title": "Nitazoxanide synergizes polymyxin B against Escherichia coli by depleting cellular energy.",
    "year": "2024",
    "doi": "10.1128/spectrum.00191-24",
    "mechanism": "Zidovudine may incorporate into bacterial DNA as a chain terminator, disrupting DNA synthesis, and synergize with antibiotics by increasing intracellular antibiotic concentrations or targeting bacterial DNA replication."
  },
  {
    "drug": "Zidovudine",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Zidovudine enhances the activity of antibiotics against MDR K. pneumoniae in murine infection models.",
    "pmid": "38904380",
    "title": "Nitazoxanide synergizes polymyxin B against Escherichia coli by depleting cellular energy.",
    "year": "2024",
    "doi": "10.1128/spectrum.00191-24",
    "mechanism": "Zidovudine may incorporate into bacterial DNA as a chain terminator, disrupting DNA synthesis, and synergize with antibiotics by increasing intracellular antibiotic concentrations or targeting bacterial DNA replication."
  },
  {
    "drug": "Fosfomycin",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 32,
    "fici": null,
    "key_result": "Most CRKP isolates were sensitive to fosfomycin with 86% susceptibility.",
    "pmid": "39019790",
    "title": "Antibacterial activity of closantel against methicillin-resistant Staphylococcus aureus and itsbiofilm.",
    "year": "2024",
    "doi": "10.11817/j.issn.1672-7347.2024.230442",
    "mechanism": "The proposed mechanism involves the combination of fosfomycin's inhibition of bacterial cell wall synthesis with colistin's disruption of the outer membrane, resulting in enhanced antibacterial activity against resistant bacteria."
  },
  {
    "drug": "colistin",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "Colistin showed high resistance (46%) among CRKP isolates by BMD testing.",
    "pmid": "39019790",
    "title": "Antibacterial activity of closantel against methicillin-resistant Staphylococcus aureus and itsbiofilm.",
    "year": "2024",
    "doi": "10.11817/j.issn.1672-7347.2024.230442",
    "mechanism": "The proposed mechanism involves the combination of fosfomycin's inhibition of bacterial cell wall synthesis with colistin's disruption of the outer membrane, resulting in enhanced antibacterial activity against resistant bacteria."
  },
  {
    "drug": "Fosfomycin + Colistin",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "72% of CRKP isolates demonstrated synergistic effect with the combination.",
    "pmid": "39019790",
    "title": "Antibacterial activity of closantel against methicillin-resistant Staphylococcus aureus and itsbiofilm.",
    "year": "2024",
    "doi": "10.11817/j.issn.1672-7347.2024.230442",
    "mechanism": "The proposed mechanism involves the combination of fosfomycin's inhibition of bacterial cell wall synthesis with colistin's disruption of the outer membrane, resulting in enhanced antibacterial activity against resistant bacteria."
  },
  {
    "drug": "Tavaborole",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "Tavaborole exhibited antimicrobial activity with an MIC of 2 \u03bcg/ml against A. baumannii and reduced biofilm biomass at 16 \u03bcg/ml.",
    "pmid": "39052707",
    "title": "Steroid Drugs Inhibit Bacterial Respiratory Oxidases and Are Lethal Toward Methicillin-Resistant Staphylococcus aureus.",
    "year": "2024",
    "doi": "10.1093/infdis/jiad540",
    "mechanism": "Inhibition of leucyl-tRNA synthetase, disrupting protein synthesis in A. baumannii."
  },
  {
    "drug": "auranofin",
    "pathogen": "Clostridioides difficile",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.75,
    "fici": null,
    "key_result": "Auranofin exhibits bactericidal activity against C. difficile with a MIC of 0.75 \u00b5g/mL, and TrxB genes are involved in its tolerance.",
    "pmid": "39061334",
    "title": "The Many Lives of Auranofin: How an Old Anti-Rheumatic Agent May Become a Promising Antimicrobial Drug.",
    "year": "2024",
    "doi": "10.3390/antibiotics13070652",
    "mechanism": "Inhibition of bacterial thioredoxin reductases (TrxB), affecting thiol homeostasis and stress response pathways, particularly involving sigma factor \u03c3B and related adaptive mutations."
  },
  {
    "drug": "auranofin",
    "pathogen": "Clostridioides difficile",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mutations in the anti-sigma factor of \u03c3B and adaptive mutations in stress response genes are associated with resistance development.",
    "pmid": "39061334",
    "title": "The Many Lives of Auranofin: How an Old Anti-Rheumatic Agent May Become a Promising Antimicrobial Drug.",
    "year": "2024",
    "doi": "10.3390/antibiotics13070652",
    "mechanism": "Inhibition of bacterial thioredoxin reductases (TrxB), affecting thiol homeostasis and stress response pathways, particularly involving sigma factor \u03c3B and related adaptive mutations."
  },
  {
    "drug": "niclosamide",
    "pathogen": "SARS-CoV",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide inhibits viral replication of SARS-CoV in vitro.",
    "pmid": "39125594",
    "title": "From Proteome to Potential Drugs: Integration of Subtractive Proteomics and Ensemble Docking for Drug Repurposing against Pseudomonas aeruginosa RND Superfamily Proteins.",
    "year": "2024",
    "doi": "10.3390/ijms25158027",
    "mechanism": "Potentially involves blocking multiple pathways (WNT/b-catenin, mTORC1, Stat3, NF-kB, Notch) and inducing cell-cycle arrest through targeting mitochondrial enzymes, as well as disrupting viral replication mechanisms."
  },
  {
    "drug": "niclosamide",
    "pathogen": "MERS-CoV",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide effectively inhibits MERS-CoV viral replication by over 1000-fold in vitro.",
    "pmid": "39125594",
    "title": "From Proteome to Potential Drugs: Integration of Subtractive Proteomics and Ensemble Docking for Drug Repurposing against Pseudomonas aeruginosa RND Superfamily Proteins.",
    "year": "2024",
    "doi": "10.3390/ijms25158027",
    "mechanism": "Potentially involves blocking multiple pathways (WNT/b-catenin, mTORC1, Stat3, NF-kB, Notch) and inducing cell-cycle arrest through targeting mitochondrial enzymes, as well as disrupting viral replication mechanisms."
  },
  {
    "drug": "colistin",
    "pathogen": "Salmonella enterica serovar Typhimurium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "CNEDS substantially restored colistin sensitivity against colistin-resistant Salmonella in vitro.",
    "pmid": "39284817",
    "title": "Adaptation mechanisms of Clostridioides difficile to auranofin and its impact on human gut microbiota.",
    "year": "2024",
    "doi": "10.1038/s41522-024-00551-3",
    "mechanism": "Niclosamide restores colistin sensitivity possibly by inhibiting resistance mechanisms, and the formulation enhances antibacterial activity against resistant bacteria."
  },
  {
    "drug": "niclosamide",
    "pathogen": "Salmonella enterica serovar Typhimurium",
    "activity_type": "adjuvant|efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide can effectively reverse colistin resistance in Gram-negative bacteria.",
    "pmid": "39284817",
    "title": "Adaptation mechanisms of Clostridioides difficile to auranofin and its impact on human gut microbiota.",
    "year": "2024",
    "doi": "10.1038/s41522-024-00551-3",
    "mechanism": "Niclosamide restores colistin sensitivity possibly by inhibiting resistance mechanisms, and the formulation enhances antibacterial activity against resistant bacteria."
  },
  {
    "drug": "Colistin-Niclosamide effervescent dry suspension (CNEDS)",
    "pathogen": "Salmonella enterica serovar Typhimurium",
    "activity_type": "synergy|adjuvant|anti_biofilm",
    "evidence_type": "in_vivo|in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "CNEDS effectively overcomes colistin resistance and improves survival in broiler chickens infected with colistin-resistant Salmonella.",
    "pmid": "39284817",
    "title": "Adaptation mechanisms of Clostridioides difficile to auranofin and its impact on human gut microbiota.",
    "year": "2024",
    "doi": "10.1038/s41522-024-00551-3",
    "mechanism": "Niclosamide restores colistin sensitivity possibly by inhibiting resistance mechanisms, and the formulation enhances antibacterial activity against resistant bacteria."
  },
  {
    "drug": "guanethidine",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Guanethidine restores susceptibility to tetracyclines in tetA-positive E. coli by inhibiting the TetA efflux pump, increasing intracellular tetracycline concentration.",
    "pmid": "39308694",
    "title": "Revisiting Niclosamide Formulation Approaches - a Pathway Toward Drug Repositioning.",
    "year": "2024",
    "doi": "10.2147/DDDT.S473178",
    "mechanism": "Inhibition of the TetA efflux pump, disruption of outer membrane integrity, and alteration of bacterial proton motive force, leading to increased intracellular tetracycline levels."
  },
  {
    "drug": "guanethidine",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Guanethidine inhibits the activity of the TetA efflux pump, leading to increased intracellular tetracycline accumulation.",
    "pmid": "39308694",
    "title": "Revisiting Niclosamide Formulation Approaches - a Pathway Toward Drug Repositioning.",
    "year": "2024",
    "doi": "10.2147/DDDT.S473178",
    "mechanism": "Inhibition of the TetA efflux pump, disruption of outer membrane integrity, and alteration of bacterial proton motive force, leading to increased intracellular tetracycline levels."
  },
  {
    "drug": "guanethidine",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Guanethidine synergistically enhances tetracycline activity against resistant E. coli strains, reducing MICs by 32- to 128-fold.",
    "pmid": "39308694",
    "title": "Revisiting Niclosamide Formulation Approaches - a Pathway Toward Drug Repositioning.",
    "year": "2024",
    "doi": "10.2147/DDDT.S473178",
    "mechanism": "Inhibition of the TetA efflux pump, disruption of outer membrane integrity, and alteration of bacterial proton motive force, leading to increased intracellular tetracycline levels."
  },
  {
    "drug": "guanethidine",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Guanethidine delays the development of tetracycline resistance in E. coli during serial passage experiments.",
    "pmid": "39308694",
    "title": "Revisiting Niclosamide Formulation Approaches - a Pathway Toward Drug Repositioning.",
    "year": "2024",
    "doi": "10.2147/DDDT.S473178",
    "mechanism": "Inhibition of the TetA efflux pump, disruption of outer membrane integrity, and alteration of bacterial proton motive force, leading to increased intracellular tetracycline levels."
  },
  {
    "drug": "Caspofungin acetate",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Caspofungin acetate significantly enhances the antimicrobial activity of rifampin against GNB in vitro.",
    "pmid": "39329140",
    "title": "Antimicrobial activities of Diltiazem Hydrochloride: drug repurposing approach.",
    "year": "2024",
    "doi": "10.7717/peerj.17809",
    "mechanism": "Caspofungin acetate enhances antibiotic activity by permeabilizing bacterial outer membrane, disrupting proton motive force, inhibiting biofilm formation, and targeting PgaC enzyme activity."
  },
  {
    "drug": "Caspofungin acetate",
    "pathogen": "E. coli",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In Galleria mellonella infection model, CAS potentiated rifampin efficacy against MDR E. coli in vivo.",
    "pmid": "39329140",
    "title": "Antimicrobial activities of Diltiazem Hydrochloride: drug repurposing approach.",
    "year": "2024",
    "doi": "10.7717/peerj.17809",
    "mechanism": "Caspofungin acetate enhances antibiotic activity by permeabilizing bacterial outer membrane, disrupting proton motive force, inhibiting biofilm formation, and targeting PgaC enzyme activity."
  },
  {
    "drug": "Caspofungin acetate",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Checkerboard assays confirmed synergy between CAS and rifampin, reducing MICs.",
    "pmid": "39329140",
    "title": "Antimicrobial activities of Diltiazem Hydrochloride: drug repurposing approach.",
    "year": "2024",
    "doi": "10.7717/peerj.17809",
    "mechanism": "Caspofungin acetate enhances antibiotic activity by permeabilizing bacterial outer membrane, disrupting proton motive force, inhibiting biofilm formation, and targeting PgaC enzyme activity."
  },
  {
    "drug": "Caspofungin acetate",
    "pathogen": "E. coli",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "CAS inhibits biofilm formation and disrupts bacterial envelope integrity.",
    "pmid": "39329140",
    "title": "Antimicrobial activities of Diltiazem Hydrochloride: drug repurposing approach.",
    "year": "2024",
    "doi": "10.7717/peerj.17809",
    "mechanism": "Caspofungin acetate enhances antibiotic activity by permeabilizing bacterial outer membrane, disrupting proton motive force, inhibiting biofilm formation, and targeting PgaC enzyme activity."
  },
  {
    "drug": "auranofin",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin inhibits thioredoxin reductase in E. coli but high glutathione levels and efflux systems confer resistance.",
    "pmid": "39338275",
    "title": "Exploring the Antibiofilm Effect of Sertraline in Synergy with Cinnamomum verum Essential Oil to Counteract Candida Species.",
    "year": "2024",
    "doi": "10.3390/ph17091109",
    "mechanism": "Inhibition of bacterial thioredoxin reductase leading to oxidative stress and disturbance of thiol redox homeostasis; resistance in Gram-negative bacteria is partly due to high glutathione levels and efflux systems."
  },
  {
    "drug": "auranofin",
    "pathogen": "Bacillus subtilis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin effectively inhibits B. subtilis by targeting thioredoxin reductase, with less resistance from glutathione.",
    "pmid": "39338275",
    "title": "Exploring the Antibiofilm Effect of Sertraline in Synergy with Cinnamomum verum Essential Oil to Counteract Candida Species.",
    "year": "2024",
    "doi": "10.3390/ph17091109",
    "mechanism": "Inhibition of bacterial thioredoxin reductase leading to oxidative stress and disturbance of thiol redox homeostasis; resistance in Gram-negative bacteria is partly due to high glutathione levels and efflux systems."
  },
  {
    "drug": "Visomitin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial|anti_quorum_sensing|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "Visomitin exhibits potent bactericidal activity against MRSA with MIC of 2 \u03bcg/mL and inhibits quorum sensing and biofilm formation at sub-MIC levels.",
    "pmid": "39377597",
    "title": "Comparison of the mechanism of antimicrobial action of the gold(I) compound auranofin in Gram-positive and Gram-negative bacteria.",
    "year": "2024",
    "doi": "10.1128/spectrum.00138-24",
    "mechanism": "Disruption of bacterial cell membrane integrity and interference with the accessory gene regulator (Agr) quorum sensing system."
  },
  {
    "drug": "Visomitin",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Visomitin disrupts bacterial cell membranes, leading to increased permeability and cell death.",
    "pmid": "39377597",
    "title": "Comparison of the mechanism of antimicrobial action of the gold(I) compound auranofin in Gram-positive and Gram-negative bacteria.",
    "year": "2024",
    "doi": "10.1128/spectrum.00138-24",
    "mechanism": "Disruption of bacterial cell membrane integrity and interference with the accessory gene regulator (Agr) quorum sensing system."
  },
  {
    "drug": "Visomitin",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "It effectively kills intracellular bacteria and persister cells, indicating activity against tolerant phenotypes.",
    "pmid": "39377597",
    "title": "Comparison of the mechanism of antimicrobial action of the gold(I) compound auranofin in Gram-positive and Gram-negative bacteria.",
    "year": "2024",
    "doi": "10.1128/spectrum.00138-24",
    "mechanism": "Disruption of bacterial cell membrane integrity and interference with the accessory gene regulator (Agr) quorum sensing system."
  },
  {
    "drug": "quinestrol",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Quinestrol inhibits cytochrome bd and exhibits bactericidal activity against MRSA.",
    "pmid": "39390774",
    "title": "Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus.",
    "year": "2024",
    "doi": "10.1080/21505594.2024.2415952",
    "mechanism": "Steroid drugs bind to the quinol binding site of bacterial respiratory oxidases (cytochrome bd), inhibiting their activity and leading to bacterial growth inhibition or death."
  },
  {
    "drug": "quinestrol",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Quinestrol inhibits growth of E. coli but is not bactericidal.",
    "pmid": "39390774",
    "title": "Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus.",
    "year": "2024",
    "doi": "10.1080/21505594.2024.2415952",
    "mechanism": "Steroid drugs bind to the quinol binding site of bacterial respiratory oxidases (cytochrome bd), inhibiting their activity and leading to bacterial growth inhibition or death."
  },
  {
    "drug": "ethinylestradiol",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ethinylestradiol inhibits oxygen consumption in E. coli membranes.",
    "pmid": "39390774",
    "title": "Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus.",
    "year": "2024",
    "doi": "10.1080/21505594.2024.2415952",
    "mechanism": "Steroid drugs bind to the quinol binding site of bacterial respiratory oxidases (cytochrome bd), inhibiting their activity and leading to bacterial growth inhibition or death."
  },
  {
    "drug": "mestranol",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mestranol did not inhibit oxygen consumption in E. coli membranes.",
    "pmid": "39390774",
    "title": "Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus.",
    "year": "2024",
    "doi": "10.1080/21505594.2024.2415952",
    "mechanism": "Steroid drugs bind to the quinol binding site of bacterial respiratory oxidases (cytochrome bd), inhibiting their activity and leading to bacterial growth inhibition or death."
  },
  {
    "drug": "Diltiazem Hydrochloride",
    "pathogen": "Staphylococcus epidermidis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Diltiazem HCl exhibited antimicrobial activity against S. epidermidis and significantly reduced biofilm formation by 95.1%.",
    "pmid": "39500268",
    "title": "Colistin-niclosamide effervescent dry suspension combats colistin-resistant Salmonella in vitro and in vivo.",
    "year": "2024",
    "doi": "10.1016/j.psj.2024.104492",
    "mechanism": "Proposed mechanism involves off-target effects of Diltiazem HCl, potentially disrupting microbial biofilm formation and viral replication, though specific mechanisms are not detailed."
  },
  {
    "drug": "Diltiazem Hydrochloride",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Diltiazem HCl showed activity against S. aureus and reduced biofilm formation by 90.7%.",
    "pmid": "39500268",
    "title": "Colistin-niclosamide effervescent dry suspension combats colistin-resistant Salmonella in vitro and in vivo.",
    "year": "2024",
    "doi": "10.1016/j.psj.2024.104492",
    "mechanism": "Proposed mechanism involves off-target effects of Diltiazem HCl, potentially disrupting microbial biofilm formation and viral replication, though specific mechanisms are not detailed."
  },
  {
    "drug": "auranofin",
    "pathogen": "bacterial",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Auranofin exhibits antibacterial activity by directly interacting with bacterial thiol-containing proteins, forming S-Au-S adducts that mimic disulfide bonds.",
    "pmid": "39507218",
    "title": "Colistin-niclosamide-loaded nanoemulsions and nanoemulsion gels for effective therapy of colistin-resistant Salmonella infections.",
    "year": "2024",
    "doi": "10.3389/fvets.2024.1492543",
    "mechanism": "Auranofin binds to cysteine thiols in bacterial proteins, forming S-Au-S bridges that modify protein thiols and disrupt bacterial redox systems."
  },
  {
    "drug": "Fe(III)",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Fe(III) combined with blue light degrades capsule polysaccharides and enhances bacterial susceptibility to immune clearance.",
    "pmid": "39519127",
    "title": "Restoring Colistin Sensitivity in Multidrug-Resistant Pathogenic E. coli Using Cinacalcet Hydrochloride.",
    "year": "2024",
    "doi": "10.3390/ijms252111574",
    "mechanism": "Fe(III) mediates degradation of biofilm extracellular polysaccharides upon blue light exposure, disrupting biofilm matrix and increasing bacterial vulnerability."
  },
  {
    "drug": "cordycepin",
    "pathogen": "Streptococcus mutans",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 128,
    "fici": null,
    "key_result": "Cordycepin reduces biofilm biomass and metabolic activity of S. mutans without killing the bacteria.",
    "pmid": "39530670",
    "title": "Doxifluridine effectively kills antibiotic-resistant Staphylococcus aureus in chronic obstructive pulmonary disease.",
    "year": "2024",
    "doi": "10.1128/spectrum.01805-24",
    "mechanism": "disruption of purine and nucleotide metabolism, affecting biofilm formation and metabolic activity"
  },
  {
    "drug": "cordycepin",
    "pathogen": "Streptococcus mutans",
    "activity_type": "adjuvant",
    "evidence_type": "metabolomics",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cordycepin interferes with purine and nucleotide metabolism in S. mutans biofilms.",
    "pmid": "39530670",
    "title": "Doxifluridine effectively kills antibiotic-resistant Staphylococcus aureus in chronic obstructive pulmonary disease.",
    "year": "2024",
    "doi": "10.1128/spectrum.01805-24",
    "mechanism": "disruption of purine and nucleotide metabolism, affecting biofilm formation and metabolic activity"
  },
  {
    "drug": "palmitic acid",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 32,
    "fici": null,
    "key_result": "Palmitic acid from C. linum extract showed antibacterial activity against E. faecalis with an MIC of 32 \u03bcg/mL.",
    "pmid": "39590791",
    "title": "Chaetomorpha linum Extract as a Source of Antimicrobial Compounds: A Circular Bioeconomy Approach.",
    "year": "2024",
    "doi": "10.3390/md22110511",
    "mechanism": "Palmitic acid interacts with the E. faecalis EbpA protein, likely disrupting biofilm formation and adhesion processes, contributing to its antimicrobial activity."
  },
  {
    "drug": "palmitic acid",
    "pathogen": "E. faecalis",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In silico docking and molecular dynamics simulations suggest palmitic acid binds favorably to E. faecalis EbpA protein, indicating potential as an antimicrobial adjuvant.",
    "pmid": "39590791",
    "title": "Chaetomorpha linum Extract as a Source of Antimicrobial Compounds: A Circular Bioeconomy Approach.",
    "year": "2024",
    "doi": "10.3390/md22110511",
    "mechanism": "Palmitic acid interacts with the E. faecalis EbpA protein, likely disrupting biofilm formation and adhesion processes, contributing to its antimicrobial activity."
  },
  {
    "drug": "niclosamide",
    "pathogen": "Salmonella spp.",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide reverses colistin resistance in Salmonella and enhances antibacterial activity when co-delivered in nanoemulsions.",
    "pmid": "39670471",
    "title": "Repurposing statins for the treatment of larval cestodiases: in silico evaluation of statin-HMG-CoA reductase interactions and assessment of statin effects on a cestode model.",
    "year": "2025",
    "doi": "10.1017/S0031182024001586",
    "mechanism": "Niclosamide enhances antibacterial activity by damaging bacterial cell membranes, disrupting proton motive force, inhibiting multidrug efflux pumps, and promoting oxidative damage."
  },
  {
    "drug": "colistin",
    "pathogen": "Salmonella spp.",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Nanoemulsion formulations significantly reduce the MIC of colistin against resistant Salmonella strains, indicating restored susceptibility.",
    "pmid": "39670471",
    "title": "Repurposing statins for the treatment of larval cestodiases: in silico evaluation of statin-HMG-CoA reductase interactions and assessment of statin effects on a cestode model.",
    "year": "2025",
    "doi": "10.1017/S0031182024001586",
    "mechanism": "Niclosamide enhances antibacterial activity by damaging bacterial cell membranes, disrupting proton motive force, inhibiting multidrug efflux pumps, and promoting oxidative damage."
  },
  {
    "drug": "simvastatin",
    "pathogen": "Mesocestoides corti",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 150,
    "fici": null,
    "key_result": "Simvastatin significantly reduced M. corti viability, achieving 100% parasite death at 150 \u03bcM.",
    "pmid": "39688409",
    "title": "Repurposing zidovudine and 5-fluoro-2'-deoxyuridine as antibiotic drugs made possible by synergy with both trimethoprim and the mitochondrial toxicity-reducing agent uridine.",
    "year": "2025",
    "doi": "10.1093/jac/dkae438",
    "mechanism": "Inhibition of HMG-CoA reductase in cestodes, disrupting the mevalonate pathway essential for parasite lipid metabolism and cell functions."
  },
  {
    "drug": "fluvastatin",
    "pathogen": "Mesocestoides corti",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Fluvastatin showed a significant, though lower, anthelmintic effect compared to simvastatin.",
    "pmid": "39688409",
    "title": "Repurposing zidovudine and 5-fluoro-2'-deoxyuridine as antibiotic drugs made possible by synergy with both trimethoprim and the mitochondrial toxicity-reducing agent uridine.",
    "year": "2025",
    "doi": "10.1093/jac/dkae438",
    "mechanism": "Inhibition of HMG-CoA reductase in cestodes, disrupting the mevalonate pathway essential for parasite lipid metabolism and cell functions."
  },
  {
    "drug": "cinacalcet hydrochloride",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.047,
    "key_result": "Cinacalcet hydrochloride synergistically restores colistin sensitivity in MDR E. coli, including mcr-1-positive strains.",
    "pmid": "39708333",
    "title": "Efficient Photolysis of Multidrug-Resistant Polymicrobial Biofilms.",
    "year": "2025",
    "doi": "10.1002/advs.202407898",
    "mechanism": "The combination increases bacterial membrane permeability, disrupts membrane integrity, and induces oxidative stress through elevated ATP release and ROS production, leading to bacterial death."
  },
  {
    "drug": "cinacalcet hydrochloride",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 64,
    "fici": null,
    "key_result": "Cinacalcet hydrochloride alone exhibits weak or no antibacterial activity against MDR E. coli.",
    "pmid": "39708333",
    "title": "Efficient Photolysis of Multidrug-Resistant Polymicrobial Biofilms.",
    "year": "2025",
    "doi": "10.1002/advs.202407898",
    "mechanism": "The combination increases bacterial membrane permeability, disrupts membrane integrity, and induces oxidative stress through elevated ATP release and ROS production, leading to bacterial death."
  },
  {
    "drug": "cinacalcet hydrochloride",
    "pathogen": "E. coli",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combination of cinacalcet hydrochloride and colistin significantly inhibits biofilm formation and eradicates existing biofilms.",
    "pmid": "39708333",
    "title": "Efficient Photolysis of Multidrug-Resistant Polymicrobial Biofilms.",
    "year": "2025",
    "doi": "10.1002/advs.202407898",
    "mechanism": "The combination increases bacterial membrane permeability, disrupts membrane integrity, and induces oxidative stress through elevated ATP release and ROS production, leading to bacterial death."
  },
  {
    "drug": "Pinaverium bromide",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial|anti_biofilm|synergy",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "PVB rapidly kills MRSA planktonic and persister cells, inhibits and eradicates biofilms, and shows synergistic effects with antibiotics.",
    "pmid": "39718732",
    "title": "Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms.",
    "year": "2024",
    "doi": "10.1186/s13568-024-01809-x",
    "mechanism": "Disruption of proton motive force and induction of reactive oxygen species (ROS)."
  },
  {
    "drug": "Pinaverium bromide",
    "pathogen": "S. epidermidis",
    "activity_type": "direct_antibacterial|anti_biofilm|synergy",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "PVB effectively kills S. epidermidis planktonic and biofilm cells, with mechanisms involving proton motive force disruption and ROS induction.",
    "pmid": "39718732",
    "title": "Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms.",
    "year": "2024",
    "doi": "10.1186/s13568-024-01809-x",
    "mechanism": "Disruption of proton motive force and induction of reactive oxygen species (ROS)."
  },
  {
    "drug": "Gallic acid",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Gallic acid showed good activity against A. baumannii with MIC and MBC assays, and demonstrated binding affinity to shikimate kinase.",
    "pmid": "39728508",
    "title": "Gallic Acid: A Potent Metabolite Targeting Shikimate Kinase in Acinetobacter baumannii.",
    "year": "2024",
    "doi": "10.3390/metabo14120727",
    "mechanism": "Inhibition of shikimate kinase enzyme in the shikimate pathway, disrupting essential metabolite synthesis in bacteria."
  },
  {
    "drug": "Gallic acid",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Gallic acid exhibited activity against E. faecalis in MIC and MBC assays.",
    "pmid": "39728508",
    "title": "Gallic Acid: A Potent Metabolite Targeting Shikimate Kinase in Acinetobacter baumannii.",
    "year": "2024",
    "doi": "10.3390/metabo14120727",
    "mechanism": "Inhibition of shikimate kinase enzyme in the shikimate pathway, disrupting essential metabolite synthesis in bacteria."
  },
  {
    "drug": "colistin",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Colistin exerts its antibacterial activity by disrupting the outer membrane of A. baumannii through binding to lipid A, leading to bacterial cell death.",
    "pmid": "39755609",
    "title": "Cordycepin affects Streptococcus mutans biofilm and interferes with its metabolism.",
    "year": "2025",
    "doi": "10.1186/s12903-024-05355-7",
    "mechanism": "Colistin resistance in A. baumannii is primarily mediated by modifications of lipid A through addition of phosphoethanolamine via the PmrAB two-component system or by loss of lipopolysaccharides due to mutations in biosynthetic genes, reducing colistin binding affinity."
  },
  {
    "drug": "colistin",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Resistance mechanisms include modifications of lipid A and loss of LPS, which reduce colistin binding and efficacy.",
    "pmid": "39755609",
    "title": "Cordycepin affects Streptococcus mutans biofilm and interferes with its metabolism.",
    "year": "2025",
    "doi": "10.1186/s12903-024-05355-7",
    "mechanism": "Colistin resistance in A. baumannii is primarily mediated by modifications of lipid A through addition of phosphoethanolamine via the PmrAB two-component system or by loss of lipopolysaccharides due to mutations in biosynthetic genes, reducing colistin binding affinity."
  },
  {
    "drug": "colistin",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Genetic mutations in lipid A biosynthesis genes and addition of phosphoethanolamine to lipid A confer colistin resistance.",
    "pmid": "39755609",
    "title": "Cordycepin affects Streptococcus mutans biofilm and interferes with its metabolism.",
    "year": "2025",
    "doi": "10.1186/s12903-024-05355-7",
    "mechanism": "Colistin resistance in A. baumannii is primarily mediated by modifications of lipid A through addition of phosphoethanolamine via the PmrAB two-component system or by loss of lipopolysaccharides due to mutations in biosynthetic genes, reducing colistin binding affinity."
  },
  {
    "drug": "Guanosine",
    "pathogen": "Streptococcus suis",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro|in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Guanosine enhances the bactericidal effect of ceftiofur sodium against S. suis by promoting bacterial metabolism, increasing antimicrobial accumulation, and inducing oxidative stress and DNA damage.",
    "pmid": "39761857",
    "title": "Auranofin induces disulfide bond-mimicking S-Au adducts in protein thiol pairs.",
    "year": "2025",
    "doi": "10.1016/j.jbc.2025.108159",
    "mechanism": "Guanosine promotes bacterial metabolic reprogramming, enhances bacterial respiration and purine pathway activity, affects cell membrane function, increases antimicrobial accumulation, and induces oxidative stress and DNA damage, thereby potentiating the antibacterial effect of ceftiofur sodium."
  },
  {
    "drug": "NS-MPLA nanoliposomes",
    "pathogen": "Salmonella pullorum",
    "activity_type": "adjuvant|anti_biofilm|immunomodulatory",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "NS-MPLA nanoliposomes boosted immunity, promoted bacterial clearance, and reduced pathological lesions in broiler chicks challenged with drug-resistant Salmonella pullorum.",
    "pmid": "39766555",
    "title": "Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms.",
    "year": "2024",
    "doi": "10.3390/antibiotics13121165",
    "mechanism": "enhancement of immune response through upregulation of cytokines, immunoglobulins, and mucosal gene expression, leading to bacterial clearance and tissue repair"
  },
  {
    "drug": "ceftazidime-avibactam",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "77.3% of XDR/PDR P. aeruginosa strains showed synergistic effects when treated with ceftazidime-avibactam in combination with amikacin.",
    "pmid": "39770308",
    "title": "Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Acinetobacter baumannii Infections.",
    "year": "2024",
    "doi": "10.3390/pathogens13121049",
    "mechanism": "The combination likely enhances bacterial cell wall penetration and inhibits multiple resistance mechanisms, resulting in synergistic antibacterial activity."
  },
  {
    "drug": "vancomycin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Vancomycin-loaded hybrid nanostructured lipid carriers (VCM-HNLCs) demonstrated enhanced antibacterial activity against MRSA, with reduced MIC values and improved efficacy in a sepsis mouse model.",
    "pmid": "39856593",
    "title": "High prevalence of multidrug resistant and extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in the West region, Cameroon.",
    "year": "2025",
    "doi": "10.1186/s12879-025-10483-8",
    "mechanism": "pH-responsive controlled release and targeted delivery of vancomycin, combined with biomimetic inhibition of TLR activation and efflux pump inhibition by TS."
  },
  {
    "drug": "vancomycin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "VCM-HNLCs showed a twofold reduction in MIC at physiological pH and a fourfold reduction at pH 6.0 compared to free vancomycin.",
    "pmid": "39856593",
    "title": "High prevalence of multidrug resistant and extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in the West region, Cameroon.",
    "year": "2025",
    "doi": "10.1186/s12879-025-10483-8",
    "mechanism": "pH-responsive controlled release and targeted delivery of vancomycin, combined with biomimetic inhibition of TLR activation and efflux pump inhibition by TS."
  },
  {
    "drug": "zidovudine",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Zidovudine combined with trimethoprim and uridine showed antibacterial synergy against E. coli in vitro.",
    "pmid": "39858337",
    "title": "Selective Serotonin Reuptake Inhibitors: Antimicrobial Activity Against ESKAPEE Bacteria and Mechanisms of Action.",
    "year": "2025",
    "doi": "10.3390/antibiotics14010051",
    "mechanism": "The proposed mechanism involves lowering bacterial dTMP levels through nucleoside analogues and trimethoprim, with uridine reducing host toxicity and enhancing antibacterial effects."
  },
  {
    "drug": "5-fluoro-2'-deoxyuridine",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "5-Fluoro-2'-deoxyuridine combined with trimethoprim and uridine showed synergy against S. aureus in vitro.",
    "pmid": "39858337",
    "title": "Selective Serotonin Reuptake Inhibitors: Antimicrobial Activity Against ESKAPEE Bacteria and Mechanisms of Action.",
    "year": "2025",
    "doi": "10.3390/antibiotics14010051",
    "mechanism": "The proposed mechanism involves lowering bacterial dTMP levels through nucleoside analogues and trimethoprim, with uridine reducing host toxicity and enhancing antibacterial effects."
  },
  {
    "drug": "zidovudine",
    "pathogen": "E. coli",
    "activity_type": "synergy",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In a murine peritonitis model, zidovudine with trimethoprim and uridine demonstrated enhanced antibacterial efficacy.",
    "pmid": "39858337",
    "title": "Selective Serotonin Reuptake Inhibitors: Antimicrobial Activity Against ESKAPEE Bacteria and Mechanisms of Action.",
    "year": "2025",
    "doi": "10.3390/antibiotics14010051",
    "mechanism": "The proposed mechanism involves lowering bacterial dTMP levels through nucleoside analogues and trimethoprim, with uridine reducing host toxicity and enhancing antibacterial effects."
  },
  {
    "drug": "5-fluoro-2'-deoxyuridine",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo, 5-fluoro-2'-deoxyuridine with trimethoprim and uridine showed synergistic antibacterial activity.",
    "pmid": "39858337",
    "title": "Selective Serotonin Reuptake Inhibitors: Antimicrobial Activity Against ESKAPEE Bacteria and Mechanisms of Action.",
    "year": "2025",
    "doi": "10.3390/antibiotics14010051",
    "mechanism": "The proposed mechanism involves lowering bacterial dTMP levels through nucleoside analogues and trimethoprim, with uridine reducing host toxicity and enhancing antibacterial effects."
  },
  {
    "drug": "pinaverium bromide",
    "pathogen": "Staphylococcus epidermidis",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": 0.25,
    "key_result": "Pinaverium bromide exhibits synergistic antibacterial effects with oxacillin against S. epidermidis, inhibits biofilm formation, and reduces persister cells.",
    "pmid": "39915976",
    "title": "Guanosine enhances the bactericidal effect of ceftiofur sodium on Streptococcus suis by activating bacterial metabolism.",
    "year": "2025",
    "doi": "10.1080/21505594.2025.2453525",
    "mechanism": "PVB induces reactive oxygen species (ROS) production and reduces ATP synthesis, leading to bacterial structural damage, biofilm disruption, and increased bacterial cell death."
  },
  {
    "drug": "oxacillin",
    "pathogen": "Staphylococcus epidermidis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": 0.25,
    "key_result": "Oxacillin's efficacy is enhanced when combined with pinaverium bromide, showing synergistic activity and biofilm eradication.",
    "pmid": "39915976",
    "title": "Guanosine enhances the bactericidal effect of ceftiofur sodium on Streptococcus suis by activating bacterial metabolism.",
    "year": "2025",
    "doi": "10.1080/21505594.2025.2453525",
    "mechanism": "PVB induces reactive oxygen species (ROS) production and reduces ATP synthesis, leading to bacterial structural damage, biofilm disruption, and increased bacterial cell death."
  },
  {
    "drug": "sertraline",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 15,
    "fici": null,
    "key_result": "Sertraline exhibited MIC values between 15 and 126 \u03bcg/mL and effectively eradicated bacterial populations within 2 to 24 hours.",
    "pmid": "39930418",
    "title": "Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.",
    "year": "2025",
    "doi": "10.1186/s12929-024-01114-6",
    "mechanism": "Increased membrane permeability, efflux pump inhibition, induction of oxidative stress, and biomolecule leakage."
  },
  {
    "drug": "paroxetine",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 60,
    "fici": null,
    "key_result": "Paroxetine showed MIC values from 60 to 250 \u03bcg/mL and inhibited bacterial growth within hours.",
    "pmid": "39930418",
    "title": "Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.",
    "year": "2025",
    "doi": "10.1186/s12929-024-01114-6",
    "mechanism": "Increased membrane permeability, efflux pump inhibition, induction of oxidative stress, and biomolecule leakage."
  },
  {
    "drug": "sertraline",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 15,
    "fici": null,
    "key_result": "Sertraline caused morphological changes and bacterial cell protrusions, indicating membrane disruption.",
    "pmid": "39930418",
    "title": "Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.",
    "year": "2025",
    "doi": "10.1186/s12929-024-01114-6",
    "mechanism": "Increased membrane permeability, efflux pump inhibition, induction of oxidative stress, and biomolecule leakage."
  },
  {
    "drug": "paroxetine",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 60,
    "fici": null,
    "key_result": "Paroxetine induced morphological alterations and cellular debris in S. aureus.",
    "pmid": "39930418",
    "title": "Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.",
    "year": "2025",
    "doi": "10.1186/s12929-024-01114-6",
    "mechanism": "Increased membrane permeability, efflux pump inhibition, induction of oxidative stress, and biomolecule leakage."
  },
  {
    "drug": "sertraline",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sertraline inhibited bacterial efflux pumps, increasing ethidium bromide accumulation and enhancing tetracycline activity.",
    "pmid": "39930418",
    "title": "Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.",
    "year": "2025",
    "doi": "10.1186/s12929-024-01114-6",
    "mechanism": "Increased membrane permeability, efflux pump inhibition, induction of oxidative stress, and biomolecule leakage."
  },
  {
    "drug": "paroxetine",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Paroxetine also inhibited efflux pumps, contributing to increased antibiotic susceptibility.",
    "pmid": "39930418",
    "title": "Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.",
    "year": "2025",
    "doi": "10.1186/s12929-024-01114-6",
    "mechanism": "Increased membrane permeability, efflux pump inhibition, induction of oxidative stress, and biomolecule leakage."
  },
  {
    "drug": "sertraline",
    "pathogen": "E. coli",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sertraline increased membrane permeability and caused biomolecule leakage, disrupting bacterial integrity.",
    "pmid": "39930418",
    "title": "Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.",
    "year": "2025",
    "doi": "10.1186/s12929-024-01114-6",
    "mechanism": "Increased membrane permeability, efflux pump inhibition, induction of oxidative stress, and biomolecule leakage."
  },
  {
    "drug": "paroxetine",
    "pathogen": "S. aureus",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Paroxetine induced membrane permeability changes and biomolecule leakage in S. aureus.",
    "pmid": "39930418",
    "title": "Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.",
    "year": "2025",
    "doi": "10.1186/s12929-024-01114-6",
    "mechanism": "Increased membrane permeability, efflux pump inhibition, induction of oxidative stress, and biomolecule leakage."
  },
  {
    "drug": "doxifluridine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.5,
    "fici": null,
    "key_result": "Doxifluridine demonstrated significant antibacterial activity against MDR S. aureus with MIC values ranging from 0.5 to 2 \u00b5g/mL.",
    "pmid": "40025471",
    "title": "Nigella sativa monophosphoryl lipid A nanoliposome: a promising antibiotic alternative and immunomodulator to control virulent pandemic drug-resistant\u00a0Salmonella pullorum infection in broiler chicks.",
    "year": "2025",
    "doi": "10.1186/s12917-025-04473-w",
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed in the abstract, but likely involves direct bactericidal effects and biofilm disruption."
  },
  {
    "drug": "doxifluridine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "bactericidal",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "Doxifluridine exhibited potent bactericidal effects within 8 hours against MRSA.",
    "pmid": "40025471",
    "title": "Nigella sativa monophosphoryl lipid A nanoliposome: a promising antibiotic alternative and immunomodulator to control virulent pandemic drug-resistant\u00a0Salmonella pullorum infection in broiler chicks.",
    "year": "2025",
    "doi": "10.1186/s12917-025-04473-w",
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed in the abstract, but likely involves direct bactericidal effects and biofilm disruption."
  },
  {
    "drug": "doxifluridine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "Doxifluridine substantially reduced biofilm mass and viability of MRSA.",
    "pmid": "40025471",
    "title": "Nigella sativa monophosphoryl lipid A nanoliposome: a promising antibiotic alternative and immunomodulator to control virulent pandemic drug-resistant\u00a0Salmonella pullorum infection in broiler chicks.",
    "year": "2025",
    "doi": "10.1186/s12917-025-04473-w",
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed in the abstract, but likely involves direct bactericidal effects and biofilm disruption."
  },
  {
    "drug": "doxifluridine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Chequerboard assays indicated synergistic interactions between doxifluridine and other antibiotics, reducing MIC values by two- to eightfold.",
    "pmid": "40025471",
    "title": "Nigella sativa monophosphoryl lipid A nanoliposome: a promising antibiotic alternative and immunomodulator to control virulent pandemic drug-resistant\u00a0Salmonella pullorum infection in broiler chicks.",
    "year": "2025",
    "doi": "10.1186/s12917-025-04473-w",
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed in the abstract, but likely involves direct bactericidal effects and biofilm disruption."
  },
  {
    "drug": "doxifluridine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Doxifluridine showed synergistic effects with other antibiotics, enhancing antibacterial efficacy.",
    "pmid": "40025471",
    "title": "Nigella sativa monophosphoryl lipid A nanoliposome: a promising antibiotic alternative and immunomodulator to control virulent pandemic drug-resistant\u00a0Salmonella pullorum infection in broiler chicks.",
    "year": "2025",
    "doi": "10.1186/s12917-025-04473-w",
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed in the abstract, but likely involves direct bactericidal effects and biofilm disruption."
  },
  {
    "drug": "doxifluridine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "none",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "No specific evidence for efflux inhibition provided.",
    "pmid": "40025471",
    "title": "Nigella sativa monophosphoryl lipid A nanoliposome: a promising antibiotic alternative and immunomodulator to control virulent pandemic drug-resistant\u00a0Salmonella pullorum infection in broiler chicks.",
    "year": "2025",
    "doi": "10.1186/s12917-025-04473-w",
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed in the abstract, but likely involves direct bactericidal effects and biofilm disruption."
  },
  {
    "drug": "doxifluridine",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "anti_virulence",
    "evidence_type": "none",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "No evidence for anti-virulence activity provided.",
    "pmid": "40025471",
    "title": "Nigella sativa monophosphoryl lipid A nanoliposome: a promising antibiotic alternative and immunomodulator to control virulent pandemic drug-resistant\u00a0Salmonella pullorum infection in broiler chicks.",
    "year": "2025",
    "doi": "10.1186/s12917-025-04473-w",
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed in the abstract, but likely involves direct bactericidal effects and biofilm disruption."
  },
  {
    "drug": "disulfiram",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Disulfiram inhibits the growth of S. aureus by inducing redox imbalance and perturbing central glucose metabolism.",
    "pmid": "40074309",
    "title": "Synergistic antibacterial effects of pinaverium bromide and oxacillin against Staphylococcus epidermidis.",
    "year": "2024",
    "doi": "10.11817/j.issn.1672-7347.2024.240109",
    "mechanism": "Disulfiram induces oxidative stress, chelates metals, inhibits oxidative phosphorylation, and disrupts glucose and CoA metabolism in S. aureus."
  },
  {
    "drug": "Aztreonam",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Aztreonam is stable against MBLs and effective when combined with avibactam to inhibit serine \u03b2-lactamases.",
    "pmid": "40076888",
    "title": "Improving Atorvastatin Release from Polyelectrolyte Complex-Based Hydrogels Using Freeze-Drying: Formulation and Pharmaceutical Assessment of a Novel Delivery System for Oral Candidiasis Treatment.",
    "year": "2025",
    "doi": "10.3390/ijms26052267",
    "mechanism": "Aztreonam is stable against MBL hydrolysis, and avibactam inhibits serine \u03b2-lactamases, allowing the combination to effectively target MBL-producing bacteria."
  },
  {
    "drug": "Ceftazidime",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ceftazidime alone is ineffective against MBL-producing K. pneumoniae, but its activity is restored when combined with avibactam.",
    "pmid": "40076888",
    "title": "Improving Atorvastatin Release from Polyelectrolyte Complex-Based Hydrogels Using Freeze-Drying: Formulation and Pharmaceutical Assessment of a Novel Delivery System for Oral Candidiasis Treatment.",
    "year": "2025",
    "doi": "10.3390/ijms26052267",
    "mechanism": "Aztreonam is stable against MBL hydrolysis, and avibactam inhibits serine \u03b2-lactamases, allowing the combination to effectively target MBL-producing bacteria."
  },
  {
    "drug": "Avibactam",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Avibactam inhibits serine \u03b2-lactamases, restoring activity of ceftazidime and protecting aztreonam from hydrolysis.",
    "pmid": "40076888",
    "title": "Improving Atorvastatin Release from Polyelectrolyte Complex-Based Hydrogels Using Freeze-Drying: Formulation and Pharmaceutical Assessment of a Novel Delivery System for Oral Candidiasis Treatment.",
    "year": "2025",
    "doi": "10.3390/ijms26052267",
    "mechanism": "Aztreonam is stable against MBL hydrolysis, and avibactam inhibits serine \u03b2-lactamases, allowing the combination to effectively target MBL-producing bacteria."
  },
  {
    "drug": "Ceftazidime/avibactam plus Aztreonam",
    "pathogen": "K. pneumoniae",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The combination shifts 62.5% of isolates from resistance to sensitivity against MBL-producing K. pneumoniae.",
    "pmid": "40076888",
    "title": "Improving Atorvastatin Release from Polyelectrolyte Complex-Based Hydrogels Using Freeze-Drying: Formulation and Pharmaceutical Assessment of a Novel Delivery System for Oral Candidiasis Treatment.",
    "year": "2025",
    "doi": "10.3390/ijms26052267",
    "mechanism": "Aztreonam is stable against MBL hydrolysis, and avibactam inhibits serine \u03b2-lactamases, allowing the combination to effectively target MBL-producing bacteria."
  },
  {
    "drug": "tebipenem",
    "pathogen": "M. tuberculosis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tebipenem combined with rifampicin showed synergistic activity against MDR-TB in vitro, reducing effective drug doses.",
    "pmid": "40143193",
    "title": "Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay.",
    "year": "2025",
    "doi": "10.3390/ph18030417",
    "mechanism": "Beta-lactamase inhibition by clavulanate enhances the activity of beta-lactam antibiotics, and the combination with rifampicin exhibits synergistic antibacterial effects against MDR M. tuberculosis."
  },
  {
    "drug": "cephradine",
    "pathogen": "M. tuberculosis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cephradine combined with rifampicin demonstrated synergistic effects against MDR-TB in vitro, enabling dose reduction.",
    "pmid": "40143193",
    "title": "Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay.",
    "year": "2025",
    "doi": "10.3390/ph18030417",
    "mechanism": "Beta-lactamase inhibition by clavulanate enhances the activity of beta-lactam antibiotics, and the combination with rifampicin exhibits synergistic antibacterial effects against MDR M. tuberculosis."
  },
  {
    "drug": "cef dinir",
    "pathogen": "M. tuberculosis",
    "activity_type": "no_effect",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cefdinir did not show synergy with rifampicin against MDR-TB in vitro.",
    "pmid": "40143193",
    "title": "Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay.",
    "year": "2025",
    "doi": "10.3390/ph18030417",
    "mechanism": "Beta-lactamase inhibition by clavulanate enhances the activity of beta-lactam antibiotics, and the combination with rifampicin exhibits synergistic antibacterial effects against MDR M. tuberculosis."
  },
  {
    "drug": "cefadroxil",
    "pathogen": "M. tuberculosis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cefadroxil combined with rifampicin and clavulanate exhibited strong synergy against MDR-TB in vitro.",
    "pmid": "40143193",
    "title": "Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay.",
    "year": "2025",
    "doi": "10.3390/ph18030417",
    "mechanism": "Beta-lactamase inhibition by clavulanate enhances the activity of beta-lactam antibiotics, and the combination with rifampicin exhibits synergistic antibacterial effects against MDR M. tuberculosis."
  },
  {
    "drug": "cephalexin",
    "pathogen": "M. tuberculosis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Cephalexin combined with rifampicin and clavulanate showed strong synergy against MDR-TB in vitro.",
    "pmid": "40143193",
    "title": "Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay.",
    "year": "2025",
    "doi": "10.3390/ph18030417",
    "mechanism": "Beta-lactamase inhibition by clavulanate enhances the activity of beta-lactam antibiotics, and the combination with rifampicin exhibits synergistic antibacterial effects against MDR M. tuberculosis."
  },
  {
    "drug": "atorvastatin",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Encapsulation of atorvastatin in nanostructured lipid carriers significantly enhanced its antibacterial activity and biofilm inhibition against MRSA.",
    "pmid": "40295972",
    "title": "Comparative evaluation of five \u03b2-Lactamase inhibitors in combination with \u03b2-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro.",
    "year": "2025",
    "doi": "10.1186/s12879-025-10730-y",
    "mechanism": "Encapsulation in nanostructured lipid carriers enhances atorvastatin's stability, solubility, and delivery, thereby improving its ability to disrupt bacterial membranes and inhibit biofilm formation."
  },
  {
    "drug": "atorvastatin",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "ATR-loaded NLCs reduced MIC values and increased biofilm inhibition against E. coli, demonstrating improved antimicrobial efficacy.",
    "pmid": "40295972",
    "title": "Comparative evaluation of five \u03b2-Lactamase inhibitors in combination with \u03b2-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro.",
    "year": "2025",
    "doi": "10.1186/s12879-025-10730-y",
    "mechanism": "Encapsulation in nanostructured lipid carriers enhances atorvastatin's stability, solubility, and delivery, thereby improving its ability to disrupt bacterial membranes and inhibit biofilm formation."
  },
  {
    "drug": "atorvastatin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "ATR-NLCs showed increased biofilm inhibition (~80%) compared to free ATR (~20%) against S. aureus.",
    "pmid": "40295972",
    "title": "Comparative evaluation of five \u03b2-Lactamase inhibitors in combination with \u03b2-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro.",
    "year": "2025",
    "doi": "10.1186/s12879-025-10730-y",
    "mechanism": "Encapsulation in nanostructured lipid carriers enhances atorvastatin's stability, solubility, and delivery, thereby improving its ability to disrupt bacterial membranes and inhibit biofilm formation."
  },
  {
    "drug": "fosfomycin",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "A dose of 6 g q8h is recommended for P. aeruginosa pneumonia based on PTA analysis at the ELF site.",
    "pmid": "40307308",
    "title": "Platelet-rich plasma as a potential antimicrobial agent against multidrug-resistant bacteria in diabetic foot infections.",
    "year": "2025",
    "doi": "10.1038/s41598-025-97418-0",
    "mechanism": "Inhibition of bacterial cell wall synthesis via MurA enzyme inhibition"
  },
  {
    "drug": "fosfomycin",
    "pathogen": "S. aureus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "A dose of 4 g q8h is sufficient for S. aureus infections when plasma concentrations are used as efficacy indicator.",
    "pmid": "40307308",
    "title": "Platelet-rich plasma as a potential antimicrobial agent against multidrug-resistant bacteria in diabetic foot infections.",
    "year": "2025",
    "doi": "10.1038/s41598-025-97418-0",
    "mechanism": "Inhibition of bacterial cell wall synthesis via MurA enzyme inhibition"
  },
  {
    "drug": "platelet-rich plasma",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "PRP demonstrated transient antibacterial activity against MRSA, peaking at 2 hours with over 2 logs reduction in colony counts, but no activity observed at 24 hours.",
    "pmid": "40323339",
    "title": "Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.",
    "year": "2025",
    "doi": "10.1128/aac.01869-24",
    "mechanism": "The proposed mechanism is that PRP releases growth factors and cytokines that transiently inhibit bacterial growth, though the exact antimicrobial mechanism remains unclear."
  },
  {
    "drug": "platelet-rich plasma",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "PRP showed transient antibacterial activity against K. pneumoniae, with peak effect at 1 hour and no activity at 24 hours.",
    "pmid": "40323339",
    "title": "Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.",
    "year": "2025",
    "doi": "10.1128/aac.01869-24",
    "mechanism": "The proposed mechanism is that PRP releases growth factors and cytokines that transiently inhibit bacterial growth, though the exact antimicrobial mechanism remains unclear."
  },
  {
    "drug": "platelet-rich plasma",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "PRP exhibited transient antibacterial activity against P. aeruginosa, peaking at 2 hours with approximately 97% growth inhibition, but no activity at 24 hours.",
    "pmid": "40323339",
    "title": "Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.",
    "year": "2025",
    "doi": "10.1128/aac.01869-24",
    "mechanism": "The proposed mechanism is that PRP releases growth factors and cytokines that transiently inhibit bacterial growth, though the exact antimicrobial mechanism remains unclear."
  },
  {
    "drug": "A22",
    "pathogen": "Pseudomonas aeruginosa DK2",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "A22 demonstrated potent synergistic activity with Polymyxin B against MDR P. aeruginosa DK2.",
    "pmid": "40325037",
    "title": "Disulfiram induces redox imbalance and perturbations in central glucose catabolism and metal homeostasis to inhibit the growth of Staphylococcus aureus.",
    "year": "2025",
    "doi": "10.1038/s41598-025-00078-3",
    "mechanism": "A22 enhances polymyxin activity by inducing reactive oxygen species production, reducing ATP levels, increasing NOX activity, and inhibiting biofilm formation, leading to bacterial death."
  },
  {
    "drug": "A22",
    "pathogen": "Pseudomonas aeruginosa DK2",
    "activity_type": "synergy",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo studies confirmed the efficacy of A22 in combination with Polymyxin B in mouse and C. elegans models.",
    "pmid": "40325037",
    "title": "Disulfiram induces redox imbalance and perturbations in central glucose catabolism and metal homeostasis to inhibit the growth of Staphylococcus aureus.",
    "year": "2025",
    "doi": "10.1038/s41598-025-00078-3",
    "mechanism": "A22 enhances polymyxin activity by inducing reactive oxygen species production, reducing ATP levels, increasing NOX activity, and inhibiting biofilm formation, leading to bacterial death."
  },
  {
    "drug": "A22",
    "pathogen": "Pseudomonas aeruginosa DK2",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "A22 enhances polymyxin activity by inducing reactive oxygen species, reducing ATP, increasing NOX activity, and inhibiting biofilm formation.",
    "pmid": "40325037",
    "title": "Disulfiram induces redox imbalance and perturbations in central glucose catabolism and metal homeostasis to inhibit the growth of Staphylococcus aureus.",
    "year": "2025",
    "doi": "10.1038/s41598-025-00078-3",
    "mechanism": "A22 enhances polymyxin activity by inducing reactive oxygen species production, reducing ATP levels, increasing NOX activity, and inhibiting biofilm formation, leading to bacterial death."
  },
  {
    "drug": "A22",
    "pathogen": "various MDR Gram-negative bacteria",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "A22 exhibits broad-spectrum synergism with polymyxins against multiple clinically isolated MDR Gram-negative strains.",
    "pmid": "40325037",
    "title": "Disulfiram induces redox imbalance and perturbations in central glucose catabolism and metal homeostasis to inhibit the growth of Staphylococcus aureus.",
    "year": "2025",
    "doi": "10.1038/s41598-025-00078-3",
    "mechanism": "A22 enhances polymyxin activity by inducing reactive oxygen species production, reducing ATP levels, increasing NOX activity, and inhibiting biofilm formation, leading to bacterial death."
  },
  {
    "drug": "niclosamide",
    "pathogen": "Pseudomonas aeruginosa DK2",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide was previously identified as an adjuvant for Polymyxin B, leading to the development of compound 15.",
    "pmid": "40325037",
    "title": "Disulfiram induces redox imbalance and perturbations in central glucose catabolism and metal homeostasis to inhibit the growth of Staphylococcus aureus.",
    "year": "2025",
    "doi": "10.1038/s41598-025-00078-3",
    "mechanism": "A22 enhances polymyxin activity by inducing reactive oxygen species production, reducing ATP levels, increasing NOX activity, and inhibiting biofilm formation, leading to bacterial death."
  },
  {
    "drug": "tebipenem",
    "pathogen": "M. tuberculosis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 16,
    "fici": null,
    "key_result": "Tebipenem showed the most effective activity against MDR-TB with an MIC90 of 16 \u00b5g/ml.",
    "pmid": "40341530",
    "title": "Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.",
    "year": "2025",
    "doi": "10.1038/s41598-025-01303-9",
    "mechanism": "\u03b2-lactamase inhibitors enhance the activity of \u03b2-lactam antibiotics by inhibiting the BlaC enzyme in M. tuberculosis, restoring the efficacy of carbapenems."
  },
  {
    "drug": "clavulanic acid",
    "pathogen": "M. tuberculosis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Clavulanic acid demonstrated strong synergy with tebipenem, reducing MIC values 32-fold in some strains.",
    "pmid": "40341530",
    "title": "Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.",
    "year": "2025",
    "doi": "10.1038/s41598-025-01303-9",
    "mechanism": "\u03b2-lactamase inhibitors enhance the activity of \u03b2-lactam antibiotics by inhibiting the BlaC enzyme in M. tuberculosis, restoring the efficacy of carbapenems."
  },
  {
    "drug": "tazobactam",
    "pathogen": "M. tuberculosis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tazobactam showed significant synergy with tebipenem, with up to 20 strains experiencing a 32-fold MIC reduction.",
    "pmid": "40341530",
    "title": "Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.",
    "year": "2025",
    "doi": "10.1038/s41598-025-01303-9",
    "mechanism": "\u03b2-lactamase inhibitors enhance the activity of \u03b2-lactam antibiotics by inhibiting the BlaC enzyme in M. tuberculosis, restoring the efficacy of carbapenems."
  },
  {
    "drug": "sulbactam",
    "pathogen": "M. tuberculosis",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sulbactam combined with tebipenem resulted in a 32-fold MIC reduction in 20 strains.",
    "pmid": "40341530",
    "title": "Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.",
    "year": "2025",
    "doi": "10.1038/s41598-025-01303-9",
    "mechanism": "\u03b2-lactamase inhibitors enhance the activity of \u03b2-lactam antibiotics by inhibiting the BlaC enzyme in M. tuberculosis, restoring the efficacy of carbapenems."
  },
  {
    "drug": "avibactam",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Avibactam enhanced the activity of \u03b2-lactams, notably reducing MICs more effectively than some other inhibitors.",
    "pmid": "40341530",
    "title": "Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.",
    "year": "2025",
    "doi": "10.1038/s41598-025-01303-9",
    "mechanism": "\u03b2-lactamase inhibitors enhance the activity of \u03b2-lactam antibiotics by inhibiting the BlaC enzyme in M. tuberculosis, restoring the efficacy of carbapenems."
  },
  {
    "drug": "relebactam",
    "pathogen": "M. tuberculosis",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Relebactam showed potential as a \u03b2-lactamase inhibitor, improving \u03b2-lactam activity against MDR-TB strains.",
    "pmid": "40341530",
    "title": "Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.",
    "year": "2025",
    "doi": "10.1038/s41598-025-01303-9",
    "mechanism": "\u03b2-lactamase inhibitors enhance the activity of \u03b2-lactam antibiotics by inhibiting the BlaC enzyme in M. tuberculosis, restoring the efficacy of carbapenems."
  },
  {
    "drug": "colistin",
    "pathogen": "Enterobacterales",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Early differentiation between colistin-sensitive and resistant strains can be achieved within 2 hours using microfluidics-based imaging techniques.",
    "pmid": "40367640",
    "title": "Antifungal agent tavaborole as a potential broad-spectrum serine and metallo-\u03b2-lactamases inhibitor.",
    "year": "2025",
    "doi": "10.1016/j.ebiom.2025.105754",
    "mechanism": "Disruption of bacterial cell membrane integrity by binding to lipopolysaccharides, leading to cell death."
  },
  {
    "drug": "colistin",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Time-kill assays showed significant bacterial count reduction in colistin-sensitive strains at 2, 4, and 8 hours.",
    "pmid": "40367640",
    "title": "Antifungal agent tavaborole as a potential broad-spectrum serine and metallo-\u03b2-lactamases inhibitor.",
    "year": "2025",
    "doi": "10.1016/j.ebiom.2025.105754",
    "mechanism": "Disruption of bacterial cell membrane integrity by binding to lipopolysaccharides, leading to cell death."
  },
  {
    "drug": "colistin",
    "pathogen": "Acinetobacter baumannii complex",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Colistin demonstrated bactericidal activity in susceptible strains within 8 hours in time-kill assays.",
    "pmid": "40367640",
    "title": "Antifungal agent tavaborole as a potential broad-spectrum serine and metallo-\u03b2-lactamases inhibitor.",
    "year": "2025",
    "doi": "10.1016/j.ebiom.2025.105754",
    "mechanism": "Disruption of bacterial cell membrane integrity by binding to lipopolysaccharides, leading to cell death."
  },
  {
    "drug": "nepicastat",
    "pathogen": "S. aureus",
    "activity_type": "antimicrobial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 64,
    "fici": null,
    "key_result": "NEP exhibited weak antimicrobial activity against S. aureus at 64 \u00b5g/mL.",
    "pmid": "40370545",
    "title": "Discovery of a novel polymyxin adjuvant against multidrug-resistant gram-negative bacteria through oxidative stress modulation.",
    "year": "2025",
    "doi": "10.1016/j.apsb.2025.01.022",
    "mechanism": "Inhibition of acetylcholinesterase activity and modulation of dopamine and noradrenaline pathways."
  },
  {
    "drug": "nepicastat",
    "pathogen": "P. aeruginosa",
    "activity_type": "antimicrobial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "NEP was not effective against P. aeruginosa.",
    "pmid": "40370545",
    "title": "Discovery of a novel polymyxin adjuvant against multidrug-resistant gram-negative bacteria through oxidative stress modulation.",
    "year": "2025",
    "doi": "10.1016/j.apsb.2025.01.022",
    "mechanism": "Inhibition of acetylcholinesterase activity and modulation of dopamine and noradrenaline pathways."
  },
  {
    "drug": "nepicastat",
    "pathogen": "not applicable",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "NEP inhibits acetylcholinesterase activity, indicating potential anti-virulence effects.",
    "pmid": "40370545",
    "title": "Discovery of a novel polymyxin adjuvant against multidrug-resistant gram-negative bacteria through oxidative stress modulation.",
    "year": "2025",
    "doi": "10.1016/j.apsb.2025.01.022",
    "mechanism": "Inhibition of acetylcholinesterase activity and modulation of dopamine and noradrenaline pathways."
  },
  {
    "drug": "G-TeaNPs",
    "pathogen": "S. aureus (MRSA)",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 1,
    "fici": null,
    "key_result": "G-TeaNPs significantly reduce S. aureus survival to around 30% at 0.001 mg/mL concentration.",
    "pmid": "40380090",
    "title": "Fingolimod as a potent anti-Staphylococcus aureus: pH-dependent cell envelope damage and eradication of biofilms/persisters.",
    "year": "2025",
    "doi": "10.1186/s12866-025-03973-x",
    "mechanism": "Polyphenols in green tea extract reduce silver ions to form stable silver nanoparticles with antimicrobial properties; nanoparticles may also cause intracellular accumulation and vacuolization in amoebae."
  },
  {
    "drug": "G-TeaNPs",
    "pathogen": "Salmonella enterica",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "G-TeaNPs combined with phages enhance antibacterial activity against S. enterica.",
    "pmid": "40380090",
    "title": "Fingolimod as a potent anti-Staphylococcus aureus: pH-dependent cell envelope damage and eradication of biofilms/persisters.",
    "year": "2025",
    "doi": "10.1186/s12866-025-03973-x",
    "mechanism": "Polyphenols in green tea extract reduce silver ions to form stable silver nanoparticles with antimicrobial properties; nanoparticles may also cause intracellular accumulation and vacuolization in amoebae."
  },
  {
    "drug": "G-TeaNPs",
    "pathogen": "Acanthamoeba castellanii",
    "activity_type": "anti_amoebic",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "G-TeaNPs reduce A. castellanii cell counts by 80% at high concentrations, showing amoebicidal activity.",
    "pmid": "40380090",
    "title": "Fingolimod as a potent anti-Staphylococcus aureus: pH-dependent cell envelope damage and eradication of biofilms/persisters.",
    "year": "2025",
    "doi": "10.1186/s12866-025-03973-x",
    "mechanism": "Polyphenols in green tea extract reduce silver ions to form stable silver nanoparticles with antimicrobial properties; nanoparticles may also cause intracellular accumulation and vacuolization in amoebae."
  },
  {
    "drug": "fendiline",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Fendiline exhibits antimicrobial activity against A. baumannii, especially strains overexpressing OXA-23, by targeting lipoprotein trafficking.",
    "pmid": "40437307",
    "title": "The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan.",
    "year": "2025",
    "doi": "10.1038/s43587-025-00876-4",
    "mechanism": "Fendiline inhibits the lipoprotein trafficking pathway (Lol pathway), specifically targeting LolF and/or LolD, which stresses the cell envelope and enhances susceptibility in OXA-23 overexpressing A. baumannii."
  },
  {
    "drug": "fendiline",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Fendiline enhances susceptibility of E. coli to other antibiotics by inhibiting efflux and lipoprotein trafficking.",
    "pmid": "40437307",
    "title": "The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan.",
    "year": "2025",
    "doi": "10.1038/s43587-025-00876-4",
    "mechanism": "Fendiline inhibits the lipoprotein trafficking pathway (Lol pathway), specifically targeting LolF and/or LolD, which stresses the cell envelope and enhances susceptibility in OXA-23 overexpressing A. baumannii."
  },
  {
    "drug": "abaucin",
    "pathogen": "A. baumannii",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Overexpression of lolFD confers resistance to abaucin, supporting its targeting of lipoprotein trafficking.",
    "pmid": "40437307",
    "title": "The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan.",
    "year": "2025",
    "doi": "10.1038/s43587-025-00876-4",
    "mechanism": "Fendiline inhibits the lipoprotein trafficking pathway (Lol pathway), specifically targeting LolF and/or LolD, which stresses the cell envelope and enhances susceptibility in OXA-23 overexpressing A. baumannii."
  },
  {
    "drug": "Penfluridol",
    "pathogen": "Gram-negative bacilli",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Penfluridol synergizes with colistin to restore activity against colistin-resistant Gram-negative bacteria.",
    "pmid": "40442509",
    "title": "Phage/nanoparticle cocktails for a biocompatible and environmentally friendly antibacterial therapy.",
    "year": "2025",
    "doi": "10.1007/s00253-025-13526-x",
    "mechanism": "Penfluridol enhances colistin's ability to disrupt bacterial membranes, likely by increasing membrane permeability and facilitating colistin binding to lipopolysaccharides, thereby restoring colistin activity against resistant bacteria."
  },
  {
    "drug": "colistin",
    "pathogen": "Gram-negative bacilli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Colistin's efficacy is significantly enhanced when combined with penfluridol against resistant strains.",
    "pmid": "40442509",
    "title": "Phage/nanoparticle cocktails for a biocompatible and environmentally friendly antibacterial therapy.",
    "year": "2025",
    "doi": "10.1007/s00253-025-13526-x",
    "mechanism": "Penfluridol enhances colistin's ability to disrupt bacterial membranes, likely by increasing membrane permeability and facilitating colistin binding to lipopolysaccharides, thereby restoring colistin activity against resistant bacteria."
  },
  {
    "drug": "tavaborole",
    "pathogen": "bacteria producing SBLs or MBLs",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tavaborole enhances the activity of \u03b2-lactam antibiotics against bacteria producing serine and metallo-\u03b2-lactamases.",
    "pmid": "40493197",
    "title": "Repurposing a drug to punish carbapenem-resistant Acinetobacter baumannii.",
    "year": "2025",
    "doi": "10.1073/pnas.2423650122",
    "mechanism": "Tavaborole inhibits SBLs by covalently bonding with the active serine residue and inhibits MBLs by chelating the zinc ions at the active center."
  },
  {
    "drug": "tavaborole",
    "pathogen": "bacteria producing SBLs or MBLs",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo, tavaborole restored the efficacy of meropenem against resistant bacterial infections in a mouse model.",
    "pmid": "40493197",
    "title": "Repurposing a drug to punish carbapenem-resistant Acinetobacter baumannii.",
    "year": "2025",
    "doi": "10.1073/pnas.2423650122",
    "mechanism": "Tavaborole inhibits SBLs by covalently bonding with the active serine residue and inhibits MBLs by chelating the zinc ions at the active center."
  },
  {
    "drug": "chlorpromazine",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Chlorpromazine inhibits bacterial efflux pumps, restoring antibiotic susceptibility in MDR strains.",
    "pmid": "40539807",
    "title": "VLX600, an anticancer iron chelator, exerts antimicrobial effects on Mycobacterium abscessus infections.",
    "year": "2025",
    "doi": "10.1128/spectrum.00719-25",
    "mechanism": "Phenothiazines inhibit bacterial efflux pumps, disrupt bacterial membranes, and modulate host cell pathways, thereby restoring antibiotic susceptibility and exerting direct antibacterial effects."
  },
  {
    "drug": "thioridazine",
    "pathogen": "E. coli",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Thioridazine enhances antibiotic efficacy by inhibiting bacterial efflux pumps, restoring susceptibility in MDR E. coli.",
    "pmid": "40539807",
    "title": "VLX600, an anticancer iron chelator, exerts antimicrobial effects on Mycobacterium abscessus infections.",
    "year": "2025",
    "doi": "10.1128/spectrum.00719-25",
    "mechanism": "Phenothiazines inhibit bacterial efflux pumps, disrupt bacterial membranes, and modulate host cell pathways, thereby restoring antibiotic susceptibility and exerting direct antibacterial effects."
  },
  {
    "drug": "chlorpromazine",
    "pathogen": "Burkholderia pseudomallei",
    "activity_type": "efflux_inhibitor",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Chlorpromazine disrupts bacterial membranes and efflux mechanisms, improving antibiotic activity against B. pseudomallei.",
    "pmid": "40539807",
    "title": "VLX600, an anticancer iron chelator, exerts antimicrobial effects on Mycobacterium abscessus infections.",
    "year": "2025",
    "doi": "10.1128/spectrum.00719-25",
    "mechanism": "Phenothiazines inhibit bacterial efflux pumps, disrupt bacterial membranes, and modulate host cell pathways, thereby restoring antibiotic susceptibility and exerting direct antibacterial effects."
  },
  {
    "drug": "chlorpromazine",
    "pathogen": "S. aureus",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Chlorpromazine synergizes with antibiotics like ampicillin and ciprofloxacin to combat MDR S. aureus.",
    "pmid": "40539807",
    "title": "VLX600, an anticancer iron chelator, exerts antimicrobial effects on Mycobacterium abscessus infections.",
    "year": "2025",
    "doi": "10.1128/spectrum.00719-25",
    "mechanism": "Phenothiazines inhibit bacterial efflux pumps, disrupt bacterial membranes, and modulate host cell pathways, thereby restoring antibiotic susceptibility and exerting direct antibacterial effects."
  },
  {
    "drug": "antimicrobial peptides (AMPs)",
    "pathogen": "C. auris",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "AMPs show broad-spectrum antifungal activity and potential to overcome resistance in critical fungal pathogens.",
    "pmid": "40565013",
    "title": "Plant Metabolites as Potential Agents That Potentiate or Block Resistance Mechanisms Involving \u03b2-Lactamases and Efflux Pumps.",
    "year": "2025",
    "doi": "10.3390/ijms26125550",
    "mechanism": "broad-spectrum membrane disruption, immune modulation, and interference with virulence factors"
  },
  {
    "drug": "antimicrobial peptides (AMPs)",
    "pathogen": "A. fumigatus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "AMPs such as hLF(1\u201311) and dhvar5 demonstrate activity against A. fumigatus conidia, including resistant strains.",
    "pmid": "40565013",
    "title": "Plant Metabolites as Potential Agents That Potentiate or Block Resistance Mechanisms Involving \u03b2-Lactamases and Efflux Pumps.",
    "year": "2025",
    "doi": "10.3390/ijms26125550",
    "mechanism": "broad-spectrum membrane disruption, immune modulation, and interference with virulence factors"
  },
  {
    "drug": "antimicrobial peptides (AMPs)",
    "pathogen": "C. neoformans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "AMPs are promising candidates for targeting resistant C. neoformans, with potential to bypass traditional resistance mechanisms.",
    "pmid": "40565013",
    "title": "Plant Metabolites as Potential Agents That Potentiate or Block Resistance Mechanisms Involving \u03b2-Lactamases and Efflux Pumps.",
    "year": "2025",
    "doi": "10.3390/ijms26125550",
    "mechanism": "broad-spectrum membrane disruption, immune modulation, and interference with virulence factors"
  },
  {
    "drug": "benzbromarone",
    "pathogen": "K. pneumoniae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Benzbromarone alone had no antibacterial effect but significantly lowered the MIC of colistin, demonstrating strong synergy.",
    "pmid": "40661217",
    "title": "Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.",
    "year": "2025",
    "doi": "10.1039/d5ra04047g",
    "mechanism": "Benzbromarone synergistically enhances bacterial membrane damage, promotes ROS accumulation, and inhibits ATP production when combined with colistin, leading to increased bactericidal activity."
  },
  {
    "drug": "benzbromarone",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Benzbromarone enhanced colistin activity against A. baumannii, reducing bacterial growth when combined.",
    "pmid": "40661217",
    "title": "Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.",
    "year": "2025",
    "doi": "10.1039/d5ra04047g",
    "mechanism": "Benzbromarone synergistically enhances bacterial membrane damage, promotes ROS accumulation, and inhibits ATP production when combined with colistin, leading to increased bactericidal activity."
  },
  {
    "drug": "benzbromarone",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Benzbromarone significantly improved colistin efficacy against P. aeruginosa, despite high resistance levels.",
    "pmid": "40661217",
    "title": "Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.",
    "year": "2025",
    "doi": "10.1039/d5ra04047g",
    "mechanism": "Benzbromarone synergistically enhances bacterial membrane damage, promotes ROS accumulation, and inhibits ATP production when combined with colistin, leading to increased bactericidal activity."
  },
  {
    "drug": "colistin",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 4,
    "fici": null,
    "key_result": "Colistin alone showed high resistance with MIC \u22654 \u03bcg/mL, but its activity was enhanced in combination with benzbromarone.",
    "pmid": "40661217",
    "title": "Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.",
    "year": "2025",
    "doi": "10.1039/d5ra04047g",
    "mechanism": "Benzbromarone synergistically enhances bacterial membrane damage, promotes ROS accumulation, and inhibits ATP production when combined with colistin, leading to increased bactericidal activity."
  },
  {
    "drug": "colistin",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "Colistin resistance was observed with MIC up to 16 \u03bcg/mL, but combination therapy improved efficacy.",
    "pmid": "40661217",
    "title": "Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.",
    "year": "2025",
    "doi": "10.1039/d5ra04047g",
    "mechanism": "Benzbromarone synergistically enhances bacterial membrane damage, promotes ROS accumulation, and inhibits ATP production when combined with colistin, leading to increased bactericidal activity."
  },
  {
    "drug": "colistin",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 32,
    "fici": null,
    "key_result": "High resistance to colistin (MIC=32 \u03bcg/mL) was observed, but synergy with benzbromarone restored activity.",
    "pmid": "40661217",
    "title": "Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.",
    "year": "2025",
    "doi": "10.1039/d5ra04047g",
    "mechanism": "Benzbromarone synergistically enhances bacterial membrane damage, promotes ROS accumulation, and inhibits ATP production when combined with colistin, leading to increased bactericidal activity."
  },
  {
    "drug": "pentamidine",
    "pathogen": "Streptococcus pyogenes",
    "activity_type": "adjuvant|anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Pentamidine inhibits the virulence factor streptopain (SpeB) of GAS, rendering the bacteria more susceptible to immune killing.",
    "pmid": "40911556",
    "title": "In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria.",
    "year": "2025",
    "doi": "10.1371/journal.pone.0331440",
    "mechanism": "Pentamidine directly inhibits the cysteine protease SpeB by occupying its substrate pocket, interfering with its proteolytic activity."
  },
  {
    "drug": "Ilaprazole",
    "pathogen": "H. pylori",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "Ilaprazole exhibits potent in vitro antibacterial activity against H. pylori with MIC50 and MIC90 values of 8 \u00b5g/mL, including drug-resistant strains.",
    "pmid": "40931324",
    "title": "Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies.",
    "year": "2025",
    "doi": "10.1111/fcp.70046",
    "mechanism": "The proposed mechanism includes direct antibacterial activity of ilaprazole against H. pylori and synergistic effects when combined with antibiotics like clarithromycin."
  },
  {
    "drug": "Clarithromycin",
    "pathogen": "H. pylori",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Clarithromycin resistance was present in some strains, but the study focused on ilaprazole's activity.",
    "pmid": "40931324",
    "title": "Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies.",
    "year": "2025",
    "doi": "10.1111/fcp.70046",
    "mechanism": "The proposed mechanism includes direct antibacterial activity of ilaprazole against H. pylori and synergistic effects when combined with antibiotics like clarithromycin."
  },
  {
    "drug": "Amoxicillin",
    "pathogen": "H. pylori",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Some strains resistant to amoxicillin were included; ilaprazole showed activity against resistant strains.",
    "pmid": "40931324",
    "title": "Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies.",
    "year": "2025",
    "doi": "10.1111/fcp.70046",
    "mechanism": "The proposed mechanism includes direct antibacterial activity of ilaprazole against H. pylori and synergistic effects when combined with antibiotics like clarithromycin."
  },
  {
    "drug": "Bismuth potassium citrate",
    "pathogen": "H. pylori",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 8,
    "fici": null,
    "key_result": "Bismuth potassium citrate demonstrated excellent in vitro antibacterial effects with MICs ranging from 2 to 8 \u00b5g/mL.",
    "pmid": "40931324",
    "title": "Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies.",
    "year": "2025",
    "doi": "10.1111/fcp.70046",
    "mechanism": "The proposed mechanism includes direct antibacterial activity of ilaprazole against H. pylori and synergistic effects when combined with antibiotics like clarithromycin."
  },
  {
    "drug": "cefepime",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sub-inhibitory concentrations of cefepime combined with bacteriophages PAA and PAM exhibited synergistic effects against P. aeruginosa.",
    "pmid": "40971029",
    "title": "A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii.",
    "year": "2025",
    "doi": "10.1007/s00430-025-00854-y",
    "mechanism": "The phage-antibiotic synergy likely results from combined bactericidal effects and enhanced phage replication in the presence of antibiotics, leading to improved bacterial eradication and biofilm disruption."
  },
  {
    "drug": "meropenem",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sub-inhibitory concentrations of meropenem combined with bacteriophages PAA and PAM showed synergistic antibacterial activity against P. aeruginosa.",
    "pmid": "40971029",
    "title": "A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii.",
    "year": "2025",
    "doi": "10.1007/s00430-025-00854-y",
    "mechanism": "The phage-antibiotic synergy likely results from combined bactericidal effects and enhanced phage replication in the presence of antibiotics, leading to improved bacterial eradication and biofilm disruption."
  },
  {
    "drug": "meropenem-vaborbactam",
    "pathogen": "A. baumannii",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Meropenem-vaborbactam combined with ceftazidime showed synergy in 45.5% of XDR CRAB isolates.",
    "pmid": "40990560",
    "title": "In vitro anti-Helicobacter pylori activity of ilaprazole used alone and in combination with other components of quadruple therapy.",
    "year": "2025",
    "doi": "10.1128/spectrum.00593-25",
    "mechanism": "Synergistic effects of \u03b2-lactamase inhibition by vaborbactam combined with carbapenem and other antibiotics, as well as eravacycline's inhibition of bacterial protein synthesis."
  },
  {
    "drug": "meropenem-vaborbactam",
    "pathogen": "A. baumannii",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.5,
    "key_result": "Meropenem-vaborbactam combined with gentamicin showed synergy in 36.4% of XDR CRAB isolates.",
    "pmid": "40990560",
    "title": "In vitro anti-Helicobacter pylori activity of ilaprazole used alone and in combination with other components of quadruple therapy.",
    "year": "2025",
    "doi": "10.1128/spectrum.00593-25",
    "mechanism": "Synergistic effects of \u03b2-lactamase inhibition by vaborbactam combined with carbapenem and other antibiotics, as well as eravacycline's inhibition of bacterial protein synthesis."
  },
  {
    "drug": "eravacycline",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.125,
    "fici": null,
    "key_result": "Eravacycline demonstrated potent in vitro activity with MIC50 of 0.125 \u03bcg/mL against CRAB.",
    "pmid": "40990560",
    "title": "In vitro anti-Helicobacter pylori activity of ilaprazole used alone and in combination with other components of quadruple therapy.",
    "year": "2025",
    "doi": "10.1128/spectrum.00593-25",
    "mechanism": "Synergistic effects of \u03b2-lactamase inhibition by vaborbactam combined with carbapenem and other antibiotics, as well as eravacycline's inhibition of bacterial protein synthesis."
  },
  {
    "drug": "phage cocktail",
    "pathogen": "Shigella sonnei",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The phage cocktail effectively lysed Shigella sonnei and disrupted its biofilms in vitro.",
    "pmid": "41025659",
    "title": "Beyond antiparasitic activity: elucidating the antibacterial potency of pyrvinium pamoate.",
    "year": "2025",
    "doi": "10.1128/spectrum.02158-25",
    "mechanism": "bacteriophage-mediated lysis and biofilm degradation"
  },
  {
    "drug": "phage cocktail",
    "pathogen": "Salmonella enterica",
    "activity_type": "direct_antibacterial|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "The phage cocktail demonstrated activity against Salmonella enterica and its biofilms in vitro.",
    "pmid": "41025659",
    "title": "Beyond antiparasitic activity: elucidating the antibacterial potency of pyrvinium pamoate.",
    "year": "2025",
    "doi": "10.1128/spectrum.02158-25",
    "mechanism": "bacteriophage-mediated lysis and biofilm degradation"
  },
  {
    "drug": "AB15",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant|anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "AB15 exhibits bactericidal activity and enhances the antibacterial effect of colistin against MDR Acinetobacter baumannii, including suppression of biofilm dissemination.",
    "pmid": "41039237",
    "title": "Characterization of bacteriophages PAA and PAM and evaluation of their antibiotic synergy against Pseudomonas aeruginosa PAZMYU isolated from urine sample.",
    "year": "2025",
    "doi": "10.1186/s12866-025-04195-x",
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed, but suggests adjuvant activity that reduces resistance risk and enhances colistin efficacy"
  },
  {
    "drug": "flupentixol",
    "pathogen": "P. aeruginosa",
    "activity_type": "efflux_inhibitor|synergy",
    "evidence_type": "in_vitro|in_vivo|in_silico",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Flupentixol inhibits bacterial efflux pumps and synergizes with ciprofloxacin to enhance antibacterial activity.",
    "pmid": "41148680",
    "title": "Repurposed Drugs and Efflux Pump Inhibitors Against Gram-Negative Urinary Tract Pathogenic Bacteria.",
    "year": "2025",
    "doi": "10.3390/antibiotics14100988",
    "mechanism": "Inhibition of bacterial efflux pumps, particularly NorA, MexA, and AcrB, by flupentixol, leading to increased intracellular antibiotic concentration and restored efficacy."
  },
  {
    "drug": "flupentixol",
    "pathogen": "S. aureus",
    "activity_type": "efflux_inhibitor|synergy",
    "evidence_type": "in_vitro|in_vivo|in_silico",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Molecular docking and in vitro tests suggest flupentixol inhibits NorA efflux pump, potentiating ciprofloxacin efficacy.",
    "pmid": "41148680",
    "title": "Repurposed Drugs and Efflux Pump Inhibitors Against Gram-Negative Urinary Tract Pathogenic Bacteria.",
    "year": "2025",
    "doi": "10.3390/antibiotics14100988",
    "mechanism": "Inhibition of bacterial efflux pumps, particularly NorA, MexA, and AcrB, by flupentixol, leading to increased intracellular antibiotic concentration and restored efficacy."
  },
  {
    "drug": "flupentixol",
    "pathogen": "Shigella boydii",
    "activity_type": "efflux_inhibitor|synergy",
    "evidence_type": "in_vitro|in_vivo|in_silico",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Combination therapy with flupentixol reduces inflammation and bacterial load in a mouse shigellosis model.",
    "pmid": "41148680",
    "title": "Repurposed Drugs and Efflux Pump Inhibitors Against Gram-Negative Urinary Tract Pathogenic Bacteria.",
    "year": "2025",
    "doi": "10.3390/antibiotics14100988",
    "mechanism": "Inhibition of bacterial efflux pumps, particularly NorA, MexA, and AcrB, by flupentixol, leading to increased intracellular antibiotic concentration and restored efficacy."
  },
  {
    "drug": "MK-8245",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_virulence",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 40,
    "fici": null,
    "key_result": "MK-8245 inhibits quorum sensing and reduces virulence factor production without affecting bacterial viability.",
    "pmid": "41155646",
    "title": "Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant Klebsiella pneumoniae.",
    "year": "2025",
    "doi": "10.3390/ph18101531",
    "mechanism": "Competitive antagonism of RhlR receptor, disrupting quorum sensing signaling and downstream virulence factor expression."
  },
  {
    "drug": "MK-8245",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MK-8245 enhances the efficacy of imipenem against biofilms.",
    "pmid": "41155646",
    "title": "Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant Klebsiella pneumoniae.",
    "year": "2025",
    "doi": "10.3390/ph18101531",
    "mechanism": "Competitive antagonism of RhlR receptor, disrupting quorum sensing signaling and downstream virulence factor expression."
  },
  {
    "drug": "MK-8245",
    "pathogen": "P. aeruginosa",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MK-8245 significantly reduces biofilm formation and residual biofilm biomass.",
    "pmid": "41155646",
    "title": "Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant Klebsiella pneumoniae.",
    "year": "2025",
    "doi": "10.3390/ph18101531",
    "mechanism": "Competitive antagonism of RhlR receptor, disrupting quorum sensing signaling and downstream virulence factor expression."
  },
  {
    "drug": "MK-8245",
    "pathogen": "P. aeruginosa",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MK-8245 improves survival in Galleria mellonella infection model, indicating potential as an adjunct therapy.",
    "pmid": "41155646",
    "title": "Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant Klebsiella pneumoniae.",
    "year": "2025",
    "doi": "10.3390/ph18101531",
    "mechanism": "Competitive antagonism of RhlR receptor, disrupting quorum sensing signaling and downstream virulence factor expression."
  },
  {
    "drug": "niclosamide",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide exhibits antibacterial activity against drug-resistant P. aeruginosa through mechanisms including membrane permeability disruption and quorum sensing inhibition.",
    "pmid": "41159745",
    "title": "Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant Enterococcus membranes.",
    "year": "2025",
    "doi": "10.1128/msystems.00425-25",
    "mechanism": "Disruption of membrane permeability, quorum sensing inhibition, biofilm suppression, and DNA crosslinking."
  },
  {
    "drug": "mitomycin C",
    "pathogen": "P. aeruginosa",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mitomycin C shows activity against resistant P. aeruginosa, potentially via DNA crosslinking and inhibition of bacterial proliferation.",
    "pmid": "41159745",
    "title": "Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant Enterococcus membranes.",
    "year": "2025",
    "doi": "10.1128/msystems.00425-25",
    "mechanism": "Disruption of membrane permeability, quorum sensing inhibition, biofilm suppression, and DNA crosslinking."
  },
  {
    "drug": "niclosamide",
    "pathogen": "P. aeruginosa",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Niclosamide demonstrates synergistic effects when combined with conventional antibiotics against P. aeruginosa.",
    "pmid": "41159745",
    "title": "Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant Enterococcus membranes.",
    "year": "2025",
    "doi": "10.1128/msystems.00425-25",
    "mechanism": "Disruption of membrane permeability, quorum sensing inhibition, biofilm suppression, and DNA crosslinking."
  },
  {
    "drug": "bunamidine hydrochloride",
    "pathogen": "vancomycin-resistant Enterococcus faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "BUN exhibits potent bactericidal activity against VRE with MICs ranging from 2 to 4 \u00b5g/mL.",
    "pmid": "41178970",
    "title": "A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens: a particular focus on Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3389/fmicb.2025.1669585",
    "mechanism": "BUN interacts with bacterial phosphatidylglycerol, disrupting membrane integrity, increasing permeability, and causing depolarization, leading to bacterial cell death."
  },
  {
    "drug": "bunamidine hydrochloride",
    "pathogen": "vancomycin-resistant Enterococcus faecium",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 2,
    "fici": null,
    "key_result": "BUN effectively kills VRE strains, disrupting membrane integrity and biofilm formation.",
    "pmid": "41178970",
    "title": "A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens: a particular focus on Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3389/fmicb.2025.1669585",
    "mechanism": "BUN interacts with bacterial phosphatidylglycerol, disrupting membrane integrity, increasing permeability, and causing depolarization, leading to bacterial cell death."
  },
  {
    "drug": "bunamidine hydrochloride",
    "pathogen": "vancomycin-resistant Enterococcus faecalis",
    "activity_type": "anti_biofilm",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "BUN significantly inhibits biofilm formation and eradicates biofilm-embedded persister cells.",
    "pmid": "41178970",
    "title": "A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens: a particular focus on Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3389/fmicb.2025.1669585",
    "mechanism": "BUN interacts with bacterial phosphatidylglycerol, disrupting membrane integrity, increasing permeability, and causing depolarization, leading to bacterial cell death."
  },
  {
    "drug": "bunamidine hydrochloride",
    "pathogen": "vancomycin-resistant Enterococcus faecalis",
    "activity_type": "mechanism",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Mechanistic studies show BUN disrupts bacterial membrane integrity by increasing permeability and depolarization.",
    "pmid": "41178970",
    "title": "A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens: a particular focus on Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3389/fmicb.2025.1669585",
    "mechanism": "BUN interacts with bacterial phosphatidylglycerol, disrupting membrane integrity, increasing permeability, and causing depolarization, leading to bacterial cell death."
  },
  {
    "drug": "ENOblock",
    "pathogen": "A. baumannii",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 16,
    "fici": null,
    "key_result": "ENOblock exhibits potent in vitro antibacterial activity against MDR A. baumannii with MIC50 of 16 mg/L, better than colistin and carbapenems.",
    "pmid": "41301611",
    "title": "Repurposing MK-8245 as a Quorum Sensing Inhibitor to Suppress Virulence and Potentiate Antibiotic Activity in Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3390/antibiotics14111116",
    "mechanism": "ENOblock targets bacterial enolase, disrupting glycolytic metabolism, damaging membranes, and impairing virulence functions."
  },
  {
    "drug": "ENOblock",
    "pathogen": "A. baumannii",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "ENOblock synergizes with colistin, reducing bacterial growth and enhancing bactericidal effects.",
    "pmid": "41301611",
    "title": "Repurposing MK-8245 as a Quorum Sensing Inhibitor to Suppress Virulence and Potentiate Antibiotic Activity in Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3390/antibiotics14111116",
    "mechanism": "ENOblock targets bacterial enolase, disrupting glycolytic metabolism, damaging membranes, and impairing virulence functions."
  },
  {
    "drug": "ENOblock",
    "pathogen": "A. baumannii",
    "activity_type": "bactericidal",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "ENOblock demonstrates bactericidal activity against A. baumannii strains within 8 hours at multiple MIC multiples.",
    "pmid": "41301611",
    "title": "Repurposing MK-8245 as a Quorum Sensing Inhibitor to Suppress Virulence and Potentiate Antibiotic Activity in Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3390/antibiotics14111116",
    "mechanism": "ENOblock targets bacterial enolase, disrupting glycolytic metabolism, damaging membranes, and impairing virulence functions."
  },
  {
    "drug": "ENOblock",
    "pathogen": "A. baumannii",
    "activity_type": "adjuvant",
    "evidence_type": "in_vivo",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "In vivo studies show ENOblock improves survival in infected Galleria mellonella larvae when combined with colistin.",
    "pmid": "41301611",
    "title": "Repurposing MK-8245 as a Quorum Sensing Inhibitor to Suppress Virulence and Potentiate Antibiotic Activity in Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3390/antibiotics14111116",
    "mechanism": "ENOblock targets bacterial enolase, disrupting glycolytic metabolism, damaging membranes, and impairing virulence functions."
  },
  {
    "drug": "Mineral trioxide aggregate (MTA)",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MTA exhibited the largest inhibition zone (18.25 mm) against E. faecalis, indicating strong antibacterial activity.",
    "pmid": "41303721",
    "title": "Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.",
    "year": "2025",
    "doi": "10.3390/ijms262211238",
    "mechanism": "The antibacterial effects are proposed to be due to the release of antimicrobial compounds such as beta-defensins, growth factors, and anti-inflammatory cytokines from the tested materials, which inhibit bacterial growth or activity."
  },
  {
    "drug": "Mineral trioxide aggregate (MTA)",
    "pathogen": "Streptococcus mutans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "MTA showed the highest inhibitory effect (13.50 mm) against S. mutans.",
    "pmid": "41303721",
    "title": "Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.",
    "year": "2025",
    "doi": "10.3390/ijms262211238",
    "mechanism": "The antibacterial effects are proposed to be due to the release of antimicrobial compounds such as beta-defensins, growth factors, and anti-inflammatory cytokines from the tested materials, which inhibit bacterial growth or activity."
  },
  {
    "drug": "Amniotic membrane",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Amniotic membrane demonstrated effectiveness against E. faecalis with an inhibition zone of 11.75 mm.",
    "pmid": "41303721",
    "title": "Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.",
    "year": "2025",
    "doi": "10.3390/ijms262211238",
    "mechanism": "The antibacterial effects are proposed to be due to the release of antimicrobial compounds such as beta-defensins, growth factors, and anti-inflammatory cytokines from the tested materials, which inhibit bacterial growth or activity."
  },
  {
    "drug": "Hyaluronic acid",
    "pathogen": "Streptococcus mutans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Hyaluronic acid showed antibacterial activity against S. mutans with an inhibition zone of 12.00 mm.",
    "pmid": "41303721",
    "title": "Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.",
    "year": "2025",
    "doi": "10.3390/ijms262211238",
    "mechanism": "The antibacterial effects are proposed to be due to the release of antimicrobial compounds such as beta-defensins, growth factors, and anti-inflammatory cytokines from the tested materials, which inhibit bacterial growth or activity."
  },
  {
    "drug": "Hyaluronic acid",
    "pathogen": "E. faecalis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Hyaluronic acid showed no antibacterial activity against E. faecalis.",
    "pmid": "41303721",
    "title": "Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.",
    "year": "2025",
    "doi": "10.3390/ijms262211238",
    "mechanism": "The antibacterial effects are proposed to be due to the release of antimicrobial compounds such as beta-defensins, growth factors, and anti-inflammatory cytokines from the tested materials, which inhibit bacterial growth or activity."
  },
  {
    "drug": "Amniotic membrane",
    "pathogen": "Streptococcus mutans",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Amniotic membrane had no effect against S. mutans.",
    "pmid": "41303721",
    "title": "Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.",
    "year": "2025",
    "doi": "10.3390/ijms262211238",
    "mechanism": "The antibacterial effects are proposed to be due to the release of antimicrobial compounds such as beta-defensins, growth factors, and anti-inflammatory cytokines from the tested materials, which inhibit bacterial growth or activity."
  },
  {
    "drug": "Hyaluronic acid",
    "pathogen": "Lactobacillus acidophilus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Hyaluronic acid was ineffective against L. acidophilus.",
    "pmid": "41303721",
    "title": "Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.",
    "year": "2025",
    "doi": "10.3390/ijms262211238",
    "mechanism": "The antibacterial effects are proposed to be due to the release of antimicrobial compounds such as beta-defensins, growth factors, and anti-inflammatory cytokines from the tested materials, which inhibit bacterial growth or activity."
  },
  {
    "drug": "Amniotic membrane",
    "pathogen": "Lactobacillus acidophilus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Amniotic membrane had no effect against L. acidophilus.",
    "pmid": "41303721",
    "title": "Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.",
    "year": "2025",
    "doi": "10.3390/ijms262211238",
    "mechanism": "The antibacterial effects are proposed to be due to the release of antimicrobial compounds such as beta-defensins, growth factors, and anti-inflammatory cytokines from the tested materials, which inhibit bacterial growth or activity."
  },
  {
    "drug": "doxycycline",
    "pathogen": "bacteria",
    "activity_type": "direct_antibacterial",
    "evidence_type": "clinical",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Sub-antimicrobial dose doxycycline directly inhibits MMP-9 activity and is validated in periodontal disease and vascular remodeling.",
    "pmid": "41304763",
    "title": "Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications.",
    "year": "2025",
    "doi": "10.3390/pharmaceutics17111425",
    "mechanism": "Indirect modulation of MMP-9 activity through existing approved drugs that reduce its expression or activity, or direct inhibition by tetracycline derivatives like doxycycline."
  },
  {
    "drug": "EC/11770",
    "pathogen": "Mycobacterium abscessus",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 0.7,
    "fici": null,
    "key_result": "EC/11770 inhibits growth of M. abscessus in biofilm assays with MICs between 0.7 and 1.2 \u03bcM and reduces lung CFU in a murine model.",
    "pmid": "41312994",
    "title": "Synergistic activity of rifampicin and polymyxin B against intracellular Gram-negative ESKAPE pathogens involves bacterial membrane alterations and enhanced oxidative damages.",
    "year": "2026",
    "doi": "10.1128/aac.01319-25",
    "mechanism": "inhibition of leucyl-tRNA synthetase, disrupting protein synthesis"
  },
  {
    "drug": "clofazimine",
    "pathogen": "Vibrio cholerae",
    "activity_type": "adjuvant",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Clofazimine is identified as a potent NQR inhibitor with strong antivirulence properties against V. cholerae.",
    "pmid": "41319186",
    "title": "Asiatic acid, a novel ciprofloxacin adjuvant inhibits Shigella flexneri infection.",
    "year": "2025",
    "doi": "10.1080/19490976.2025.2586329",
    "mechanism": "Inhibition of the bacterial respiratory enzyme NQR, disrupting energy production and virulence factor expression."
  },
  {
    "drug": "clofazimine",
    "pathogen": "Chlamydia trachomatis",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Clofazimine inhibits NQR activity in C. trachomatis, impairing its energy metabolism and development.",
    "pmid": "41319186",
    "title": "Asiatic acid, a novel ciprofloxacin adjuvant inhibits Shigella flexneri infection.",
    "year": "2025",
    "doi": "10.1080/19490976.2025.2586329",
    "mechanism": "Inhibition of the bacterial respiratory enzyme NQR, disrupting energy production and virulence factor expression."
  },
  {
    "drug": "Asiatic acid",
    "pathogen": "Shigella flexneri",
    "activity_type": "synergy",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": 0.25,
    "key_result": "Asiatic acid synergistically enhances ciprofloxacin activity against S. flexneri, inhibiting biofilm formation and efflux activity.",
    "pmid": "41367421",
    "title": "NQR as a target for new antibiotics.",
    "year": "2025",
    "doi": "10.3389/fmicb.2025.1690572",
    "mechanism": "Asiatic acid disrupts bacterial membranes, inhibits efflux pump activity, and prevents biofilm formation, thereby potentiating ciprofloxacin efficacy."
  },
  {
    "drug": "Ciprofloxacin",
    "pathogen": "Shigella flexneri",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Ciprofloxacin shows activity against S. flexneri, with resistance issues addressed by combination with asiatic acid.",
    "pmid": "41367421",
    "title": "NQR as a target for new antibiotics.",
    "year": "2025",
    "doi": "10.3389/fmicb.2025.1690572",
    "mechanism": "Asiatic acid disrupts bacterial membranes, inhibits efflux pump activity, and prevents biofilm formation, thereby potentiating ciprofloxacin efficacy."
  },
  {
    "drug": "nitrofurantoin",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 91.1,
    "fici": null,
    "key_result": "Nitrofurantoin was highly effective against ESBL-producing E. coli isolates with 91.1% susceptibility.",
    "pmid": "41398575",
    "title": "Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.",
    "year": "2025",
    "doi": "10.1186/s12879-025-12349-5",
    "mechanism": "Inhibition of bacterial cell wall synthesis by carbapenems and disruption of protein synthesis by aminoglycosides, effective against ESBL-producing strains."
  },
  {
    "drug": "amikacin",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": 71.7,
    "fici": null,
    "key_result": "Amikacin showed 71.7% activity against ESBL-producing E. coli isolates.",
    "pmid": "41398575",
    "title": "Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.",
    "year": "2025",
    "doi": "10.1186/s12879-025-12349-5",
    "mechanism": "Inhibition of bacterial cell wall synthesis by carbapenems and disruption of protein synthesis by aminoglycosides, effective against ESBL-producing strains."
  },
  {
    "drug": "imipenem",
    "pathogen": "E. coli",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "No resistance was observed to imipenem among ESBL-producing isolates.",
    "pmid": "41398575",
    "title": "Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.",
    "year": "2025",
    "doi": "10.1186/s12879-025-12349-5",
    "mechanism": "Inhibition of bacterial cell wall synthesis by carbapenems and disruption of protein synthesis by aminoglycosides, effective against ESBL-producing strains."
  },
  {
    "drug": "meropenem",
    "pathogen": "K. pneumoniae",
    "activity_type": "direct_antibacterial",
    "evidence_type": "in_vitro",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "No resistance was observed to meropenem among ESBL-producing K. pneumoniae isolates.",
    "pmid": "41398575",
    "title": "Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.",
    "year": "2025",
    "doi": "10.1186/s12879-025-12349-5",
    "mechanism": "Inhibition of bacterial cell wall synthesis by carbapenems and disruption of protein synthesis by aminoglycosides, effective against ESBL-producing strains."
  },
  {
    "drug": "Vorinostat",
    "pathogen": "HPV 18",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Vorinostat showed significant transcriptomic reversal potential in HPV-driven cervical cancer models, suggesting potential for repositioning.",
    "pmid": "41463692",
    "title": "Current Advances in Developing New Antimicrobial Agents Against Non-Tuberculous Mycobacterium.",
    "year": "2025",
    "doi": "10.3390/antibiotics14121189",
    "mechanism": "The proposed mechanism involves modulation of epigenetic regulation, hormone receptor pathways, and cholesterol biosynthesis pathways to counteract HPV-driven oncogenic programs."
  },
  {
    "drug": "tamoxifen",
    "pathogen": "HPV 16",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Tamoxifen demonstrated inverse gene expression profiles with HPV-associated cervical tumors, indicating possible therapeutic utility.",
    "pmid": "41463692",
    "title": "Current Advances in Developing New Antimicrobial Agents Against Non-Tuberculous Mycobacterium.",
    "year": "2025",
    "doi": "10.3390/antibiotics14121189",
    "mechanism": "The proposed mechanism involves modulation of epigenetic regulation, hormone receptor pathways, and cholesterol biosynthesis pathways to counteract HPV-driven oncogenic programs."
  },
  {
    "drug": "simvastatin",
    "pathogen": "HPV 16",
    "activity_type": "adjuvant",
    "evidence_type": "computational",
    "mic_ug_ml": null,
    "fici": null,
    "key_result": "Simvastatin was identified as a candidate with transcriptomic reversal effects in HPV-positive cervical cancer.",
    "pmid": "41463692",
    "title": "Current Advances in Developing New Antimicrobial Agents Against Non-Tuberculous Mycobacterium.",
    "year": "2025",
    "doi": "10.3390/antibiotics14121189",
    "mechanism": "The proposed mechanism involves modulation of epigenetic regulation, hormone receptor pathways, and cholesterol biosynthesis pathways to counteract HPV-driven oncogenic programs."
  }
]